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Summary
The asialoglycoprotein receptor (ASGPR), composed of the subunits H1 and H2, is
predominantly expressed on the sinusoidal surface of mammalian hepatocytes and
involved in the endocytosis of desialylated multiantennary glycans with terminal Gal or
GalNAc residues via the clathrin-coated pit pathway. Although investigated for many
years, the physiological function and ligands are still unknown. Until nowadays, only
polyclonal antibodies and two monoclonal against the ASGPR are reported. However,
no monoclonal antibodies, which are specifically directed against the carbohydrate
recognition domain (CRD), responsible for Gal binding and internalization, are available.
Such antibodies would be precious tools for ASGPR examination. In addition, since the
human ASGPR is a promising liver-specific therapeutic target, an antibody-based high
affine and specific drug or gene delivery system would be valuable.
The H1-CRD was recombinantly expressed in E.coli and purified active H1-CRD was
used for immunization to produce antibodies. Because the published expression and
purification method of Meier et al.26 yielded only an H1-CRD amount of 130?g/L culture,
various E.coli strains, vectors, expression conditions and renaturation procedures were
tested. With the optimized expression in E.coli AD494(DE3), which was transformed with
the H1-CRD cDNA-encoding pET3b vector, and with the following modified purification
procedure, 55mg (20mg/L) active H1-CRD were successfully produced.
For analytical purpose, polyclonal antibodies directed against the H1-CRD (anti-H1)
were obtained by chicken immunization and IgY purified from egg yolk by PEG
precipitation. The 12g (45mg/egg) purified total IgY contained approximately 7% anti-H1
specific IgY. Total IgY and isolated anti-H1 specific IgY antibodies showed to be suitable
in various immunochemical in vitro methods but not in immunocytochemistry.
Although the amino acid sequences of the mouse and human ASGPR H1-CRD are 79%
identical, monoclonal antibodies were successfully produced by the hybridoma
technology. Eight of twenty hybridomas were selected and cloned for further
characterization of their monoclonal antibodies: in vitro in immunoblotting,
immunoassays, Biacore assays and in epitope mapping, on cell in flow cytometry and
fluorescence microscopy and in tissue in immunohepatohistochemical tests. Two of
them, C14.6 and particularly C11.1 showed a very interesting profile, not only for
application in immunochemical techniques but probably also for diagnostic and
therapeutic use.
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1 Introduction
The liver is the main metabolic organ, is involved in production of inflammatory
mediators and serum plasma proteins. Hence, hepatocytes are an attractive target for
selective gene therapy to correct genetic defects, such as analbuminaemia, hemophilia
and lipoprotein receptor deficiency, or for specific delivery of drugs to cure hepatitis B
and C and hepatocellular carcinoma.1
One potential liver specific receptor is the asialoglycoprotein receptor (ASGPR), a
carbohydrate binding protein (lectin), which specifically recognizes desialylated glycans
with terminal galactose (Gal) or galactosamine (GalNAc) residues, for the internalization
via the clathrin-mediated endocytosis pathway.
Until nowadays, many attempts were undertaken to specifically deliver galactosylated
carriers to the liver.2 However, as carbohydrate-protein interactions are exceptionally
weak, higher affine glycomimetics or antibodies would be of great advantage for targeted
therapies.
Although such a promising therapeutic receptor, there exists no antibody-based delivery
system to the ASGPR and even, there is only reported of some polyclonal and of two
partially characterized monoclonal antibodies directed against the whole ASGPR.
However, no monoclonal antibodies exist, which specifically interact with the
carbohydrate binding site of the human ASGPR3,4,5,6,7.
This branding task was the topic of this thesis, namely the production and
characterization of monoclonal and polyclonal antibodies directed against the
carbohydrate recognition domain of the human hepatic ASGPR.
In the following, the first part will introduce the ASGPR to get familiar with its structure
and function. Furthermore, some methodological information to the recombinant
production of the carbohydrate binding-domain, which served as antigen, is enclosed.
The second part will deal with the counterpart of the antigen, the antibody. On the one
hand, the production of antibodies in vivo, which results in different types of antibodies,
the antibody structures and the antibody characteristics, will briefly be mentioned. On the
other hand, the production of antibodies in vitro will be outlined to understand where
monoclonal and polyclonal antibodies are originated. The third part finally will give some
theoretical background to the various immunochemical methods, which were applied for
the characterization of the different antibodies.
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1.1 The hepatic asialoglycoprotein receptor
The hepatic ASGPR was first reported by Ashwell G. et al.8 and is also designated
Ashwell lectin, hepatic lectin (HL) or hepatic binding protein.
1.1.1 Location of the ASGPR
The hepatic ASGPR is predominantly expressed on the sinusoidal, basolateral surface
of hepatocytes.
In human, homologous ASGPR are only found on primary cells like peritoneal
macrophages, immature dendritic cells and granulocytes (but were absent on T-cells, B-
cells, neutral killer cells, monocytes and mature dendritic cells)9,10, on renal proximal
tubular epithelial cells11, on sperm 12 and on thymocytes 13. In great contrary to rat, human
Kupffer cells do not express the ASGPR.14
The ASGPR was also identified on continuous human hepatic cell lines like HepG2,15
HUH-7,16 and PRF/5 hepatoma cells but not on Chang or SK-Hep1 hepatoma cells. Also
extrahepatic human cell lines like HT-2917 and Caco-2 18 intestinal epithelial cells, Tera-1
embryonal carcinoma cells and surprisingly Jurkat lymphoblastic cells were ASGPR-
positive. Other extrahepatic cell lines like HeLa fibroblastic cells, HL-60R promyelocytic
cells, WISH amnion cells, A498 kidney cells and U87-MG neuronal cells did not express
the ASGPR.5
The Gal / GalNAc specific hepatic lectins of mammalian, like mouse, rat, rabbit and
human, exhibit high amino acid sequence homologies, but also the phylogenetically
more distant birds, like chicken possess an analogous but glucosamine (GlcNAc)
specific hepatic lectin.19
1.1.2 Structure of the ASGPR
To deduce the primary structure of the ASGPR (see Figure 1), the cDNA was isolated
from HepG2 cells.
Structure of the human ASGPR
The ASGPR is a heterooligomeric glycoprotein, formed by two homologous subunits, the
major H1 and the minor H2. The subunit composition in and the size of the functional
receptor are still not established and are controversially reported. The estimated minimal
size of the active ASGPR is 140kDa.20 In agreement with that, Hardy et al .21 proposed a
trimeric core, composed of two H1 and one H2. But Bider et al.22 demonstrated, that H1
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and H2 preferentially form heterotetramers in a ratio of 2:2 and Henis et al.23 concluded,
that the ASGPR consists of a trimeric H1 core which can associate with one to three H2,
resulting in H1:H2 heterooligomers of 3:1 to 1:1.
Figure 1: Human hepatic ASGPR, a heterooligomeric complex composed of homologous H1 and H2
subunits, model by Hardy et al. The H1 subunit is a type-II integral glycoprotein with the cytoplasmic N-
terminal domain (1), the transmembrane domain (2) and two extracellular domains: the twice N-glycosylated
stalk region and the C-terminal CRD, containing three calcium ions. The H1-CRD forms three conserved
intramolecular disulfide bridges and binds calcium-dependent to Gal or GalNAc. The essential calcium ion
for binding is located in site 2 (?) whereas the other two calcium ions in sites 1 (?) and 3 (?) are necessary
for the structure. They are coordinated by 11 amino acid residues ( ). The primary structure is folded into 6
long ?-strands (?1-?6) and 2 short ?-strands (s?1, s?2), which form 3 ?-sheets, 2 ?-helices (?1, ?2) and 5
loops (L1-L5). The active binding site (bold) lies in the region of L4, L5, ?4 and ?5 and contains the calcium
2. This calcium ion is coordinated to Q239, D241, E252, N264, D265 and O atoms of two water, which are
replaced by O atoms of 3’ and 4’ OH of GalNAc upon binding. GalNAc in addition undergoes interactions
with 6 amino acid residues (Q239, D241, W243, E252, D253, N264).
Glycosylated H1 and H2 are about 46kDa (deglycosylated about 34kDa)6 and 50kDa in
size. They are mainly distinct in an 18 amino acid insert, which is only present in H2,24
and in the number of N-linked glycosylations, that are two for H1 and three for H2. Both
are similar organized integral proteins and exhibit 58% amino acid sequence
identity.3,24,25
Structure of the H1 subunit
The H1 subunit is a type-II membrane glycoprotein, which spans 290 amino acid
residues and is composed of the N-terminal cytoplasmic domain, the single-spanning
transmembrane domain and the extracellular domain, formed by a stalk region and the
C-terminal carbohydrate recognition domain (CRD).25
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The cytoplasmic domain encloses 40 residues and encodes the tyrosine-based sorting
signal YXXØ (Tyr5Gln6Asp7Leu8) for endocytosis, is transiently phosphorylated at Tyr5,
Ser16 and Ser37, and is palmitoylated at Cys36.
The transmembrane domain includes about 20 residues.
The stalk region is formed by about 80 residues and carries two N-linked glycosylations
(Asp79PheThr, Asp147GlySer) with terminal sialyl acids, which are probably essential to
retain the receptor in its active state. The heptad repeats stalk region may oligomerize
with the stalk regions of other subunits to constitute a ?-helical coiled coil stalk.22
The H1-CRD of 145 residues finally is a globular domain, which contains three calcium
ions and three intramolecular S-S bonds. Therefore, the H1-CRD belongs to the long-
form C-type lectins.
The structure of the H1-CRD domain
The X-ray structure of the 16’860Da H1-CRD was elucidated by Meier et al.26
The H1-CRD is a globular domain with the C-terminus close to the N-terminus. The
primary structure is folded to six long and two short ?-strands, which are arranged in
three ?-sheets, two ?-helices and five loops. Three calcium ions are an integral part of
the H1-CRD. The two calcium ions in sites 1 and 3 contribute to the structural
maintenance, whereas the calcium in site 2 is essential for Gal and GalNAc binding. This
calcium, together with loop 4, the glycine rich loop 5, ?-strand 4 and ?-strand 5 form the
sugar binding site (Arg236-Cys268). The binding site is enclosed by an intramolecular
disulfide bridge (Cys181-Cys276) and contains an internal S-S bond (Cys254-Cys268). The
third disulfide linkage could not be positioned in X-ray, but was proposed to pair Cys164
and Cys152 or Cys153.
1.1.3 ASGPR-ligand interaction – determinants of high avidity binding
Binding mode
The binding mode of GalNAc to the H1-CRD was proposed according to Drickamer et
al.27 In this model, Gal NAc interacts with carboxy and amino groups of six amino acid
residues (Q239, D241, W243, E252, D253, N264) in the binding site. In addition, the 3’ and 4’
hydroxy groups of GalNAc replace the O atoms of two water molecules, which are
coordinated to the calcium in site 2.
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Structure of the ligands
The ligands are complex-type N-linked desialylated glycans with terminal ?-Gal or ?-D-
GalNAc residues, e.g. asialoorosomucoid (ASOR) and asialofetuin (ASF). The affinities
are low, but about 20-fold higher for GalNAc compared to Gal. 28 Surprisingly, Park et
al.29 reported, that H1 also bound to sialylated glycans with terminal Sia?-2,6-GalNAc.
High avidity binding of ligands to the ASGPR
The ligand specificity of the ASGPR mainly depends on the terminal sugar, the ligand
valency and the carbohydrate spacing. The affinity of GalNAc and especially of Gal to
the CRD is low. Simultaneous binding of multiantennary glycosides to multiple subunits
of the ASGPR increases the avidity significantly. Whereas the affinity of a
monoantennary galactoside is only in the mM range, the avidity of a triantennary or
tetraantennary galactoside is in the nM range. Hardy et al.21 as well as Henis et al.23
concluded, that the interaction of the triantennary or tetraantennary ligand involves one
H2 and two H1 binding sites of the ASGPR. This simultaneous binding is only possible
when the terminal sugars are at least 1.5nm spaced.30,31
Furthermore, the ASGPR must be functional and active. H2 homooligomers alone
cannot, but H1 homooligomers are able to bind to asialoorosomucoid.11,32 Additionally,
mouse H1 alone can bind to ASOR, but for high affinity binding and for endocytosis, the
ASGPR must be a heterooligomeric complex composed of both subunits, the H1 and the
H2.33,34
Finally, the N-linked glycosides on the stalk of the ASGPR must be sialylated. The
hyposialylated ASGPR is inactive. This was presumed to be the result of self-binding to
the exposed penultimate Gal among subunits of the ASGPR.35
1.1.4 ASGPR-mediated endocytosis pathways
Glycans with terminal Gal or GalNAc are selectively internalized into hepatocytes by
clathrin-mediated endocytosis via the ASGPR, an endocytic recycling receptor.36 In
contrast, glycans with terminal Man are targeted to Kupffer cells (see Figure 2).
Tolchinsky et al.37 and Yik et al .38 reported, that there exist ASGPR subpopulations,
which mediate distinguishable, parallel endocytosis pathways, the state 1 and the state
2. Both follow the common clathrin-coated pit pathway, but state 2 exhibit some
peculiarities and is more stringent regulated. The internalization and recycling pathways
were mainly investigated in HepG2 cells.
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ASGPR subpopulations
H2 exists in three isoforms, designated H2a, H2b and H2c, which result from distinct
DNA splicing. They differ in a 19 amino acid cytoplasmic insert and a 5 amino acid
juxtamembrane insert, which serves as a cleavage signal. H2a express both inserts and
get cleaved proteolytically. Hence, the entire ectodomain is secreted into the blood and
H2a does not oligomerize with H1 to ASGPR complexes. H2b contains the 19 residues
insert but lacks the pentapeptid signal, and H2c lacks both inserts and therefore undergo
no proteolysis. Both form membrane-anchored complexes with H1 but were never
present in the same ASGPR complex. As a consequence, there exist two distinct
ASGPR subpopulations, the H1/H2b and the H1/H2c heterooligomers. The H2b but not
H2c can be phosphorylated at Ser of the 19 residues insert, which enables receptor
modulation. Hence, H1/H2b complexes were proposed to mediate the faster state 2
endocytosis and H1/H2c complexes to traffic to the slower state 1 pathway.38
Kupffer cell
Sinusoid
?
?
?
?
?
??
?
?
?
?
?
?
?
?
?? ?
Bile
Hepatocyte
State 2Pathway State 1
ASGPR: inactive ; active ; Kupffer cell receptor ; Ligand
Figure 2: Selective uptake of glycoconjugates with terminal Gal or GalNAc into hepatocytes via the ASGPR-
mediated endocytosis pathways. In contrast glycoconjugates with terminal Man are targeted to Kupffer cells.
? Ligand binding; ? ASGPR-ligand clustering; ? ASGPR-ligand internalization in clathrin-coated vesicles; ?
ASGPR-ligand dissociation and fusion with CURL; ? ASGPR inactivation; ? Segregation of ASGPR and
ligand by fission of CURL into ligand-containing and ASGPR-containing vesicles; ? ligand delivery to
lysosomes and degradation; ? ASGPR reactivation in the trans-golgi-network; ? ASGPR recycling; ?
clathrin recycling.
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ASGPR endocytosis pathway
The ASGPR is highly abundant in HepG2 cells, with about 2.25·105/cells. 50-80% of
them are found at the surface and the remaining ones intracellular. It is internalized
constitutively and also in the absence of ligand, but upon ligand binding, the endocytosis
rate increases and the number of surface receptors decreases. 3,39
The ASGPR-ligand complexes cluster in clathrin-coated pits and recruit clathrin-
associated adaptor complexes, which recognize the Tyr-containing endocytosis signal of
H1. After invagination into the clathrin-coated vesicles, the clathrin cages unseat and
the early endosomes fuse with the CURL (compartment for uncoupling of receptors and
ligands). In the acidic environment of pH 5.4 in these prelysosomal endocytic vesicles,
the ASGPR and the ligand dissociate and segregate by fission of CURL into receptor-
containing and ligand-containing vesicles. The ligand is delivered to lysosomes for
degradation, whereas the ASGPR recycles to the sinusoidal plasma membrane.40
State 1 versus state 2 pathway
Only about 20% of ligands are endocytosed by the slower state 1 pathway, whereas the
faster state 2 pathway mediates about 80% of ligand internalization and degradation and
therefore is at least 7 times more efficient.
Table 1: Differences between state 1 and state 2 endocytosis pathways of the H1/H2c and H1/H2b ASGPR.
Endocytosis pathway State 1 State 2
ASGPR complex H1/H2c H1/H2b
Dissociation, KD (ASOR) Fast, 1.6nM Slow, 3.9nM
ASGPR I/R cycle Yes
I: (ATP depletion, drugs, low temperature)
R: (Cys palmitoylation)
No
Constitutive recycling No Yes
In the state 1 endocytosis pathway, dissociation of ASGPR-ligand complexes is
mediated by acidification in the CURL, that causes the lost of calcium affinity in the
ASGPR. The efficiency of dissociation is dependent on the ligand concentration in the
vesicle. In contrast, in the state 2 pathway, the ASGPR-ligand complex dissociation is
caused by ASGPR inactivation due to ATP depletion. Hence, the efficiency of ligand
release is independent of its concentration in the CURL, is rapid and complete. Prior to
recycling to the surface, the ASGPR is reactivated by Cys palmitoylation, probably at H1
or H2b. Beside this inactivation / reactivation cycle, another peculiarity is, that the state 2
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ASGPR internalizes and recycles constitutively and also in the absence of ligands,
whereas the state 1 ASGPR does not (see also Table 1).
Modulation of the ASGPR endocytosis
As already mentioned, hyposialylation of the N-linked carbohydrate chains on the stalk
keeps the ASGPR in an inactive state due to self-binding to the exposed terminal Gal.
This allows fast receptor up-regulation, i.e. the increase of the glucose concentration
enhances the number of active ASGPR and their binding affinity, whereas the total
number of ASGPR at the surface remains constant.41 However, IL-1 ?, IL-6 and TNF- ?
rise and ethanol lowers the total number of ASGPR in the plasma membrane.42
1.1.5 Physiological functions of the ASGPR
The ASGPR is investigated for about thirty years, but nevertheless, neither the
endogenous ligand(s) nor the physiological function(s) are established.
Although homozygous H1 or H2-deficient knockout mice are unable to clear ASOR, they
display no phenotypic abnormalities and do not accumulate desialylated glycoproteins or
glycolipids. The ASGPR is postulated to clear defective desialylated plasma
glycoproteins.43 Beside ASOR and ASF, chylomicron remnants and low density
lipoproteins bind and hence, the ASGPR may be involved in lipid uptake in vivo.44 The
ASGPR may also play a potential role in the phagocytosis of dying cells, since the
isolated ASGPR mediates mitogen-stimulated cellular cytotoxicity.45
Furthermore, the ASGPR is reported to be involved in several hepatic disorders.
Autoimmune hepatitis is connected with the appearance of autoantibodies against the
H1 in human.46 The ASGPR is inhibited by IgA and may be involved in pathogenesis of
IgA nephropathy and cirrhosis.47 In addition, the ASGPR also recognizes exogenous
glycans on pathogens like Hepatitis B and Marburg virus, which are reported to enter
hepatocytes via the ASGPR.48,49
1.1.6 Recombinant expression of protein in E.coli
In vitro, protein can be produced in bacterial, yeast, insect or mammalian expression
systems. In contrast to eukaryotic expression, in procaryotic expression, proteins are not
posttranslationally modified.
The recombinant production of a mammalian protein in E.coli consists of three stages.
The first stage is the construction of the E.coli expression system and is composed of
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the cDNA cloning into the expression vector followed by the transformation of the
recombinant plasmid into E.coli expression strains. In the second stage, the protein is
expressed in the culture of recombinant E.coli in soluble form or in insoluble inclusion
bodies. The protein accumulates in the reductive cytoplasm, is directed to the oxidative
periplasm or is secreted into the medium. In the third stage, the expressed protein is
purified from the expression culture and renatured to the native and active protein (see
Figure 3).50
Figure 3: Overexpression of recombinant mammalian protein in E.coli. ? Cloning of cDNA into the
expression vector to get the recombinant plasmid; ? Transformation of E.coli with recombinant plasmid; ?
Expression of protein in a culture of transformed E.coli; ? Cell lysis and isolation of insoluble inclusion
bodies ? Reductive solubilization of inclusion bodies; ? Oxidative refolding of soluble denatured protein; ?
Refolding of soluble protein.
1.1.6.1 Construction of E.coli expression systems – the “protein factories”
In a fist step, the E.coli system is constructed. The protein-encoding cDNA is amplified
with a high-fidelity DNA polymerase to prevent mutations in the coding region, then is
introduced into expression vectors and transformed into E.coli strains. The optimal
vector-E.coli strain combination mainly depends on the features of the recombinant
protein, i.e. the content of Cys, solubility, stability and the content of rare E.coli codons.
The best expression system must be determined empirically.
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Expression vectors – keep in the cell or turn out of the cell
The expression vector guides the protein expression, directs the expression rate and the
location. An efficient E.coli expression vector contains a strong and regulated promotor
for efficient transcription, a Shine-Dalgarno site for rRNA binding, the translation initiation
codon ATG for translation start and a transcription terminator. In addition, the vector
requires an origin of DNA replication and a selection marker. The regulatory gene to
control the promotor activity and expression level can be integrated in the vector or in
the E.coli chromosome. The pET3b vector51 for example is under the control of the
strong T7 promotor that enables transcription by the T7 RNA polymerase. The gene for
T7 RNA polymerase (?DE3) is encoded by the E.coli genome, under the control of the
IPTG-inducible lacUV5 promoter. The inducer IPTG permits to initiate the protein
expression and to regulate the expression rate.
The vectors, which guide the protein to the periplasmic space or into the medium
includes additionally a signal sequence for secretion. Optionally, the expression vector
may encode a fusion tag or protein to enhance the efficient translation initiation, to
improve native folding, stability and solubility of the expressed protein and to facilitate
the protein purification. The pEZZ18 vector for example encodes the protein A signal
sequence for secretion and the ZZ domain, a synthetic IgG binding domain, which is
fused to the recombinant protein. This enables to direct the fusion protein into the
medium and to purify it simply by affinity to IgG.
Commonly, cytoplasmic production is simpler, but the protein tends to accumulate in
inclusion bodies and the reductive environment hinders the formation of disulfide
bridges. In contrast, periplasmic production or secretion is often difficult, because the
protein has to cross the membrane. However, the oxidizing environment of the
periplasmic space enables the pairing of disulfide bridges and facilitates proper folding.
Nevertheless, also in the periplasm, the protein can aggregate in inclusion bodies
especially, when the protein contains multiple S-S bonds.52
E.coli strain – selection of the most generous host by try and error
There exist many E.coli expression strains. They differ in their features to support
folding, solubility and stability of the expressed protein. The vector and the encoded
protein define the strains that are suitable, but they must be established empirically.
In E.coli, the cytoplasmic thioredoxin-glutaredoxin system catalyzes reductive processes
and hinders disulfide pairing.53 The E.coli strains, which are deficient in this system, e.g.
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AD494(DE3) and Rosetta-gami(DE3)TM offer a more oxidizing cytoplasmic environment
and that enables the formation of S-S bonds. The protease-deficient E.coli strains
minimize protein degradation during expression, but also during purification. The E.coli
strains, which coexpress the tRNA for rare E.coli codons, e.g. Rosetta-gami(DE3)TM
facilitate the expression of proteins with a high number of rare amino acids.
1.1.6.2 Expression
The production level of a recombinant E.coli expression system is not only influenced by
E.coli intrinsic factors, i.e. the expression vector and the E.coli strain, but also by E.coli
extrinsic expression conditions: i.e. the medium, the cell density, the temperature, the
pH, the aeration, the inducer concentration and the expression period.
There exist no general rules and the optimal expression conditions must be determined
for each individual recombinant expression system empirically.
1.1.6.3 Protein purification and protein renaturation from inclusion bodies
Cytoplasmic overexpressed protein often accumulates in high dense, insoluble and
inactive inclusion bodies. The protein in inclusion bodies is shielded from proteolytic
attack. The aggregate contains relatively pure denatured protein in oxidized and
reduced, monomeric and multimeric states. The inclusion body formation is mostly
advantageous for purification. The main difficulty is to recover active protein.
The renaturation of isolated inclusion bodies is a two-step procedure: i.e. the reductive
solubilization and the oxidative refolding.54 There exist no general rules for efficient
renaturation. Solubilization and refolding must be optimized empirically for each
individual protein.
Reductive solubilization55
The solubilization consists of three steps: the cell lysis, the isolation of inclusion bodies
and the solubilization of inclusion bodies proteins. The cells are completely disrupted by
sonication, by French press or by enzymatic cleavage with lysozyme and the inclusion
bodies are isolated by centrifugation. To remove contaminations of membrane proteins,
the isolated inclusion bodies are stringently washed. The inclusion bodies are solubilized
with denaturants (urea, guanidine HCl), which form hydrophobic interactions with the
protein, and the misspaired disulfide bridges are reversible broken with reductants, i.e.
?-mercaptoethanol or dithiothreitol.
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Oxidative refolding56
The major problem of oxidative refolding is the competition between intramolecular
folding and intermolecular aggregation. This competition mainly depends on refolding
conditions, i.e. the ionic buffer strength, the protein concentration and purity, the
temperature, the pH, the time and the presence of folding enhancers. The tendency to
aggregate is correlated with the protein itself and the number of S-S bonds.
• Protein concentration. Only denatured protein but not native protein is susceptible
to aggregation. A low concentration of denatured protein minimizes intermolecular
interaction and favors folding. Mostly, the protein is fast diluted to avoid a high local
concentration of denatured protein and the formation of instable folding
intermediates.
• Temperature. The temperature significantly influences the refolding rate.
• pH. The pH defines the protein charge. At its isoelectric point, the protein is
minimal soluble and preferentially aggregates. A neutral to alkaline pH enables
rapid disulfide bridge formation while an acidic pH inhibits disulfide pairing.57
• Time. The time for refolding varies from seconds to days. The oxidative refolding
often requires longer periods of up to weeks.
• Folding enhancers: Folding enhancers are low molecular weight additives, which
interfere with protein refolding mainly by slight destabilization: i.e. denaturants in
subdenaturing concentrations, glycerol, metal ions if proteins contain cofactors in
the native state and ligands to destabilize folding intermediates and stabilize native
folded protein. In oxidative refolding of Cys-containing proteins, a thiol-active
redox-system, mostly reduced and oxidized glutathione enable reshuffling of
misspaired Cys and facilitate the formation of correct disulfide bridges. In the S-S
reshuffling, glutathione interacts in a first stage with one Cys thiol group of the
protein to form a mixed disulfide and in a second stage, the mixed disulfide reacts
with a second Cys thiol group of the protein to form a disulfide bond.58 In proteins
with multiple disulfide bonds, the number of possible combinations for S-S bonds
pairing increases rapidly: e.g. with 7 Cys, 48 folding intermediates may be formed.
Refolding of solubilized inclusion bodies is mostly performed by dilution and dialysis or
gel filtration. During dialysis, solubilizing agents are slowly removed and simultaneously,
stable conformational intermediates are formed, which are finally converted into the
native and active protein.
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1.2 The antibodies – structure, feature and production
The antibodies, also called immunoglobulins are glycoproteins, which have all the same
basic structure but exhibit highly diverse binding specificities.
1.2.1 Antibody structure
The antibody structure (see Figure 4) can be described from a molecular or functional
point of view.
Molecular antibody structure
The basic Y-shaped antibody molecule is composed of two identical heavy (H) and two
identical light (L) chains, those are held together by inter-chain disulfide bonds and non-
covalent interactions. The chains can be divided into two main regions, based on the
variability of their amino acid sequence: the constant (C) and the variable (V) region. The
regions are formed by one to four globular domains of about 110 amino acid residues,
which all include an intra-chain disulfide bond.
The light chain (23kDa) contains one N-terminal V domain (VL) and one C-terminal C
domain (CL). The heavy chain (50-70kDa) is composed of one N-terminal V domain (VH)
but of three or four C-terminal C domains (CH1-4).
The primary structure of the V domain is fold to four ?-strands of framework regions
(FR1-4), which enclose three loops of hypervariable complementarity-determining
regions (CDR1-3).
Each CDR consists of 5 to 10 highly variable amino acid residues. However, all except
CDR3 of the H chains exhibit one out of few main chain conformations, which are
designated canonical structures. The framework regions contain conserved amino acid
residues and form the backbone of the CDR1-3.
Functional antibody structure
The basic antibody can be divided into two major functional regions, the fragments
having the antigen binding site (Fab) and the fragment that crystallize (Fc). A hinge
region connects the two identical Fab regions to one Fc region.
The variable monovalent Fab region is composed of the aligned N-terminal domains of
one H and one L chain. Within the Fab region, the VL and VH form together the variable
fragment Fv and a disulfide bond pairs the CL and CH1. The Fab provides the antigen
binding and the specificity.
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The flexible hinge region allows lateral and rotational movement of the Fab, which is
important for binding to the antigen. The hinge region links the two heavy chains with
disulfide bridges. The number of S-S bonds and the length of the hinge region define the
degree of flexibility.
The constant Fc region is formed by the associated C-terminal domains of the two H
chains, i.e. CH2, CH3 (and CH4), and exhibits various effector functions.
Depending on the class, antibodies differ in their effector functions: i.e. the fixation and
activation of complement, the binding to Fc receptors on macrophages, which promote
phagocytosis, or the interaction with Fc receptors on lymphocytes and natural killer cells,
which induce cytotoxicity (see following section).
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Figure 4: Basic antibody structure. The functional structure is divided into the fragments, which the antigen
(Fab), the fragment, that crystallizes (Fc) and the hinge region. S-S bonds (—) and sugar (hexagon).
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Antibody classes and subclasses
Based on the primary structure (gene sequence) of the CH, antibodies can be grouped
into various classes and subclasses (isotypes). Different species express a distinct set of
isotypes. Mammalian murine antibodies are classified into IgM, IgG, IgA, IgD and IgE
immunoglobulins, which differ in their H chain isotypes of μ, ?, ?, ? and ?, respectively.
The IgG are further subdivided into IgG1, IgG2a, IgG2b and IgG3 subclasses. In
contrast, avian chicken antibodies are grouped into IgM, IgY and IgB, having a μ, ? or ?
H chain isotype. IgY and IgB are also called chicken IgG and IgA.
The classes vary mainly in the number of CH and in the number and position of disulfide
bridges and glycosylations (see Figure 5 and Table 2). IgM, IgG and IgY are N-
glycosylated at CH2 in the Fc. Some are also reported to carry N-linked glycosylations in
the Fv, which may interfere with the antigen binding.59 In contrast to the glycosylations of
the Fc, the Fv carbohydrate chains are at the surface of the antibody and are accessible
to lectin binding.60
The L chain is of the types ? or ? for mammals and only of the type L for avian.
IgM
IgG1, IgG2
IgG3
IgY
Figure 5: Murine IgM, murine IgG and chicken IgY structure.
IgM
The secreted pentameric IgM molecule (900kDa) is decavalent. It contains an additional
J chain (15kDa), which is responsible for oligomerization of the extra CH4 domains and is
N-glycosylated at CH2. Generally, the IgM is the typical antibody of the primary
response, which does not undergo affinity maturation and therefore binds with low
affinity but high avidity.
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The secreted IgM antibody in the serum can fix complement and agglutinate antigen but
cannot cross the placenta.
IgG
The monomeric IgG molecule (150kDa) is divalent and N-glycosylated at Asn297 in the
CH2. The IgG subclasses mainly vary in the number of S-S bonds and the length of the
hinge region. Generally, the IgG antibody binds the antigen with high affinity as it is the
typical antibody of the secondary immune response and therefore is maturated.
The IgG comprises the major antibody in the serum. It can cross the placenta, can fix the
complement and bind to the Fc receptors on macrophages, monocytes and some
lymphocytes.
IgY
The monomeric IgY molecule (180kDa) is divalent, includes additional CH4 domains but
lacks the hinge region and therefore is less flexible than IgG. In addition to the CH2
domain, also CH3 is N-glycosylated.
61
The IgY is the main serum antibody and the only yolk antibody. In contrast to IgG and
IgM, it can neither activate complement nor bind to mammalian Fc receptors.62,63
The avian IgY is suggested to be the phylogenetically progenitor of mammalian IgG and
IgE.64
Table 2: Characteristics and features of the different antibody classes of mice and chicken.65,66,67,68
IgM IgG IgY
MW 900kDa 150kDa 180kDa
Heavy chain 80kDa 55kDa 65 – 67kDa
μ ? ?
Light chain 25kDa 25kDa 23 – 25kDa
? or ? ? or ? L
(μ2?2)5 or (μ2?2)5 ?2?2 or ?2?2 ?2L2
Valency 10 2 2
Carbohydrate 12% 3%
Hexose 5% 1% 2.2%
Cell Immature B Mature B
Function Primary response Secondary response Secondary response
Complement activation Strong Medium No
Fc receptor binding Yes Yes No
Protein A and G binding No Yes No
Protein L binding Yes Yes Yes†
Papain digest 2 Fab + Fc 2 Fab + Fc
Pepsin digest F(ab)2 + Fc 2 Fab + Fc
Isoelectric point 7.8 6.8
Acidic stability Low High
Heat stability Low High
†: Depending on literature
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1.2.2 Immune response – the avian and mammalian humoral immune
system
Birds and mammals divided more than 300 million years ago. Although, their cellular and
humoral immune systems and immunoglobulins are not identical, they exhibit many
analogies. The avian immunoglobulin classes IgM, IgY and IgB exhibit similar functions
to the mammalian IgM, IgG/E and IgA, but differ in the structure. However, the important
mechanism, which is responsible for antibody diversity differs significantly. In mammals,
diversity is introduced by gene recombinations and somatic mutations, whereas in avian,
diversity originates from gene conversions.
B-lymphocytes arise from progenitor stem cells in the mammalian bone marrow or in the
avian bursa of fabricius. In these primary lymphoid organs, the antigen-independent
gene rearrangement takes place, followed by the antigen-dependent clonal selection in
the mammalian secondary lymphoid organs, the spleen and lymph nodes, or in the
bursa of fabricius again, as birds have no lymph nodes.
1.2.2.1 Antibody diversity
Antigen-independent gene recombination of mammals
Mammalian progenitor germline DNA encodes different variable (V), joining (J) gene
segments for L chains and in addition different diversity (D) gene segments for H chains.
During differentiation of B-cells, one V and one J gene segment recombine and arrange
with the C region to form the functional VJC gene of the L chain. In addition one D, one J
and one V gene segment recombine and arrange with the C region to form the functional
VDJC of the H chain. The variability is further increased, due to imprecise DNA
recombination, which introduces random nucleotides at the recombination sites of V, D
and J gene segments, and due to point mutation in the recombined gene. The random
association of these different H and L chains allows the production of about 1012 distinct
antigen binding sites (see Figure 6).69
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Figure 6: Gene rearrangement of the murine light and heavy chain and class switching of the heavy chain.
? Gene segment recombination (first ?1 and second ?2), ? Point mutation and random nucleotide insertion.
Antigen-independent gene conversion of birds
In avian progenitor stem cells, the antibody repertoire is developed by a distinct
strategy.70 Avian DNA only encodes one single V and J gene segment, but additionally
several pseudo V gene segments. The V and J gene segment recombines to the
functional VJC gene and creates only limited diversity by imprecise DNA recombination
at the recombination site of the V and J gene segments. In the following gene
conversion, the variability is further increased by exchange of various V gene segments
with pseudo V gene segments and by point mutations (see Figure 7).
L Chain rearrangement
? V-JC recombination
Functional L gene
Converted functional L gene
? Gene conversion
25 Vpseudo 1 J 1 C1 V
Figure 7: Gene rearrangement of the chicken light chain.
The different mechanisms of the antibody repertoire formation in birds compared to
mammals, result in antibodies of distinct characteristics.
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1.2.2.2 Clonal selection
The first exposure to an antigen induces a relatively weak primary immune response.
The exposed antigen binds to specific surface immunoglobulins on B-cells. After
internalization and processing, antigen fragments are bound to the major
histocompatibility complex II (MHCII) and are presented to helper T-cells. The interaction
of the T-cell receptor on helper T-cells, and the antigen-MHCII complex on B-cells is
essential. It stimulates the differentiation and proliferation of B-cells to plasma and
memory cells. The plasma cells only live 3 to 4 days. They are responsible for antibody
secretion and are essential for the first immune response. The long-living memory cells
on the other hand, do not secret antibodies but are inevitable for promotion of a strong
and fast secondary immune response after reexposure to the antigen.
Because surface B-cell receptors and secreted antibodies express the same antigen
binding site, only antigen-specific B-cell clones are selected. Their proliferation is
accompanied by hypermutation of V regions, which allows affinity maturation, and by the
class switching.
The hypermutation of V regions leads to B-cells with different antigen affinities. The
cells, which exhibit higher affinity compared to the original B-cell, were preferentially
selected for proliferation.
The class shifting does not contribute to diversity, but allows adapting the antibodies to
different effector functions during immune response. Another type of CH gene is
recombined with the same VH gene.
Hence, in the primary immune response, IgM are most abundant. In the secondary
response, affinity-matured mammalian IgG or avian IgY predominate.71
1.2.3 Antigen-antibody interface
The antibody recognizes not the entire antigen. Only the antigen combining site is in
close contact with the antigenic site of the antigen.
1.2.3.1 Antigenic site and antigen combining site
The antigenic site of the antigen and the antigen combining site of the antibody are
designated epitope and paratope, respectively.
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Epitope
The antigenic sites are areas at the antigen surface and are called (structural) epitopes.
Depending on the epitope architecture, the epitopes are grouped to continuous or
discontinuous epitopes. Continuous epitopes are also designated linear or sequential
epitopes and consist of a coherent part of the primary sequence. Discontinuous epitopes
are also called assembled and conformational epitopes and contain amino acid
residues, which are separated in the primary sequence, but brought to close proximity in
the folded antigen.
The borderline between discontinuous and continuous epitopes however is fluent.
Discontinuous epitopes usually contain several continuous stretches of a few contiguous
residues and conversely, continuous epitopes tend to include a number of indifferent
residues, that are not involved in the binding interaction.72 90% of the structural epitopes
on the surface of a native antigen are suggested to be mainly discontinuous.72
Paratope
The six CDR of the VL and VH those are aligned in the Fv form the antigen combining
site. The CDR1-3 of L chain and the CDR1-2 of the H chain, which are encoded by the V
and J gene segments, accept a small number of main chain conformations, i.e. the
canonical structures. In contrast, the CDR3 of the H chain is mainly encoded by the D
gene segment and folded to various different conformations (see Figure 8).
The specificity and affinity of the antigen binding site to the antigen mostly depend on
the canonical structure, the size and polarity of the amino acid residues at the surface
and on the relative position of the six CRD.73,74 Especially the CDR3 of the H chain
contributes to binding.75
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Figure 8: Encoding of the heavy and light chain amino acid sequences. V and J gene segments of the light
chain encode CDR 1-3. The V gene segment of the heavy chain encodes CDR1-2 and mainly gene
segment D, but also J encodes CDR3. Inter-chain S-S bonds enclose CDR1 and CDR2 of the heavy and the
light chain, respectively.
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Epitope-paratope interaction
The interaction of the epitope and the paratope induces conformational changes to
optimize the complementarity in shape and charge. Their contacting surface is about
600-900Å2 and is formed by 15 to 20 amino acid resides of the structural epitope and the
paratope.75 Thereof, only 3 to 5 residues significantly contribute to binding. These are
designated functional epitope and paratope.
The binding is mainly mediated by Van der Waals interactions and hydrogen bonds, but
less by salt bridges or hydrophobic interactions.75 Hence, epitopes contain amino acids
His, Lys, Ala, Leu, Asp and Arg with high frequency.76
The antibody affinities range from KD 10
-5-10-12M. The higher affine antibodies of the
second immune response often comprise affinities of KD ? 10-7M. The antibody avidity is
the overall stability of the antibody-antigen complex and depends on the antibody affinity
as well as on the antibody and antigen valency.65
1.2.3.2 Antigenicity and immunogenicity
The immunogenicity refers to the ability to elicit an immune response, whereas the
antigenicity refers to the ability to be recognized by the product of an immune response,
i.e. T-cell receptor, B-cell receptor and antibody.
Factors, intrinsic to the antigen, define the antigenicity of the epitopes. But, which of
these antigenic sites are immunogenic depends on factors extrinsic to the antigen, the
host species-defined factors.76
Intrinsic factors
The properties, intrinsic to the antigen are the accessibility, the hydrophilicity and the
mobility.
The accessibility of surface amino acid residues may be hindered by posttranslational
modifications, i.e. glycosylations. The hydrophilicity and polarity of amino acid residues
in the epitope has to be complementary to the paratope to allow hydrogen bonding and
Van der Waals contacts. The flexibility and segmental mobility, e.g. high in loops, may
be essential to achieve optimal epitope-paratope complementarity.
In the prediction of epitopes, most algorithms only consider intrinsic factors. Hence, they
are based on the physicochemical properties of amino acids in the primary sequence
and therefore only permit to predict continuous epitopes.76
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Putative epitopes must span a part of the surface to be accessible. Therefore, they
mainly include hydrophilic amino acid residues. Hopp and Woods77 suggested, that
antigenic sites could be predicted from the primary sequence by determination of the
most hydrophilic part of the sequence. Since a functional epitope often spans 3 to 5
amino acid residues, the antigenicity algorithm of Hopp and Woods averages the
hydrophilicity parameters for overlapping segments of six amino acid residues. Parker et
al.78 used a modified hydrophilic scale. Fraga 79 extended this approach by considering
recognition factors. They reflect the probability, that hydrophilic amino acids may interact
with one another and therefore may be buried in the protein, despite to be hydrophilic.
The antigenicity algorithm of Welling et al.80 is based on the property of amino acid
residues to be recognized by antibodies. An antigenicity scale was derived statistically
from known epitopes. The antigenic potential is highest for Leu, followed by His, Asp,
Thr and Ala, but low for Cys, Asn, Gly, Met and Phe and lowest for Ile.
Most often, the algorithms of Hopp and Woods, and of Kyte and Doolittle are used.81
Extrinsic factors
As mentioned before, only some of all antigenic sites will be immunogenic due to
properties, extrinsic to the antigen, i.e. the self-tolerance, the set of MHCII and T-B
reciprocity.
Antigens, that are highly homologous to a protein of the host species initiate self-
tolerance. However in another species, the same antigen may be immunogenic.
Each individual has another set of MHCII. Rarely, an individual may lack an MHCII for
the antigen. This is more frequent in inbred strains, which all have the same MHCII set,
than in outbred strains.
To initiate an immune response, an antigen must provide three different binding sites:
the B-cell epitope, the MHCII binding site and the T-cell epitope. As a consequence, the
antigen must have a minimal size of 3 – 5kDa to be immunogenic.
First, a B-cell epitope must be accessible for binding to the B-cell receptor. After antigen
phagocytosis, processing and migration to the B-cell surface, the antigen fragment(s)
must furthermore have a binding site for MHCII to allow antigen presentation to helper T-
cells. Finally, the MHCII-bound antigen fragment must provide a T-cell epitope, which
can simultaneously be recognized by the T-cell receptor to promote cell-to-cell
communication between B-cells and helper T-cells.
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The intrinsic factors have to be considered for the antigen selection, to use entire
antigen protein, protein fragment or modified antigen. The extrinsic factors influence the
antibody production, i.e. the selection of the host animal and the dose for immunization
(see Section 1.2.4.1.1).
1.2.4 Production of monoclonal and polyclonal antibodies
The production of monoclonal antibodies consists of three stages: the immunization, to
stimulate antigen specific B-cells in vivo, the selection of immortalized antigen-specific
B-cell clones in vitro and the propagation of selected B-cell clone in vitro, followed by
isolation of antibodies from supernatant.
In contrast, the production of polyclonal antibodies is only composed of one stage: the
immunization in vivo, directly followed by isolation of antibodies from collected sera or
egg yolks. As a consequence, polyclonal and monoclonal antibodies have distinct
characteristics:
Polyclonal antibodies are produced from various distinct plasma cell clones. Each
provides an antibody, specific to one single epitope. Therefore, polyclonal antibodies are
a mixture of various antibodies and antibody classes, directed against distinct epitopes.
Since the monoclonal antibody production includes an in vitro clone selection step,
identical monoclonal antibodies are secreted from one single clone. They are
homogenous, specific to one single epitope and exhibit defined affinity and specificity.
Another important feature is, that monoclonal antibody-secreting clones provide an
infinite antibody source, whereas polyclonal antibodies are limited.
1.2.4.1 Monoclonal antibody production
Monoclonal antibodies are produced by the phage and ribosome technology or
classically by the hybridomas technology from Köhler and Milstein.82
Hybridoma expression systems are advantageous for the production of antibodies,
because myeloma cells are professional immunoglobulin-secreting cells and are able to
make posttranslational modifications. Proper glycosylations are important for the
antibody function83.
1.2.4.1.1 In vivo stage  - the immunization
The immunization is only successful, if the antigen is immunogenic. The immunogenicity
depends on factors intrinsic and extrinsic to the antigen (see Section 1.2.3.2). These
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factors can be modulated by selection of species, antigen dose and form, injection site
and adjuvant:65
• Host species. For monoclonal antibodies, mice are still the standard species.
Mainly inbred strains like Balb/c are chosen, but in case of low response, other
strains, particularly outbred strains, like NMRI mice, may be of advantage.
• Antigen dose. The dose must lie within the immunogenic window. Lower, but also
higher doses, may induce tolerance. The dose is commonly 5 – 50?g/injection
and should not exceed 500?g/injection for mice.
• Antigen form. Particular antigens are much stronger immunogens than soluble
molecules. The aggregation of proteins or the coupling to carrier proteins may
therefore enhance the immune response.
• Injection route. Subcutaneous (sc) and intraperitoneal (ip) injections are
commonly used for immunization and boost of mice with soluble or particulate
immunogen with adjuvant. Final boost however should be applied intravenous
(iv) without adjuvant to induce a short-lived strong response.
• Adjuvant. They are unspecific stimulators of the immune response that ensure a
strong, memory-enhanced immune response. Most adjuvants are composed of
two components, one for sustained antigen release and the other to recruit
antigen-presenting cells to the injection site. The Incomplete Freund’s adjuvant
includes unmetabolizable mineral oil i.e. croton oil, that forms a stable water-in-oil
emulsion with the aqueous antigen solution, and prolongs the immune response.
The Complete Freund’s adjuvant additionally contains heat-inactivated
Mycobacteria tuberculosis or butyricum, which induce local inflammation.
Mice are primed but also boosted to promote affinity maturation and class switch to IgG.
A final boost about three days prior to fusion synchronizes maturation and increases
portion of antigen-specific B-cells in the spleen.
1.2.4.1.2 In vitro stage – the somatic hybridization and clonal selection
The hybridoma technology of Köhler G. and Milstein C.82 allows the infinite growth of
antibody-secreting cells. The main steps to achieve the desired, stable hybridomas are:
the PEG fusion of myeloma cells and splenocytes, the drug selection of hybrid cells
(hybridomas), the screening for desired hybridomas and their cloning (see Figure 9).
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The B lymphoblastic myeloma cells provide the correct genes for continuous cell division
in culture and are gene defective, for selection; e.g. the P3-X63Ag8.653 myeloma cell
line, which is derived from Balb/c mice, lacks the ability to produce immunoglobulins and
is 8-azaguanine resistant. The antibody-secreting B-cells contribute the functional
rearranged immunoglobulin genes for production of an antibody with defined specificity.
PEG fusion “myeloma cells + splenocytes = fusion cells”
Splenocytes and myeloma cells are fused with the help of polyethylene glycol (PEG,
OH(CH2CH2O)nH). The PEG destabilizes the plasma membranes and allows adjacent
cells to combine to a single cell with two or more nuclei. However generally, only about
1% of all cells are fused and only 0.001% form viable hybrids. The hybridomas are
instable due to the abnormal number of chromosomes. During cell division, the
chromosomes are not equally segregated and up to 40% may be lost, including the gene
that encodes the functional rearranged immunoglobulin.
The propagation of the delicate hybridoma cells can either be stimulated with feeder-
cells or with conditioned medium, containing proliferation-stimulating factors, e.g. growth
factors and IL-6. The feeder-cells, commonly splenocytes, macrophages or T-
lymphocytes, provide growth factors and increase the cell density.
Drug selection “fusion cells – (splenocytes + myeloma cells) = hybridomas”
After fusion, (un)fused mortal splenocytes, (un)fused immortal myeloma cells or fused
immortal hybridomas cells are mixed. Splenocytes die after three to four days, but
myeloma cells have to be killed to select the hybridomas.
The 8-azaguanine resistant myeloma cells are hypoxanthine-guanine phosphoribosyl-
transferase (HPRT) mutants. The HPRT enzyme catalyzes the condensation of
phosphoribosyl-pyrophosphate and a purine base to form a purine monophosphate
nucleotide, in the nucleotide salvage pathway. As a consequence, myeloma cells can
only provide nucleotides by the de novo pathway.
The myelomas die in HAT (hypoxanthine, aminopterine and thymidine) containing
medium. The aminopterine hampers the de novo synthesis of pyrimidines directly and of
purines indirectly. Hybridomas have the mutated HPRT gene of myeloma cells, but also
the functional HPRT gene of the splenocytes. Hence, they can provide nucleotides by
the salvage pathway in the presence of thymidine and hypoxanthine precursors.
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Figure 9: PEG fusion of antibody-producing splenocytes and HPRT-defective myeloma cells, followed by
HAT selection of hybridomas.
Hybridoma screening
Normally 500 to 1’000 hybridomas are obtained from one fusion and thereof, about 90%
are positive in screen.
The hybridoma screening is of main importance, because it determines the hybridomas,
which are further expanded and cloned. Hence, the screening assay must be fast to
allow testing of all hybridomas in a short time, but most crucial, must be selective for the
desired antibody feature. Common assay types are the antigen-capturing ELISA and the
antibody-capturing ELISA, but also functional assays are applied.
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Single-cell cloning by limited dilution
A specific antibody-secreting hybridoma can either be a single clone or a mixture of
different hybridoma clones, which produce distinct antigen-specific or irrelevant
antibodies or even no antibodies. Such hybridomas are separated in single-cell cloning
by limited dilution (see Figure 10). In limited dilution, cells are diluted to concentrations of
1 cell/well culture or less. To keep such diluted and isolated cells viable, small culture
volumes and feeder layers or conditioned medium with proliferation-stimulating factors
are essential.
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Figure 10: Single-cell cloning by limited dilution.
Single-cell cloning also allows the selection of more stable clones or of clones, which
secrete a switched isotype of the antibody.
1.2.4.1.3 Propagation of hybridoma clones – the “antibody factories”
In the past, monoclonal antibodies were produced in vivo by injection of hybridoma
clones into the peritoneal cavity of mice, but nowadays, they are obtained from in vitro
hybridoma clone cultures. The secreted monoclonal antibodies are then simply
harvested from culture supernatant.
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1.2.4.2 Polyclonal antibody production
Polyclonal antibodies are commonly produced in mammals like rabbits, goats, sheep
and mice, but seldom in chicken. In 1980, IgY antibodies from egg yolk were for the first
time used as a source of polyclonal antibodies, by Polson et al.84
As chicken is phylogenetically more distant to mammals, the production and the features
of polyclonal IgY differ in some aspects from polyclonal IgG:
• Immunogenicity. Highly conserved mammalian antigens may be immunogenic in
chicken but not in mammals.
• Epitope recognition. Chicken antibodies may recognize other epitope structures
than mammalian, resulting in antibodies with distinct specificities.85.
• Antibody collection. Chicken egg collection is non-invasive, whereas mammalian
bleeding is invasive.85
• Rheumatoid factors and complement. Chicken antibodies do neither interact with
mammalian rheumatoid factors nor activate mammalian complement system.
This is advantageous in some immunoassays.62,86
• Protein A and G. Chicken antibodies do neither interact with Protein A nor G87,88.
The binding to Protein L is controversial discussed.
• Yield. The monthly amount of polyclonal IgY produced from one hen is about ten
times the yield obtained from the bleeding of one rabbit in the same period.
The majority of these differences are a plus for IgY.
IgY are successfully applied in various immunochemical techniques, e.g. in
immunoblotting, immunoprecipitation,89 immunoassay, immunohistochemistry 90 and
Biacore assay.91
1.2.4.2.1 In vivo stage – from immunization to antibodies in the egg yolk
The successful immunization of chicken, which initiates a long-lasting immune response,
depends on the same factors as valid for mammals (see Section 1.2.4.1.1). The antigen
needs a minimal molecular weight of at least 5 – 10kDa to be immunogenic. Generally,
100 – 250?g antigen with adjuvant are injected intramuscularly or subcutaneously.92
About 16 days after immunization, antigen-specific IgY antibodies appear in the serum
and 3 to 4 days later in the yolk. Within following 10 days, they reach peak concentration
and remain high for at least 70 days, without further boosting.85
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In the ovary, IgY antibodies are selectively and actively transported from hen circulation
to the yolk.93 The yolk is surrounded by the vitellin membrane, passes down the oviduct,
where the egg white, that contains ovalbumin-bound IgM and IgB, is secreted, and is
finally wrapped by the shell membrane and the shell. Hence, the egg yolk only contains
IgY but no IgM or IgB. This is an important advantage for the isolation of IgY antibodies.
1.2.4.2.2 In vitro stage – the isolation of IgY antibodies from eggs
The standard purification method for mammalian IgG antibodies is by affinity to Protein A
or G, but chicken IgY antibodies bind to none.94 Until now, no standard method is
established for avian IgY extraction. But most of reported methods follow a common
multi-step strategy, which is the consequence of the egg composition (see Figure 11).
Egg composition
The yolk is an oil-in-water emulsion, which is formed by 33% oily yolk granules and 66%
watery phase. Latter is composed of 48% water, 17% proteins and 1% carbohydrates.
The yolk proteins belong mainly to four groups: 47% vitellin-lipovitellin (400kDa), 39%
vitellelin, 10% livetin and 4% phosvitin (36kDa). The livetins comprise the ?-globulin like
IgY (180kDa), the albumin-like ?-livetin (54kDa) and the ?2-glycoprotein-like ?-livetin.
The concentration of total and specific IgY in the yolk and the serum are similar. One
yolk contains about 6mg total IgY, and 2 to 10% of total IgY antibodies are antigen-
specific IgY.92
IgY extraction methods
The majority of reported IgY purification procedures follow a multi-step strategy,
composed of precipitation steps and of chromatographic steps. They vary substantially
in yield, purity and biological affinity of IgY, but can hardly be compared in literature.
In a typical IgY extraction, egg white and egg yolk are separated first, to avoid the
contamination of yolk with IgB and IgM from egg white. After removal of yolk lipids, the
total IgY, which contain the antigen-specific and irrelevant IgY, are extracted. Depending
on the application, the antigen-specific IgY must be isolated (see Figure 12).
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Figure 11: Extraction of specific IgY from egg yolk. ? Separation of the egg white and yolk; ? Removal of
lipids to get the total proteins; ? Extraction of the total IgY from the total proteins; ? Isolation of the specific
IgY from the total IgY.
Lipids are mainly precipitated with salts (ammonium sulfate,95 dextran sulfate, 96 PEG 97)
or extracted with organic solvent97,98. Two other simple but effective methods are
reported by Jensenius et al.96 and by Atika et al.99, the repeated freeze / thaw and the
water dilution method.
After removal of disturbing lipids, the total IgY can efficiently be salt,96 or PEG84,100
precipitated or are chromatographically purified by gel filtration, by ion exchange on
MonoQ and DEAE,85 or by thiophilic interaction chromatography on T-gel.101
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1.3 Application of antibodies in immunochemical techniques
The application of an antibody in different immunochemical methods allows the
characterization of the antigen and antibody as well as the comparison of distinct
antibodies, directed against the same antigen.
Monoclonal antibodies may exhibit technique restrictions and must be validated for each
method. Five major factors determine the success of an antibody in an immunochemical
technique: the avidity and the specificity for the antigen, the alteration of the epitope, the
antigen accessibility and in indirect methods the quality of secondary reagents.
• Avidity. The avidity is mainly defined by the antibody affinity and valency but also
influenced by the local epitope concentration. Avidity effects arise, when several
distinct antibodies can simultaneously bind to an antigen, when one antibody can
simultaneously bind multiple identical epitopes on a homooligomeric antigen and
when one antibody can bridge two adjacent fixed monomeric antigens.
• Specificity. The specificity of antibodies, directed against denaturation-sensitive
epitopes is often higher. Antibodies, which recognize denaturation-resistant
epitopes, are more susceptible to cross-react with related epitopes of irrelevant
proteins.
• Epitope alteration. The immunochemical preparation procedure may alter the
epitope structure, mainly due to denaturation of the native structure and due to
chemical modification of amino acid residues in cell and tissue fixation.
• Epitope accessibility. The presence of competing molecules, the posttranslational
antigen modification and the antigen orientation on the cell or in the tissue
influence the access of antibodies to their epitope.
The detection can either be direct or indirect. In direct methods, the purified antigen-
specific antibody is labeled and directly binds to the antigen. In indirect methods, the
binding of unlabeled pure or crude antigen-specific primary antibody is detected with a
labeled secondary anti-Ig antibody.
Although the indirect detection includes an additional step, it is commonly favored,
because the signal amplification increases sensitivity and because the purification and
labeling of the antigen-specific antibody can be circumvented.
In the following sections, the different immunochemical techniques, which were applied
for the characterization of the monoclonal and polyclonal antibodies, are described.
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1.3.1 Immunoblotting
The immunoblotting allows to investigate antigen features and to characterize
antibodies. The antigen is not only identified due to interaction with the specific antibody
but also due to its molecular weight. The method is quite sensitive, especially in
combination with immunoprecipitation.65
In immunoblotting, the antigen-containing (crude) proteins are separated by denaturing
SDS-PAGE or native PAGE, and protein bands are blotted to a membrane. Following
blocking of unoccupied binding sites on the membrane, antigen is captured with an
antigen-specific enzyme-labeled or unlabeled antibody. Unlabeled antibody is in an
additional step detected with the enzyme-labeled anti-Ig-specific antibody. The antigen-
antibody complex is finally localized by the enzyme-catalyzed conversion of a colorless
substrate to the colored chromogen precipitate (see Figure 12).
? ? ? ?
Figure 12: Indirect immunoblotting. ? Separation of the antigen-containing proteins by denaturing SDS
PAGE or native PAGE ? Blotting of proteins onto the membrane ? Antigen capturing with the antigen-
specific primary antibody ? Detection of the primary antibody with the enzyme-labeled secondary antibody
? Signal development by the enzyme-catalyzed conversion of the soluble colorless chromogen to an
insoluble colored chromogen.
For most application, the indirect detection with an enzyme-labeled anti-Ig-specific
antibody is best.
In immunoblotting, the native antigen is denatured or may change conformation and
therefore, the binding of antibodies to denaturation-sensitive epitopes is hindered. A high
local antigen concentration on the blot enables avidity effects and permits even low-
affine antibodies to bind.
The sensitivity of immunoblotting, using polyclonal antibodies is high, but background
may be strong too. Monoclonal antibodies may fail due to epitope denaturation, but may
also cross-react due to strong avidity. Therefore, mostly pooled distinct monoclonal
antibodies or affinity-purified polyclonal antibodies work best.
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1.3.2 Immunoassay
The immunoassay permits to explore antigens and antibodies qualitatively and
quantitatively.102
The three main classes of immunoassays are the antibody-capture, the antigen-capture
and the antibody-sandwich assay, which are applied in innumerable variations.
The antibody-capture assay is often used to determine the antibody and antigen
presence and level (hybridomas screening, antibody, serum titer determination), to
determine antibody isotypes and to compare epitopes. Furthermore, the indirect
antibody-capture assay permits to estimate the affinity or avidity, which is defined as the
concentration of antibody required for half maximal binding.
In an antibody-capture immunoassay, the antigen is attached to the solid support. After
blocking of remaining free binding sites on the solid support, the antigen-specific
enzyme-labeled or unlabeled antibody is captured by the antigen. In an additional step,
unlabeled antibody is detected with the enzyme-labeled anti-Ig antibody. The presence
of the antigen-antibody complex is finally visualized and quantified, after enzymatic
conversion of the colorless substrate to the soluble colored chromogen (see Figure 13).
Figure 13: Indirect antibody-capture immunoassay ? Immobilization of antigen on the solid support and
blocking of remaining binding sites ? Capturing of the antigen-specific antibody ? Detection of the primary
antibody with enzyme-labeled anti-Ig-specific antibody ? Signal development by the enzyme-catalyzed
conversion of the soluble colorless substrate to the soluble colored chromogen.
The sensitivity is mainly affected by the amount of the antigen, bound to the solid
support, the avidity and specificity of the antibody and the type of labeling. The increase
of local antigen concentration and consequently of avidity effects, allows low-affine
antibodies to bind. The immobilization may change the conformation of native antigen.
For most application, the indirect detection with enzyme-labeled anti-Ig antibody is
sufficient.
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In a competition antibody-capture immunoassay, the capacity of an antibody to inhibit
binding of another antibody or a ligand can be determined. If they recognize identical,
overlapping or adjacent but sterically interfering epitopes, they compete for binding.
In the direct competitive GalNAc-polymer immunoassay by Stokmaier103 the antigen is
immobilized on the solid support and unoccupied binding sites are blocked. The antigen-
specific antibody competes with the enzyme-labeled GalNAc-polymer for binding to the
antigen. Finally, antigen-bound GalNAc-polymer is quantified by enzymatic conversion of
the soluble colorless substrate to the soluble colored product (see Figure 14).
Figure 14: Direct competitive antibody-capture immunoassay. ? Immobilization of antigen on the solid
support ? Competition of the enzyme-labeled GalNAc-polymer with the antigen-specific antibody for binding
to the antigen ? Detection of the enzyme-catalyzed conversion of the soluble colorless substrate to the
soluble colored chromogen.
In these immunoassays, avidity-dependent constants but no absolute affinity-defined
constants of the antibodies are determined. But they are suitable for the ranking of
antibodies of the same isotype.
In the antigen-capture assay, the antigen-specific antibody is bound to the solid support
and the antigen caught. In the sandwich assay, the antigen, bound to the immobilized
antigen-specific antibody is additionally detected with a distinct labeled antigen-specific
antibody.
The sensitivity of the immunoassay, using polyclonal antibodies, is often low and the
background high. Monoclonal antibodies work excellent, but rarely fail due to epitope
denaturation and a too low avidity. The applicability of affinity-purified polyclonal
antibodies or of pooled distinct monoclonal antibodies is excellent.
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1.3.3 Immunocytochemistry
Immunostaining of cells can be used to pinpoint the subcellular localization of an antigen
and to follow its change in response to stimuli.65
The two main classes of staining are the intracellular staining of cellular or internalized
antigens and the extracellular staining of surface antigens. There exist a panel of
variants, which mainly differ in the need of cell fixation and permeabilization to preserve
cell architecture.
In the extracellular immunostaining of surface antigen, EGTA-detached adherent cells
and suspension cells are prepared and optionally fixed. The surface antigen is captured
with antigen-specific fluorochrome-labeled or unlabeled antibody. Unlabeled antibody is
detected with fluorochrome-labeled anti-Ig-specific antibody. The antigen-antibody
complex is finally visualized by fluorescence microscopy or quantified by flow cytometry
(see Figure 15).
Figure 15: Indirect extracellular immunofluorescence staining of surface antigen. ? Detachment of adherent
cells and optionally fixation of suspension and adherent cells ? Capturing of surface antigen with the
antigen-specific antibody ? Detection of the antigen-specific antibody with the fluorochrome-labeled anti-Ig
antibody ? Quantification of the fluorescent antigen-antibody complexes by flow cytofluorimetry.
Flow cytofluorimetry provides a statistical profile of the cell population and allows
distinguishing cell subpopulations.
In the intracellular immunofluorescence staining of endocytosed antibody-antigen
complex, the EGTA-detached adherent cells and suspension cells are prepared first.
The surface antigen is captured with the fluorochrome-labeled or unlabeled antigen-
specific antibody. Following internalization of the antigen-antibody complex, cells are
fixed. Unlabeled antigen-specific antibody is detected with fluorochrome-labeled anti-Ig-
specific antibody after cell permeabilization. The fluorescent label is finally visualized by
fluorescence microscopy (see Figure 16).
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Figure 16: Indirect intracellular immunofluorescencence staining of the internalized antigen-antibody
complex ? Preparation of suspension and EGTA-detached adherent cells ? Antigen capturing with the
antigen-specific antibody and internalization of the antigen-antibody complex ? Cell fixation and
permeabilization ? Detection of the antigen-specific antibody with fluorochrome-labeled anti-Ig antibody ?
Visualization of fluorescent label by fluorescence microscopy.
The major determinants of the cell immunostaining are the local antigen concentration,
the epitope accessibility and, if cells are fixed, the epitope alteration and masking.
The cell fixation prevents antigen leakage and maintains the cell structure, but can alter
the epitope and therefore hinders antibody binding, although the antigen is present. The
cells are either fixed by protein precipitation with hydrophilic organic solvent, i.e. acetone
or ethanol, or by protein cross-linking. Formalin or (para)formaldehyde link primary
amino groups of Lys and form lattices, which maintain the molecules at their original
location. These fixed cells have to be permeabilized with detergent, like saponine to
provide antibody access to intracellular antigens.
Normally, indirect staining is recommended, but direct staining can be advantageous in
double staining.
In immunostaining, polyclonal antibodies exhibit high sensitivity, but also background
may be high. Monoclonal antibodies are less sensitive but more specific. However,
monoclonal antibodies may fail due to antigen modification during fixation, or due to
surface antigen alteration during cell detachment. Affinity-purified polyclonal and pooled
monoclonal antibodies generally stain excellent.
1.3.4 Immunohistochemistry
The immunostaining of tissues is used to examine the localization and distribution of the
antigen in physiological and pathological tissue. Cells and tissues, which express an
antigen or a homologous protein, can be identified and the antibody specificity can be
verified. Furthermore, it permits to investigate missexpression, exclusive expression or
misslocalization of an antigen under pathological conditions.65
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This technique preserves the tissue architecture and allows the recognition of cell types.
In immunostaining, the tissue is fixed and mostly embedded in paraffin. Tissue sections
are devaxed and the antigen retrieved. After optional blocking, the antigen-specific
antibody is captured by the surface antigen and detected with the enzyme-labeled anti-Ig
antibody. The presence of the antigen-antibody complex is finally visualized after the
enzymatic conversion of the colorless soluble substrate to the insoluble colored
chromogen and the counterstaining of the tissue section (see Figure 17).
Figure 17: Indirect immunostaining of the surface antigen in tissue. ? Fixation, embedding of tissue and
antigen retrieval in the devaxed tissue section ? Capturing of the surface antigen with the antigen-specific
antibody ? Detection of the bound antigen-specific antibody with the enzyme-labeled anti-Ig antibody ?
Detection of the enzyme-catalyzed conversion of soluble colorless substrate to insoluble colored chromogen
? Counterstaining and visualization by microscopy.
The immunostaining of tissue has many constraints: the local antigen concentration is
low, the epitopes may be altered, masked or inaccessible by fixation or incomplete
antigen retrieval, and the antibody may cross-react. Hence, also antibodies, which work
excellent in all other described immunochemical methods, may easily fail.
All kinds of antibodies, polyclonal, affinity-purified polyclonal, pooled monoclonal and
individual monoclonal antibodies can be applied and may work excellent. Generally,
sensitivity with polyclonal antibodies is higher due to avidity effects and due to the
recognition of denaturation-resistant epitopes, which is important in paraformaldehyde-
fixed, paraffin-embedded tissue.
1.3.5 Immunoaffinity / Mass spectrometry (epitope mapping)
Epitope mapping allows the identification of monoclonal antibodies, which recognize
distinct epitopes on the same antigen or the determination of antigen modification sites.
There exist many techniques for epitope mapping, but each of these has its limitations.
One constraint is, that almost all methods fail in the determination of conformation-
dependent epitopes, which enclose about 80% of all epitopes.104 In addition, they are
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time-consuming, as they are based on libraries of overlapping antigen fragments, which
have to be prepared first, by synthetic peptide synthesis, by gene fragment expression
or by phage display.
The sensitive and rapid method by Suckau et al.105 and Macht et al .106 enables the
determination of conformation-dependent epitopes by mass spectrometry and includes a
set of two complementary experiments, the epitope excision and the epitope extraction.
In epitope excision, the antigen-specific antibody is covalently coupled to the Sepharose
matrix. The native or acetylated antigen is bound to the immobilized antibody and
enzymatically digested. After removal of unbound fragments, the epitope-containing
antigen fragment is eluted and identified by matrix-assisted laser desorption ionization
Fourier-transformation cyclotron resonance (MALDI-FT-ICR, see Figure 18).
Figure 18: Epitope excision. ? Covalent coupling of the antigen-specific antibody to the Sepharose matrix ?
Capturing of antigen by the immobilized antibody ? Enzymatic proteolysis of bound antigen ? Elution of the
epitope-containing antigen fragment ? Identification of the epitope fragment by MALDI-FT-ICR.
In epitope extraction, the native or acetylated antigen is enzymatically digested in
solution. The epitope-containing antigen fragment is captured by the immobilized,
antigen-specific antibody, and after removal of unbound fragments, it is eluted and
identified by MALDI-FT-ICR (see Figure 19).
Figure 19: Epitope extraction. ? Covalent coupling of the antigen-specific antibody to the Sepharose matrix
and enzymatic digest of antigen in solution ? Capturing of the epitope-containing antigen fragment ? Elution
of the epitope-containing antigen fragment ? Identification of the epitope fragment by MALDI-FT-ICR.
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The method bases on the high resistance of antibodies against proteolytic digest
compared to the resistance of other proteins, and on the shielding effect,107 that protects
the epitope in the antigen-antibody complex from enzymatic degradation.
Digest with trypsine or ?-chymotrypsine is suitable for most antigens, resulting in
fragments of adequate size of 500 – 3’000kDa.
1.3.6 Surface Plasmon Resonance - Biacore
Biacore (Biolmolecular Interaction Analysis) is used for the qualitative and quantitative
analysis of bispecific interactions in real time. Affinities and binding kinetics can be
determined and epitopes be mapped.
In Biacore antibody-capturing, the antigen is coupled to the dextran matrix of the sensor
chip. In the injection phase, the antigen-specific antibody flows over the antigen surface
and can associate. In the postinjection phase, the antibody dissociates. Finally, the
antigen surface is regenerated to remove the remaining bound antibody (see Figure 20).
Figure 20: Surface Plasmon Resonance (Biacore) antibody-capturing in real time. ? Immobilization of the
antigen on the dextran matrix of the sensorchip ? Association of the antigen-specific antibody to the antigen
surface ? Dissociation of the antibody from the antigen surface ? Regeneration of the antigen surface.
The merits of Biacore are that no antibody labeling or purification is needed, and that the
dissociation constant (KD), the association rate (kon), dissociation rate (koff) and the
binding mode can rapidly be determined. Affinities of antibodies can range from KD 10
-5M
to 10-12M.
Exact affinities can be calculated for monoclonal antibodies, but for polyclonal
antibodies, only overall avidity can be measured.
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1.3.7 Monoclonal versus polyclonal antibodies
In most immunochemical techniques, polyclonal and monoclonal antibodies are
applicable.
Polyclonal antibodies allow the staining of fixed cells, since they bind to distinct
denaturation-sensitive and resistant epitopes. For the same reason, multiple binding to
one antigen molecule can occur, that result in stronger stain. However, as polyclonal
include not antigen-specific antibodies, background problems are common, due to
unspecific or specific binding to irrelevant proteins. This drawback can be avoided by
immunoaffinity purification of polyclonal antibodies to get polyclonal antigen-specific
antibodies, which are excellent in immunochemical techniques
Monoclonal antibodies commonly work good or excellent in all immunochemical
methods, but since they bind only to one single epitope, they may fail in some
techniques due to low avidity, epitope alteration or modification or due to hindered
epitope access. The background is seldom high, but cross-reactions may cause
troubles. Pooling of distinct non-competitive monoclonal antibodies bypass this problem
(see Table 3).
Table 3: Choice of antibodies in immunochemical methods.
Immunochemical method Blotting Assay Staining Epitope affinity
Polyclonal Ab Total Good Fair Good Not recommended
Affinity pure Excellent Excellent Better Not recommended
Monoclonal Ab Individual Good Good Better Best
Pooled Excellent Excellent Not
recommended
Not recommended
Specificity / cross-reaction Common Occasional Common Occasional
Epitope Denatured Most native Native /
denatured
Native / denatured
Access Multimeric binding No Common Possible Common
Antigen modification Possible Possible Possible Possible
Antigen orientation No No Common No
Factors for success Denatured
epitope
High-affinity Ab
Epitope
alteration
Specificity
Epitope damage
High-affinity Ab
Kinetic Local Ag concentration Mixed Mixed Mixed Low
Ag Fixed Free / fixed Fixed Free
Ab Free Fixed / free Free Fixed
Binding kinetic Slow Fast Slow
Antibody affinity 10-6-10-8M 10-6-10-8M
High-affinity antibodies perform better in all immunochemical techniques, due to the
higher stability and due to the increased number of antibody-antigen complexes.
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1.4 Thesis
In the last few years various polyclonal antibodies against the entire human ASGPR or
against specific regions of the ASGPR were raised in rabbit or goat but not in chicken.
Bischoff et al.3,37 produced various polyclonal antibodies, directed against peptides at the
C-terminus of H1 or H2, i.e. in the CRD domains or against the juxtamembrane
sequence with the pentapeptide signal insert only present in H2a. Bider et al.4 also
generated polyclonal antibodies, recognizing a C-terminal peptide in the CRD domain,
specific to the epitope E277 – E286 of H1 and to H2. Finally, Yik et al.38 got antibodies,
specific to the same area of the H1-CRD, the epitope C276 – L291, to the H2-CRD, and to
the 19-residue insert, only present in H2a and H2b.
Interestingly, Park et al.5 raised polyclonal but not monoclonal antibodies in mice. The
antibodies are directed against residues C164 – Y180 of the H1-CRD, the part of helix ?1,
which exhibits the lowest homology to the murine H1-CRD.
In contrast to the many polyclonal antibodies, there are only reports of two monoclonal
antibodies against the entire human ASGPR. First, the monoclonal antibody of Schwartz
et al.6 was raised against the entire ASGPR isolated from human liver. Its epitope may
be present on the H1 and / or the H2 domain, as nothing is told. Second, Kohgo et al.7
selected the monoclonal antibody 302011, which is also directed against the full-length
human ASGPR. In addition, one reported monoclonal antibody is directed against the rat
H1 subunit. This monoclonal antibody 8D7 however cross-reacts with the human H1
subunit. Finally, one monoclonal antibody against the entire rat and human ASGPR, with
unknown epitope, is commercially available at Calbiochem.108
For investigating the ASGPR function and for analytical, diagnostic and therapeutic
application, monoclonal antibodies directed against the H1-CRD would be especially
precious.
The final goal of this Ph.D. thesis was to produce and characterize monoclonal
antibodies, particularly blocking antibodies against the H1-CRD, which can be used as
an analytical tool for ASGPR isolation and purification, for testing of potential ASGPR
agonists and antagonists, for drug targeting to hepatocytes, metabolic studies and the
specific blocking of physiological processes.
First, mg quantities of H1-CRD had to be produced for immunization and antibody
characterization. The recombinant E.coli expression system for the H1-CRD production
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was available from Prof. Spiess,158 and Meier M. et al.26 had already published an H1-
CRD purification method.
The monoclonal antibodies, produced by the hybridoma technology, should be
characterized, and especially their ability to block the binding of ligands be investigated.
Therefore, the design of a competitive ELISA was planned. The epitope and probably
the paratope of the most promising antibodies should further be mapped.
To complete the set of investigational tools, also polyclonal antibodies against the H1-
CRD should be raised and characterized.
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2 Materials and Methods
Substances and equipments are listed in Appendix 1 (page 269).
2.1 Database research
2.1.1 Sequence alignments
The H1 subunit (ASGPR-1), the H1-CRD and its binding site sequence were aligned
with homologous protein sequences of homo sapiens but also of mus musculus and
gallus gallus, using the programs of Basic Local Alignment Search Tool (BLAST)109 of
the National Center for Biotechnology Information (NCBI) server.
Local similarities were searched with protein-protein BLAST (blastp) in non-redundant
GenBank CDS (translations, RefSeq proteins, Brookhaven Protein Data Bank PDB,
Swiss Protein Database SwissProt, PIR and PRF) with expect 10, word size 3 and
matrix BLOSUM62 or with expect 20’000, word size 2 and matrix PAM30.
Nucleotide or protein sequences were aligned with bl2seq110 with both strands options,
expect 10.0 and word size 11.
Multi-sequence alignments were performed with the T-COFFEE program111 of Expert
Protein Analysis System (ExPASy), available on the proteomics server of the Swiss
Institute of Bioinformatics.
2.1.2 Epitope prediction plots
Plots for B-cell epitope prediction in the H1-CRD and its binding site were performed
with the help of the ProScale program of ExPASy, using the algorithms of Hopp and
Woods112, Parker 78 and Welling 80 for antigenicity prediction, of Kyte and Doolittle 113,
Sweet and Eisenberg114, Janin 115, Fauchere116 and Manavalan 117 for hydrophobicity plots
and the buried and accessible residues algorithms and Fraga recognition factor79
algorithm for accessibility plots.
Window size was 9 with a linear weight variation model. Scales were normalized from 0
to 1 to allow overlay of the different plots using the Prism4 software.
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2.2 Cloning, expression and purification of H1 Carbohydrate
Recognition Domain
2.2.1 Buffers and Media
2.2.1.1 Buffers
TAE (40mM TrisOAc, 1mM EDTA)
TBE 0.5x (45mM TrisBorate, 1mM EDTA)
TE (10mM TrisHCl, 1mM EDTA, pH 8.0)
TBS (20mM TrisHCl, 500mM NaCl, pH 7.5)
TTBS (20mM TrisHCl, 500mM NaCl, 0.05% Tween20, pH 7.5)
TTBS-Ca20 (20mM TrisHCl, 500mM NaCl, 20mM CaCl2, 0.05% Tween20, pH 7.5)
2.2.1.2 Media
Media were prepared as described in Sambrook J. et al.118
LB medium
10.0g Bacto tryptone, 5.0g Bacto yeast and 10.0g NaCl were dissolved in 950ml water.
Upon setting the pH to 7.5 with NaOH (1M), the volume was adjusted to 1’000ml with
water. The medium was autoclaved for 20min at 121°C and was stored at 4°C until use.
LB/agar plate
10.0g Bacto tryptone, 5.0g Bacto yeast and 10.0g NaCl were dissolved in 950ml water.
Upon setting the pH to 7.5 with NaOH (1M), 15.0g Bacto agar was added and the
volume was adjusted to 1’000ml with water. The medium was autoclaved for 20min at
121°C and cooled to 50°C while stirring magnetically. 1ml of antibiotic stock 1’000x (see
Table 4) were diluted in the medium, before 40ml/plate were poured into Petri dishes.
The solid LB/agar plates were enveloped with parafilm and stored at 4°C until use.
TB medium
12.0g Bacto tryptone, 24.0g Bacto yeast and 4.0ml glycerol were dissolved to 900ml in
water and separately, 2.31g KH2PO4 and 12.54g K2HPO4 were solved to 100ml in water.
Both, TB and phospate buffer were autoclaved for 20min at 121°C and stored at 4°C.
Just prior to use, they were combined (9:1) to get the TB medium.
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SOC medium
2.0g Bacto tryptone, 0.5g Bacto yeast, 1ml NaCl (1M), 0.5ml KCl (1M) and 1ml MgCl2
(2M) were dissolved to 95ml in water. Upon setting the pH to 7.0 with NaOH (1M), the
volume was adjusted to 99ml with water. The medium was autoclaved for 20min at
121°C and was cooled to room temperature (RT) before 1ml sterile filtered glucose (2M)
was added.
2.2.2 General DNA methods
2.2.2.1 OD600 measurement
The cell density of E.coli cultures was controlled spectrometrically by measuring the
optical density at 600nm (OD600) according to Sambrook J. et al.
118
Cell densities were calculated with Equation 1 using a conversion factor at OD600 of
5.0·108 cells/ml.
c = f ?OD600 (Eq. 1)
Equation 1: Calculation of the E.coli cell density (c) in cultures by measuring OD600 using the conversion
factor (f) of E.coli (5.0·108 cells/ml).
E.coli culture aliquots were diluted to suitable concentrations in medium. 300?l diluted
culture or blank (medium) were transferred into plastic semi-micro cuvettes and the
turbidity was measured at OD600 in a SmartSpec3000 cuvette spectrophotometer.
2.2.2.2 Bacteria cultivation and storage
E.coli strains were cultured as described by Sambrook J. et al.118 and by the pET
System manual.119
In cultures of E.coli transformants, ampicilline, which is sensitive to low pH and ?-
lactamase was replaced by carbenicilline. 1% glucose was included in the medium to
suppress the basal protein expression.
Table 4: Antibiotics and selective markers for cultivation of different E.coli strains and its transformants.
E.coli strain Antibiotic resistance Plasmid Selective marker
JM109 No + pET3b
+ pEZZ18
+ carb (100?g/ml)
JM109(DE3) No + pET3b + carb (100?g/ml)
AD494(DE3) kan (15?g/ml) + pET3b + carb (100?g/ml)
Rosetta-gami(DE3) kan (15?g/ml), tet (12.5?g/ml), cam (34?g/ml) + pET3b + carb (100?g/ml)
Top10 kan (15?g/ml), amp (50?g/ml), tet (12.5?g/ml) + pEZZ18 +  X-gal
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Table 4 shows the antibiotics and selection markers, which were included in the media
of used E.coli strains and their transformants.
2.2.2.2.1 Overnight and starter cultures
A few ?l E.coli were scratched from the frozen glycerol stock using a pipet tip and were
inoculated into 3ml medium containing 3?l of each suitable antibiotic stock 1’000x and
150?l glucose (20%) in a loosely closed culture tube (14ml). The culture was incubated
overnight at 37°C, while shaking with 300rpm in a slightly oblique position.
2.2.2.2.2 Cultures on LB / agar plate for short time storage
A few ?l E.coli overnight cultures were streaked on LB / agar plates containing suitable
antibiotics, using a loop. The culture dishes were incubated cover-side up overnight at
37°C. afterwards, they were enveloped with parafilm and stored up to 1month at 4°C.
2.2.2.2.3 Glycerol stocks (15%) for long time storage
3ml LB medium in a culture tube were supplemented with 3?l of each suitable antibiotic
stock 1’000x prior to the inoculation with 200?l E.coli overnight culture. The culture was
incubated at 37°C, while shaking with 300rpm in a slightly oblique position until an OD600
of 0.6-0.8 was reached. 850?l aliquots were transferred to cryotubes and mixed with
150?l sterile glycerol by vortexing, followed by immediate shock-freezing in liquid
nitrogen (N2). The frozen glycerol stocks were stored for indefinite time at –80°C.
2.2.2.2.4 MgCl2 / CaCl2 competent cells
Chemocompetent E.coli were prepared according to Morrison D.A.120.
3ml LB medium in a culture tube containing no antibiotics or 3?l of each suitable
antibiotic stock 1’000x of were inoculated with 30?l E.coli overnight culture and
incubated at 37°C, while shaking with 300rpm in a slightly oblique position until an OD600
of approximately 0.8 was reached. Cells were collected by centrifugation at 3’000rcf for
20min at 4°C and the pellet was washed once with 1ml ice-cold MgCl2 (100mM),
followed by centrifugation as before. The pellet was resuspended in 1ml ice-cold MgCl2
by vortexing, and the cells were made competent by incubation on ice for 20min. After
centrifugation as before, the pellet was resuspended in 255?l ice-cold CaCl2 (100mM)
and was thoroughly mixed with 45?l glycerol without vortexing, immediately followed by
shock-freezing of 20?l and 50?l aliquots in liquid N2. Competent E.coli cells were stored
at –80°C.
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2.2.2.3 Plasmid extraction
Plasmid DNA of E.coli transformants was prepared by alkali lysis according to Sambrook
J. et al.118
One clone of transformed E.coli was cultured in 2ml LB medium containing appropriate
antibiotics (see Section 2.2.2.2) overnight at 37°C. Cells were harvested at 16’000rcf for
1min and after complete removal of the supernatant by tapping onto a paper towel, the
bacterial pellet was resuspended in 100?l ice-cold solution 1 (25mM TrisHCl, 50mM
glucose, 10mM EDTA, pH 8.0) by vortexing and was gently mixed with 200?l solution 2
(200mM NaOH, 1% SDS) by inverting the tube five times. Following incubation on ice for
5min, 150?l ice-cold solution 3 (3M KOAc, 2M acetic acid) was added and dispersed by
gently vortexing until precipitated proteins were resuspended completely. The lysate
was incubated on ice for 5min and cleared by centrifugation at 11’000rcf for 5min at 4°C.
1 volume supernatant was extracted with 1 volume chloroform-phenol (1:1) by vortexing
followed by spinning at 11’000rcf for 3min at 4°C. The upper phase was combined with 2
volumes ethanol by vortexing and the DNA was precipitated during incubation for 2min.
After centrifugation at 11’000rcf for 3min at 4°C, the DNA pellet was rinsed once with 2
volumes ice-cold ethanol (70%) and air-dried for 10min. The purified plasmid DNA was
dissolved in 25-50?l TE buffer (pH8.0) containing RNase A (20?g/ml) and was stored at
–20°C.
2.2.2.4 Agarose-gel electrophoresis
Agarose-gel electrophoresis was performed according to Sambrook J. et al.118 The
resolution is optimal for DNA in the range of 0.5-7kbp on a 1% gel, of 0.4-6kbp on a
1.2% gel, of 0.2-3kbp on a 1.5% gel and of 0.1-2kbp on a 2% gel.
DNA sample preparation
DNA samples and the molecular DNA ladder were diluted to 10?l with TE buffer (pH8.0),
mixed with 2?l gel loading buffer 6x and spun down.
Agarose-gel preparation
0.8g to 1.6 g agarose was dissolved in 80ml TBE buffer 0.5x by heating in a microwave
until boiling. The agarose solution was cooled to about 50°C. The gel was supplemented
with 0.8?l ethidium bromide solution (10mg/ml) and poured into a horizontal
electrophoresis chamber (100·100mm, 16 pockets).
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Electrophoresis
The solid 1-2% agarose-gel containing ethidium bromide (0.1?g/ml) was overlaid with
TBE buffer 0.5x just prior to use. After loading samples into the gel-pockets, the gel
electrophoresis was run at 80-100mV (0.8 to 1mV/mm).
Ethidium-stained DNA fragments were visualized under UV light and documented using
GelDoc2000 and the software Quantity One 4.1.
2.2.2.5 NaOAc / ethanol precipitation
The DNA was purified and concentrated by NaOAc / ethanol precipitation according to a
method modified from Sambrook J. et al.118
0.9 volume DNA sample was placed on ice for 5min and mixed with 0.1 volume NaOAc
(3M, pH6.5), and then 2.5 volumes ethanol absolute were added. After incubation for 1h
at –80°C and centrifugation at 11’000rpm for 20min at 4°C, the DNA pellet was twice
washed with 2 volumes ice-cold ethanol 70%. The purified DNA pellet was air-dried for
5min at 37°C and dissolved in 0.45volume TE buffer (pH8.0) containing RNase A
(20?g/ml).
2.2.2.6 Quantification of DNA
The DNA was quantified by different methods, depending on the amount, the
concentration and the purity of the DNA.
2.2.2.6.1 Quantification of plasmid dsDNA by A260:A280 measurement
The plasmid dsDNA concentration was determined spectrophotometrically by measuring
the absorbance at 260nm (A260) according to Sambrook J. et al.
118
The concentration was calculated with Equation 2 using the conversion factor at A260 for
dsDNA (50?g/ml). The DNA purity was controlled, by comparing the absorbance at
260nm to 280nm (A280). The ratio of A260:A280 for pure DNA lies in the range of 1.6-1.8.
c = f ?A260 (Eq. 2)
Equation 2: Calculation of the plasmid dsDNA concentration (c) by measuring of the absorbance at (A260)
using the conversion factor (f) of dsDNA (50?g/ml).
The plasmid dsDNA samples were diluted in TE buffer (pH8.0) to a concentration up to
50?g/ml. 300?l samples or blank (TE buffer, pH8.0) were transferred into a quartz semi-
micro cuvette (path length 1cm) and the absorbance was measured at 260nm and
Benefit and Application of Antibodies Against the H1-CRD Materials and Methods
50
280nm in a SmartSpec3000 cuvette spectrophotometer. Using the SmartSpec software,
concentrations of plasmid dsDNA and ratios of A260:A280 were calculated.
2.2.2.6.2 Quantification of plasmid dsDNA by agarose-gel electrophoresis
The quantification of plasmid DNA by ethidium bromide staining on an agarose-gel was
modified from Sambrook J. et al.118
The ? dsDNA standard was diluted in TE buffer (pH8.0) to 0.25, 0.5, 1.0, 2.0, 3.0, 4.5,
6.0, 8.0 and 10.0?g/ml and the sample to concentrations in the range of the standard.
10?l standards and samples were mixed with 2?l gel loading buffer 6x and run on an
agarose-gel containing ethidium bromide (0.1?g/ml) following the method described in
Section 2.2.2.4.
Using the GelDoc2000 and Quantity One 4.1 software, the gel was photographed (UV
mode) and the standard calibration curve were drawn to estimate the content of plasmid
dsDNA in the samples.
2.2.3 Cloning
2.2.3.1 Amplification of H1-CRD cDNA by Polymerase chain reaction
21bp forward primer (H1fw) including a Nde I restriction site and backward primer
(H1bw) coding for two stop codons adjacent to a BamH I restriction site were used for
the amplification of the H1-CRD-encoding cDNA of the pET3H1 plasmid (H1-CRD
cDNA).
2.2.3.1.1 Calculation of melting temperature and annealing temperature
The melting temperature (Tm) of the selected primers was calculated according to the
two empirical equations of Wetmur J.G. et al.121 (Equation 3) and of Suggs S.V. et al .122
(Equation 4).
Tm(°C) = 81.5 + 0.41(g%+c%) + 16.61g[Na
+] – 500/length (Eq. 3)
Equation 3: Melting temperature (Tm) estimation according to Wetmur: Tm calculation of a primer of defined
length containing g% guanosine and c% cytosine, dissolved in a 0.05M Na+.
Tm(°C) = 2°C(a+t) + 4°C(c+g) (Eq. 4)
Equation 4: Melting temperature (Tm) estimation according to Suggs: Tm determination of a primer
containing a adenine, t thymidine, c cytosine and g guanosine nucleotides.
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The forward primer H1fw 5’-catatgggctcagaaaggacc-3’ (calculated Tm 57.6°C and 64°C)
was used in combination with the backward primer H1bw 5’-ggatccttattaaaggagagg-3’
(calculated Tm 53.7°C and 60°C) or with the M13 standard primer 5’-tgtaaaacgacggccag-
3’ (calculated Tm 35.8°C and 54°C).
For both primer pairs the annealing temperature was set 5°C below the Tm of the primer
with the lower Tm. The annealing temperatures were therefore 48°C for primer pair H1fw
/ H1bw and 45°C for primer pair H1fw / M13.
2.2.3.1.2 Polymerase chain reaction using Taq and Pfu DNA polymerase
The polymerase chain reaction (PCR) method was adapted from the Taq P C R
handbook123, originally based on the method by Mullis K. et al.124.
For n samples, n·40?l mastermix 1 or 2 were assembled on ice according to Formulation
1 and distributed into n PCR tubes. 25-250ng of template DNA (purified pET3H1 plasmid
DNA, see Section 2.2.2.3) diluted to 10?l in water or 10?l water (negative control) were
added to the mastermix and amplified using the oil-free iCycler thermal cycler.
Mastermix 1 Mastermix 2
Taq PCR buffer 10x 5?l
Pfu PCR buffer 10x 5?l
dNTP mix (10mM) 1?l 1?l
Forward primer H1fw (20?M) 1?l 1?l
Backward primer H1bw (20?M) 1?l 1?l
Taq DNA polymerase (5U/?l) 0.5?l
Pfu DNA polymerase (2.5U/?l) 0.1?l 1?l
Nanopur water 31.4?l 31?l
40?l 40?l
Formulation 1: Composition of the mastermix 1 and 2 for 50?l PCR reactions to get final concentrations of
200?M dNTP (dATP, dCTP, dGTP, dTTP), 400nM forward primer, 400nM backward primer, 2.5U Taq DNA
polymerase and / or 2.5U Pfu DNA polymerase in PCR buffer 1x.
After 2-3min initial denaturation at 94°C, the amplification of H1-CRD cDNA was run for
32-36 cycles of 30s denaturation at 94°C, 30s annealing at the appropriate temperature
and 1min (with Taq / Pfu DNA polymerases) or 2min (with Pfu DNA polymerase)
extension at 72°C. The final extension was for 10min at 72°C.
The PCR products were analyzed by agarose-gel electrophoresis as described in
Section 2.2.2.4. The H1-CRD cDNA was ligated into plasmid vectors without or after
trimming of cDNA ends (see Section 2.2.3.2).
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2.2.3.2 Digest of H1-CRD cDNA and plasmid vectors pEZZ18 for ligation
The restriction of H1-CRD cDNA and plasmid vectors pEZZ18 prior to the ligation was
planned using the Cloning Manager software.
The plasmid vector pEZZ18 has one restriction site for Sma I (2932) and BamH I (2935)
but no restriction site for Nde I in the multiple-cloning site. BamH I produce 5’-gatcc-
protruding termini allowing the specific cohesive, so-called “sticky” ligation. Sma I
produce blunt termini and was therefore used for the unspecific blunt ligation (see
Appendix 3, page 280).
2.2.3.2.1 Restriction digest of H1-CRD cDNA
The PCR-amplified H1-CRD cDNA was digested with BamH I, producing 5’-sticky cDNA
fragments for blunt-sticky ligation into pEZZ18.
Pfu DNA polymerase-amplified H1-CRD cDNA (see Section 2.2.3.1) was cut with BamH
I at the 5’ end according to the instructions of the manufacturer.
BamH I digest
NE BamH I buffer 10x 3?l
H1-CRD cDNA (Pfu-amplified) 20?l
BSA (1mg/ml) 3?l
Water 2.5?l
BamH I (10U/?l) 1.5?l
30?l
Formulation 2: Composition of BamH I restriction digest of H1-CRD cDNA.
30?l BamH I restriction digest (Pfu-amplified H1-CRD cDNA, 0.01% BSA, 15U BamH I in
NE BamH I buffer) was assembled on ice in a 1.5ml tube according to Formulation 2 and
briefly spun down. After incubation at 37°C for 3h, while shaking with 300rpm, the BamH
I was inactivated by incubation at 85°C for 15min, while shaking with 300rpm.
The restricted H1-CRD cDNA were analyzed by agarose-gel electrophoresis (see
Section 2.2.2.4) and purified by NaOAc / ethanol precipitation or by agarose-gel
extraction (see Section 2.2.2.4) prior to ligation.
2.2.3.2.2 Restriction digest and dephosphorylation of plasmid vector pEZZ18
Restriction digest of plasmid vectors pEZZ18 with Sma I and BamH I
The plasmid vector was either cut with the restriction enzyme Sma I for blunt-blunt
ligation or double digested with Sma I and BamH I for blunt-sticky ligation.
Benefit and Application of Antibodies Against the H1-CRD Materials and Methods
53
The plasmid vector pEZZ18 was first digested according to the manufacturer
instructions.
Sma I digest BamH I digest
Y+ / Tango buffer 10x 5?l -
Plasmid pEZZ18 30?l -
Plasmid pEZZ18 (Sma I-digested) - 25?l
Water 10?l 10?l
Sma I (10U/?l) 5?l -
BSA (10mg/ml) 1.5?l
NE BamH I buffer 10x 1.5?l
BamH I (10U/?l) 2?l
50?l 40?l
Formulation 3: Composition of the restriction digest of pEZZ18 with Sma I or BamH I.
50?l Sma I restriction digest (pEZZ18 plasmid DNA, 50U Sma I in Y+ / Tango buffer) was
mixed according to Formulation 3 in a 1.5ml tube and was briefly spun down prior to
incubation overnight at 30°C, while shaking with 300rpm. Then, 40?l BamH I restriction
digest (Sma I-digested linear pEZZ18 plasmid DNA, 0.01% BSA, 20U BamH I in NE
BamH I buffer) was assembled and was incubated for 3h at 37°C, while shaking again
with 300rpm. Finally restriction enzymes were inactivated during incubation at 65°C for
20min, while shaking with 300rpm.
Dephosphorylation of digested plasmid vector pEZZ18
The linear plasmid vector pEZZ18 was dephosphorylated with calf intestinal alkaline
phosphatase (CIAP) according to the manufacturer instructions.
Dephosphorylation reaction 1
(Sma I-digested pEZZ18)
Dephosphorylation reaction 2
(Sma I / BamH I-digested pEZZ18)
CIAP buffer 10x 4?l 5?l
Plasmid pEZZ18 (digested) 25?l 40?l
Water 8?l 2?l
CIAP (1U/?l) 3?l 3?l
40?l 50?l
Formulation 4: Composition of the dephosphorylation reaction of the linearized plasmid vector pEZZ18.
40?l dephosphorylation reaction 1 (25?l Sma I-digested pEZZ18 DNA, 3U CIAP in CIAP
buffer) and 50?l dephosphorylation reaction 2 (40?l Sma I and BamH I-digested pEZZ18
DNA, 3U CIAP in CIAP buffer) was assembled according to Formulation 4, was vortexed
and briefly spun down. After incubation for 30min at 37°C, the dephosphorylation was
stopped by inactivation of the alkaline phosphatase at 85°C for 15min, while shaking
with 300rpm.
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The digested and dephosphorylated plasmid vector pEZZ18 was analyzed by agarose-
gel electrophoresis (see Section 2.2.2.4) and purified by NaOAc / ethanol precipitation or
by agarose-gel extraction (see Section 2.2.2.5) prior to ligation.
2.2.3.3 Ligation
2.2.3.3.1 Molar ratio of H1-CRD cDNA to plasmid vector pEZZ18
A molar DNA ratio of insert : plasmid vector in the range of 3:1 to 1:3 is
recommended.125 The amount of H1-CRD cDNA and plasmid vector pEZZ18 was
calculated using Equation 5.
Mi
Mv
? bpi
bpv
? xv = xi (Eq. 5)
Equation 5: Amount of H1-CRD cDNA (xi) for ligation into a known amount of plasmid vector (xv) in a molar
ratio of insert : plasmid (Mi:Mv) of 3:1 to 1:3. The size of the H1 cDNA PCR fragment (bpi) is 450bp
(undigested), 445bp (BamH I-digested) or 443bp (Nde I and BamH I-digested). The plasmid vector pEZZ18
is 4591bp (Sma I-digested) or 4588bp (Sma I and BamH I-digested) in length (bpv).
2.2.3.3.2 Ligation of H1-CRD cDNA into pEZZ18 vector
The blunt-blunt ligation of the purified undigested H1-CRD cDNA (see Section 2.2.3.1.2)
into the purified Sma I-digested and dephosphorylated pEZZ18blunt vector (see Section
2.2.3.2.2) or the blunt-sticky ligation of the purified BamH I-digested H1-CRD cDNA into
the purified Sma I and BamH I-digested and dephosphorylated pEZZ18sticky vector using
T4 DNA ligase was performed according to the manufacturer instructions.
The molar ratio of insert : plasmid was chosen 1:1
Ligation into pEZZ18blunt Ligation into pEZZ18sticky
T4 DNA ligase buffer 10x 2?l 2?l
Plasmid pEZZ18 vector DNA (xv/vv) xv xv
H1-CRD cDNA (xi/vi) vi vi
Water 8?l-(vv+vi) 11?l-(vv+vi)
PEG6000 50% 2?l 1?l
T4 DNA ligase (MBI Fermentas) 8?l 6?l
20?l 20?l
Formulation 5: Composition of the reaction for the ligation of H1-CRD cDNA into the pEZZ18 plasmid
vector.
20?l blunt ligation reaction (xv plasmid pEZZ18blunt, xi H1-CRD cDNA, 5% PEG6000, 8U
T4 DNA ligase in T4 DNA ligase buffer) and 20?l sticky ligation reaction (xv plasmid
pEZZ18sticky, xi H1-CRD cDNA, 2.5% PEG6000, 6U T4 DNA ligase in T4 DNA ligase
buffer) were set up in 1.5ml tubes on ice according to Formulation 5. After briefly
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spinning down, the ligation reactions were incubated overnight at 16°C, followed by the
ligase inactivation for 10min at 65°C.
Recombinant plasmids (pEZZ18H1blunt, pEZZ18H1sticky) were used without purification to
transform the E.coli cloning strain JM109 (see Section 2.2.3.4).
2.2.3.4 Transformation
In the plasmid pET3H1, the expression of the H1-CRD cDNA is under the control of a T7
promoter. The plasmid was first amplified by transformation of recA- and endA- E.coli
cloning strain JM109. For protein expression, the extracted plasmid pET3H1 was used
to transform ?DE3 lysogenic E.coli expression strains JM109(DE3), AD494(DE3) and
Rosetta-gami(DE3). The plasmid-encoded ampicilline resistance allowed the selection of
transformants (see Table 4).
Plasmids pEZZ18, pEZZ18H1blunt and pEZZ18H1sticky use a lacUV5 promoter. For the
plasmid amplification E.coli JM109 and for the expression E.coli cloning and expression
host Top10 were used. JM109 transformants can be selected with ampicilline and Top10
transformants by ?-complementation (see Appendix 4, page 281).
Plasmids pET3H1, pEZZ18, pEZZ18H1blunt and pEZZ18sticky were transformed into
chemocompetent E.coli cells according to the manufacturer instructions and to the
Competent Cell Manual126.
Two aliquots of 20-50?l chemocompetent E.coli cells in 1.5ml tubes were thawed in ice-
water. 1-2?l pEZZ18H1 ligation reaction, 5-10ng purified plasmid pEZZ18H1 or pET3H1
(see Section 2.2.2.3 and 2.2.2.5) or water for negative control were added and mixed by
flicking. After incubation on ice for 20min, the plasmid was transformed into E.coli cells
by heat shock for 45s at 42°C on a heating block without shaking, immediately followed
by the incubation in ice-water for 2min. Cells were diluted with 80?l SOC medium and
incubated for 1h at 37°C, while shaking with 300rpm. 50-100?l transformed E.coli were
plated on a LB / agar plate containing selective marker and incubated cover-side down
overnight at 37°C.
A number of transformed clones were analyzed to control the transformation (see
Section 2.2.3.5) followed by freezing of selected E.coli clones (see Section 2.2.2.2.3).
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2.2.3.5 Analysis of E.coli transformants
2.2.3.5.1 PCR analysis
Colony PCR
The colony PCR of E.coli transformants were performed according to the pET System
Manual.119
Colonies of transformed E.coli were picked from the transformation LB / agar plate (see
Section 2.2.3.4) using a pipet tip and were suspended in 25?l TritonX100 (0.1%) by
pipetting and vortexing. After incubation for 1h at 55°C, while shaking with 300rpm, cell
lysates were cleared at 16’000rcf for 5min.
10?l lysate supernatants were taken and hold template DNA was amplified by PCR (see
Section 2.2.3.1.2). The presence of H1-CRD cDNA was verified using insert-specific
primers H1fw and H1bw and additionally, the orientation of H1-CRD cDNA in
pEZZ18H1blunt was checked using the H1-CRD DNA-specific primer H1fw in combination
with the plasmid vector-specific primer M13 (annealing temperature 45°C).
PCR products were analyzed by agarose-gel electrophoresis (see Section 2.2.2.4).
Standard PCR
Colonies of transformed E.coli were picked from the transformation LB / agar plate (see
Section 2.2.3.4) using a pipet tip and were inoculated into 3ml LB medium containing
appropriate antibiotics followed by incubation overnight at 37°C, while shaking with
300rpm (see Section 2.2.2.2.1).
The plasmid DNA was extracted (see Section 2.2.2.3). 10?l of ten to hundred times
diluted plasmid DNA in water were taken and hold template DNA was amplified by PCR
(see Section 2.2.3.1.2) using the H1-CRD DNA-specific primer pair H1fw and H1bw
(annealing temperature 48°C).
PCR products were analyzed by agarose-gel electrophoresis (see Section 2.2.2.4).
2.2.3.5.2 Restriction digest analysis
Colonies of transformed E.coli were picked from the transformation LB /agar plate (see
Section 2.2.3.4) using a pipet tip and were inoculated into 3ml LB medium containing
suitable antibiotics, followed by incubation overnight at 37°C, while shaking with 300rpm,
according to the procedure described in Section 2.2.2.2.1. The plasmid DNA was
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extracted (see Section 2.2.2.3) and either digested with Nde I or double digested with
Nde I and BamH I, according to the manufacturer instructions.
Nde I
digest
Nde I & BamH I
digest
Negative
control
Blank
control
NE 2 buffer 10x 2?l 2?l 2?l 2?l
Plasmid DNA 14?l 14?l 14?l -
BSA (1mg/ml) 2?l 2?l 2?l 2?l
Water 1?l - 2?l 14?l
Nde I (20U/?l) 1?l 1?l - 1?l
BamH I (10U/?l) - 1?l - 1?l
20?l 20?l 20?l 20?l
Formulation 6: Setup of the restriction digest with Nde I or of the double digest with Nde I and BamH I. Both
enzymes are 100% active in NE 2 buffer.
20?l restriction digests (extracted plasmid DNA, 0.01% BSA, 10U BamH I and / or 20U
Nde I in NE 2 buffer) were assembled in 1.5ml tubes according to Formulation 6, spun
down briefly and were incubated for 3h at 37°C, while shaking with 300rpm.
Restriction digest controls containing all components except restriction enzymes in
negative control or except plasmid DNA in blank control were set up in parallel.
The digested plasmid DNA was analyzed by agarose-gel electrophoresis, according to
the procedure described in Section 2.2.2.4.
2.2.3.5.3 Plasmid DNA sequence verification of E.coli expression clone
A starter culture of the selected E.coli expression clone in 3ml LB medium containing
suitable antibiotics was prepared as described in Section 2.2.2.2.1 and was incubated
for 9h at 37°C, while shaking with 300rpm.
One loop of starter culture was streaked on a LB / agar plate containing antibiotics
according to Section 2.2.2.2.2 and was incubated coverside-down overnight at 37°C.
The cultured LB / agar plate was sent for sequencing at Microsynth GmbH sequencing
group (Balgach). The plasmid DNA was sequenced in both directions using the T7
primer for forward sequencing and the T7term primer for backward sequencing of the
complementary strand.
Sequences of H1-CRD cDNA were verified by the alignment with H1-CRD DNA
sequence (accession 1DV8) using BLAST programs bl2seq, blastn and blastx of the
NCBI server.
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2.2.4 General protein methods
2.2.4.1 TCA / acetone precipitation
Proteins of E.coli culture samples were purified and ten times concentrated by TCA /
acetone precipitation according to the pET System manual.119
The pellet of 1-2ml E.coli culture sample was suspended in 1 volume PBS (pH7.5). The
sample was mixed with 0.1 volume ice-cold TCA (100%) by vortexing and proteins were
precipitated during incubation on ice for 30min. After collection at 16’000rcf for 10min at
4°C, the pellet was once washed with 0.1 volume ice-cold acetone and centrifuged at
16’000rcf for 5min at 4°C. The purified protein pellet was air-dried for 1h prior to
dissolving in 0.1 volume PBS (pH7.5) by sonication in a water bath for a few minutes.
The concentrated protein sample was mixed with the same volume reducing sample
buffer 2x (80mM TrisHCl, 100mM DTT, 15% glycerol, 2% SDS, 0.006% bromophenol
blue, pH 6.8) followed by sonication in a water bath for 5min and boiling for 5min at
95°C, while shaking with 1’200rpm. The reduced and denatured sample was centrifuged
at 16’000rcf for 5min and stored at –20°C until SDS-PAGE and Western blot analyses
(see Sections 2.2.4.2 and 2.2.4.3).
2.2.4.2 Polyacrylamide-gel Electrophoresis and staining
The discontinuous polyacrylamide-gel electrophoresis (PAGE) was performed according
to the Protein Methods,127 derived originally from Ornstein L. 128, Davis B.J. 129 and
Laemmli E.K.130. Proteins were separated in the native PAGE under native conditions
and in the denaturing SDS-PAGE under reducing or non-reducing conditions.
2.2.4.2.1 Reducing SDS-PAGE
Proteins were separated according to their molecular weight on a SDS-PAGE gel by the
method of Laemmli.
Protein sample preparation
The low or high molecular weigh marker, the reference sample and protein samples
were diluted to an suitable volume in water, combined with 0.25 volume sample buffer 5x
(200mM TrisHCl, 37.5% glycerol, 5% SDS, 250mM DTT or 2M ?-mercaptoethanol,
0.015% bromophenol blue, pH 6.8) by vortexing and were boiled for 5min at 95°C, while
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shaking with 1’200rpm. Denatured samples were spun down briefly and stored on ice
until use.
Polyacrylamide-gel preparation
The percentage of polyacrylamide in the gel was adjusted, dependent on the molecular
weight of analyzed proteins. The resolution for proteins with a molecular weight in the
range of 16-68kDa was best on a 10% gel, of 14-55kDa on a 12% gel and of 16-68kDa
on a 15% gel. The thickness of the gel was chosen, in dependence of the protein
concentration and the following procedure. Generally, 1.0mm gels were prepared for
staining and 1.5mm gels for electroblotting.
Inner and outer glass plates, spacers (0.75-1.5mm) and the comb (0.75-1.5mm, 15teeth)
were rinsed with water and ethanol prior to assembly. The separating gel solution
(375mM TrisHCl, x% polyacrylamide, 1% SDS, 0.05% TEMED, 0.03-0.1% APS, pH 8.8)
was mixed according to Formulation 7, was poured immediately and mounted with some
?l water. After polymerization, the stacking gel (125mM TrisHCl, 5% polyacrylamide, 1%
SDS, 0.1% TEMED, 0.03-0.1% APS, pH6.8) was mixed, immediately poured and the
comb was introduced prior to polymerization.
Separating gel x% Stacking gel
Acrylamide solution 30% (acrylamide:bisacrylamide 37.5:1)
Water
TrisHCl 1.875M (pH8.8)
TrisHCl 1.25M (pH6.8)
Sodiumdodecylsulfate (SDS) 10%
N,N,N,N‘-Tetramethylethylenediamine (TEMED)
Ammoniumpersulfate (APS) 10-40%
0.5·xml
11.8-(0.5·x)ml
3.0ml
150μl
7.5μl
50μl
1.7ml
7.2ml
1.0ml
100μl
10μl
33μl
15.0ml 10.0ml
Formulation 7: Composition of the separating gel containing x% polyacrylamide and of the stacking gel.
Electrophoresis
After complete polymerization, gels were submersed in running buffer (25mM Tris,
200mM glycine, 0.1% SDS) and samples were loaded into the gel-pockets using a
Hamilton syringe. The electrophoresis was run at a constant current of 30mA/gel
(stacking gel) and of 40mA/gel (separating gel) in a Mini Protean gel cell.
After PAGE, gel slabs were stained with silver stain for qualitative protein analysis (see
Section 2.2.4.2.4) and with Coomassie Brilliant Blue G250 stain for quantitative analysis
(see Section 2.2.4.4.3) or were blotted to nitrocellulose (see Section 2.2.4.3)
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2.2.4.2.2 Non-reducing SDS-PAGE
The non-reducing SDS-PAGE followed the same procedure as described for reducing
SDS-PAGE (see Section 2.2.4.2.1) but differed in the sample buffer composition by
excluding reductants ?-mercaptoethanol and DTT.
2.2.4.2.3 Native SDS-PAGE
The native PAGE followed the same procedure as described for reducing SDS-PAGE
(see Section 2.2.4.2.1) but gels, running and sample buffers contained no SDS and no
reductants ?-mercaptoethanol and DTT and samples were not denatured by boiling.
2.2.4.2.4 Silver staining
Electrophoretically separated proteins on a PAGE gel slab were silver-stained using the
Pharmacia Biotech Silver staining kit according to the instruction manual, originally
derived from the method of Heukeshoven J. et al.131 that allows the detection of protein
down to 2-10ng/band.
The PAGE gel slab was incubated in 125ml fixation buffer (40% ethanol, 10% acetic
acid) in a plastic container for 30min, while shaking with 70rpm and was soaked in
125ml sensitizing solution (30% ethanol, 68mg/ml NaOAc, 2mg/ml NaThiosulphate,
0.125% glutaraldehyde) for 30min, while shaking with 70rpm. After washing three times
in about 200ml water for 5min, the gel slab was stained in 125ml silver solution
(2.5mg/ml silvernitrate, 0.015% formaldehyde) for 20min, while shaking with 70rpm and
distained twice in about 200ml water for 1min. The stain of protein bands was developed
in 125ml developing solution (25mg/ml NaCarbonate, 0.0075% formaldehyde) for an
appropriate time and stopped in 125ml stopping solution (14.6mg/ml Na2EDTA·2H2O)
during incubation for 5min, followed by rinsing once in about 200ml water.
Stained gels were documented using the GelDoc2000 and Quantity One 4.1 software.
2.2.4.3 Electroblotting and immunostaining (immunoblotting)
Separated proteins on a PAGE gel were electrophoretically blotted to the nitrocellulose
membrane according to a semi-dry transfer method adapted from Kyhse-Andersen J. et
al.132 Three different buffers, originally derived from Towbin H. et al.133 were used.
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2.2.4.3.1 PAGE
Sample proteins were separated by SDS-PAGE or native PAGE according to the
protocol described in Section 2.2.4.2.
2.2.4.3.2 Electroblotting
18 sheets of Whatman 3M absorbent paper and 1 sheet of nitrocellulose membrane
(pore size 0.2?m) were cut to the size of the PAGE gel (60mm·85mm) and the
membrane was wet in water. To assemble the blot sandwich, 6 papers were soaked for
a few minutes in anode buffer 1 (300mM Tris, 20% methanol) and piled up on the bottom
anode, followed by 3 papers and the membrane soaked in anode buffer 2 (25mM Tris,
20% methanol), the PAGE gel and 9 papers soaked in cathode buffer (40mM 6-
aminocaproic acid, 20% methanol) and the cathode at the top. After electroblotting for
90min at 15V using a TransBlot semi-dry transfer cell, the blotted PAGE gel was silver-
stained (see Section 2.2.4.2.4) and the nitrocellulose membrane was colored with
Ponceau S prior to the immunostaining.
2.2.4.3.3 Staining
Ponceau S staining of blotted total proteins
The blotted nitrocellulose membrane was stained in Sigma Ponceau S solution (0.1%) in
a plastic container for a few minutes, while shaking with 70rpm and was distained twice
in about 100ml water. Visible protein bands were marked with pencil before
immunostaining.
Immunostaining of blotted specific protein
The unspecific binding to the blotted nitrocellulose membrane was blocked during
incubation in 50ml blocking buffer (4% non-fat dried milk powder in TBS) in a plastic
container for 4h (or overnight at 4°C), while shaking with 70rpm. After washing three
times in about 50ml TTBS-Ca20 (20mM CaCl2 in TTBS) for 5min, the blot was incubated
in 10ml primary antibody solution (anti-H1 antibodies according to Table 5, 1% BSA in
TTBS-Ca20) overnight at 4°C (or for 2h at room temperature), while shaking with 70rpm.
The membrane was washed three times in about 50ml TTBS-Ca20 for 5min prior to the
incubation in 10ml secondary antibody (alkaline phosphatase (AP)-labeled antibodies
according to Table 5, 1% BSA in TTBS-Ca20) for 2h, while shaking with 70rpm. After
washing twice thoroughly in about 50ml TTBS-Ca and once in about 50ml TBS for 5min,
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bands of the specific protein were revealed in 10ml substrate solution (0.4% NBT/BCIP,
100mM TrisHCl, 100mM NaCl, 5mM MgCl2, pH 8.8) for an appropriate time. The stain
was stopped, by rinsing the membrane briefly in water or 5mM EDTA (pH8.0).
Table 5: Primary and secondary antibodies, which were used for immunostaining.
Primary antibody Working dilution Secondary antibody Working dilution
Monoclonal anti-H1 IgG 0.5-5?g/ml GAM-IgG(whole)-AP 1:2’000 to 1:5000
Anti-H1 IgG-containing supernatants No GAM-Ig(polyvalent)-AP 1:2000 to 1:5000
Anti-H1 IgY-containing total IgY 100?g/ml RACh-IgY(whole)-AP 1:5000
The immunostained blot was documented using the GelDoc2000 and Quantity One 4.1
software (white mode).
2.2.4.4 Protein quantification
2.2.4.4.1 Protein quantification by A280 measurement
The protein concentration was spectrophotometrically estimated, by measuring the
absorbance at 280nm (A280) according to Harlow E. et al.
102, originally derived from
Layne E.134 and Peterson G.L.135.
Concentrations were calculated with Equation 6 using the protein-specific conversion
factors at A280 for BSA (0.7mg/ml), IgM (1.2mg/ml), IgG (1.35mg/ml) and for IgY (1.31-
1.44mg/ml).67 The method is sensitive in the range of 0.2-2mg/ml proteins.127
c = f ?A280 (Eq. 6)
Equation 6: Calculation of the protein concentration (c) by measuring absorbance at 280nm (A280) using
protein-specific conversion factors (f).
Samples were diluted to suitable concentrations with sample buffer (blank).
300?l sample or blank were transferred into a quartz semi-micro cuvette (path length
1cm) and the absorbance was measured at 280nm in a SmartSpec3000 cuvette
spectrophotometer.
Sample concentrations were calculated using the SmartSpec or Excel software.
2.2.4.4.2 Protein quantification by Bradford assay
The Bradford assay, originally introduced by Bradford M.M.136 was performed according
to the standard method, the micro method137 or the spot method. 102 The assay is
sensitive in the range of 25-200?g/ml proteins.127
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Bradford standard assay
The BSA standard was diluted to 0, 20, 40, 60, 80, 100, 120, 160 and 200?g/ml and
samples were diluted in sample buffer (blank) to concentrations in the range of the
standard. Standards and samples were measured in duplicates or triplicates.
20?l BSA standard dilutions, protein samples or blank were mixed with 50?l NaOH (1M)
by pipetting in semi-micro cuvettes (path length 1cm) prior to addition of 1’000?l dye
solution (0.01% Coomassie Brilliant Blue G250, 10% phosphoric acid 85%, 5% ethanol).
After mixing by inversion and incubation for at least 5min, the absorbance was
measured within 1h at 595nm in a SmartSpec3000 cuvette spectrophotometer.
Using SmartSpec or Excel software, the linear regression graph of standards was drawn
and, if the correlation coefficient R2 was > 0.95, concentrations of the samples were
calculated.
Bradford micro assay
The BSA standard was diluted to 0, 100, 200, 400, 600, 800 and 1’000?g/ml and
samples were diluted in sample buffer (blank) to concentrations in the range of the
standard. Standards and samples were measured in duplicates or triplicates.
10?l BSA standard dilutions, protein samples or blank were transferred to wells on 96-
well culture plates, already containing 200?l dye solution (0.01% Coomassie Brilliant
Blue G250, 10% phosphoric acid 85%, 5% ethanol) and were mixed by tapping the
plate. After incubation for at least 5min, the absorbance was measured within 1h at
595nm in a Spectramax190 plate reader.
Using the software Spectramax PRO 4.0 or Excel, the linear regression graph of
standards was drawn and, if the correlation coefficient R2 was > 0.95, concentrations of
the samples were calculated.
2.2.4.4.3 Protein quantification by SDS-PAGE
The protein quantification on a SDS-PAGE gel was performed according to the
Coomassie Brilliant Blue G method by Smith B.J. et al.137, derived from Reisner A.H. et
al.138 The assay is sensitive in the range of 10ng/mm2 to 5?g/mm2 protein.
The BSA standard was diluted to 0, 5, 10, 20, 50, 100 and 200?g/ml and samples were
diluted in water to a concentration in the range of the standard.
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10?l standard and sample dilutions were mixed with 5?l non-reducing sample buffer 3x
(120mM TrisHCl, 37.5% glycerol, 5% SDS, 0.009% bromophenol blue, pH 6.8) and were
boiled for 5min at 95°C, while shaking with 1’200rpm.
The non-reducing SDS-PAGE was run, following the protocol in Section 2.2.4.2.2.
The run PAGE gel was incubated in 50ml fixation buffer (20% ethanol, 5% glacial acetic
acid) for 20min, while shaking with 70rpm, and then was three times washed with about
200ml water for 5min. After staining for 90min in 50ml dye solution (0.01% Coomassie
Brilliant Blue G250, 10% phosphoric acid 85%, 5% ethanol) while shaking with 70rpm,
the stained gel was washed in water that contained some cotton wool until complete
distain of background.
Using the GelDoc2000 and Quantity One 4.1 software, the gel was photographed (white
mode) and the standard calibration curve was drawn to calculate the amounts of sample
protein.
2.2.5 H1-CRD expression and purification
2.2.5.1 H1-CRD expression
The H1-CRD was expressed in pET3H1 transformed E.coli clones (see Section 2.2.3.4)
as described in the pET System Manual.119
3ml starter cultures (see Section 2.2.2.2.1) of E.coli expression clones in LB or TB
medium with appropriate antibiotics (see Table 4) and with glucose (1%) were incubated
at 37°C overnight. After centrifugation at 3’000rcf for 5min, cells were resuspended in
3ml fresh medium, prior to the dilution into 50ml fresh medium to get an OD600 of 0.1
(5·107cells/ml). The culture was incubated at 37°C, while shaking with 300rpm, until an
OD600 of 0.8-1.0 was reached. The expression was induced by addition of 0.4mM IPTG
followed by incubation for another 5h at 37°C, while shaking with 300rpm. After cooling
on ice for 5min, cells were harvested at 3’000rcf for 10min at 4°C and the pellet was
stored at 4°C overnight or at –20°C for several days.
2.2.5.2 Optimization of the H1-CRD expression
2.2.5.2.1 Selection of the E.coli expression strain and clone
The H1-CRD was expressed (see Section 2.2.5.1) in a number of pET3H1-transformed
clones of each E.coli expression strain  (see Section 2.2.3.4).
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Proteins of the culture pellets and media, harvested prior to and after expression, were
purified and concentrated by TCA / acetone precipitation and were analyzed on a
reducing SDS-PAGE gel (see Section 2.2.4.2.1).
2.2.5.2.2 Selection of expression conditions
A pET3H1 transformed E.coli clone (see Section 2.2.3.4) was cultured in different media.
The expression was not induced for negative control or induced at different OD600 by
addition of various concentrations of IPTG.
Expression of H1-CRD in different culture medias
At the same time, the expression of H1-CRD (see Section 2.2.5.1) was performed for 5h
in LB and in TB media containing suitable antibiotics and glucose (1%) or no glucose.
Expression of H1-CRD at different OD600
Simultaneously, the H1-CRD expression (see Section 2.2.5.1) was not induced or
induced at six different OD600 in the range of 1.0-6.0 and was performed for 700min.
Induction of H1-CRD expression with different IPTG concentrations
In parallel, the H1-CRD expression (see Section 2.2.5.1) was induced with 0.2mM,
0.4mM and 0.8mM IPTG or was not induced (negative control) and was run for 700min
after induction.
Expression analysis
Every 50min, the OD600 of cultures was measured (see Section 2.2.2.1), the pH was
monitored using indicator sticks, and 1ml samples were taken out. Samples were cooled
on ice for 5min and were centrifuged at 16’000rcf for 5min. Pellets and media were
stored separately at –20°C until analyses.
Proteins of the pellets and media were purified and concentrated by TCA / acetone
precipitation and were analyzed by reducing SDS-PAGE (see Section 2.2.4.2.1). Growth
curves were drawn and doubling times were calculated using the Prism4 software.
2.2.5.3 Optimization of the H1-CRD purification
2.2.5.3.1 Fraction analysis of the selected E.coli expression clone
The analysis of the medium, the total cell protein and its periplasmic, soluble and
insoluble cytoplasmic fractions to ascertain the localization of expressed H1-CRD in a
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pET3H1 transformed E.coli expression clone (see Section 2.2.3.4) was performed
according to the pET System Manual.119
The E.coli expression clone was cultured in 100ml LB and TB medium containing
antibiotics and glucose (1%). After taking out a 10ml aliquot (negative control), the H1-
CRD was expressed in remaining 90ml culture for 4h (see Section 2.2.5.1).
Medium proteins and total cell proteins
1ml of the expression culture was centrifuged at 10’000rcf for 10min at 4°C. Then, the
medium was transfered to a new tube and the pellet was dried by tapping the tube onto
a paper towel prior to its resuspension in 1ml PBS.
Periplasmic fractions
Cells of 80ml expression culture were harvested by centrifugation at 10’000rcf for 10min
at 4°C and were resuspended in 0.5 volume sucrose buffer (30mM TrisHCl (pH8.0), 20%
sucrose, 1mM EDTA). After incubation for 30min, while shaking with 70rpm, cells were
collected by centrifugation at 10’000rcf for 10min at 4°C, were resuspended in 0.5
volume ice-cold MgSO4 (5mM) and placed on ice for 10min, while shaking with 70rpm.
Cells were centrifuged at 10’000rcf for 10min at 4°C again before 1ml supernatant was
transferred to a new tube for precipitation of periplasmic proteins.
The pellet of the periplasmic fraction was stored on ice until using for preparation of the
soluble cytoplasmic fraction.
Soluble cytoplasmic fraction
The pellet of the periplasmic fraction, derived from 80ml culture, was resuspended in 0.1
volume cold TrisHCl 20mM (pH7.5) and was lysed completely by sonication with 12
bursts (20s sonication / 10s break, 80% duty) on ice. After centrifugation at 14’000rcf for
10min, 100?l supernatant were transferred to a new tube for the precipitation of
cytoplasmic soluble proteins.
The pellet of the soluble cytoplasmic fraction was stored on ice until using to prepare the
insoluble cytoplasmic fraction.
Insoluble cytoplasmic fraction
The pellet of the soluble cytoplasmic fraction, derived from 80ml culture, was twice
washed with 0.1 volume TrisHCl 20mM (pH7.5) and centrifuged at 10’000rcf for 5min.
The pellet was resuspended in 0.1 volume SDS (1%) and was boiled for 5min at 95°C,
while shaking with 1’200rpm before cytoplasmic insoluble proteins were precipitated.
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Analysis
Proteins of the medium, total cell proteins, periplasmic proteins cytoplasmic soluble and
insoluble proteins, derived from 1ml culture, were ten times concentrated by TCA /
acetone precipitation (see Section 2.2.4.1) prior to the analysis by reducing SDS-PAGE
(see Section 2.2.4.2.1).
2.2.5.3.2 Inclusion bodies denaturation and reduction
Three 500ml expression cultures (see Section 2.2.5.1) of an E.coli clone were pooled
and split to three equal aliquots to get the same starting pellet. Proteins of the inclusion
bodies were denatured and reduced, comparing the “fast dilution” (FD), the “no fast
dilution” (NFD) and the “inclusion body” (IB) solubilization methods in parallel.
FD solubilization method
The not preclearing FD method was performed according to Meier M. et al.26
The pellet, derived from 500ml expression culture, was suspended in 2.5ml prechilled
denaturation buffer (20mM TrisHCl, 0.01% ?-mercaptoethanol, 8M urea, pH 8.0). Cells
were lysed by 12 bursts of 20s sonication and 10s stops on ice, and debris was removed
by ultracentrifugation at 32’800rcf for 20min at 4°C. This lysis cycle was repeated twice.
The resulting 0.9 volume lysate solution was supplemented with 0.1 volume precooled
high salt buffer 10x (5M NaCl, 250mM CaCl2, 0.3% ?-mercaptoethanol, denaturation
buffer) prior to the incubation on ice for 1h, while shaking with 70rpm. After fast dilution
with 3 volumes prechilled dilution buffer (20mM TrisHCl, 500mM NaCl, 25mM CaCl2, pH
7.5), the diluted lysate solution was cleared by ultracentrifugation at 32’800rcf for 20min
at 4°C.
Proteins of the cleared lysate solution were refolded by dialysis in different buffer
systems (see Section 2.2.5.3.3).
NFD solubilization method
The not preclearing NFD method is a modification of the method by Meier M. et al.26 and
was developed empirically.
The pellet, derived from 500ml expression culture was suspended in 25ml precooled
denaturation buffer (20mM TrisHCl, 0.01% ?-mercaptoethanol or 1mM DTT, 8M urea,
pH 8.0). Cells were lysed by 24 bursts of 20s sonication and 10s stops on ice, and
debris was removed by ultracentrifugation at 32’800rcf for 20min at 4°C. This lysis cycle
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was repeated twice but only using 2.5ml denaturation buffer for suspending the debris
pellet. NaCl, CaCl2 and ?-mercaptoethanol or DTT were added to concentrations of
500mM, 25mM and 0.3% or 1mM, respectively. After incubation on ice for 1h, while
shaking with 70rpm, followed by dilution with 0.5 volume prechilled dilution buffer (20mM
TrisHCl, 500mM NaCl, 25mM CaCl2, pH 7.5), the diluted lysate solution was cleared by
ultracentrifugation at 32’800rcf for 20min at 4°C.
Proteins of the cleared lysate solution were refolded by dialysis in different buffer
systems (see Section 2.2.5.3.3).
IB solubilization method
The preclearing IB method was developed empirically according to the Protein
methods.127
The pellet, derived from 500ml expression culture (about 3g bacterial pellet wet weight),
was suspended in 30ml (10ml/g pellet wet weight) precooled lysis buffer (20mM TrisHCl,
500mM NaCl, 10% sucrose, pH 8.0). Cells were lysed by 24 bursts of 20s sonication
and 10s stops on ice, and IB were collected by ultracentrifugation at 32’800rcf for 20min
at 4°C. This lysis and washing cycle was repeated four times with 30ml prechilled lysis
buffer (10ml/g pellet wet weight) and once with 5ml precooled IB washing buffer (20mM
TrisHCl, 10mM EDTA, 1% TritonX-100, 1M urea, pH 8.0). Following complete removal of
the supernatant by tapping dry on a paper towel, the IB pellet was weighted to get the IB
wet weight. Then, it was dissolved in 100?l/mg (IB wet weight) prechilled extraction
buffer (20mM TrisHCl, 1mM DTT, 8M urea, pH 8.0), 1mM PMSF) by 12 bursts of 20s
sonication and 10s stops on ice. After incubation for 1h, while shaking with 700rpm,
followed by dilution with 200?l/mg (IB wet weight) precooled extraction buffer to final
concentrations of 1mM DTT and 8M urea, the diluted IB solution was cleared by
ultracentrifugation at 32’800rcf for 20min at 4°C.
Proteins of the IB solution were refolded by dialysis in different buffer systems (see
Section 2.2.5.3.3).
2.2.5.3.3 H1-CRD refolding
Cleared FD, NFD and IB lysate solutions (see Section 2.2.5.3.2) were dialyzed against
different refolding buffer combinations.
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Preparation of dialysis tubes
The method for the preparation of ZelluTrans 6.0 dialysis tubes was adapted from
Deutscher M.P.55 and the ZelluTrans Roth product information.
ZelluTrans Roth 6.0 dialysis tubes (25·200mm, 10 pieces) were swollen in 500ml
soaking buffer (10mM NaHCO3, 1mM EDTA, pH8.0) of 80°C to 90°C for 30min with
gentle stirring magnetically. After washing three times in 500ml water of 60°C, 40°C and
20°C, respectively for 10min with gentle stirring, swollen tubes were stored at 4°C in
1mM EDTA (pH8.0).
Refolding of H1-CRD in different buffer systems
The refolding system A according to Spiess M. et al.26 used one basic refolding buffer
(20mM TrisHCl, 0.5M NaCl, 25mM CaCl2, pH 7.5) without any refolding additives.
Refolding systems B to D were adapted from A using the same basic refolding buffer but
were supplemented either with 0.1mM DTT and / or 30% glycerol or with 1mM reduced /
0.2mM oxidized glutathione (GSH / GSSG) according to Table 6. The FD and the NFD
lysate solution were refolded in refolding systems A and C whereas the IB lysate solution
was refolded in refolding systems B and D.
Table 6: Refolding buffer systems A to D.
Additives to the basic refolding buffer*Refolding
system Buffer change 0 and 1 Buffer change 2 and 3 Buffer change 4 and 5
Lysate
solution
A - - - FD, NFD
B 0.1mM DTT - 1mM GSH / 0.2mM GSSG IB
C -
30% glycerol
-
30% glycerol
1mM GSH / 0.2mM GSSG
-
FD, NFD
D 0.1mM DTT
30% glycerol
-
30% glycerol
1mM GSH / 0.2mM GSSG
-
IB
*: Basic refolding buffer: 20mM TrisHCl (pH 7.5), 0.5M NaCl, 25mM CaCl2
Cleared FD, NFD and IB lysate solutions were split up and each sample (equivalent to
250ml expression culture) was transferred into swollen dialysis tubes (25·200mm tubes).
All samples were dialyzed separately, each against 200ml prechilled refolding buffer
(250ml measuring cylinder of same diameter and length), with gentle stirring
magnetically.
Refolding buffers were replaced five times with fresh buffer according to Table 6 after
dialysis for 8-13h, respectively. Following the final dialysis for 2-3h, the refolded protein
samples were cleared by ultracentrifugation at 44’000rcf for 1h at 4°C and the H1-CRD
of each sample was purified by affinity chromatography (see Section 2.2.5.3.4).
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2.2.5.3.4 H1-CRD affinity purification on Gal-Sepharose by FPLC
Coupling of galactose to Sepharose
The galactose was coupled to activated Sepharose 6B according to the divinylsulfone
method of Fornstedt N. et al.139. The Gal-Sepharose and the blank Sepharose were
prepared in parallel.
The packed Sepharose 6B was three times washed with 1 volume water and centrifuged
at 1’100rcf for 5min. The Sepharose was suspended in 1 volume carbonate buffer
(500mM Na2CO3, pH11.0) and was activated by addition of 0.1 volume divinylsulfone
prior to the incubation for 1h, while shaking with 1’000rpm. After washing on a glass fritte
(borosilicate 3.3, pore 4) with 100 volumes water, the activated Sepharose was split into
two portions and was suspended in 1 part-volume Gal solution (20% galactose in
500mM Na2CO3, pH10.0) or blank solution (500mM Na2CO3, pH10.0) for coupling
overnight, while shaking with 300rpm. Coupling slurries were centrifuged at 3’100rcf for
5min, were washed three times with water and resuspended in 1 part-volume carbonate
buffer (500mM NaCO3, pH8.5) before they were blocked with 0.02 part-volume ?-
mercaptoethanol for 2h, while shaking with 300rpm. After washing three times with 10
part-volumes water, the slurries were packed into BioScale MT-2, MT-10 or MT-20
column (2ml, 10ml or 20ml bed-volume) according to the column instruction manual
using ultrafiltered water (0.45?m) and an operating flow rate of 2ml/min.
Specificity control of H1-CRD binding to Gal-Sepharose by HPLC
The specificity of the H1-CRD binding to Gal-Sepharose was controlled as described by
Ricklin D140.
The cleared solution of refolded proteins (see Section 2.2.5.3.3) was applied to Gal-
Sepharose and blank Sepharose BioScale MT-2 columns (2ml bed-volume).
H1-CRD affinity purification on Gal-Sepharose by FPLC
H1-CRD was purified by affinity to Gal-Sepharose according to Spiess M. et al.26 by
FPLC. The purification was performed with degassed buffers at 4°C on a BioLogic
workstation, using the EZLogic software.
The cleared solution of refolded proteins (see Section 2.2.5.3.3), equivalent to 100ml
expression culture, was loaded onto the Gal-Sepharose BioScale MT-10 column (10ml
bed-volume), equilibrated with washing buffer (20mM TrisHCl, 500mM NaCl, 25mM
Benefit and Application of Antibodies Against the H1-CRD Materials and Methods
71
CaCl2, pH7.8 at 20°C) at a flow rate of 1ml/min. Contaminating proteins were washed
out isocratically with 2 bed-volumes washing buffer at a flow rate of 1ml/min until the
baseline was reached. Then, the Gal-bound H1-CRD was eluted isocratically with 2 bed-
volumes elution buffer (20mM TrisHCl, 500mM NaCl, 2mM EDTA, pH7.8 at 20°C) at a
flow rate of 1ml/min. The eluating protein was detected by monitoring the A280
absorbance and was collected in fractions.
Protein Fractions were analyzed by PAGE (see Section 2.2.4.2), were pooled and
quantified by Bradford assay (see Section 2.2.4.4.2).
2.2.5.4 Size exclusion chromatography of the H1-CRD by FPLC
The gel filtration method was developed according to the Amersham Handbook141.
The size exclusion chromatography (SEC) by FPLC was performed at 4°C on a BioLogic
workstation, using the software EZLogic. Three different SEC buffers were tested: SEC0
(20mM TrisHCl, 120mM NaCl, pH 7.8), SECCa (20mM TrisHCl, 120mM NaCl, 2mM
CaCl2, pH7.8) and SECEDTA (20mM TrisHCl, 120mM NaCl, 2mM EDTA, pH 7.8).
When the SEC was run with SECEDTA buffer, 3mM EDTA was added to the H1-CRD
solution prior to injection.
The affinity-purified H1-CRD (see Section 2.2.5.3.4) was concentrated in Centricon filter
devices YM-10.000 at 4’800rcf and 4°C and was transferred into collection tubes by
spinning at 650rcf for 2min at 4°C, prior to SEC.
The Bio-Prep SE100/17 column (15ml bed-volume, 8·300mm) was equilibrated with
SEC buffer at a flow rate of 0.3ml/min overnight. 300?l concentrated H1-CRD solution
was injected and the SEC was run isocratically at a flow rate of 0.3ml/min. Eluting
proteins were detected by monitoring the A280 absorbance, were collected in fractions
and analyzed by PAGE (see Section 2.2.4.2).
300?l Biorad gel filtration standard (670kDa, 158kDa, 44kDa, 17kDa, 1.35kDa) was used
for the calibration. The standard calibration curve was drawn and retention times of
monomeric and dimeric H1-CRD were calculated using the Prism4 software.
2.2.5.5 Preparative scale production of the H1-CRD
The expression and the purification were ten times up-scaled for the preparative H1-
CRD production.
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The H1-CRD was expressed in 500ml cultures of an E.coli expression clone (see
Section 2.2.5.1). Pellet proteins of 5’000ml expression culture were solubilized by the FD
or the NFD method, using the reductant ?-mercaptoethanol (see Section 2.2.5.3.2). The
solution of solubilized proteins was dialyzed against 4’000ml precooled basic refolding
buffer (buffer system A) in a 5’000ml beaker glass (see Section 2.2.5.3.3). The solution
of refolded proteins was split to 5 portions. One portion was applied to a Gal-Sepharose
BioScale MT-20 column in a single run. The column was run at a flow rate of 1ml/min
and was washed with 4-5 bed-volumes washing buffer (see Section 2.2.5.3.4). The
column flow through, the wash and eluting fractions were analyzed by SDS-PAGE (see
Section 2.2.4.2).
The solution of pooled elution fractions, derived from 5’000ml expression culture, was
transferred into swollen dialysis tubes (see Section 2.2.5.3.3) and dialyzed against
4’000ml precooled dialysis buffer (20mM TrisHCl, 120mM NaCl, 2mM CaCl2, pH 7.8) in
a 5’000ml beaker glass at 4°C, gently stirring on a magnetic stirrer. After 15h dialysis,
the buffer was replaced once with prechilled fresh buffer.
The dialyzed H1-CRD solution was concentrated in Centricon filter devices YM-10.000
at 4’800rcf and 4°C and was transferred into collection tubes by spinning at 650rcf for
2min at 4°C.  The concentrated H1-CRD solution was stored at –20°C in aliquots.
Concentrated H1-CRD was quantified by Bradford assay (see Section 2.2.4.4.2).
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2.3 Production and purification of polyclonal antibodies
2.3.1 Hen immunization and egg handling
Immunization of hens and egg collection was performed as described by Bootz F.142
Preparation of antigen
The galactose affinity and SEC-purified H1-CRD (see Sections 2.2.5.3.4 and 2.2.5.4)
was diluted to 40?g/ml in sterile PBS. For priming 500?l antigen solution was emulsified
with 500?l Complete Freund’s adjuvant and for boosts 500?l antigen solution was
emulsified with 500?l Incomplete Freund’s adjuvant.
Antigen injection
Three 22 weeks old hybrid laying hens were primed subcutaneously with 1’000?l antigen
/ CFA emulsion (20?g H1-CRD) and were boosted subcutaneously with 1’000?l antigen /
IFA emulsion (20?g H1-CRD) every 21-28 days.
Egg handling
Preimmune eggs were collected. Eggs of immunized hens were collected, starting day
14 after the first boost, and were stored at 4°C until IgY extraction.
2.3.2 IgY purification
2.3.2.1 Purification optimization
After separation of the egg white and the yolk, lipids were removed, trying out three
different methods, and total IgY were extracted, looking at three different methods.
2.3.2.1.1 Egg white and yolk separation
The egg was broken, the yolk was separated from the egg white and rolled on a filter
paper to remove traces of egg white. The yolk vitellin membrane was punctured and the
yolk collected in a measuring cylinder.
2.3.2.1.2 Protein / Lipid separation methods
Lipids and some proteins were removed, comparing the freeze / thaw (F/T) method
modified from Jensenius J.C. et al.96 and Devi C.M et al.99, the water dilution (WD)
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method of Atika E.M et al.98 and the PEG 3.5% precipitation (PEG) method of Polson A.
et al.100.
Freeze / Thaw method
10ml yolk was diluted to 100ml in water and the pH was adjusted to pH7.0 with NaOH
(1M). The yolk solution was frozen three times at –20°C overnight and thawed at 4°C
overday. Lipids were precipitated at 2’000rcf for 20min and the supernatant was cleared
by centrifugation at 4’000rcf for 20min, followed by filtration using MILLEX GP filters
(0.22?m).
Water dilution method
10ml yolk was diluted to 100ml in water and the pH was adjusted to pH5.0 with HCl
3.7%). The yolk solution was incubated overnight at 4°C and cleared by
ultracentrifugation at 13’000rcf for 25min at 4°C, followed by filtration using MILLEX GP
filters (0.22?m).
PEG8000 3.5% precipitation method
10ml yolk was diluted to 50ml in phosphate buffer (100mM Na2HPO4, pH7.6). 3.5%
PEG8000 was added and dissolved, stirring for 10min. Lipids were precipitated at
2’900rcf for 20min at 4°C and the supernatant filtered using Macherey-Nagel filters
MN615.
2.3.2.1.3 Protein / total IgY separation methods
Yolk protein solutions (see Section 2.3.2.1.2) were split into three equal portions.
Thereof, total IgY antibodies were extracted, comparing the ammoniumsulfate
precipitation (AS) method of Swendsen L. et al.143, the PEG precipitation (PEG) method
of Polson A. et al.84 and the PEG / ethanol precipitation (PEG/EtOH) method of Polson
A. et al.100 at the same time.
Ammoniumsulfate 50% precipitation method
Ammoniumsulfate was added to the yolk protein solution to 25% saturation and the
suspension was stirred in ice-water for 20min, followed by centrifugation at 2’900rcf for
45min at 4°C. Ammoniumsulfate was dissolved in the cleared yolk solution to a final
saturation of 50% and precipitated IgY were collected at 2’900rcf for 45min at 4°C.
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Precipitated IgY were dissolved in 1ml (0.1 yolk volume) KPBS (1.5mM KH2PO4, 8mM
Na2HPO4, 137mM NaCl, 2.7mM KCl).
PEG8000 12% precipitation method
PEG8000 was added to the yolk protein solution to a final saturation of 12% and the
suspension was stirred for 30min, followed by centrifugation at 2’900rcf for 45min at 4°C.
Precipitated IgY were dissolved in 25ml phosphate buffer (100mM Na2HPO4, pH7.6) and
precipitated a second time with 12% PEG8000. After spinning at 2’900rcf for 45min at
4°C, collected IgY were dissolved in 1ml (0.1 yolk volume) KPBS.
PEG8000 12% / ethanol 50% precipitation method
IgY were extracted according to the PEG 12% precipitation method but collected IgY
were dissolved to 2.5ml in phosphate buffer and additionally precipitated by addition of
50% ethanol of –20°C, after cooling the IgY solution on ice to about 0°C. The IgY
suspension was incubated on ice for 1h and ultracentrifuged at 13’000rcf for 25min at
0°C. The precipitated IgY were dissolved in 2.5ml (0.75 yolk volume) phosphate buffer.
2.3.2.1.4 Dialysis of IgY solutions
Dialysis tubes (ZelluTrans Roth 6.0, 25mm) were prepared as described in Section
2.2.5.3.3. 1 volume IgY solution was transferred into swollen dialysis tubes and was
dialyzed against 1’000 volumes KPBS or phosphate buffer at 4°C, stirring magnetically.
The buffer was twice exchanged within 30h.
After addition of 0.02% NaN3, the IgY solution was stored at 4°C.
2.3.2.1.5 Extraction of specific anti-H1 IgY
The antigen H1-CRD was coupled to agarose using the AminoLink® Plus Immobilization
Kit according to the manufacturer instructions144.
Buffer exchange of H1-CRD
The disturbing primary amine Tris of the H1-CRD solution (see Section 2.2.5.5) was
removed by buffer exchange to HEPES buffer (pH7.2) using Biomax ultrafree 0.5
centrifugal devices (MWCO 10’000). The needed volume H1-CRD solution was
concentrated at 10’000rcf for 10min, the buffer exchanged by spinning six times with
500?l HEPES buffer at 10’000rcf for 10min and the dialyzed H1-CRD diluted to 2ml in
HEPES buffer (pH7.2) to a final concentration of 2mg/ml H1-CRD.
Benefit and Application of Antibodies Against the H1-CRD Materials and Methods
76
Coupling of H1-CRD antigen to agarose
2ml AminoLink agarose slurry 50% were equilibrated with HEPES buffer (pH7.2) and
activated with 40?l NaCyanoborohydrid solution (5M NaCyanoborohydrid, 10mM
NaOH). 2ml H1-CRD solution (2mg/ml) were added and H1-CRD was coupled by
incubation overnight. The coupled agarose slurry was washed with 5ml HEPES buffer
and blocked with 4ml quenching buffer (1M TrisHCl, 0.05% NaN3, pH 7.4), while shaking
over-head. Finally, coupled slurry was washed with 15ml washing buffer (1M NaCl,
0.05% NaN3).
Anti-H1 IgY affinity purification on H1-CRD agarose
2ml dialyzed IgY solution (see Section 2.3.2.1.3) was applied onto the H1-CRD agarose
column (1ml bed-volume), was equilibrated with 6 bed-volumes phosphate buffer
(100mM Na2HPO4, pH7.6) and incubated for 1h. After washing with 12 bed-volumes
phosphate buffer, bound IgY were eluted with 8 bed-volumes 100mM glycine (pH2.5-
3.0). 500?l fractions were collected in 1.5ml tubes containing 75?l TrisHCl (1M, pH7.5)
for neutralization. The specific IgY-containing fractions were detected by Bradford spot
assay or absorbance A280 measurement (see Section 2.2.4.4) and were pooled.
After addition of 0.02% NaN3, the solution of specific IgY was stored at 4°C.
2.3.2.2 Preparative scale extraction of total IgY by PEG precipitation
The optimized method was ten times scaled up for preparative extraction of total IgY.
125ml yolk was diluted to 500ml in phosphate buffer and lipids were removed by the
PEG3.5% method (see Section 2.3.2.1.2). Total IgY were extracted from total yolk
proteins by the PEG 12% precipitation method (see Section 2.3.2.1.3). Purified IgY were
dissolved in 20ml KPBS and were dialyzed against 5’000ml KPBS (see Section
2.3.2.1.4). The buffer was exchanged three times every 5-10h.
The dialyzed IgY solution was preserved with 0.02% NaN3 and stored at 4°C.
2.3.2.3 Analysis
The purity of the total and the specific IgY were controlled by PAGE and the activity was
tested by immunoblotting and AP-ELISA (see Sections 2.2.4.2, 2.2.4.3 and 2.4.2.5.1).
The yield was determined by Bradford assay or A280 measurement (see Section 2.2.4.4).
The characterization of IgY was performed according to Section 2.5.
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2.4 Production and purification of monoclonal antibodies
2.4.1 Buffers and media
2.4.1.1 Buffers
KPBS (1.5mM KH2PO4, 8mM Na2HPO4, 137mM NaCl, 2.7mM KCl)
T-Ca20 (20mM TrisHCl, 20mM CaCl2, pH 7.5)
TBS (20mM TrisHCl, 120mM NaCl, pH 7.5)
TTBS (20mM TrisHCl, 120mM NaCl, 0.05% Tween20, pH 7.5)
TTBS-Ca20 (20mM TrisHCl, 120mM NaCl, 20mM CaCl2, 0.05% Tween20, pH 7.5)
2.4.1.2 Media
FCS was heat inactivated for 30min at 56°C in a water bath and supplemented medias
(see Formulation 8) were filtered using disposable StericupTM (0.22?m) prior to use.
DMEM-10: DMEM high-glucose with 10% FCS
10%
2mM
100U/ml
100?g/ml
Dulbecco’s Modified Eagle’s medium high-glucose (4.5mg/ml glucose, NaPyruvate)
FCS
L-glutamine
Penicilline
Streptomycine
DMEM-15: DMEM high-glucose with 15% FCS
15%
2mM
100U/ml
100?g/ml
Dulbecco’s Modified Eagle’s medium high-glucose (4.5mg/ml glucose, NaPyruvate)
FCS
L-glutamine
Penicilline
Streptomycine
IMDM-5: IMDM with 5% FCS
5%
25mM
2mM
50?g/ml
Iscove’s Modified Dulbecco’s medium
FCS
HEPES
GlutaMAX
Gentamicin
IMDM-10: IMDM with 10% FCS
10%
25mM
2mM
50?g/ml
Iscove’s Modified Dulbecco’s medium
FCS
HEPES
GlutaMAX
Gentamicin
HT-IMDM-5: IMDM with 5% FCS and HT 1x
5mM
800?M
IMDM-5
Hypoxanthine
Thymidine
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HAT-IMDM-5: IMDM with 5% FCS and HAT 1x
5mM
20?M
800?M
IMDM-5
Hypoxanthine
Aminopterine
Thymidine
RPMI-0: RPMI1640
1x
1mM
2mM
100?g/ml
RPMI1640 without L-glutamine
NEAA
Sodium pyruvate
GlutaMAX
Kanamycine
RPMI-6: RPMI1640 with 6% FCS (low IgG)
6%
RPMI-0
FCS (low IgG)
RPMI-10: RPMI1640 without L-glutamine with 10% FCS
10%
RPMI-0
FCS
6-RPMI-15: RPMI1640 without L-glutamine with 15% FCS and IL-6
15%
1%
RPMI-0
FCS
Human IL-6
6?-RPMI-15: RPMI1640 without L-glutamine with 15% FCS, IL-6 and ?-metcaptoethanol
15%
1%
10?M
RPMI-0
FCS
Human IL-6
?-mercaptoethanol
HT-RPMI-15: RPMI1640 with 15% FCS and HT 1x
15%
5mM
800?M
RPMI-0
FCS
Hypoxanthine
Thymidine
df-RPMI-10: RPMI1640 with 10% FCS, human IL-2 and hGMCSF
10%
8%
10%
RPMI-0
FCS
Human IL-2 supernatant
Human granulocyte-macrophage colony-stimulating factor supernatant
HAT6?-RPMI-15: RPMI1640 with 15% FCS, IL-6, ?-mercaptoethanol and HAT 1x
15%
5mM
20?M
800?M
1%
10?M
RPMI-0
FCS
Hypoxanthine
Aminopterine
Thymidine
Human IL-6
?-mercaptoethanol
Formulation 8: Composition of supplemented cell culture media.
Cells in a “bad shape” were temporarily cultured in medium including 1% human IL-6.
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2.4.2 General methods
2.4.2.1 Viability check and cell counting by trypan blue
The cell number and the viability were verified according to the protocol of Harlow E. et
al.102
The cell suspension was combined with the same volume trypan blue stain 0.4% and
filled into an improved Neubauer counting chamber. White living cells and blue dead
cells of four big squares (1mm2, volume 0.1mm3) were counted with 100 times
magnification under the microscope (IM, binocular KpI-W10x/18, objective Ph1F10/0.25,
Zeiss). The cell density was calculated using Equation 7 and the viability was estimated
using Equation 8.
ccells /ml = nviable ?
d ?104
f
(Eq. 7)
Equation 7: Determination of the cell density, using an improved Neubauer counting chamber. The cell
density (c) (cells/ml) of a cell suspension, d times diluted with trypan blue was calculated by counting the
number of viable cells nviable in f big squares.
v% =
nviable
ntotal
?100% (Eq. 8)
Equation 8: Determination of the cell viability, using an improved Neubauer counting chamber. The cell
viability v (%) of a cell suspension, stained with trypan blue was calculated by counting the number of viable
cells (nviable) compared to the total number of cells (ntotal).
2.4.2.2  Cell thawing
Cells were thawed according to a protocol provided by Gober H.J.145.
Cells, frozen at –185°C (see Section 2.4.2.4), were quickly thawed at 37°C in a water
bath and immediately diluted with 1ml DPBS in the cryotube while pipetting carefully up
and down. Cells were washed in 30ml DPBS and collected at 125rcf for 10min.
Following another wash in 10ml DPBS, the cell pellet was broken by tapping the tube
and suspended to about 5·105cells/ml in supplemented culture medium. 2ml/well were
dispersed into a 24-well plate and incubated at 37°C (5% CO2, 100% humidity).
After about 1h, the shape of the cells was controlled under the microscope and high
dense cultures were split.
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2.4.2.3 Cell cultivation
2.4.2.3.1 Collagen coating of culture plates and flasks
Culture flasks and plates were coated following the protocol of Stokmaier D.103
About 10?l/cm2 sterile collagen solution (0.25mg/ml collagen S, 500mM acetic acid
(pH2.8), sterile) was spread in culture flasks and plates overnight at 4°C. The collagen
coating was neutralized by washing twice with about 40?l/cm2 DPBS. Coated flasks and
plates were stored at 4°C until use.
2.4.2.3.2 Cell splitting and propagation
Cells were cultured according to Harlow E. et al.102 and according to the protocols of the
group of De Libero G.145 or of Stokmaier D.103
Cell cultures were examined under the microscope (IM, binocular KpI-W10x/18,
objectives F2.5/0.08, Ph1F10/0.25, F-LD20/0.025, Zeiss) to look for contamination and
to inspect the shape, the viability and the density of cells (see Section 2.4.2.1) prior to
splitting or propagation. Different cell lines were cultured in 96-well plates (200?l/well),
24-well plates (2ml/well), 6-well plates (5ml/well), T25 flasks (7ml) and T75 flasks (20ml).
The detailed composition of the cell media can be found in Section 2.4.1.2.
Isolated primary cells (monocytes, dendritic cells)
Human monocytes were resuspended at 5·105cells/ml in df-RPMI-10 (see Section
2.4.1.2) and 3ml/well plated on 6-well plates. Monocytes differentiated to dendritic cells
during incubation at 37°C (5% CO2, 100% humidity) for 4 days.
Suspension cells (myelomas, hybridomas, HL-60, Jurkat, K-652, THP-1)
After diluting cells to about 5·105cells/ml in RPMI-10 (see Section 2.4.1.2), 2ml/well were
distributed in 24-well plates and incubated at 37°C (5% CO2, 100% humidity).
In dense cultures, cells were suspended by pipetting and split 1:2 to 1:4 with RPMI-10.
Adherent cells (HepG2, SK-Hep1)
Cells were resuspended at 1·106cells/ml in DMEM-10 (see Section 2.4.1.2). 5ml/well
HepG2 were distributed in collagen coated 6-well plates and 5ml/well SK-Hep1 in
untreated 6-well plates.
In confluent cultures, the medium was removed and cells rinsed once with DPBS. The
trypsin / EDTA solution was distributed, immediately removed and cells detached during
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incubation at 37°C for 2-5min. Detached cells were washed in DPBS and collected at
125rcf for 10min. The pellet was loosened by tapping the tube and resuspended in fresh
DMEM-10.
HepG2 were split 1:5 to 1:10 into collagen-coated flasks or plates and SK-Hep1 were
diluted 1:10 to 1:20 into untreated flasks or plates.
2.4.2.4 Cell freezing
Cells were frozen following the procedure of Harlow E. et al.102 modified by Fischer R.146
One day before freezing, cells were split 1:2 to 1:10 in fresh medium.
Cells (4-8 wells of 24-well plates, 2 wells of 6-well plates, 1 T25 flask) were counted and
the viability checked (see Section 2.4.2.1). After centrifugation at 400rcf for 5min at 4°C,
the cell pellet was resuspended in the remaining medium by tapping the tube and was
diluted into cold freezing medium (90% FCS, 10% DMSO) to get about 3·106 vital
cells/ml. 0.5-1.0ml aliquots were distributed in labeled cryotubes, which were placed in a
styropore support. Cells were immediately frozen, for 2h at –20°C first, then 1day at
–80°C prior to storage in liquid N2 for infinite time.
Cells were frozen following the procedure of Harlow E. et al.102 modified in the protocol
of De Libero G.145
Cells were frozen following the same procedure as described above but cells were
collected at 125rcf for 2min at 4°C and diluted to about 1·106 vital cells/ml in cold
freezing medium. 0.5-1.0ml aliquots were immediately frozen in a styropore support for
1-10days at –80°C prior to storage in liquid N2.
2.4.2.5 Screening ELISA
2.4.2.5.1 Alkaline phosphatase ELISA
The alkaline phosphatase ELISA was modified from Fischer R.146.
The culture medium served as negative control and the serum of immunized mice
(1:1’000 in blocking buffer) was used as positive control.
MaxiSorb ELISA plates were coated with 100?l/well H1-CRD solution (3?g/ml H1-CRD,
20mM CaCl2 in TBS, pH7.5) and were incubated overnight at 4°C. After washing twice
with 250?l/well washing buffer (20mM CaCl2, 0.05% Tween20 in TBS, pH7.5) using the
plate washer or the multi-dispense multi-channel pipet, remaining binding sites were
blocked with 250?l/well blocking buffer (4% milk powder in TBS, pH7.5) during
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incubation for 2h at RT. Wells were washed three times with 250?l/well washing buffer.
80?l supernatant samples, negative and positive controls were incubated for 2h at RT
and wells were washed three times with 250?l/well washing buffer. After incubation with
80?l/well AP-labeled goat-anti-mouse antibody solution (GAM-IgG(whole molecule)-AP
or GAM-Ig(polyvalent)-AP 1:1’000 to 1:5’000 in blocking buffer) for 2h at RT, wells were
washed five times with 250?l/well washing buffer again. 80?l/well substrate solution
(1mg/ml p-nitrophenylphosphate, 500mM MgCl2, 10% diethanolamine, pH9.8) was
distributed and the color was developed for 15-20min at RT prior to read the absorbance
at 405nm in a Spectramax190 plate reader.
2.4.2.5.2 Horse radish peroxidase ELISA
The horseradish peroxidase ELISA was adapted from De Libero G.145.
The culture medium served as negative control and serum of immunized mice (1:1’000
in blocking buffer) was used as positive control.
MaxiSorb ELISA plates were coated with 70?l/well coating solution (3-5?g/ml H1-CRD,
20mM CaCl2 in TBS, pH7.5) and were incubated overnight at 4°C, covered with lid and
parafilm. After washing once with 200?l/well washing buffer (20mM CaCl2, 0.05%
Tween20 in TBS, pH7.5), plates were tapped dry on paper towels and blocked with
150?l/well blocking buffer (1% BSA, 20mM CaCl2, 0.05% Tween20 in TBS, pH7.5)
during incubation for 1h at RT. Wells were washed twice with 200?l/well washing buffer,
tapped dry and were incubated with 50?l/well supernatant sample (nude or diluted in
blocking buffer), negative control or positive control for 1h at RT (or 30min at 37°C). After
three times washing with 200?l/well washing buffer and tapping dry, 50?l/well
horseradish peroxidase (HRP)-labeled anti-mouse antibody solution (GAM-
Ig(polyvalent)-HRP or GAM-Ig(H+L chain)-HRP 1:5’000 in blocking buffer) were
distributed and incubated for 1h at RT. Plates were washed five times with 200?l/well
washing buffer, followed by incubation with 90?l/well Sigma Fast OPD substrate solution
for 5min in the dark. The color development was stopped by addition of 50?l/well H2SO4
(10%) and the absorbance was read at 490nm in a Spectramax190 plate reader.
2.4.3 Production of hybridomas
2.4.3.1 Immunization
Mize were immunized by Fischer R.146 and by De Libero G.145
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2.4.3.1.1 Immunization of NMRI outbred mice by Fischer R.
Preparation of antigen
For immunization of three mice, affinity-purified H1-CRD (see Section 2.2.5.5) was
diluted to 400?g/ml in sterile PBS and stored at –20°C until use.
Prior to priming three mice, 300?l antigen solution was emulsified with 300?l CFA
(1mg/ml heat inactivated M. tuberculosis, 85% paraffin oil, 15% mannide monooleat)
using two Hamilton syringes connected by a valve. The water phase was first pressed
into the oil phase, and then pressed from one syringe to the other to get a very thick w/o
emulsion.
Just prior to boost, 300?l antigen solution was emulsified with 300?l IFA (85% paraffin
oil, 15% mannide monooleat) the same way. For final boost, the antigen solution was
diluted in sterile PBS to 200?g/ml.
Antigen injection
Three 8-10 weeks old female wildtype NMRI outbred mice (specific pathogen free) were
primed with 100?l antigen / CFA emulsion (20?g H1-CRD) subcutaneously in the neck
and boosted at least twice with 100?l antigen / IFA emulsion (20?g H1-CRD)
subcutaneously in the neck every 3 weeks after immunization.
For final boosts, 200?l antigen solution (20?g H1-CRD) without adjuvant was injected
subcutaneously in the neck 3, 2 and 1 day prior to fusion.
2.4.3.1.2 Immunization of Balb/c inbred mice by De Libero G.
Preparation of antigen
For immunization of three Balb/c mice, affinity-purified H1-CRD (see Section 2.2.5.5)
was diluted to 2mg/ml in pyrogen-free sterile NaCl 0.9% Braun and sterile filtered. 500?l
aliquots were stored at –20°C until use.
Prior to priming three mice, 500?l antigen solution was emulsified with 500?l thoroughly
vortexed CFA using two syringes, connected by a two-way valve. The water phase was
first pressed into the oil phase, and then pressed from one syringe into the other until a
very thick white w/o emulsion was formed. After pressing into one syringe, a needle was
connected to immunize mice.
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Just prior to boost, 500?l antigen solution was emulsified with 500?l IFA the same way.
For final boost, the antigen solution was diluted in pyrogen-free sterile NaCl 0.9% Braun
to 1mg/ml.
Antigen injection
Three 7-8 weeks old female wildtype Balb/c inbred mice were primed with 200?l antigen
/ CFA emulsion (200?g H1-CRD) intraperitoneally and boosted at least twice with 200?l
antigen / IFA emulsion (200?g H1-CRD) intraperitoneally every 2 weeks.
For final boost, 200?l antigen solution (200?g H1-CRD) without adjuvant was injected
retro-ocular intravenously or intraperitoneally 3 days prior to fusion.
2.4.3.1.3 Serum titer determination
100?l venous blood of immunized mice was taken retro-ocularly using a glass capillary.
The venous blood was coagulated in a 1.5ml tube for 20min at 37°C in a water bath. The
coagulate was broken off by flicking the tube and incubated on ice for 20min prior to
centrifugation at 3’000rpm for 5min at 0°C. Cleared serum was stored at –20°C.
Sera of immunized mice, of an unimmunized Balb/c mouse for negative control and of a
previously immunized NMRI mouse for positive control were diluted to 10-2, 10-3, 10-4 and
10-5 in PBS and tested in HRP-ELISA according to the procedure described in Section
2.4.2.5.2. All samples were measured in duplicate.
2.4.3.2 Polyethylene glycol fusion
Splenocyte-myeloma hybridomas were formed following the polyethylene glycol (PEG)
fusion procedure of Fischer R.146 and De Libero G.145 originally introduced by Köhler G.
and Milstein C.82
2.4.3.2.1 PEG1500 fusion of NMRI splenocytes and P3X63-Ag8.563 myeloma cells by
the method of Fischer R.
The PEG1500 fusion method of Fischer R. is adapted from Harlow E. et al.102 originally
modified from the procedure of Galfre G. et al.147.
Myeloma cell culture
Three days prior to fusion, Balb/c myeloma cells P3X63-Ag8.563 were thawed (see
Section 2.4.2.2) and cultured in IMDM-10 (see Section 2.4.1.2) at 37°C (5% CO2, 100%
humidity).
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Macrophage feeder layer
Unimmunized Balb/c mice were stimulated with 20ng lipopolysaccharid intraperitoneally
about 9 days prior to fusion and euthanized six days later with methoxyflurane or CO2.
The abdominal skin of ethanol-(70%)-disinfected mice was removed, using sterile
tweezers and scissors, prior to injection of 10ml sterile, prechilled PBS into the
peritoneal cavity. The stomach was gently moved for 5min to detach the peritoneal
macrophages. The suspension was aspirated and macrophages were collected at
1’000rpm for 5min, resuspended by tapping the tube and diluted to 50ml in IMDM-5 (see
Section 2.4.1.2). 100?l/well macrophage feeder suspension was plated into 96-well
plates and incubated at 37°C (5% CO2, 100% humidity) until fusion.
PEG1500 fusion
The day after the last final boost, the NMRI mouse was anaesthized with Metofane® and
decapitated using scissors. The blood of the arteria carotis was collected to get the
serum after coagulation and centrifugation at 16’000rcf for 5min. The serum was stored
at –20°C until used as a positive control in the screening ELISA.
The spleen of the ethanol-(70%)-disinfected mouse was prepared using sterile tweezers
and scissors. After removal of fat tissue and rinsing with PBS, the spleen was
homogenized in a glass potter with 4ml PBS at 37°C by moving the piston five times up
and down. Suspended cells were collected at 280rcf for 5min, the pellet loosened by
tapping the tube and diluted to 50ml in PBS at 37°C. Splenocytes and P3X63-Ag8.563
myeloma cells were counted (see Section 2.4.2.1).
After collecting splenocytes at 280rcf for 5min, the cells were diluted in a calculated
volume of myeloma cell suspension in a 50ml Falcon tube to get a ration of splenocytes :
myeloma cells of 3:1. Combined cells were spun again and were washed three times
with 50ml PBS at 37°C before the supernatant was removed completely.
While turning the tube manually, 1 volume PEG1500 at 37°C (1ml per 5·107
splenocytes) was added within 10s, using a syringe with needle. After incubation for 90s
at 37°C, cells were slowly diluted with PBS at 37°C while turning the tube continuously,
adding 1 volume within the 1st min followed by 2, 4, .…, 2n-1 volumes within the 2nd, 3rd,
…, nth min until a total cell suspension of 50ml was obtained. Fused cells were gently
spun at 125rcf for 5min, then the pellet was resuspended by tapping the tube and cells
were diluted with 40ml IMDM-5. 50?l/well cell fusion was distributed in eight 96-well
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plates, which were already plated with 100?l/well macrophage feeder layer and cells
were incubated at 37°C (5% CO2, 100% humidity) in a Nuaire IR autoflow incubator.
The day after fusion, 50?l/well selective IMDM-5 medium containing HAT 4x (20mM
hypoxanthine, 80?M aminopterine, 3.2mM thymidine) were added to get HAT-IMDM-5
and plates were further incubated at 37°C (5% CO2, 100% humidity) for 21 days.
2.4.3.2.2 PEG4000 fusion of Balb/c splenocytes and P3X63-Ag8.563 myeloma cells by
De Libero G.
Myeloma cell culture
Balb/c myeloma cells P3X63-Ag8.563 were thawed (see Section 2.4.2.2) and cultured in
RPMI-10 (see Section 2.4.1.2) at 37°C (5% CO2, 100% humidity). When confluent and
one day prior to fusion, cells were split 1:2 to 1:3.
Preparation of PEG4000 solution
In a glass tube, 2.2ml GKN (3M), 0.8ml sterile water and 40?l NaOH (100mM) were
mixed and therein, 2.0g PEG4000 was solubilized till just dissolved by shaking in boiling
water.
PEG4000 fusion
Three days after the final boost, the Balb/c mouse was euthanized with CO2. The blood
was collected to get the serum after coagulation and centrifugation at 800rcf for 2min.
The serum was stored at –20°C until used as a positive control in the screening ELISA.
The spleen of the ethanol-(70%)-disinfected mouse was prepared using sterile tweezers
and scissors. After removal of fat tissue, the spleen was pressed with the pistil through a
cell sieve into a Petri dish containing a few ml MEM. Tissue clumps were homogenized
using a Pasteur pipet. After a twice sedimentation of remaining clumps for 2min in 15ml
Falcon tubes, splenocytes of the supernatant were collected at 1’000rpm for 10min and
were resuspended in 10ml MEM. Splenocytes and P3X63-Ag8.563 myeloma cells were
counted (see Section 2.4.2.1).
The splenocytes and the myeloma cells suspension were combined in a 50ml Falcon
tube, to get a ratio of splenocytes : myeloma cells of 5:1, and were diluted to 50ml with
MEM . The combined cells were gently spun at 125rcf for 10min and were washed once
in 50ml before the supernatant was removed completely.
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While shaking the tube manually in a water bath at 37°C, 1ml prewarmed PEG4000
solution was slowly added drop by drop. After incubation for 1min in the water bath at
37°C without shaking, cells were diluted slowly with about 50ml RPMI at 37°C within
10min, adding drop by drop at the beginning and gradually speeding up while gently
shaking. The cell fusion was incubated at 37°C in the water bath for 5min, was
centrifuged at 125rcf for 10min and was resuspended in 100ml 6?-RPMI-15 (see Section
2.4.1.2). 100?l/well cell fusion was distributed in ten 96-well plates and was incubated at
37°C (5% CO2, 100% humidity) in a Revca ultima incubator.
The day after fusion, 100?l/well selective 6?-RPMI-15 medium containing HAT 2x
(10mM hypoxanthine, 40?M aminopterine, 1.6mM thymidine) were added to get HAT6?-
RPMI-15 and plates were further incubated at 37°C (5% CO2, 100% humidity) for 14
days.
2.4.3.3 Hybridoma cultivation and screening
2.4.3.3.1 NMRI hybridoma cultivation and screening
NMRI hybridomas were cultured according to Harlow E. et al.102 and Fischer R.146
The day 21 post-fusion, plates were checked for living hybridomas under the
microscope. 100?l/well supernatant was replaced by fresh HAT-IMDM-5 of 37°C and
tested in an AP screening ELISA (see Section 2.4.2.5.1). Fusion plates were screened
by AP-ELISA again, the days 28 and 35 post-fusion.
200?l dense hybridomas in ELISA-positive wells on fusion plates were expanded to a
24-well macrophage feeder layer plate (1ml macrophages, see Section 2.4.3.2.1). 200?l
cell suspension of the 24-well plate was transferred back to the fusion plate for back-up
purpose.
Dense hybridomas on 24-well plates were checked by AP screening ELISA prior to
expansion of still positive hybridomas to 6ml/well with fresh HT-IMDM-5 (see Section
2.4.1.2) on a 6-well plate and further to 8-10ml in T25 flasks.
Hybridomas were frozen at –185°C in 2 batches of at least 3 cryotubes (see Section
2.4.2.4).
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2.4.3.3.2 Balb/c hybridoma cultivation and screening
Balb/c hybridomas were cultured according to De Libero G.145
The day 14 post-fusion, plates were controlled for living hybridomas under the
microscope and 100?l supernatant were checked in HRP screening ELISA (see Section
2.4.2.5.2). ELISA-positive hybridomas were transferred to every odd column on a 96-
well plate and were diluted to 200?l/well with HT-RPMI-15 (see Section 2.4.1.2). After
expansion of dense hybridomas to the even columns, hybridomas were tested by HRP
screening ELISA again. Dense and ELISA-positive hybridomas were diluted from 2 wells
of the 96-well plates to 2ml HT-RPMI-15 in one well on a 24-well plate and 200?l cell
suspension was transferred back to the 96-well plate for back-up purpose.
Hybridomas were expanded to 4 wells on the 24-well plate in HT-RPMI-15 for freezing at
–185°C in 2 batches of at least 3 cryotubes (see Section 2.4.2.4). The supernatant at
freezing time was tested again by HRP screening ELISA.
All hybridomas were stored in two different N2 tanks.
2.4.3.4 Terasaki cloning
Hybridomas were cloned on Terasaki-plates following the method of De Libero G.145
Hybridomas cloning
Hybridomas were thawed (see Section 2.4.2.2) the day before cloning and were cultured
in RPMI-10 at 37°C (5% CO2, 100% humidity).
Cells were counted (see Section 2.4.2.1) and diluted to 500, 150, 50 and 15cells/ml in 6-
RPMI-15 (see Section 2.4.1.2). 20?l/well cell suspension were distributed into labeled
60-well Terasaki-plates, using an ethanol (70%) and flame-sterilized Terasaki-pipettor.
Obtained 10 cloning plates with 0.3cell/well, 6 plates with 1cell/well, 3 plates with
3cells/well and 2 plates with 10cells/well were immediately incubated at 37°C (5% CO2,
100% humidity) for 10-12 days without opening of the incubator.
Clone cultivation and screening
The day 10-12 post-cloning, cell-positive wells were counted under the microscope to
estimate the plating efficiency (plating ratio at that 37% of wells are negative). Clones of
dilutions with at least three times less cells/well were transferred to every odd column on
96-well plates, which contained already 200?l/well 6-RPMI-15.
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About 19 days post-cloning, transferred clones were tested by AP or HRP screening
ELISA (see Section 2.4.2.5) and positive clones were expanded to the even columns on
the 96-well plates and further to 24-well plates (see Section 2.4.3.3.2).
A selected number of clones of the highest dilutions were frozen at –185°C in different
N2 tanks and in two batches of at least 2 cryotubes.
2.4.4 Production of monoclonal antibodies
2.4.4.1 Propagation of clones
Selected clones were propagated following the procedure of De Libero G.145
A clone was thawed (see Section 2.4.2.2) and expanded step by step by diluting 1:2 to
1:4 in RPMI-10 at 37°C (5% CO2, 100% humidity). As soon as dense cell growth was
established, the pooled cells of one entire 24-well plate were counted (see Section
2.4.2.1) and 2·106 cells were frozen in 2 cryotubes at –185°C (see Section 2.4.2.4). The
remaining cells were collected at 400rcf for 5min, were suspended in 36ml RPMI-6 (see
Section 2.4.1.2) and 6ml/well were distributed in a 6-well plate.
Dense cells of one full 6-well plate were diluted to 75ml in RPMI-6 in a T175 flask. After 3-
4 days, cells were expanded to 125ml in RPMI-6 and another 3-4 days later, they were
diluted to 250ml in RPMI-0 to a final FCS (low IgG) concentration of 3%. The yellowish
supernatant of still living cells was harvested at 400rcf for 5min and cleared by filtration
using StericupTM (0.22?m). After addition of 0.02% NaN3, the cleared supernatant was
stored at 4°C until affinity purification (see Section 2.4.4.2).
The cell pellet was resuspended in 75ml fresh RPMI-6 in a T175 flask and the cells were
propagated another time following the same procedure.
2.4.4.2 Affinity purification
2.4.4.2.1 Ig? purification on Protein L-Sepharose spinning columns
Monoclonal Ig were affinity-purified analytically on Nab Protein L spin columns according
to the manufacturer instructions.
10ml cleared supernatant (mAb in RPMI -10) was applied to a 0.1ml Protein L spin
column in aliquots of 500?l. Loaded column was incubated for 30min or overnight at
4°C, while shaking with 100rpm, followed by spinning at 5’000rcf for 1min. After washing
twice with 400?l PBS (pH7.5), bound antibodies were eluted four times with 200?l
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elution buffer into a 1.5ml tube containing 20?l 1M TrisHCl (pH8.0). Then, the spin
columns were three times washed with 400?l PBS for neutralization. Collected fractions
were analyzed (see Section 2.4.4.2.5).
After addition of 0.02% NaN3, the antibody solution was stored at 4°C.
2.4.4.2.2  IgG1 purification on a Protein A-agarose column (FPLC)
Monoclonal IgG1 were purified on an AffiGel Protein A-agarose cartridge, following the
high-salt method of Harlow E. et al.102, originally adapted from Ey P.L. et al.148. The
Protein A-agarose cartridge was run at 4°C by FPLC on a BioLogic work station with the
EZLogic software using degassed buffers of 4°C.
NaCl and glycine were dissolved in the cleared supernatant to 3.3M NaCl and 1.5M
glycine (see Section 2.4.4.1) and the pH was adjusted to pH9.0 with 1M NaBorat (pH9.0)
prior to filtration with StericupTM (0.22?m).
100ml high-salt supernatant was loaded onto the AffiGel Protein A cartridge (1ml bed-
volume), which was equilibrated with washing buffer 1 (50mM NaBorate, 3M NaCl, pH
9.0) at a flow rate of 1ml/min. The column was first washed with 5 volumes washing
buffer 1, then with 10 volumes using a gradient from washing buffer 1 (100%) to washing
buffer 2 (10mM NaBorate, 3M NaCl, pH 9.0, 100%) and finally with 5 volumes washing
buffer 2 at a flow rate of 1ml/min. The antibodies were eluted with 10 volumes glycine
(100mM, pH4.0). Eluting antibodies, which were detected by absorbance A280
measurement, were collected in fractions of 1ml into 1.5ml tubes that contained 50?l
TrisHCl (1M, pH8.8) for neutralization. The column was neutralized by washing with 5ml
washing buffer 2 and 5ml water at a flow rate of 1ml/min. The collected fractions were
analyzed (see Section 2.4.4.2.5) and pooled for quantification.
After addition of 0.02% NaN3, the antibody solution was stored at 4°C.
2.4.4.2.3 IgG1 and IgG2a purification on a Protein G-Sepharose column (FPLC)
Monoclonal IgG1 and IgG2a were affinity-purified on a HiTrap Protein G-Sepharose
column, according to a method modified from the manufacturer instructions and Nelson
P.N.149. The Protein G-Sepharose column was run at 4°C by FPLC on a BioLogic
workstation with the EZLogic software using degassed buffers of 4°C.
100ml or 200ml cleared supernatant (see Section 2.4.4.1) was loaded onto one or two
coupled HiTrap Protein G HP columns (1ml bed-volume), equilibrated with 5ml PBS
(pH7.5), at a flow rate of 0.2ml/min. After washing with 10 volumes PBS (pH7.5) at a
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flow rate of 0.2ml, bound antibodies were eluted with 10 volumes glycine (100mM,
pH3.0) at a flow rate of 0.4-1ml/min. Eluting antibodies were detected by monitoring of
A280 absorbance and 1ml fractions were collected in 1.5ml tubes, which contained 50?l
TrisHCl (1M, pH8.8) for neutralization. The column was neutralized, by washing with 5ml
washing buffer and 5ml water, at a flow rate of 1ml/min. The collected fractions were
analyzed (see Section 2.4.4.2.5) and pooled for quantification.
After addition of 0.02% NaN3, the antibody solution was stored at 4°C.
2.4.4.2.4 IgM purification on a H1-CRD-Sepharose column (FPLC)
H1-CRD was coupled to Sepharose using Pierce AminoLink Plus kit (see Section
2.3.2.1.5), packed into a BioScale MT-1 (1ml) column and used for affinity purification of
monoclonal IgM. The H1-CRD-Sepharose column was run at 4°C by FPLC on a
BioLogic workstation using the EZLogic software following a method modified from the
manufacturer instructions. All buffers were degassed by filtration (0.45?m) and of 4°C.
100ml cleared supernatant (see Section 2.4.4.1) was loaded onto the H1-CRD-
Sepharose column (1ml bed-volume), equilibrated with washing buffer (20mM TrisHCl,
500mM NaCl, 20mM CaCl2, pH7.5 at 20°C), at a flow rate of 0.2ml/min. Contaminating
proteins were washed out isocratically with 10 volumes washing buffer at a flow rate of
0.2ml/min, until the baseline was reached. The antibodies were eluted isocratically with
10 volumes glycine (100mM, pH3.0) and were detected by absorbance A280
measurement. The antibody peak was collected in 1ml fractions into 1.5ml tubes, which
contained 50?l TrisHCl (1M, pH8.8) for neutralization. The column was neutralized, by
washing with 5ml TBS-Ca20 and with 5ml water. Antibody fractions were analyzed (see
Section 2.4.4.2.5) and pooled for quantification.
After addition of 0.02% NaN3, the antibody solution was stored at 4°C.
2.4.4.2.5 Analysis
The purity of antibody fractions was analyzed by SDS-PAGE (see Section 2.2.4.2) and
the activity of diluted antibodies was controlled by HRP-ELISA (see Section 2.4.2.5.2).
The antibody concentration was determined by absorbance A280 measurement, by
Bradford assay and by SDS-PAGE quantification (see Section 2.2.4.4).
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2.5 Antibody characterization
2.5.1 Protein assays
2.5.1.1 Polyacrylamide-gel Electrophoresis
Anti-H1 mAb and pIgY were controlled by reducing, non-reducing SDS-PAGE and native
PAGE (see Section 2.2.4.2).
2.5.1.2 Immunoblotting
2.5.1.2.1 Immunoblotting of antibodies
Purified monoclonal anti-H1 antibodies were run by PAGE, blotted to a nitrocellulose
membrane and were stained (see Section 2.2.4.3). After blocking and washing, the mAb
were directly immunostained with a secondary antibody.
2.5.1.2.2 Immunoblotting of the H1-CRD
The native and reduced-alkylated H1-CRD (see Section 2.5.1.4.1) were run by reducing
SDS-PAGE, the native and native-alkylated H1-CRD were applied to non-reducing SDS-
PAGE and in addition, the native H1-CRD was separated by native PAGE. The H1-CRD
bands on the PAGE gels were blotted to a nitrocellulose membrane (see Section
2.2.4.3).
After blocking and washing, the membrane was cut into pieces, which represented each
antigen sample once. Pieces were incubated separately in 2ml antibody solution (0.5?g-
5.0?g/ml purified anti-H1 mAb, 1% BSA, in TTBS-Ca20) in small Petri dishes (diameter
60mm) or in 5ml antibody solution (100?g/ml purified anti-H1 total pIgY, 1% BSA in
TTBS-Ca20 or anti-H1 mAb supernatant) in large Petri dishes (diameter 1’000mm),
covered with parafilm, overnight at 4°C, while shaking with 70rpm. Then, the pieces
were three times washed in TTBS-Ca20, before they were incubated separately in 3-5ml
secondary antibody solution (GAM-IgG(whole)-AP, GAM-Ig(polyvalent)-AP or RACh-
IgY(whole)-AP 1:2’000 to 1:5’000, 1% BSA in TTBS-Ca20) in large Petri dishes
(diameter 100mm), covered with parafilm for 2h at RT, while shaking with 70rpm. The
pieces were washed twice in TTBS-Ca20 and once in TBS, prior to casting in 3-5ml
substrate solution (100mM TrisHCl, 100mM NaCl, 5mM MgCl2, 0.4% NBT/CIP, pH 8.8)
in large Petri dishes. Finally, the color development was stopped in 5mM EDTA (pH8.0).
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2.5.1.3 Colorimetric assay
2.5.1.3.1 Isotyping ELISA
The isotype of the monoclonal anti-H1 antibodies was determined with the SBA
Isotyping Kit according to the HRP screening ELISA (see Section 2.4.2.5.2) but using
different isotype-specific HRP-labeled antibodies GAM-Ig(isotype M, G1, G2a, G2b, ? or
?)-HRP (1:300) and polyvalent HRP-labeled antibody GAM-Ig(H+L)-HRP (1:300).
2.5.1.3.2 Titration ELISA
Anti-H1 mAb and pIgY were titrated following a slightly modified method of the HRP
screening ELISA (see Section 2.4.2.5.2). All incubation steps were performed in plates,
which were covered with a lid and parafilm or were placed in a humidified chamber.
MaxiSorb ELISA plates were coated with 70?l/well coating solution (3-6?g/ml H1-CRD,
20mM CaCl2 in TBS, pH7.5) overnight at 4°C, were once washed with 200?l/well TTBS-
Ca20 (20mM CaCl2, 0.05% Tween20 in TBS, pH7.5), TTBS-Ca2 (2mM CaCl2, 0.05%
Tween20 in TBS, pH7.5) or TTBS-Ca0 (10mM EDTA, 0.05% Tween20 in TBS, pH7.5)
and were blocked with 150?l/well blocking buffer (1% BSA in TTBS-Ca) for 2h at RT.
After washing twice with 200?l/well TTBS-Ca and thoroughly tapping dry on paper
towels, 50?l/well purified anti-H1 mAb solutions (range of 0.001-30?g/ml anti-H1 mAb,
1% BSA in TTBS-Ca) or blank (1% BSA in TTBS-Ca) were distributed in duplicate or
triplicate and were incubated for 2h at RT. The plates were washed three times with
200?l/well TTBS-Ca and were tapped dry on paper towels followed by the detection with
50?l/well HRP-labeled antibody solution (GAM-Ig(H+L)-HRP 1:1’000, 1% BSA in TTBS-
Ca) for 2h at RT. After thoroughly washing five times with 200?l/well TTBS-Ca and
tapping dry, 90?l/well OPD Sigma Fast substrate solution was added and the plate was
incubated in the dark for 10min. The color development was stopped with 50?l/well HCl
(3.6%) and the absorbance was read at 490nm in a Spectramax190 plate reader.
2.5.1.3.3 Competitive GalNAc-polymer assay
The competition of anti-H1 mAb and GalNAc for binding to the H1-CRD was tested in
the GalNAc-polymer assay of Stokmaier D.103 based on Weitz-Schmidt G. et al.150.
Formation of ?-GalNAc-polymer-biotin-streptavidin-POD complex
20?l biotinylated ?-GalNAc-polymer (1mg/ml, 5mol% biotin, 20mol% GalNAc), 80?l
streptavidin-POD-conjugate (500U/ml), 20?l FCS and 80?l HAB-Ca (20mM HEPES),
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150mM NaCl, 1mM CaCl2, pH 7.4) were mixed in a 1.5ml tube and the complex was
formed during incubation for 2h at 37°C. The ?-GalNAc-polymer complex solution
(100?g/ml) was stored at 4°C in the dark.
Polymer assay
The evaporation was prevented by incubation in a humidified chamber during assay.
MaxiSorb ELISA plates were coated with 100?l/well coating solution (3?g/ml H1-CRD in
HAB-Ca) overnight at 4°C. The coating was discarded, the plates were tapped dry on
paper towels and the wells were blocked with 150?l/well blocking buffer (3% BSA in
HAB-Ca) for 1h at 4°C. After washing three times with 200?l/well HAB-Ca and tapping
dry on paper towels, 50?l/well ?-GalNAc-polymer complex (0.6?g/ml in HAB-Ca)
solution, followed by 50?l/well purified anti-H1 mAb solutions (range of 2-200?g/ml anti-
H1 mAb in HAB-Ca), HAB-Ca or EDTA solution (5mM EDTA in HAB-Ca) were
distributed in triplicate and incubated for 1h at 37°C. The plates were washed twice with
200?l/well HAB-Ca and were tapped dry on paper towels before 100?l/well Sigma Fast
OPD solution or Biorad ABTS solution were added. After an incubation of 10min in the
dark, the color development was stopped with 100?l/well acid (HCl 3.6%, OPD or 2%
oxalic acid, ABTS) and the absorbance was read at 490nm (OPD) or 415nm (ABTS) in a
Spectramax190 plate reader.
The titration curve was drawn and the EC50 was calculated using the Prism4 software.
2.5.1.4 Epitope mapping
The epitopes of anti-H1 mAb were mapped by matrix-assisted laser desorption
ionization Fourier-transformation cyclotron resonance (MALDI-FT-ICR) following the
epitope excision and extraction method of Przybylski M.151 based on Macht M. et al.106
2.5.1.4.1 Reduction and alkylation of the H1-CRD
The native H1-CRD (see Section 2.2.5.5) was diluted to 1mg/ml (equivalent to 412?M
Cys) in T-Ca20 (50mM TrisHCl, 20mM CaCl2, pH 8.0) and was reduced with a 50-fold
molar excess of dithiothreitol (equivalent to 20.6mM DTT) to Cys during incubation for 1h
at 56°C, while shaking with 1’200rpm.
The native H1-CRD (1mg/ml H1-CRD in T-Ca20) and the reduced H1-CRD (1mg/ml H1-
CRD, 20.6mM DTT in T-Ca20) were alkylated with 2.5-fold molar excesses of
iodoacetamide (IAA, equivalent to 51.5mM IAA) to DTT for 1h in the dark.
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2.5.1.4.2 Preparation of the anti-H1 mAb-Sepharose column
Buffer exchange of anti-H1 mAb
Disturbing primary amines Tris and glycine in anti-H1 mAb solutions (100mM glycine,
TrisHCl buffered, see Section 2.4.4.2) were removed by buffer exchange to coupling
buffer (200mM NaHCO3, 500mM NaCl, pH 8.3) using Microcon YM-10 spin devices
(MWCO 10’000). The volume of the purified mAb solution that contained 300?g mAb,
was concentrated at 14’000rcf for 30min and the buffer was exchanged by spinning
three times with 500?l coupling buffer at 14’000rcf for 30min. The mAb concentrate was
diluted to 100?l in coupling buffer and was spun out of the device at 1’000rcf for 3min.
The device membrane was tree times extracted with 100?l coupling buffer and was spun
into the same 1.5ml tube to get 400?l mAb solution (750?g/ml).
Coupling of anti-H1 mAb to Sepharose
133.3mg cyanobromide-activated Sepharose 4B (1mg swells to 3?l) were swollen in
400?l anti-H1 mAb solution (750?g/ml in coupling buffer) and were coupled during
incubation for 1h, while shaking at 1’200rpm.
The coupled mAb-Sepharose slurry was packed into a 1ml Mobicol column containing a
lower filter, and an upper filter was placed in the luer cap. The remaining activated sites
were quenched with 5ml blocking buffer by washing drop by drop. After rinsing three
times sequentially with 5ml acetic buffer (200mM NaCH3COO, 500mM NaCl, pH 4.0)
and 5ml blocking buffer, the column was incubated for 1h, while shaking with 600rpm.
Then, the packed column was three times washed the same way with 5ml acetic buffer
and 5ml blocking buffer, followed by the neutralization with 5ml T-Ca20.
2.5.1.4.3 Epitope extraction of digested H1-CRD
Trypsine digest of H1-CRD
20?l native H1-CRD (1mg/ml H1-CRD in T-Ca20) or reduced and alkylated H1-CRD
(1mg/ml H1-CRD, 20.6mM DTT, 51.5mM IAA in T-Ca20) was digested with 0.4?l
trypsine (100?g/ml trypsine in T-Ca20, 0.02mg/mg H1-CRD), for 5h at 37°C, while
shaking with 700rpm.
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Epitope extraction of trypsine-digested H1-CRD
The anti-H1 mAb-Sepharose column was equilibrated with 10ml T-Ca20 before 20?l
trypsine-digested H1-CRD (1mg/ml, to get a molar ratio of antibody : H1-CRD of 2:1)
solution was loaded by direct application to the Sepharose, and then was incubated for
2h, while shaking with 700rpm. The column was rinsed drop by drop with 40ml T-Ca20
and the bound epitope fragment was eluted once or twice by incubation with 500?l TFA
(0.1%) for 15min, while shaking with 700rpm.
The flow through, wash and elution samples were lyophilized and desalted prior to MS
analysis (see Section 2.5.1.4.5).
ZipTip desalting
The lyophilized sample was dissolved in 15?l TFA (0.1%), was sonicated in a water bath
for 5min and spun down. The ZipTip C18 (Millipore) was wet three times with acetonitrile
(50%) by slow aspiration followed by complete extrusion. The ZipTip was equilibrated
five times with TFA (0.1%) before the sample was loaded by twenty cycles of slow
aspiration and extrusion. After washing twice with TFA (0.1%), the desalted sample was
eluted with 4?l elution solution (0.1% TFA, 50% acetonitrile) by five cycles of aspiration
and extrusion.
2.5.1.4.4 Epitope excision of mAb-bound H1-CRD
Epitope excision of mAb-bound H1-CRD by digesting with trypsine
The anti-H1 mAb-Sepharose column was equilibrated with 10ml T-Ca20, loaded with
20?l native H1-CRD (1mg/ml in T-Ca20) or alkylated H1-CRD (see Section 2.5.1.4.1)
solution to get a molar ratio of antibody : H1-CRD of 2:1. The H1-CRD was directly
administered onto the Sepharose and incubated for 2h, while shaking with 700rpm. The
column was rinsed drop by drop with 10ml T-Ca20 and bound H1-CRD was digested
with 20?l trypsine solution (0.02mg/ml in T-Ca20, 0.02mg/mg H1-CRD) for 5h at 37°C,
while shaking with 700rpm. After washing the column drop by drop with 40ml T-Ca20,
bound epitope fragments were eluted once or twice by incubation 500?l TFA (0.1%) for
15min.
The column was regenerated, by washing with 10ml TFA (0.1%) and with 20ml T-Ca20
and samples (wash, flow through, elution) were lyophilized and desalted (see Section
2.5.1.4.3) prior to MS analysis (see Section 2.5.1.4.5).
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Epitope excision of mAb-bound H1-CRD by digesting with proteinase K
The epitope excision followed the same procedure, but bound H1-CRD was digested
with 40?l proteinase K solution (0.05mg/ml in T-Ca20, 0.1mg/mg H1-CRD) for 4h at
37°C, while shaking with 700rpm.
Epitope excision of mAb bound H1-CRD by digesting with ?-chymotrypsine
The epitope excision was performed following the procedure above, but bound H1-CRD
was digested with 20?l ?-chymotrypsine solution (0.02mg/ml in T-Ca20, 0.02mg/mg H1-
CRD) for 2-4h at 30°C, while shaking with 700rpm.
Epitope excision of mAb-bound trypsine-digested H1-CRD by double digesting with
pronase K
The epitope excision was performed according to the procedure above, but 20?l solution
of trypsine-digested H1-CRD (see Section 2.5.1.4.3) was loaded and after washing, was
additionally digested with 200?l pronase solution (0.5mg/ml in T-Ca20, 5mg/mg H1-
CRD) for 18h at 40°C, while shaking with 700rpm.
2.5.1.4.5 MS measurement
Desalted samples were measured as described by Stefanescu R.151 using MALDI-FT-
ICR or electro-spray ionization Fourier-transformation cyclotron resonance (ESI-FT-
ICR).
2.5.1.4.6 Solid phase synthesis of acylated epitope fragments and biotin labeling
The solid phase synthesis of epitope fragments and the purification by C18 reverse
phase HPLC (0% acetonitrile / 100% TFA 0.1% gradient to 80% acetonitrile / 20% TFA
0.1%) was performed as described by Stefanescu R.151
Fragments were C-terminal acetylated and for ELISA experiments they were additionally
N-terminal biotinylated.
2.5.1.4.7 Extraction of acetylated epitope fragments
The extraction of acetylated epitope fragments (see Section 2.5.1.4.6) was carried out
following the procedure in Section 2.5.1.4.3. 50?l epitope fragment solution (10nM
fragment in T-Ca20) was loaded.
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2.5.1.4.8 Epitope ELISA with acetylated biotin-labeled epitope fragments
Epitope ELISA was performed according to the protocol of Przybylski M.151
Anti-H1 mAb-capturing ELISA
MaxiSorb ELISA plates were coated with 100?l/well streptavidine solution (5?g/ml
streptavidine in T-Ca20) for 2h at RT, were washed four times with 200?l/well TTBS-
Ca20, dried by aspiration and 100?l/well biotinylated epitope fragments (range of
0.0001-20?M in T-Ca20) were bound for 2h at RT. Coated wells were washed four times
with 200?l/well TTBS-Ca20, dried by aspiration and were blocked with 200?l/well
blocking buffer (5% BSA in TTBS-Ca20) for 2h at RT. After incubation with 100?l/well
anti-H1 mAb solution (1?g/ml anti-H1 mAb, 1% BSA in T-Ca20) for 2h and washing four
times with 200?l/well TTBS-Ca20, bound mAb was detected with 100?l/well HRP-
labeled antibody (GAM-Ig(H+L)-HRP 1:1’000, 1% BSA in T-Ca20). The plates were
thoroughly washed four times with 200?l/well TTBS-Ca20, dried by aspiration prior to
addition of 90?l/well OPD Sigma Fast substrate solution and incubation for 10min in the
dark. The color development was stopped with 50?l/well HCl (3.6%) and the absorbance
was read at 490nm in a Spectramax190 plate reader.
Epitope-capturing ELISA
MaxiSorb ELISA plates were coated with 100?l/well anti-H1 mAb solution (2?g/ml anti-
H1 mAb in T-Ca20) overnight at 4°C, were washed four times with 200?l/well TTBS-
Ca20, dried by aspiration and were blocked with 200?l/well blocking buffer (5% BSA in
TTBS-Ca20) for 2h at RT. After washing once with 200?l/well TTBS-Ca20, the coated
plates were incubated with 100?l/well biotinylated epitope fragments (40?M biotinylated
fragment in T-Ca20) for 2h at RT. Wells were washed four times with 200?l/well TTBS-
Ca20, dried by aspiration and the fragment were tagged with 100?l/well HRP-labeled
antibody (1?g/ml anti-biotin IgG-HRP 1:1’000, 1% BSA in TTBS-Ca20) for 2h at RT. The
plates were thoroughly washed four times with 200?l/well TTBS-Ca20, dried by
aspiration prior to addition of 90?l/well OPD Sigma Fast substrate solution and
incubation for 10min in the dark. The color development was stopped with 50?l/well HCl
(3.6%) and the absorbance was read at 490nm in a Spectramax190 plate reader.
2.5.1.5 Surface plasmon resonance
Kinetics of the anti-H1 mAb binding to monomeric and dimeric H1-CRD surfaces were
measured by surface plasmon resonance (SPR, Biacore) as described by Ricklin D.140
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2.5.2 Cell assays
2.5.2.1 Fluorescence flow cytometry
2.5.2.1.1 Intracellular flow cytometry of fixed cells
The intracellular immunofluorescence staining of hybridoma cells was performed after
blocking secretion of antibodies, following the protocol of De Libero G.145
The screening ELISA-positive hybridoma B01 was used as positive control, the ELISA-
negative hybridoma A12 as negative control and unstained cells served as blank.
Blocking of antibody secretion
10?g/ml Brefeldin A was added to the hybridoma cultures 12h prior to staining.
Preparation of cells
The cells were counted (see Section 2.4.2.1) and collected at 280rcf for 5min. After
dilution to 5·106cells/ml in DPBS, 100?l/well cell suspension was distributed in a 96-well
U bottom plate to get 5·105cells/well.
Paraformaldehyde fixation of cells
The cells were spun at 1’500rpm for 2min and the supernatant was discard by fast
flicking the plate. After washing twice with 200?l/well DPBS, the cells were fixed with
200?l/well paraformaldehyde (2%) buffer during incubation for 15min.
Intracellular fluorescence staining
The fixed cells were collected at 280rcf for 2min, were washed twice with 200?l/well
FACS buffer 1 (0.5% HSA, 0.02% NaN3 in DPBS) and twice with 200?l/well FACS buffer
2 (0.1% saponine in FACS buffer 1) followed by permeabilization during an incubation
with 20?l/well Fluorescein isothiocyanate (FITC)-labeled goat anti-mouse antibody
solution (GAM-IgG(H+L)-FITC, 1:50 in FACS buffer 2) for 25min in the dark. Stained
cells were washed three times with 200?l/well FACS buffer 2 and were resuspended in
200?l/well FACS buffer 1 before they were transferred into FACS tubes for
measurement of the emission in FL-1 at 530nm after excitation at 488nm using a
FACScan reader.
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2.5.2.1.2 Extracellular flow cytometry of not fixed or fixed cells
The extracellular immunofluorescence staining on different human cell lines was
performed according to the protocol of De Libero G.145
C15sn or the positive hybridoma B01 and the monoclonal anti-ASGPR1 (Calbiochem)
were used for positive controls B3sn, mcl2 or the negative hybridomas A12 for negative
control and unstained cells were used for blank.
Detachment of adherent HepG2 and SK-Hep1 and of weak adherent dendritic cells
Cells were detached according to Seow Y.Y.11
The adherent cells HepG2 and SK-Hep1 were washed once with DPBS and were
detached by incubation with EDTA solution (2.5mM EDTA in DPBS, pH 8.0) for 5min at
37°C or on ice by enforced pipetting and scratching.
Weak adherent dendritic cells were detached by incubation on ice for 5min and enforced
pipetting.
Blocking of monocytes and THP-1 cells
THP-1 and monocytes were collected at 400rcf for 5min and were washed once with
FACS buffer (0.5% BSA, 0.02% NaN3 in DPBS) before they were incubated with 100-
500?l human serum for 20min on ice.
Preparation of cells
The detached adherent cells, blocked suspension cells and HL-60, JS-7, Jurkat, K-652
suspension cells were collected with 400rcf for 5min and were resuspended in DPBS for
counting (see Section 2.4.2.1). After washing once in FACS buffer (0.5% BSA or HSA,
0.02% NaN3 in DPBS), the cell pellet was broken by tapping the tube. Washed cells
were diluted to 5·105cell/ml in FACS buffer and 200?l/well cell suspension was
distributed in a 96-well U bottom plate to get 1·105cells/well. The plate was spun at
1’500rpm for 2min at 4°C, and the supernatant was discarded by fast flicking followed by
washing twice with 200?l/well DPBS.
Optional paraformaldehyde fixation of cells
The cells were fixed with 200?l/well paraformaldehyde (2%) buffer during incubation for
15min at RT. After spinning the plate at 1’500rpm for 2min at 4°C, the cells were washed
twice with 200?l/well prechilled FACS buffer.
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Extracellular fluorescence staining
The not fixed or optionally fixed cells were incubated with 50?l/well prechilled
supernatant or with 20?l/well precooled purified monoclonal antibody solution (20?g/ml
mAb in FACS buffer) for 20min on ice followed by washing twice with 200?l/well
precooled FACS buffer and spinning at 1’500rpm for 2min at 4°C. The cells were stained
with 20?l/well R-phycoerythrine (RPE) or FITC-labeled goat anti-mouse antibody
solution (GAM-Ig(H+L)-RPE or GAM-Ig(H+L)-FITC, 1:50 in precooled FACS buffer)
during incubation for 20min at 4°C in the dark. The stained cells were washed three
times with 200?l/well precooled FACS buffer, were resuspended in 200?l/well FACS
buffer, which contained 5ng/ml probidiumiodide and were transferred to FACS tubes on
ice. The emission was measured in FL-1 at 530nm for FITC-stained and in FL-2 at
585nm for RPE-stained cells after excitation at 488nm using a FACScan reader. The
probidium-stained dead cells that were detected in FL-3 at 670nm were excluded.
2.5.2.2 Immunofluorescence microscopy with HepG2 and SK-Hep1 cells
The immunofluorescence microscopy of HepG2 and SK-Hep1 cells was performed
following the optimized protocol of Stokmaier D.103
2.5.2.2.1 Labeling of antibodies and asialofetuin with Texas Red fluorochrome
The anti-H1 mAb and pIgY were labeled with Texas Red (TR) using FluoReporter®
Texas Red-X protein labeling Kit according to the kit instruction manual.
The disturbing primary amines glycine and Tris in the mAb solution (100mM glycine,
TrisHCl buffered, see Section 2.4.4.2) were removed by exchanging the buffer to PBS
using Microcon YM10 centrifugal filter devices (MWCO 10’000).
The needed volume of dye solution was calculated using the following Equation 9.
Vdye =
cAb ?VAb ?817 ?200 ?5
145000
(Eq. 9)
Equation 9: Calculation of the needed volume dye solution Vdye for the defined volume antibody solution VAb
with an antibody concentration cAb above 1mg/ml.
20?l NaHCO3 buffer (1M, pH8.3) was mixed with 200?l antibody solution (2mg/ml
antibody in KPBS) or asialofetuin solution (2mg/ml asialofetuin in KPBS) before
calculated volume dye stock solution (1 vial dye dissolved in 100?l DMSO) was slowly
added to the buffered antibody solution, while magnetically stirring. After incubation for
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1h in the dark, the solution of labeled antibody was dialyzed in Slide-A-Lyzer® mini
dialysis units (MWCO 10’000) against 100ml KPBS overnight at 4°C in the dark.
Particles were removed by centrifugation at 16’000rcf for 5min and the solution of
labeled antibody was stored at 4°C in the dark.
2.5.2.2.2 Preparation of cell cultures on coverslips
Paraformaldehyde fixation buffer
The paraformaldehyde solution (0.3g paraformaldehyde, 8.8ml water, 10?l NaOH 1M) in
a closed 15ml tube was heated in a water bath of 60°C until the solution cleared up.
After cooling to RT, 1ml KPBS 10x (15mM KH2PO4, 80mM Na2HPO4, 1.37M NaCl,
27mM KCl) and 20?l HCl (1M) were added and the pH was checked with indicator sticks
to be pH7.0-7.5.
The fixation buffer (3% paraformaldehyde in KPBS, pH 7.0-7.5) was always prepared
freshly.
Mowiol mounting buffer
25g Mowiol was dissolved in 100ml KPBS and was combined with 50ml glycerol and N-
propylgallate (0.75%). After stirring for 8h, the mounting buffer was cleared by
ultracentrifugation at 13’000rcf for 15min and was stored airtight at 4°C in the dark.
Collagen coating of coverslips
Coverslips were cleaned, degreased and roughened according to the protocol of
Salmons Lab152.
The single coverslips were washed in water and were treated in HCl (1M) for 4h at 50-
60°C. After cooling down to RT, the coverslips were sonicated three times for 30min in in
a bath of water and three times for 30min in a bath of 50%, 70% and 95% ethanol,
respectively.
The coverslips were stored in ethanol (95%) until use.
The pretreated coverslips were dried and briefly flamed over a Bunsen burner.
1coverslip/well were placed into a 12-well plate using sterile tweezers and were coated
with 60?l/well collagen solution (1mg/ml collagen S, 500mM acetic acid, pH2.8)
overnight at 4°C. After washing the collagen-coated coverslips once with 1ml/well DPBS,
they were stored in 1ml/well DPBS at 4°C until use.
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Cell cultivation on collagen-coated coverslips
2·105cells were seeded into a well with a collagen-coated coverslip and were incubated
in 1ml/well DMEM-15 (see Section 2.4.1.2) at 37°C (5% CO2, 100% humidity).
2.5.2.2.3 Immunodetection of anti-H1 antibody binding to fixed cells
The immunostaining was adapted from Novikoff P.153 and Seow Y.Y.11
Direct immunodetection of binding with Texas Red-labeled antibodies
After a one-day culture period, the cells on coverslips were carefully washed once or
twice with 1ml/coverslip DPBS and were fixed with fixation buffer for 30min or overnight
at 4°C. The fixed cells were washed three times with 1ml/coverslip DPBS and were
permeabilized with 1ml/coverslip permeabilization solution (1% Triton-X100 in DPBS) for
15min. After washing once with 1ml/coverslip DPBS, the autofluorescence of the
permeabilized cells was quenched with NaBorohydride solution (10mg/ml
NaBorohydride in DPBS) for 15min on ice. The quenched cells were washed abundantly
with 1ml/coverslip DPBS until bubbles disappeared and were FCS-starved in
1ml/coverslip DPBS for 1h followed by incubation with 100-200?l/coverslip TR-labeled
anti-H1 antibody (10-40?g/ml anti-H1 mAb-TR or pIgY-TR in DPBS) or asialofetuin (5-
20?g/ml asialofetuin-TR in DPBS) for 2h in the dark. After washing three times with
1ml/coverslip DPBS, the coverslips were mounted onto glass slides.
Indirect immunodetection of binding with labeled secondary antibodies
The cells were prepared as described above but after FCS starvation, the cells were
incubated with 100-200?l/coverslip anti-H1 antibody (10-20?g/ml anti-H1 mAb in DPBS
or supernatant) for 2h, were washed twice with 1ml/coverslip DPBS and were stained
with 100-200?l/coverslip labeled secondary antibody (DAM-IgG(H+L)-Cy3 1:3’000 or
GAM-IgG(H+L)-AlexaFluor488 1:800 in KPBS) for 1h in the dark. After washing three
times with 1ml/coverslip DPBS, the coverslips were mounted onto glass slides.
Mounting of coverslips onto glass slides
The coverslips were rinsed with water, were tapped dry with a Kimberly clark paper
towel and were mounted with one drop Mowiol mounting buffer onto glass slides. After
drying for 30min in the dark, the mounted slides were stored at 4°C in the dark until
microscopy.
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Fluorescence microscopy and photography of the slides
The fluorescence-stained cells were examined under an Apofluorescence microscope
(Zeiss) with 630 times magnification (binocular 10x/20, objective 63x/1.25oil (Ph3plan-
neofluor 440481). The red fluorescence filter (BP546, FT580, LP590) and the green
fluorescence filter (450-490, FT510, 515-565) were used for investigation of slides.
The pictures of the slides were taken on a Kodak ELITE 400 film for dia-positives (1600
ASA) and were scanned with a Canon PI CS-U4.1X flat bed scanner.
2.5.2.2.4 Immunodetection of anti-H1 antibody internalization into cells prior to fixation
The immunostaining was adapted from Novikoff P.153 and Seow Y.Y.11
Direct immunodetection of internalized Texas Red-labeled anti-H1 antibodies
The cells on coverslips were carefully washed once or twice with 1ml/coverslip DMEM
and were FCS-starved in DMEM for 1h at 37°C (5% CO2, 100% humidity). The starved
cells were incubated with 200?l/coverslip TR-labeled anti-H1 antibody (10-40?g/ml anti-
H1 mAb-TR or pIgY-TR in DPBS) or asialofetuin (5-20?g/ml asialofetuin-TR in DPBS)
and for 40min at 37°C (5% CO2, 100% humidity) in the dark. After washing three times
with 1ml/coverslip DPBS, the stained cells were fixed with 500?l/coverslip fixation buffer
for 30min in the dark. The fixed cells were washed three times with 1ml/coverslip PBS
again before the coverslips were mounted onto glass slides and were analyzed under
the fluorescence microscope as described in Section 2.5.2.2.3
Indirect immunodetection of internalized labeled secondary antibodies
The cells were prepared as described above but after FCS starvation, the cells were
incubated with 200?l/coverslip anti-H1 antibody (10-20?g/ml anti-H1 mAb in KPBS or
supernatant) for 40min at 37°C (5% CO2, 100% humidity), were washed three times with
1ml/coverslip DPBS and additionally were permeabilized with 1ml/coverslip Triton-X100
(0.1% Triton-X100, PBS) for 15min in the dark. Permeabilized cells were washed three
times with 1ml/coverslip DPBS and were stained with 200?l/coverslip labeled secondary
antibody (GAM-IgG(H+L)-Cy3 1:3’000 in KPBS) for 1h in the dark. After washing three
times with 1ml/coverslip DPBS, the coverslips were mounted onto glass slides and were
analyzed under the fluorescence microscope as described in Section 2.5.2.2.3.
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2.5.3 Tissue assays
2.5.3.1 Immunostaining of liver tissue
The immunostaining of human liver tissue was performed by Terracciano L.154.
Briefly, the sections of paraformaldehyde-fixed, paraffin-embedded human liver tissue
were dewaxed. The antigen of dewaxed sections in PBS was retrieved by various
treatments: the microwaving in citrate buffer (pH 6.0) at 98°C for 30min or 60min, the
steaming in citrate buffer (pH 6.0, pH 1-2 and pH 10-11) at 120°C for 5min, the
proteinase K treatment with 3 drops within 5min, the pronase XIV (1mg/ml) treatment at
37°C for 15min or at 4°C for 30min and the trypsine (1mg/ml) treatment at RT for 30min.
Optionally, the endogenous avidin/biotin activity was blocked. The sections were
dehydrated in methanol-peroxide for 30min and were blocked with murine serum for
30min, followed by incubation in primary antibody solution (200-300?g/ml purified anti-
H1 IgG, 1:50, 1:100, 1:200 and 1:400). The primary antibody was captured with avidin-
labeled anti-mouse Ig for 30min and with biotin-labeled HRP for 30min. The sections
were finally stained with diaminobenzidine (DAB) substrate and were counterstained
with Harris’ hematoxylin, prior to mounting.
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3 Result
3.1 ASGPR database research
3.1.1 ASGPR and H1-CRD alignments
The amino acid sequence alignment of the human asialoglycoprotein 1 (ASGPR-1) with
the mouse and chicken hepatic lectins (MHL-1 and ChHL-1) resulted in 80% sequence
identity or 87% similarity to the MHL-1 and only 39% identity or 47% similarity to the
ChHL-1. The area of the binding site showed higher homologies with 93% identical or
96% similar amino acids to the MHL-1 and 55% identical or 60% similar amino acids to
the ChHL-1 (see Figure 21).
seqLech_human    MTKEYQDLQHLDNEE-SDHHQLRKGPPPPQPLLQRLCSGPRLLLLSLGLSLLLLVVVCVI
seqLech_mouse    MTKDYQDFQHLDND--NDHHQLRRGPPPTPRLLQRLCSGSRLLLLSSSLSILLLVVVCVI
seqLech_chicken ----------MDEERLSDNVRLYKGGSIRQGLRSFAAVYVLLALSFLLLTLLSSVSLARI
     :*:: .*: :* :* .    * .  .    * * *::* * :. *
seqLech_human    GSQNSQLQEELRGLRETFSNFTASTEAQVKGLSTQGGNVGRKMKSLESQLEKQQKDLSED
seqLech_mouse    TSQNSQLREDLLALRQNFSNLTVSTEDQVKALSTQGSSVGRKMKLVESKLEKQQKDLTED
seqLech_chicken AALSSKLSTLQSEPKHNFSS----------------------------------------
   : .*:* :..**.
seqLech_human    HSSLLLHVKQFVSDLRSLSCQMAALQGNGSERTCCPVNWVEHERSCYWFSRSGKAWADAD
seqLech_mouse    HSSLLLHVKQLVSDVRSLSCQMAAFRGNGSERICCPINWVEYEGSCYWFSSSVRPWTEAD
seqLech_chicken RDSLLFPC--------------------GAQSR----QWEYFEGRCYYFSLSRMSWHKAK
  :. **: *:: :* .* **:** * .* .*.
seqLech_human NYCRLEDAHLVVVTSWEEQKFVQHHIGPVNTWMGLHDQN--GPWKWVDGTDYETGFKNWR
seqLech_mouse KYCQLENAHLVVVTSRDEQNFLQRHMGPLNTWIGLTDQN--GPWKWVDGTDYETGFQNWR
seqLech_chicken AECEEMHSHLIIIDSYAKQNFVMFRTRNERFWIGLTDENQEGEWQWVDGTDTRSSFTFWK
*. .:**::: * :*.*: : . *:** *:* * *:****** .:.* *:
seqLech_human PEQPDDWYGHGLGGGEDCAHFTDDGRWNDDVCQRPYRWVCETELDKASQEPPLL
seqLech_mouse PEQPDNWYGHGLGGGEDCAHFTTDGRWNDDVCRRPYRWVCETKLDKAN------
seqLech_chicken EGEPNNR-----GFNEDCAHVWTSGQWNDVYCTYECYYVCEKPLPK--------
    :*:: * .*****. .*:*** *  :***. * *
Figure 21: T-COFFEE alignment of Lech_human (ASGPR-1) with Lech_mouse (MHL-1) and Lech_chicken
(ChHL-1). Identical amino acids are indicated with stars, similar amino acids with points. The sequence of
the CRD is written in bold and the binding site is shaded in grey.
The H1-CRD of the human ASGPR-1 was aligned with the CRD of the
asialoglycoprotein receptor 1 of the species, which were selected for the antibody
productions: the mouse (mus musculus) to produce monoclonal and the chicken (gallus
gallus) to get polyclonal antibodies. Furthermore, the H1-CRD amino acid sequence was
compared with the amino acid sequences of homologous receptors in human (homo
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sapiens), mouse and chicken: the asialoglycoprotein receptor 2 (ASGPR-2), the
macrophage Gal/GalNAc-specific lectin (Mmgl) on macrophages, the Kupffer cell
receptor on Kupffer cells and the dendritic cell-specific ICAM-3-grabbing nonintegrin
(DC-SIGN, CD209) on dendritic cells.
Table 7: Amino acid sequence homologies. Alignment of the human ASGPR-1, the H1-CRD or the binding
site of the H1-CRD with the same and homologous receptors in human, mouse and chicken.
No Sequence ID Identity (similarity)
Receptor CRD Binding site
1 Lech_human 100% 100% 100%
2 Lech_chicken 37% (51%) 37% (51%) 42%
3 Lech_mouse 64% (73%) 79% (91%) 93% (96%)
4 Leci_human 48% (59%) 67% (78%) 66% (72%)
5 Leci_mouse 43% (55%) 60% (71%) 63% (69%)
6 Mmgl_human 52% (66%) 71% (81%) 84% (87%)
7 Mmgl_mouse 50% (65%) 67% (80%) 78% (84%)
8 Kucr_human
9 Kucr_mouse 28% (45%) 41% (52%) -
10 209_human 38% (51%) 38% (51%) 36% (42%)
11 209_mouse 38% (55%) 38% (55%) 36% (36%)
The comparison showed, that the CRD domains of these receptors on its own exhibited
higher homologies with 37-79% identical or 51-91% similar amino acids than the entire
receptors with 37-64% identical or 41-73% similar amino acids. When only the
sequences of the binding site were aligned, the homologies are further increased to 63-
93% identity or 69-96% similarity compared to the ASGPR-1, ASGPR-2 and Mmgl in
human and mouse. No significant homologies were found for Kucr and DC-SIGN in
human and mouse and for ChHL-1 (see Table 7, Figure 22).
seqLech_human    --GNGSERTCCPVNWVEHERSCYWFSRSGKAWADADNYCRLEDAHLVVVTSWEEQKFVQ-
seqLech_chicken -------CGAQSRQWEYFEGRCYYFSLSRMSWHKAKAECEEMHSHLIIIDSYAKQNFVM-
seqLech_mouse    --GNGSERICCPINWVEYEGSCYWFSSSVRPWTEADKYCQLENAHLVVVTSRDEQNFLQ-
seqLeci_human    --SNGSQRTCCPVNWVEHQGSCYWFSHSGKAWAEAEKYCQLENAHLVVINSWEEQKFIV-
seqLeci_mouse    ----SNGTECCPVNWVEFGGSCYWFSRDGLTWAEADQYCQLENAHLLVINSREEQDFVV-
seqMmgl_human    --NASTEGTCCPVNWVEHQDSCYWFSHSGMSWAEAEKYCQLKNAHLVVINSREEQNFVQ-
seqMmgl_mouse    --NNGSEVACCPLHWTEHEGSCYWFSESEKSWPEADKYCRLENSHLVVVNSLEEQNFLQ-
seqKucr_mouse    --TQNQVLQLIAQNWKYFNGNFYYFSRDKKPWREAEKFCTSQGAHLASVTSQEEQAFLV-
seq209_human     -AAVERLCHPCPWEWTFFQGNCYFMSNSQRNWHDSITACKEVGAQLVVIKSAEEQNFLQL
seq209A_mouse    -AGVDRLCRSCPWDWTHFQGSCYFFSVAQKSWNDSATACHNVGAQLVVIKSDEEQNFLQ-
seq209B_mouse    -TELFRLCRLCPWDWTFLLGNCYFFSKSQRNWNDAVTACKEVKAQLVIINSDEEQTFLQ-
seq209C_mouse    -SQINRLCRPCPWDWTVFQGNCYFFSKFQQNWNDSVNACRKLDAQLVVIKSDDEQSFLQ-
seq209D_mouse    AEVHDGLCQPCARDWTFFNGSCYFFSKSQRNWHNSTTACQELGAQLVIIETDEEQTFLQ-
seq209E_mouse    -SEVDRLCRLCPWDWTFFNGNCYFFSKSQRDWHDSMTACKEMGAQLVIIKSHEEQSFLQ-
.* *::*    * .:   *    ::*  : :  :* *:
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seqLech_human    HHIGPVN-TWMGLHD--QNGPWKWVDGTDYETGF--KNWRPEQPDDWYGHGLGGGEDCAH
seqLech_chicken FRTRNER-FWIGLTDENQEGEWQWVDGTDTRS--SFTFWKEGEPNN-----RGFNEDCAH
seqLech_mouse    RHMGPLN-TWIGLTD--QNGPWKWVDGTDYETGF--QNWRPEQPDNWYGHGLGGGEDCAH
seqLeci_human    QHTNPFN-TWIGLTD--SDGSWKWVDGTDYRHNY--KNWAVTQPDNWHGHELGGSEDCVE
seqLeci_mouse    KHRSQFH-IWIGLTD--RDGSWKWVDGTDYRSNY--RNWAFTQPDNWQGHEQGGGEDCAE
seqMngl_human    KYLGSAY-TWMGLSD--PEGAWKWVDGTDYATGF--QNWKPGQPDDWQGHGLGGGEDCAH
seqMmgl_mouse    NRLANVV-SWIGLTD--QNGPWRWVDGTDFEKGF--KNWAPLQPDNWFGHGLGGGEDCAH
seqKucr_mouse    QTTSSGD-HWIGLTDQGTEGIWRWVDGTPFNNAQSKGFWGKNQPDNWR-HRNGEREDCVH
seq209_human     QSSRSNRFTWMGLSDLNQEGTWQWVDGSPLLPSFK-QYWNRGEPNNV------GEEDCAE
seq209A_mouse    QTSKKRGYTWMGLIDMSKESTWYWVDGSPLTLSFM-KYWSKGEPNNL------GEEDCAE
seq209B_mouse    QTSKAKGPTWMGLSDLKKEATWLWVDGSTLSSRFQ-KYWNRGEPNNI------GEEDCVE
seq209C_mouse    QTSKEKGYAWMGLSDLKHEGRWHWVDGSHLLFSFM-KYWNKGEPNNE------WEEDCAE
seq209D_mouse    QTSKARGPTWMGLSDMHNEATWHWVDGSPLSPSFT-RYWNRGEPNNV------GDEDCAE
seq209E_mouse    QTSKKNSYTWMGLSDLNKEGEWYWLDGSPLSDSFE-KYWKKGQPNNV------GGQDCVE
    *:** *   :. * *:**: * :*:: :**..
seqLech_human FTDDGRWNDDVCQRPYRWVCETELDK-ASQEPPLL-------------
seqLech_chicken VWTSGQWNDVYCTYECYYVCEKPLPK----------------------
seqLech_mouse FTTDGRWNDDVCRRPYRWVCETKLDK-AN-------------------
seqLeci_human VQPDGRWNDDFCLQVYRWVCEKRRNA-TGEVA----------------
seqLeci_mouse ILSDGHWNDNFCQQVNRWVCEKRRNI-TH-------------------
seqMngl_human FHPDGRWNDDVCQRPYHWVCEAGLGQ-TSQE-----------------
seqMmgl_mouse ITTGGPWNDDVCQRTFRWICEMKLAK-ES-------------------
seqKucr_mouse VRQ--QWNDMACGSSYPWVCKKSTGW-SAARVG---------------
seq209_human FSGNG-WNDDKCNLAKFWICKKSAAS-CSRDEEQFLSPAPATPNPPPA
seq209A_mouse FRDDG-WNDTKCTNKKFWICKKLSTS-CPSK-----------------
seq209B_mouse FAGDG-WNDSKCELKKFWICKKSATP-CTEG-----------------
seq209C_mouse FRGDG-WNDAPCTIKKYWICKKSAMS-CTEK-----------------
seq209D_mouse FSGDG-WNDLSCDKLLFWICKKVSTSSCTTK-----------------
seq209E_mouse FRDNG-WNDAKCEQRKFWICKKIATT-CLSKW----------------
   . ***  * : *:
Figure 22: T-COFFEE alignment of Lech_human (ASGPR-1) with the same receptor in mouse
(Lech_mouse, MHL-1) and chicken (Lech_chicken, ChHL-1) and in addition with homologous receptors on
the surface of macrophages (Mmgl_mouse, Mmgl_human = CLE14_HUMAN), Kupffer cells (Kucr_mouse,
Kucr_human not known) and dendritic cells (209A-E_mouse, 209_human). Identical amino acids are
indicated with stars, similar amino acids with points. The sequence of the binding site is shaded in grey.
3.1.2 H1-CRD epitope prediction
The antigenicity, hydrophobicity and accessibility of amino acid residues were estimated
and superimposed in plots to predict the putative epitope sequences of the H1-CRD.
The highest antigenicities were suggested for the amino acids 13-17, 26-31, 34-37 and
133-140, which lie outside of the binding site, but also for 91-98 and 109-120, which are
positioned in the binding site of the H1-CRD. In these putative antigenic areas, the
amino acid sequences are hydrophobic and accessible. This is especially true for amino
acids 91-95 and 115-119 of the binding site, and these have therefore a good chance to
be recognized as epitopes (see Figure 23).
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Figure 23: Epitope prediction using program ProScale (ExPASy, window 9, weighting 100%). Values of
each score set were normalized (highest value 1.0, lowest value 0). The normalized score sets were
superimposed to calculate the mean blot curve. A: Antigenicity algorithms from Woods et al, Parker and
Welling. B: Hydrophobicity algorithms from Kyte et al, Janine, Manavalan and Fauchere. C: Accessibility
algorithms.
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3.2 Cloning, expression and purification of H1-CRD
Mg amounts of the H1-CRD were necessary for immunization first, and then for the
screening and characterization of the obtained antibodies.
3.2.1 Preparative scale expression in E.coli JM109pET3H1
The yield of the H1-CRD, determined by Bradford assay, was very low with only 128-
164?g/L JMpET3H1 culture in LB medium.
As a consequence, the antigen production has had to be optimized first. To reach a
highly efficient H1-CRD production, four different E.coli expression strains and two
vectors were tested first to identify an optimal production clone. In a second step,
various conditions of the H1-CRD expression in the selected production clone were
investigated and finally, the H1-CRD purification procedure was improved.
3.2.2 Optimization of the E.coli expression system
3.2.2.1 Plasmid pET3H1 expression system
The recombinant pET3b vector that codes for the H1-CRD cDNA (pET3H1) was
amplified in the E.coli cloning strain JM109 prior to its transformation into DE3-lysogenic
E.coli expression strains JM109(DE3), AD494(DE3) and Rosetta-gami(DE3)TM.
The selected clones of all pET3H1 plasmid-transformed strains JMpET3H1, ADpET3H1
and RGpET3H1 were controlled by standard PCR and by restriction digest with Nde I
and BamH I to confirm the correct integrity of the pET3H1.
In standard PCR, a 450bp fragment that corresponds to the 447bp cDNA of H1-CRD
was specifically amplified from the plasmid DNA of all picked clones (see Figure 24A).
The undigested plasmid DNA of JMpET3H1 and ADpET3H1 clones showed the two
fragments of the not linearized circular and the supercoiled pET3H1 plasmid of
approximately 5’000bp. The plasmid DNA of RGpET3H1 clones resulted in four bands,
which derived from unlinearized circular and supercoiled forms of pET3H1 and pRARE.
In the single digest with Nde I, the plasmid DNA of clones from all E.coli strains was
linearized to the 5’054bp fragment of the pET3H1. In the double digest with Nde I and
BamH I, the plasmid was further cut into the 447bp H1-CRD cDNA fragment and the
4’607bp fragment of the pET3 vector. For RGpET3H1 clones, the additional fragments of
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4’700bp in the single and of 1’000bp and 3’700bp in the double digest were found.
These originated from pRARE (see Figure 24B).
B
1         2       3         41         2
A
Figure 24: Transformation control of clones from E.coli JMpET3H1 (not shown), ADpET3H1 and
RGpET3H1 (not shown) on ethidium-stained agarose-gels. A: Standard PCR. The DNA was 10-1000 times
diluted for the amplification with primers H1fw and H1bw and the Taq DNA polymerase or Taq / Pfu DNA
polymerases. Amplified fragment (1) and marker (2) B: Restriction digest. The single digest of pET3H1 with
Nde I (2) should result in the 5’054bp fragment of linearized pET3H1 and for double digest with Nde I and
BamH I (1) in fragments of 447bp and 4’607bp. The undigested circular and supercoiled plasmid DNA (3)
and the marker (4).
The standard PCR as well as the restriction digest confirmed the correct transformation
of the clones and therefore provided three different pET3H1 expression systems: the
JMpET3H1, the ADpET3H1 and the RGpET3H1.
3.2.2.2 Plasmid pEZZ18H1 expression system
Two strategies for cloning the H1-CRD cDNA into the multiple cloning site of vector
pEZZ18 were tried: a 3’-blunt / 5’-blunt-ended ligation and a 3’-sticky / 5’-blunt-ended
ligation. Both should result in a recombinant pEZZ18H1 plasmid, which carries the H1-
CRD cDNA in the correct open reading frame and contains the restriction sites of Nde I
and BamH I, followed by two stop codons. Only in the 3’-blunt / 5’-blunt-ended ligation,
the cDNA can be ligated in inverse orientation.
The H1-CRD cDNA was amplified using Pfu DNA polymerase and was ligated 3’-blunt /
5’-blunt-ended into the Sma I-digested and dephosphorylated pEZZ18. For 3’-sticky / 5’-
blunt-ended ligation, the amplified H1-CRD cDNA was cut with BamH I prior to its
introduction into the Sma I and BamH I double-digested and dephosphorylated pEZZ18
vector. Both recombinant plasmids were transformed into the E.coli cloning host JM109
and the E.coli expression and cloning host Top10.
All clones were screened by colony PCR using Taq DNA polymerase and two different
primer pairs: the presence of the cDNA was confirmed with cDNA-specific primers H1fw
and H1bw, whereas the orientation of the cDNA was verified with the cDNA-specific
primer H1fw combined with the plasmid-specific primer M13 standard. The amplification
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of the H1-CRD cDNA failed for all clones. Therefore, it was presumed, that JM109 and
Top10 were transformed with recircularized original pEZZ18.
This was confirmed by the restriction digest of the plasmid DNA using Nde I. The
recombinant pEZZ18H1 should result in three fragments of 459bp, 1465bp and 3118bp,
but only two fragments of 450bp and 4100pb were obtained, identical to the Nde I-
digested pEZZ18 vector (458bp, 4133bp).
In the context of the promising results with pET3H1 transformants, the strategy of this
expression system was no longer pursued.
3.2.2.3 Selection of a high expressing E.coli production clone
The different clones of JMpET3H1, ADpET3H1 and RGpET3H1 were cultured in LB and
TB medium, containing antibiotics and 1% glucose. The expression of H1-CRD was
induced with 1mM IPTG.
On a reducing SDS-PAGE gel, the total cell proteins were compared prior to after 5h
expression. An additional huge orange 17kDa band of the H1-CRD was observed for
clones of ADpET3H1, especially for ADpET3H1.4. Only a weak additional band was
visible for clones of RGpET3H1, but none was detected for clones of JMpET3H1. For all
five clones, no H1-CRD was present in the expression culture media (see Figure 25).
0 m1a1 a2 m2 a3 m3 a5a4 m5m4
0 a1p1 p2 a2 p3 a3 p5p4 a5a4
Figure 25: Silver-stained reducing SDS-PAGE gel 15 % of the TCA / acetone precipitated total proteins from
clones of JMpET3H1, ADpET3H1 and RGpET3H1. Total TB medium proteins (m) and total pellet proteins
prior (p) and after (a) 5h expression. H1-CRD (0) and clones JMpET3H1.1 (1), ADpET3H1.1 (2),
ADpET3H1.4 (3), RGpET3H1.2 (4), RGpET3H1.3.
The high expression level of ADpET3H1.1 and ADpET3H1.4 was confirmed by the
purification of the H1-CRD from 200ml expression cultures according to the method of
Meier et al.26 The yields, determined by Bradford assay, were excellent for both clones,
but was substantially higher for ADpET3H1.4 with 1450?g/L compared to 250?g/L
culture for ADpET3H1.1.
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3.2.2.4 Sequence verification of the H1-CRD
Plasmid DNA sequencing and H1-CRD MS was used to verify, that the selected clone
ADpET3H1.4 expresses correct full-length H1-CRD.
Plasmid pET3H1 verification by DNA sequencing
The plasmid DNA of clone ADpET3H1.4 was sequenced, starting with primer T7 for the
plus strand and with primer T7term for the minus strand determination. The 583 bases
sequence of the plus strand overlapped with the 417 bases sequence of the minus
strand in all 417 bases. Both strands contained one uncertain nucleotide, but these were
unequivocal defined by the overlap with the complementary strand.
PET3H1.4: 39 ggctcagaaaggacctgctgcccggtcaactgggtggagcacgagcgcagctgctactgg 98
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ASGPR-1: 614 ggctcagaaaggacctgctgcccggtcaactgggtggagcacgagcgcagctgctactgg 673
PET3H1.4: 99 ttctctcgctccgggaaggcctgggctgacgccgacaactactgccggctggaggacgcg 158
    ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ASGPR-1: 674 ttctctcgctccgggaaggcctgggctgacgccgacaactactgccggctggaggacgcg 733
PET3H1.4: 159 cacctggtggtggtcacgtcctgggaggagcagaaatttgtccagcaccacataggccct 218
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ASGPR-1: 734 cacctggtggtggtcacgtcctgggaggagcagaaatttgtccagcaccacataggccct 793
PET3H1.4: 219 gtgaacacctggatgggcctccacgaccaaaacgggccctggaagtgggtggacgggacg 278
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ASGPR-1: 794 gtgaacacctggatgggcctccacgaccaaaacgggccctggaagtgggtggacgggacg 853
PET3H1.4: 279 gactacgagacgggcttcaagaactggaggccggagcagccggacgactggtacggccac 338
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ASGPR-1: 854 gactacgagacgggcttcaagaactggaggccggagcagccggacgactggtacggccac 913
PET3H1.4: 339 gggctcggaggaggcgaggactgtgcccacttcaccgacgacggccgctggaacgacgac 398
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ASGPR-1: 914 gggctcggaggaggcgaggactgtgcccacttcaccgacgacggccgctggaacgacgac 973
PET3H1.4: 399 gtctgccagaggccctaccgctgggtctgcgagacagagctggacaaggccagccaggag 458
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ASGPR-1: 974 gtctgccagaggccctaccgctgggtctgcgagacagagctggacaaggccagccaggag 1033
PET3H1.4: 459 ccacctctcctttaat  474
||||||||||||||||
ASGPR-1: 1034 ccacctctcctttaat 1049
Figure 26: Blastn (NCBI, matrix 1-3) alignment of the plus strand sequence of the pET3H1 sequencing,
searching databases Genbank, EMBL, DDJ, and PDB. The identity was 436/436 nucleotides (strand
plus/plus) to the published sequence of the asialoglycoprotein receptor 1 with ID |HUMASGPR1| (1277bp,
human asialoglycoprotein receptor H1 mRNA, complete cds).
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The plus strand sequence of pET3H1 was identical to the published sequence by Meier
et al.26 and confirmed ADpET3H1 to encode correct H1-CRD (see Figure 26).
H1-CRD sequence verification by Mass Spectrometry
The translated positive strand sequence of pET3H1 plasmid (see Figure 26) aligned with
the H1-CRD sequence proved the correct coding of pET3H1 in ADpET3H1.4. They were
100% identical over the entire 144 amino acids sequence of the H1-CRD in blastp (see
Figure 27).
PET3H1: 2  GSERTCCPVNWVEHERSCYWFSRSGKAWADADNYCRLEDAHLVVVTSWEEQKFVQHHIGP 61
GSERTCCPVNWVEHERSCYWFSRSGKAWADADNYCRLEDAHLVVVTSWEEQKFVQHHIGP
ASGPR-1: 148  GSERTCCPVNWVEHERSCYWFSRSGKAWADADNYCRLEDAHLVVVTSWEEQKFVQHHIGP 207
PET3H1: 62  VNTWMGLHDQNGPWKWVDGTDYETGFKNWRPEQPDDWYGHGLGGGEDCAHFTDDGRWNDD 121
VNTWMGLHDQNGPWKWVDGTDYETGFKNWRPEQPDDWYGHGLGGGEDCAHFTDDGRWNDD
ASGPR-1: 208  VNTWMGLHDQNGPWKWVDGTDYETGFKNWRPEQPDDWYGHGLGGGEDCAHFTDDGRWNDD 267
PET3H1: 122  VCQRPYRWVCETELDKASQEPPLL 145
VCQRPYRWVCETELDKASQEPPLL
ASGPR-1: 268  VCQRPYRWVCETELDKASQEPPLL 291
Figure 27: Blastp (NCBI, matrix BLOSUM62) alignment of the translated plus strand sequence of the
pET3H1 sequencing, searching databases non-redundant Genbank cds. The identity was 100% (144/144
residues) with 0% (0/144 residues) gaps in the alignment with sp |P07306| (291residues, human
asialoglycoprotein receptor H1).
The calculated monoisotopic molecular weight (ProtParam, ExPASY) of the H1-CRD
with a starting Met is 16991.5Da when all 7Cys are reduced or is 16985.5Da when 6 Cys
are involved in disulfide bridges. Without the first Met, a molecular weight of 16860.3Da
with reduced Cys and of 16854.3.6Da for the H1-CRD with 3 S-S bonds is calculated.
In the ESI-FT-ICR, a mass of 16930.3Da was measured. The difference to the
calculated mass, when the starting Met missed and 3 S-S bonds were formed, was
+76Da. Due to the elemental composition and the use of ?-mercaptoethanol for
reduction during H1-CRD purification, it was supposed, that one ?-mercaptoethanol
molecule was linked to the free Cys (see Figure 28).
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C
Calculated Measured
Element + Met - Met - Met / + ?-ME
C 751 746 748 748
H* 1065 1056 1060 1060
N 211 210 210 210
O 228 227 228 228
S 9 8 9 9
MW 16985.5 16854.3 16930.3 16930.3
Figure 28: ESI-FT-ICR of the H1-CRD, produced in ADpET3H1.4. A: Spectrum prior to deconvolution. B:
Deconvoluted spectrum. C: Molecular mass of the H1-CRD, calculated with ProtParam (ExPASy) and
measured by ESI-FT-ICR.
In addition, native and reduced alkylated H1-CRD was digested with trypsine and its
fragments were measured by MALDI-FT-ICR. Except for fragments F1 (residues 1-5),
F4 (residues 25-27) and F12 (residues 138-145), all expected fragments were found.
The three missing fragments were the smallest with molecular weights of 291.166 -
854.462Da.
Two disulfide bridges were identified, which linked Cys7-Cys8 and Cys36-Cys131. The third
S-S bond, linking Cys109-Cys123 was not detectable. Probably, this double fragment of
4719.993Da was too large for the detection in this measurement mode (see Figure 29).
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Figure 29: MALDI-FT-ICR of the H1-CRD, produced in ADpET3H1.4. Spectra, tables and schematic
diagrams of found fragments are shown. A: Native H1-CRD, digested with trypsine. B: Reduced alkylated
H1-CRD, digested with trypsine.
1 7 17 24 27 37 53 76 88 128117 137 145
F2 F3 F5 F6 F7 F8 F9 F10 F11
F11F5
Fragment Amino acid residues
No. [M+H]+ No. Sequence
F2
F2
1472.641
1470.625
6-17 2 free Cys
S-S bond intra
F3 948.403 18-24 1 Cys
F5 1184.479 28-37 1 Cys
F6 1882.955 38-53
F7 2698.354 54-76
F8 1417.627 77-88
F9 3287.362 89-117 1 Cys
F10 1451.649 118-128 1 Cys
F11 1122.514 129-137 1 Cys
F5+11 2303.980 S-S bond
A
1 5 17 24 27 37 53 76 88 128117 137 145
F2 F3 F6 F8 F10 F11
F11+12
2
0
1
4
.9
8
8
Fragment Amino acid residues
No. [M+H]+ No. Alkylation
F2 1586.743 6-17 2 Cys alkylated
F3 1005.455 18-24 1 Cys alkylated
F6 1882.955 38-53
F8 1417.627 77-88
F10 1508.599 118-128 1 Cys alkylated
F11 1179.565 129-137 1 Cys alkylated
2015.009 129-145 1 Cys alkylated
B
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3.2.3 Optimization of expression conditions
ADpET3H1.4 was cultured in the two media, LB and TB, containing antibiotics and
glucose 1%. The expression was induced at six cell densities of OD600 of 1 - 6 with three
IPTG concentrations in the range of 0.2mM - 0.8mM and was run for a period of 9h.
During growth and expression, temperature and shaking were kept at 37°C and 300rpm.
3.2.3.1 IPTG concentration and expression period in E.coli ADpET3H1.4
The expression of the H1-CRD in ADpET3H1.4, which was cultured in 50ml TB medium,
was not induced or was induced with 0.2mM, 0.4mM or 0.8mM IPTG at an OD600 of 1.
During growth and expression, the OD600 and pH monitoring showed, that after a lag
phase of less than 50min, ApET3H1.4 grew with a mean doubling time of 46.2min until
an OD600 of about 5-6, and then entered the stationary phase, with a plateau at OD600 of
about 8. When the H1-CRD was induced, the growth of ADpET3H1.4 immediately
stopped. The OD600 even slightly decreased in the first 5h after induction, but then
started a second slower growth phase with a mean doubling time of 140min.
The transition from log phase to stationary phase in the not induced ADpET3H1.4
culture was accompanied by a decrease of the pH to 4.5, whereas in induced cultures,
the pH remained constantly at pH 7.5 (see Figure 30).
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Figure 30: Growth and pH curve of ADpET3H1.4 during growth and expression phase. The H1-CRD
expression was induced with 0mM, 0.2mM, 0.4mM or 0.8mM IPTG at an OD600 of 1.
On a reducing SDS-PAGE gel, the total cell proteins of ADpET3H1.4 before to during
expression were compared. The gel showed, that the H1-CRD was not baseline-
produced preliminary to the induction. No significant 17kDa band was detected for not
induced ADpET3H1.4. In contrast, for induced ADpET3H1.4, the additional 17kDa band
of H1-CRD appeared with increasing intensity during the first 3h of the expression, and
then remained constant until 5-6h after induction. In the following 3h till the end of the
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expression, the intensity of the 17kDa band decreased, while simultaneously the bands
of other cell proteins became more prominent. This is in agreement with the up going
OD600. No H1-CRD was detected in the concentrated media of the expression cultures
(see Figure 31).
0 0h 1h 2h 3h 4h 5h 6h 7h 8h 9h
Figure 31: Silver-stained reducing SDS-PAGE gel 15% of precipitated and concentrated total cell proteins
from ADpET3H1.4 prior to (0h) and after 1-9h expression and of pure H1-CRD (0).
The intensity of the H1-CRD band was slightly stronger for ADpET3H1.4 induced with
0.4mM, compared to 0.2mM and 0.8mM.
In conclusion, the highest H1-CRD yield was obtained when the H1-CRD expression
was induced with 0.4mM IPTG and was run for 5h.
3.2.3.2 ADpET3H1.4 cell density at induction time
The expression of the H1-CRD in ADpET3H1.4 TB cultures was induced with 0.4mM
IPTG at different OD600 of 1, 2, 3, 4 and 5 during log phase and at an OD600 of 5.5 after
the exponential growth phase.
The OD600 measurement confirmed the same growth behavior of ADpET3H1.4 as
described in the previous section, with a first log phase, followed by the plateau phase
after induction and a second growth phase. However, when induced at an OD600 of 3 or
higher, the pH decreased down to 6.5 during expression (see Figure 32).
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Figure 32: Growth of, and H1-CRD expression in E.coli production clone ADpET3H1.4. Cell densities (A)
and pH (B) were compared during growth and expression, inducing with 0.4mM IPTG at OD600 of 1 - 6.
To sum up, the H1-CRD expression was optimal when started at a cell density of below
an OD600 of 3.
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3.2.3.3 Growth medium of ADpET3H1.4
ADpET3H1.4 was cultured in LB and TB medium with or without glucose 1%. The
expression of the H1-CRD was not induced or induced with 0.4mM IPTG.
The OD600 measurement showed, that the doubling time in TB medium was shorter than
in LB medium, with calculated doubling times of 44.4min compared to 50.8min.
Furthermore, the stationary phase was reached at a higher OD600 of 5 in TB medium
compared to LB (see Figure 33A).
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Figure 33: A: Doubling times of ADpET3H1.4 in LB or TB medium, containing glucose 1%. The doubling
time was 50.8min (SEM 1.2min) in LB and 44.3min (SEM 1.3min) in TB medium, calculated using nonlinear
regression fit (equation exponential growth). B: H1-CRD yield in ADpET3H1.4 TB and LB cultures with or
without glucose 1%. Compared to LB medium, the yield in TB medium was 98.2% (SEM 6.2%) and in LB
medium with 1% glucose 214.4% (SEM 88.2%).
When H1-CRD expression was induced at the same OD600, no difference in the yields
was detected on a reducing SDS-PAGE gel. But the addition of 1% glucose seemed to
have a variable, but positive effect onto the H1-CRD yield (see Figure 33B).
3.2.4 Optimization of purification procedures
The H1-CRD location within the bacterial cell was identified first. Dependent on this, the
purification procedure was adapted and optimized.
3.2.4.1 Identification of the H1-CRD localization in E.coli ADpET3H1.4
An ADpET3H1.4 culture, which was induced with 0.4mM IPTG at an OD600 of 1 after 5h
expression, was split into the medium, the periplasmic, the soluble cytoplasmic and the
insoluble cytoplasmic fraction.
A reducing SDS-PAGE gel showed, that the 17kDa H1-CRD band was only present in
the insoluble cytoplasmic fraction and as intense as in the total cell proteins. Therefore,
the H1-CRD is exclusively present in the form of inclusion bodies (see Figure 34).
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Figure 34: Silver-stained reducing SDS-PAGE gel 15% of fractions from an ADpET3H1.4 expression
culture. Concentrated (equivalent / normalized to the same culture volume) total proteins of the medium (2)
and the pellet (1) with its fractions: periplasmic (3), soluble cytoplasmic (4) and insoluble cytoplasmic fraction
(5).
3.2.4.2 Renaturation and affinity chromatography of the H1-CRD
The H1-CRD was expressed for 5h in 500ml ADpET3H1.4 LB cultures, containing 1%
glucose, after induction with 0.4mM IPTG at an OD600 of 1. Harvested cultures were
combined and split to three equal aliquots to get the same starting material for all
purification procedures.
The inclusion body proteins were solubilized in three parallel procedures: the “fast
dilution” (FD) method, the “non fast dilution” (NFD) method and the “inclusion body” (IB)
method. Obtained denatured and reduced proteins of each procedure were split into two
equal aliquots: proteins of the FD and NFD portions were refolded in the two refolding
systems, A and C (FDA, NFDA, FDC, NFDC), and proteins of the IB portions were
renatured in two other refolding systems, B and D (IBB, IBD). The buffer compositions
differed in the content of glycerol, reductant DTT and reshuffling glutathione. The
portions of refolded H1-CRD were separately extracted by Gal-Sepharose affinity FPLC.
The FD solubilization in combination with refolding system A (FDA) was identical to the
published method by Meier et al.26
3.2.4.2.1 Denaturation and reduction by the FD, NFD and IB method
On a silver-stained reducing SDS-PAGE gel, no H1-CRD was detected in the FD-
solubilized pellets of the clearing ultracentrifugation after solubilization and after
refolding. The same band pattern was obtained for NFD-solubilized pellets, on a PAGE
gel. The IB solubilization showed traces of H1-CRD in inclusion body washes.
Furthermore, the ultracentrifugation pellets after reductive denaturation and after
refolding were almost pure H1-CRD.
3.2.4.2.2 Refolding in buffer systems A to D
The protein solutions prior to refolding differed in the content of reductant and denaturing
agents. The concentration was lower for FD-treated than for NFD-treated proteins.
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Furthermore, the protein concentrations varied, whereas the highest was determined in
the lysate solution after FD solubilization and lowest after IB solubilization. The volume
of the FD lysate solution was 1.3-fold smaller compared to the NFD and the IB lysate
solution. As a consequence, the buffer exchange rate and the dilution rate of reducing
and denaturing agents during refolding were not identical, when dialyzing against the
same volume of refolding buffer (see Table 8).
Table 8: Final concentration of additives to the basic refolding buffer (20mM TrisHCl (pH7.5), 0.5M NaCl,
25mM CaCl2) after 6 refolding steps.
Concentration of additives, denaturants and reductantsMethod Buffer
system
dilution
step
Dilution
in total Refolding start Refolding end
FD A and C* 8.4 5.3·105
(8.46)
2M urea
0.01% ?-mercaptoethanol
5.7·10-6M urea
2.8·10-8% ?-mercaptoethanol
1mM GSH / 0.2mM GSSG*
0.4% glycerol*
NFD A and C* 6.3 6.3·104
(6.36)
4.8M urea
0.02% ?-mercaptoethanol
7.6·10-5M urea
3.2·10-7% ?-mercaptoethanol
1mM GSH / 0.2mM GSSG*
0.4% glycerol*
NFD A and C* 6.3 6.3·104
(6.36)
4.8M urea
2mM DTT
7.6·10-5M urea
3.2·10-5mM DTT
1mM GSH / 0.2mM GSSG*
0.4% glycerol*
IB B and D* 6.4 6.9·104
(6.46)
8M urea
1mM DTT
1.2·10-4M urea
1.5·10-5mM DTT
1mM GSH / 0.2mM GSSG
0.4% glycerol*
dilution
step
=
Vlysate +Vbuffer( )
Vlysate
; dilution in total=
dilution
step
?
?
?
?
?
?
numberofsteps
During the first refolding step, considerable amounts of proteins precipitated in the FDA
and the FDC solution. The same happened in the NFDA and the NFDC solution, when
proteins had been reduced with DTT for solubilization before. In contrast, in the IBB and
the IBD solution and in the NFDA and the NFDC solution, when reduced with ?-
mercaptoethanol before, just about no precipitate was formed. Additionally, a more than
8 times dilution in less than 10h also provoked protein precipitation. If no precipitate
occurred in the first refolding step, no precipitate formed during the following steps.
3.2.4.2.3 Affinity chromatography
The refolded active H1-CRD was extracted from the different solutions, i.e. the FDA, the
FDC, the NFDA, the NFDC, the IBB and the IBD, by affinity to the Gal-Sepharose.
Volumes, equivalent to the same volume of ADpET3H1.4 expression culture were
applied to the column in one run.
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Yield
The comparison of the areas under the elution peak clearly showed, that the yield of the
FD-renatured H1-CRD was significantly lower than of the NFD and IB-renatured H1-
CRD (see Figure 35).
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Figure 35: Overlay of Gal-Sepharose FPLC chromatograms. The volumes of FDA (1), FDC (2), NFDA (3),
NFDC (4), IBB (5) and IBD (6) equivalent to 100ml ADpET3H1.4 expression culture were applied to the 10ml
Gal-Sepharose column.
This agreed with the analysis on reducing SDS-PAGE gels and with the quantification of
the eluted H1-CRD by Bradford assay.
In the FD-derived H1-CRD, the 17kDa H1-CRD band not only appeared in the elution,
but also significantly in the flow through. Comparing the amount of H1-CRD in the flow
through to the amount in the protein solution prior to FPLC, a substantial portion of the
H1-CRD was inactive. In contrast, the NFD-derived H1-CRD was mainly active. The
intense 17kDa band was visible in the elution, while only traces were detected in the flow
through. Similarly, the IB-derived H1-CRD was predominantly present in the elution. In
the flow through, only a minor portion of inactive H1-CRD remained and almost no other
proteins were present due to the inclusion body wash prior to reduction (see Figure 36).
FD
1a 1b 2
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1a 1b 2
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1a 1b 2
Figure 36: Silver-stained reducing SDS-PAGE gel 15% of the H1-CRD purification following six different
procedures: three denaturation methods FD, NFD and IB in combination with refolding buffer systems A and
C or B and D showing raising (a) and falling (b) fraction of the elution peak (1) and column flow through (2).
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The IB methods provided the highest yields of active H1-CRD with 22mg/L ADpET3H1.4
culture followed by the NFD methods with similar yields of 20mg/L. Only half of this
yielded the FD methods with 11mg/L in mean (see Figure 37).
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Figure 37: Comparison of the H1-CRD yields from an ADpET3H1.4 expression culture, derived after
purification following the six different procedures. FDA yielded 10.2mg/L (SEM 1.2mg/L), FDC 11.8mg/L
(SEM 2.2mg/L), NFDA 20.1mg/L (SEM 2.0mg/L), NFDC 20.5mg/L (SEM 2.2mg/L), IBB 21.9mg/L (SEM
0.7mg/L) and IBD 22.4mg/L (SEM 3.6mg/L).
Purity
The reducing and non-reducing SDS-PAGE gel confirmed the high purity of the active
H1-CRD independent of the used purification method.
Interestingly, the conformity of the active H1-CRD was only fairly dependent on the
denaturation method, but was significantly influenced by the used refolding system.
When H1-CRD was refolded in the refolding system A (FDA and NFDA) double bands of
14kDa and 17kDa for monomeric species and of 28kDa and 34kDa for dimeric species
were visible. In contrast, when refolded in the other refolding systems (FDC, NFDC, IBB
and IBD) monomeric and dimeric H1-CRD only appeared as a single band of 17kDa and
34kDa, respectively (see Figure 38).
1a 1b 2a 2b 3a 3b 4a 4b 5a 5b 6a 6b
A
1a 1b 2a 2b 3a 3b 4a 4b 5a 5b 6a 6b
B
Figure 38: Silver-stained reducing (A) and non-reducing (B) SDS-PAGE gel 15% of the H1-CRD, eluted
from the Gal-Sepharose affinity column, showing the protein of the rising (a) and falling (b) peak.
Comparison of the six purification procedures: FDA (1), FDC (2), NFDA (3), NFDC (4), IBB (5) and IBD (6).
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Furthermore, the H1-CRD, which was derived from the different renaturation procedures,
varied in the ratio of monomeric to dimeric H1-CRD. The portion of dimeric species was
highest for the FD-treated and lowest for the IB-treated H1-CRD.
3.2.4.2.4 Effect of reductants
The NFD solubilization was performed using the two reductants ?-mercaptoethanol
(NFD?-ME) and DTT (NFDDTT). Unexpectedly during refolding, the NFD?-ME-derived
proteins remained soluble in the form of a slightly turbid solution, while the NFDDTT-
treated proteins precipitated nearly quantitatively.
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Figure 39: A: Overlay of Gal-Sepharose FPLC chromatograms of the NFD?-ME (2) and NFDDTT (1) derived
H1-CRD. B: Silver-stained reducing SDS-PAGE gel 15% of the NFD?-ME and NFDDTT, showing pure H1-CRD
reference (0), cleared protein solution (1) and pellet (2) prior to dilution, cleared protein solution (3) and
pellet (4) prior to refolding, cleared protein solution (5) and pellet (6) after refolding, column flow through (7),
wash (8) and elution fractions (9-12).
In the Gal-Sepharose extraction almost no H1-CRD elution peak was detected for
NFDDTT, but an immense peak for NFD?-ME appeared. The reducing SDS-PAGE gel
confirmed, that the precipitate of the NFDDTT refolding almost uniquely consisted of H1-
CRD. As a consequence, only traces of H1-CRD were detected in the cleared protein
solution after refolding and in the elution (see Figure 39).
3.2.4.2.5 Control of Gal-Sepharose binding specificity
The purified active H1-CRD clearly bound to Gal-Sepharose and did not elute until
EDTA was added. In contrast, the H1-CRD not interacted with blank Sepharose. No
elution peak was detected and therefore, the binding of the H1-CRD was proved to be
specific for galactose (see Figure 40).
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Figure 40: HPLC chromatograms of the H1-CRD binding to Gal-Sepharose (A) and to blank Sepharose (B)
with elution peak (e).
To sum up, the highest yield was achieved, when the H1-CRD was expressed for 5h in
an ADpET3H1.4 TB or LB culture with glucose 1%, after induction with 0.4mM IPTG at
an OD600 below 3. The active H1-CRD, which accumulated in the form of inclusion
bodies, was most successfully purified, when the proteins were denatured by the NFD
method and were refolded in the buffer systems A or C before the H1-CRD was
extracted by affinity to Gal-Sepharose.
3.2.5 Preparative scale expression in E.coli ADpET3H1.4
The expression conditions were optimized for 50ml cultures. Adaptations during scale up
were not necessary. Stepwise scale up, starting with 200ml and going up to 500ml
culture volumes showed, that yields/L expression culture remained constant.
The preparative production of H1-CRD in ADpET3H1.4 was started in parallel to the
optimization of the production. Therefore, the H1-CRD was purified, following partially
optimized methods (see Table 9).
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Figure 41: Silver-stained reducing SDS-PAGE gel 15% of the purified active H1-CRD after FPLC and
concentrating by Centricon. Higher molecular bands than the 17kDa band were supposed to be due to
incomplete reduction of the H1-CRD.
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The reducing SDS-PAGE gel confirmed the high H1-CRD purity of all batches, after
extraction by Gal-Sepharose FPLC (see Figure 41).
The H1-CRD yields after purification by the FDA method were 0.9mg/L ADpET3H1.4 LB
culture, 3.3mg/L LB culture with and 2.7mg/L TB culture with 1% glucose, determined by
Bradford assay. After H1-CRD purification by the NFDA method, higher yields of 5.9mg/L
in LB with 1% glucose and of 6.1mg/L in TB with 1% glucose were obtained (see Table
9).
Table 9: Yields of the preparative expressions in JMpET3H1.4 and ADpET3H1.4, determined by Bradford
assay.
Clone Medium Method Culture Yield/batch Yield/L
JMpET3H1.4 LB FD 15L 2.302mg 0.153mg/L
Total 15L 2.302mg 0.153mg/L
LB FD 2L 1.827mg 0.914mg/L
LB / 1% glucose FD 6L 19.642mg 3.274mg/L
ADpET3H1.4
LB / 1% glucose NFD 5L 29.437mg 5.887mg/L
ADpET3H1.4 TB / 1% glucose FD 0.5L 1.366mg 2.672mg/L
ADpET3H1.4 TB / 1% glucose NFD 0.5L 3.080mg 6.160mg/L
Total 14L 55.352mg 3.954mg/L
Overall 29L 57.654mg 1.988mg/L
H1-CRD stability and storage
Periodically thawed and refrozen H1-CRD was compared to H1-CRD, which was
continuously kept frozen. The silver-stained reducing SDS-PAGE gel showed the same
band pattern, identical to the pattern prior to freezing. The H1-CRD was not degraded at
–20°C and was not sensitive to repeated freezing.
3.2.6 Size exclusion chromatography
The purified active H1-CRD was applied to a Sephadex SEC column to remove traces of
other proteins and to separate monomeric and dimeric H1-CRD. Interestingly, the SEC
separation of the H1-CRD in buffer with 20mM calcium (SECCa), no calcium (SEC 0) and
1mM EDTA (SECEDTA) produced completely different results (see Figure 42, Figure 43).
Buffer with 20mM calcium
In SECCa buffer, only traces of protein eluted at the calculated time, but the main peak
came, when the buffer was switched to water and the ionic strength approximated to
zero. The non-reducing SDS-PAGE gel showed, that monomeric and dimeric H1-CRD
eluted together.
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Figure 42: FPLC chromatograms of the SEC experiment using different buffers. The buffer of SECCa
contained 20mM calcium, the buffer of SEC0 no calcium and the buffer of SECEDTA included 2mM EDTA.
Determined elution times for dimeric and monomeric H1-CRD were 28min and 32min respectively.
Recoveries of H1-CRD were 78% for the SECCa, 87% for the SEC0 and 80% for the SECEDTA.
Buffer without calcium
In SEC0 buffer, the H1-CRD started to elute at the determined elution time. Several small
peaks overlapped and eluted over a long period of time. The non-reducing SDS-PAGE
gel confirmed, that all peaks were composed of monomeric and dimeric species of H1-
CRD, but in different ratios. In peak 1, the 14kDa and the 28kDa bands of H1-CRD were
visible together with traces of other proteins. Peaks 2-4 additionally showed the 17kDa
and the 34kDa proteins and peak 5 only contained the 17kDa and the 34kDa proteins,
expected for the H1-CRD.
Buffer with 1mM EDTA
In SECEDTA buffer, proteins eluted in one main, but incompletely separated double peak
at the expected elution time. Additionally, two small peaks appeared, one prior and one
after the double peak. The non-reducing SDS-PAGE gel indicated, that the two small
peaks contained irrelevant proteins. At least, the double peak was pure H1-CRD with a
mainly dimeric H1-CRD fraction at the bottom of peak 1, a mixed fraction in the area of
the peak overlap and only monomeric H1-CRD in the descendent branch of peak 2.
The purity of the H1-CRD was highly improved by SEC. The main impurities of 14kDa,
22kDa, 40-45kDa and 66kDa were removed. Only traces of a 36kDa protein were
detected, which can probably be deduced to the incomplete reduction of H1-CRD.
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Figure 43: Silver-stained reducing and non-reducing SDS-PAGE gel 15% and native PAGE gel 15% of the
SEC-purified active H1-CRD used for immunization. Hen 1, hen 2 and hen 3 were immunized with H1-CRD
of the last fractions of SECCa with 20mM calcium, SEC0 without calcium and SECEDTA with 1mM EDTA,
respectively. The gel shows fractions of the SECCa, SEC0 and SECEDTA over the time course.
The SECCa allowed the extraction of other proteins. The SEC0 was neither suitable for
the separation of monomeric and dimeric species nor for the removal of other proteins.
Finally, the SECEDTA was partially successful in the separation of monomeric and dimeric
species.
In conclusion, having a stock of more than 50mg affinity-purified active H1-CRD and
1.15mg affinity and SEC-purified active H1-CRD, the basis was established to start the
production of monoclonal and polyclonal anti-H1 antibodies, respectively.
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3.3 Production and purification of polyclonal antibodies
3.3.1 Production of IgY
The highly pure active H1-CRD, which was purified by affinity to Gal-Sepharose and by
SEC (see Figure 43), was emulsified with Complete Freunds’ Adjuvant or Incomplete
Freunds’ Adjuvant. Three hybrid leg hens were primed with 20?g H1-CRD/CFA emulsion
sc at day 1 and were boosted with 20?g H1-CRD/IFA emulsion sc at days 20, 59, 84,
133. From day 34 to 224, 271 eggs were collected and pooled prior to purification.
3.3.2 Purification of IgY
There exists no standard method for the extraction of IgY from yolks, but most
procedures are composed of two main steps: the removal of lipids, followed by the
separation of IgY from total yolk proteins.
3.3.2.1 Optimization of the total IgY extraction
Three methods for each step were selected and combined. The lipids were removed by
the “freeze / thaw” (FT), the “water dilution” (WD) or the PEG 3.5% (PEG) method, and
the total IgY were precipitated with ammoniumsulfate (AS), PEG 12% (PEG) or PEG
12% / ethanol (PEG/ETOH). The total IgY, which were derived from the nine
procedures, were compared in terms of their purity, yield and activity.
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Figure 44: Silver-stained reducing SDS-PAGE gel 12% of extracted polyclonal total IgY (1), purified by the 9
different procedures M1-M9 and the LMW marker (0). The amounts of IgY per band on gel were normalized
to 20?l yolk (0.0015 egg).
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Purity
The F/T, the WD and the PEG method precipitated lipids quantitatively. The following
extraction of the total IgY with PEG and PEG/EtOH methods yielded highly pure IgY
antibodies. On the reducing SDS-PAGE gel, the 24kDa and 66kDa bands of the light
and heavy chains were intensely stained and only traces of 36kDa and 45kDa proteins
were detected in the PEG-derived, but not in the PEG/EtOH-derived total IgY. In
contrast, the AS-derived total IgY were contaminated with substantial amounts of other
yolk proteins (see Figure 44).
Yield
The total yolk proteins and the total IgY antibodies were quantified by Bradford micro-
assay and the yields were normalized to the amount/egg. Comparing the lipid and the
total IgY precipitation separately, the PEG method provided highest amount of total yolk
proteins with 792mg/egg, followed by the WD method with 323mg/egg and the F/T
method with 195mg/egg in mean (see Figure 45). The highest total IgY yield resulted
from the AS method with a 23% portion of the total yolk proteins. This was substantially
more than from the PEG method with a 6% and the PEG/EtOH method with only a 2%
portion of the total yolk proteins in mean (see Figure 46).
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Figure 45: Extraction of the total yolk proteins and total IgY. The yield/egg of total yolk proteins extracted by
the F/T, the WD or the PEG method and % IgY of total yolk proteins extracted by the AS, the PEG or the
PEG/EtOH method were compared. The yield of total yolk proteins by the F/T method was 195mg/egg (SEM
6mg/egg) by the WD method 323mg/egg (SEM 53mg/egg) and by the PEG method 792mg/egg
(SEM18mg/egg). The yield of total IgY received by the AS method was 98mg/egg (SEM 33/egg), by the
PEG method 21mg/egg (SEM 6mg/egg) and by the PEG/EtOH method 10mg/egg (SEM 5mg/egg). The
yield of IgY normalized to the yield of total yolk proteins resulted in 23% (SEM 6%) for the AS method, 6%
(SEM 2%) for the PEG method and 3% (SEM 2%) for the PEG/EtOH method.
Overall, the highest yield with 149mg/egg IgY resulted from procedure M4, which was
composed of the WD and the AS method, followed by 108mg/egg IgY from procedure
M7 that consisted of the PEG and the AS method (see Figure 49).
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Figure 46: Comparison of the nine IgY purification procedures. The yield of the IgY in % of the total yolk
proteins was arranged by the lipid precipitation methods.
Activity
The activities of the total yolk proteins and of the total IgY antibodies were tested in an
AP-ELISA and the absorbances were normalized to the activity/egg. Looking the lipid
and the IgY precipitation separately, the highest activity of the total yolk proteins was
retained by the WD method with 2897AU/egg, followed by the PEG method with
2297AU/egg and the lowest by the F/T method with 1925AU/egg (see Figure 47). The
highest activity of the total IgY was obtained by the PEG method with a 13.6% portion of
the total protein activity. This was only slightly higher than by the AS method with a
11.8% portion. A substantially lower activity remained by the PEG/EtOH method with a
9.0% portion of the total protein activity (see Figure 48).
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Figure 47: Activity of the IgY after lipid precipitation with F/T, WD and PEG and after IgY precipitation with
AS, PEG and PEG/EtOH. The total yolk protein activity was 1925AU/egg (SEM 44/egg) after F/T,
2897AU/egg (SEM 236/egg) after WD and 2297AU/egg (SEM 137/egg) after PEG. The total IgY activity
reached, was by the AS method 22.7AU/egg (SEM 6.4/egg), by the PEG method 6.2AU/egg (SEM 1.9/egg)
and by the PEG/EtOH method 2.6AU/egg (SEM 1.7/egg). The total IgY activity in percentage of the activity
of the total yolk proteins was by the AS method 11.8% (SEM 4.7%), by the PEG method 13.6% (SEM 4.1%)
and by PEG/EtOH 9.0% (SEM 2.5%).
Overall, the highest activity provided procedure M7 with 484AU/egg, closely followed by
procedure M8, which was composed of PEG and PEG, with 448AU/egg. The lowest
activity remained with procedure M1 that consisted of F/T and AS, with 94AU/egg.
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Figure 48: Activity of the yolk proteins and of the polyclonal total IgY in AP-ELISA, detected with an AP-
labeled rabbit anti-chicken IgG (whole molecule) and in percentage of the total protein activity. The activities
were normalized to the activity per one egg (13.4ml yolk).
In conclusion, the highest H1-CRD binding activity was obtained with M7-derived IgY,
but the reducing SDS-PAGE indicated, that the AS precipitation was only partially
effective (see Figure 49). The resulting polyclonal IgY were of low purity. As a
consequence, M8 was the procedure of choice. M8-derived IgY were nearly as active as
M7-derived IgY, but were highly pure. Alternatively, procedure M6, composed of W/D
and PEG/EtOH could be preferable, if traces of PEG in the M8-derived IgY would disturb
the IgY interaction. The second precipitation of the total IgY with EtOH removed PEG
effectively.
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Figure 49: Comparison of the nine different purification procedures M1-M9. The yields were determined by
Bradford assay (A) and the activities were measured in an AP-ELISA (B).
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3.3.2.2 Extraction of specific anti-H1 IgY
The polyclonal H1-CRD-specific (anti-H1) IgY were extracted from total polyclonal IgY by
H1-CRD-Sepharose (H1-Sepharose) affinity chromatography (see Figure 50A).
The comparison of the areas under the elution peaks indicated, that the highest amount
of anti-H1 IgY per egg were extracted from total IgY of M4 (M4H1), followed by IgY of M8
(M8H1) (see Figure 50B). No elution peak was detected when total IgY of preimmune
eggs were applied to the H1-CRD column.
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Figure 50: Extraction of specific anti-H1 IgY from total IgY of the different procedures M1-M9 (M1H1-M9H1)
on an H1-CRD-Sepharose column, detecting proteins by A280 measurement. A: Chromatogram of an anti-H1
IgY extraction. B: Overlayed elution peaks of the anti-H1 IgY extraction chromatograms.
Yield
The quantification of the eluted anti-H1 IgY by Bradford assay and A280 measurement
confirmed, that procedure M4H1 yielded the highest amount of specific IgY with
4.3mg/egg, followed by M8H1 and M5H1 with 2.1mg/egg and 2.0mg/egg, respectively.
With procedures M1H1, M2H1 and M7H1, only approximately five to seven times lower
anti-H1 IgY yields were received (see Figure 51).
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Figure 51: Yield of the specific anti-H1 IgY antibodies extracted from total IgY of M1-M9 by affinity using an
H1-CRD-Sepharose column.
When looking the fraction of anti-H1 IgY in the total IgY, the highest portion of anti-H1
IgY was obtained by M2H1, M5H1 and M8H1, which all included the PEG precipitation. This
agreed with the excellent total IgY purity of the PEG-derived compared to the AS-derived
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IgY. The AS-based procedures M1H1, M4H1, and M7H1 included only a minute portion of
1-3% specific IgY (see Figure 52).
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Figure 52: Fraction of the specific anti-H1 IgY in percentage of the total IgY, arranged according to the
procedures M1-M9.
Purity
The reducing SDS-PAGE gel clearly indicated, that the excellent yield of M4H1 was
caused by the presence of irrelevant proteins of mainly 36 to 45kDa. The same bands
were visible in all specific IgY, extracted from AS-derived total IgY of procedures M1H1,
M4H1 and M7H1. In the anti-H1 IgY, obtained from PEG-derived total IgY of procedures
M2H1, M5H1 and M8H1, only the 24kDa and 66kDa bands of the light and heavy chains
appeared (see Figure 53).
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Figure 53: Silver-stained reducing SDS-PAGE gel 12%, showing the specific anti-H1 IgY of procedures
M1H1 (1), M2H1 (2), M4H1 (3), M5H1 (4), M7H1 (5), M8H1 (6) and the LMW marker (0).
Activity
The high activity of the specific IgY was confirmed in the AP-ELISA. A strong
absorbance was seen for specific IgY of M1H1 to M9H1.
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3.3.2.3 Optimized IgY extraction
The AS-derived procedures resulted in the highest yields, with 37-148mg/egg total IgY
from procedures M1, M4 and M7 and with 4.3mg/egg specific IgY from procedure M4H1,
but the IgY were of low purity. Other yolk proteins were not quantitatively removed.
Therefore, these methods were not suitable. Of the remaining procedures, M8 showed
not only highest yield of total IgY with 30mg/egg, but also of specific IgY with 2mg/egg.
Hence, the procedure M8 was selected for the preparative IgY purification (see Table
10).
Table 10: Yields of IgY from one egg, purified by nine different procedures.
Method Protein / egg IgY / egg Specific IgY / egg
yield yield % of protein yield % of IgY % of protein
M1 183.0mg 36.6mg 20.0% 0.6mg 1.4% 0.32%
M2 200.6mg 9.6mg 4.8% 0.7mg 7.1% 0.35%
M3 201.8mg 0.9mg 0.4% - - -
M4 425.2mg 148.6mg 34.9% 4.3mg 3.0% 1.02%
M5 245.4mg 24.6mg 10.0% 2.0mg 6.8% 0.80%
M6 300.3mg 18.0mg 6.0% - - -
M7 310.9mg 107.7mg 13.2% 1.0mg 0.9% 0.35%
M8 818.1mg 29.8mg 10.8% 2.1mg 7.0% 0.76%
M9 274.5mg 11.9mg 4.6% - - -
3.3.2.4 Preparative scale purification of total IgY
The polyclonal total IgY antibodies were purified from 25-30eggs per batch, following
procedure M8. The reducing SDS-PAGE gel showed in the total IgY of all 8 batches only
the light and heavy chains and no irrelevant proteins. Consequently, the purity of the
total IgY antibodies was high (see Figure 54).
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Figure 54: Silver-stained reducing SDS-PAGE gel 12% of the total IgY (1-4) extraction by procedure M8 in
preparative scale and the LMW marker (0).
The overall yield was 11.8g total IgY, estimated by A280 measurement. Compared to the
IgY yield from M8 during optimization of 30mg/egg, scale up resulted in a 1.5-fold
increased extraction efficiency, with a yield of 45mg/egg.
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3.3.3 IgY characterization
3.3.3.1 In vitro characterization
Immunoblotting
The total IgY specifically immunostained reduced, non-reduced and native H1-CRD.
Interestingly, on the immunoblot of the non-reduced and native H1-CRD, the band
intensity of the dimeric species was stronger than of the monomeric species. In contrary,
on the non-reducing SDS-PAGE gel and native PAGE gel of the same H1-CRD batch,
the ratio of dimeric and monomeric bands was stained vice versa. In addition, other
bands of higher molecular weights were detected on the immunoblot, but were not seen
on the corresponding PAGE. They matched in their weight to the oligomeric aggregates
(trimers, tetramers, …) of the H1-CRD (see Figure 55).
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Figure 55: Immunoblot with total IgY. H1-CRD was blotted from reducing and non-reducing SDS-PAGE gels
and from a native PAGE gel 15% to nitrocellulose, followed by immunostaining with 20?g/ml total IgY and
AP-labeled rabbit anti-chicken IgG (whole molecule) in dilution 1:5000: blots of native (1), non-reduced (2)
and reduced (3) H1-CRD and non-reducing (4) SDS-PAGE gel of the H1-CRD.
No cross-reaction with the LMW marker proteins was visible.
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3.3.3.2 On cell characterization
Immunofluorescence microscopy
Texas Red-labeled IgY stained ASGPR-positive HepG2 but also ASGPR-negative SK-
Hep1 cells very weakly (see Figure 56).
HepG2
SK-Hep1
Figure 56: Immunofluorescence microscopy picture of directly stained HepG2 and SK-Hep1 cells. The
Texas Red-labeled specific anti-H1 IgY (40?mg/ml, 220nM) was endocytosed into living cells, followed by
paraformaldehyde fixation.
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3.4 Production and purification of monoclonal antibodies
3.4.1 Production of hybridomas
3.4.1.1 Immunization of mice
The active H1-CRD used for immunization of mice was purified by Gal-Sepharose
affinity chromatography.
3.4.1.1.1 Immunization of NMRI outbred mice
Three batches of three female 8-10 weeks old NMRI mice were primed sc in the neck,
with 20?g H1-CRD in CFA, and were boosted sc at least twice, every three weeks, with
20?g H1-CRD in IFA. Mice were finally boosted with 20?g H1-CRD sc without adjuvant
at days 3, 2 and 1 prior to fusion (see Table 11).
Table 11: Schedule of the NMRI mice immunizations with H1-CRD and PEG fusions of splenocytes with
myeloma cells.
Immunization Day Mouse Antigen injection Remarks
Priming 1 1-3 20?g H1-CRD / CFA, sc.
Boost 1 ~ 20 1-3 20?g H1-CRD / IFA, sc.
Boost 2 ~ 40 1-3 20?g H1-CRD / IFA, sc.
Serum titer Not determined
Myeloma cells 77 P3X63-Ag8.563 cells ready in culture
Final boost 1 77 3 20?g H1-CRD, sc.
Final boost 2 78 3 20?g H1-CRD, sc.
Final boost 3 79 3 20?g H1-CRD, sc.
Fusion 3 (RB.A) 80 3 PEG1500 fusion, NMRI feeder layer
Myeloma cells 40 P3X63-Ag8.563 cells ready in culture
Final boost 1 40 1 20?g H1-CRD, sc.
Final boost 2 41 1 20?g H1-CRD, sc.
Final boost 3 42 1 20?g H1-CRD, sc.
Fusion 4 (RB.B) 43 1 PEG1500 fusion, Balb/c feeder layer
3.4.1.1.2 Immunization of Balb/c inbred mice
One batch of three female 6 weeks old Balb/c mice was primed ip, with 200?g H1-CRD
in CFA, and was boosted ip, with 200?g H1-CRD in IFA, at days 21 and 60.
The serum titer of specific anti-H1 antibodies was determined by HRP-ELISA. Three
days prior to fusion, the mouse with the highest titer was finally boosted iv, with 200?g
H1-CRD without adjuvant. Although the antigen solution was tested to be pyrogen-free,
the first two mice died after final boosting iv. As a consequence, the last mouse was
finally boosted ip (see Table 12).
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Table 12: Schedule of the Balb/c mice immunizations with H1-CRD and PEG fusions of splenocytes with
myeloma cells.
Immunization Day Mouse Antigen injection Remarks
Priming 1 1-3 200?g H1-CRD / CFA, ip.
Boost 1 21 1-3 200?g H1-CRD / IFA, ip.
Boost 2 60 1-3 200?g H1-CRD / IFA, ip.
Serum titer 72 1-3 Dilution 1:300-1:100000
Myeloma cells 77 P3X63-Ag8.563, start culture
Final boost 83 1 200?g H1-CRD, iv. Mouse with highest serum titer, died
Fusion 1 86 Mouse dead
Final boost 87 2 200?g H1-CRD, iv. Mouse with middle serum titer, died
Fusion 2 90 Mouse dead
Final boost 87 3 200?g H1-CRD, ip. Mouse with lowest serum titer
Fusion 3 (RB.C) 90 PEG4000 fusion,
3.4.1.2 Fusion and hybridoma screening
3.4.1.2.1 PEG fusion of NMRI splenocytes with myeloma cells
The splenocytes of an immunized NMRI mouse were fused with murine myeloma cells
P3X63-Ag8.563 using PEG1500. Two of nine fusions (fusion A and B) succeeded, while
the others failed.
Fusion A
The fusion A was performed at day 80 after priming and the fused cells were distributed
in plates, which contained a feeder-layer of NMRI macrophages.
After 21 days incubation in selective HAT medium without feeding, the supernatants of
all wells on the fusion plates were screened by AP-ELISA, every 7 days. The first screen
at day 22 post fusion resulted in 31, the second screen at day 29 post fusion in
additional 16 and the third screen at day 36 post fusion in 5 new positive hybridomas.
During expansion of these 52 ELISA-positive hybridomas, 34 stopped growing and
further 12 stopped the secretion of antibodies. The remaining 6 hybridomas of fusion A
were successfully expanded from macrophage-coated 96-well to coated 24-well plates
and further to 6-well plates without coating, they were frozen in liquid nitrogen (see Table
13). While cultivating, the selective HAT-supplemented medium was replaced with HT-
supplemented and further with nonselective medium.
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Table 13: Reasons for the loss of positive hybridomas from fusions A and B, during transfer and expansion,
until freezing in liquid nitrogen.
Reason Hybridomas
Stop growth A01, A02, A03, A05, A06, A07, A08, A09, A10, A13, A14, A15, A21, A22,
A23, A27, A29, A30, A31, A32, A34, A35, A36, A37, A38, A39, A40, A44,
A46, A48, A49, A50, A51, A52
Stop Ab production A12, A16, A17, A18, A19, A20, A26, A28, A33, A42, A43, A45
Instable positive hybridomas A04, A11, A24, A25
Positive hybridomas A41, A47
B01, B02
Fusion B
Cells of fusion B were fused at day 39 and were distributed on plates with Balb/c
macrophage feeder-layer. The fusion B resulted in 2 positive hybridomas, which were
expanded for freezing (see Table 13).
3.4.1.2.2 PEG fusion of Balb/c splenocytes with myeloma cells
Splenocytes of an immunized Balb/c mouse were fused with myeloma cells P3X63-
Ag8.563 at day 90 after priming and cells were plated without feeder-layer, but in IL-6-
supplemented medium.
Hybrid cells were incubated in selective HAT-containing medium for 14 days without
feeding. At day 15 post fusion, the supernatants of all wells on the fusion plates were
screened by HRP-ELISA, showing 63 of 480 wells to be positive. 48 hybridomas were
expanded to 24-well plates, but thereof 8 gave up growing and 21 stopped the antibody
production. From remaining 19 hybridomas of fusion C, 8 stayed slightly and 11 were
clearly positive in ELISA, until freezing in liquid nitrogen. During cultivation, the medium
was switched to HT-containing medium for a period of 2 weeks, and then to nonselective
medium (see Table 14).
Table 14: Reasons for the loss of positive hybridomas from fusions C, during transfer and expansion, until
freezing in liquid nitrogen.
Reason Hybridomas
Stop growth C02, C06, C07, C08, C36, C38, C40, C45
Stop Ab production C01, C03, C04, C05, C10, C12, C13, C15, C20, C24, C25, C29-32,
C37, C39, C41-44
Instable positive hybridomas C26, C27, C28, C33, C34, C35, C46, C47
Positive hybridomas C09, C11, C14, C16, C17, C18, C19, C21, C22, C23, C48
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3.4.1.3 Fingerprint characterization of hybridomas
3.4.1.3.1 Isotyping
The heavy chain isotypes of the 18 hybridomas included all subclasses of antibodies.
38% belonged to IgM and 61% to IgG. These were subdivided into 44% of IgG1, 11% of
IgG2a and 6% of IgG2b (see Figure 57).  The light chain isotype was always ?.
Isotype Hybridoma
IgM A47, C16, C19, C21, C22, C27, C28
IgG1 B01, C09, C11, C18, C23, C26, C33, C48
(C28, C35)
IgG2a C14, C35
IgG2b C17
y y
IgM IgG
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25
50
75
100 IgM
IgG2a
IgG2b
IgG1
isotype
Figure 57: Isotyping of the 18 hybridomas from fusions A to C.
3.4.1.3.2 Immunoblotting
The blots of reduced, non-reduced and native H1-CRD were stained in supernatants of
the 20 different hybridomas, i.e. the A47, B01, C09, C11, C14, C16, C17, C18 C19, C21,
C22, C23, C26, C27, C28, C33, C35, C39, C46 and the C48.
The antibodies of the 6 hybridomas B01, C09, C11, C14, C18, C23 and C48 bound to
reduced, non-reduced as well as native H1-CRD. In contrast to C11, C18, C23 and C48,
which showed similar band intensities with H1-CRD in all three states, B01, C09 and
C14 preferentially recognized reduced H1-CRD. Furthermore, for all hybridomas except
for C14, a stronger signal was obtained with dimeric compared to monomeric H1-CRD
species on the non-reducing blot, although on the corresponding SDS-PAGE gel, signal
intensities of both species were vice versa.
Interestingly, the antibodies of hybridoma C17 interacted with reduced and native, but
not with non-reduced H1-CRD. In contrary, the antibodies of the 7 hybridomas A47, C16,
C19, C21, C22, C33 and C35 exceptionally stained H1-CRD in reduced, but not in non-
reduced and native state. Finally, no band was detected neither on the reducing, non-
reducing nor the native immunoblot, when stained with supernatants of the 4 hybridomas
C26, C27, C28 and C46 (see Figure 58).
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Figure 58: Immunoblot of the H1-CRD, staining in supernatant of the 20 hybridomas and with AP-labeled
goat anti-mouse Ig (whole molecule). The reducing, non-reducing and native blots were stained in the same
batches of supernatant.
3.4.1.3.3 ELISA
Specificity to H1-CRD and H2-CRD
Identical amounts of H1-CRD and H2-CRD were coated on the same plate and
differences in binding to the antibodies of the hybridoma supernatants were detected by
HRP-ELISA.
All supernatants were positive with H1-CRD and H2-CRD but differed in the signal
intensities. The antibodies in the supernatant of the 13 hybridomas C09, C14, C16, C17,
C18, C19, C21, C22, C23, C27, C28, C33 and C46 recognized the H1-CRD and the H2-
CRD to a similar extent. In contrast, the 5 hybridomas A47, B01, C11, C26 and C48 and
the sera of H1-immunized mice preferentially bound to H1-CRD. Compared to the H2-
CRD, the absorbance increased more than 10% (see Figure 59).
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Figure 59: Differences in the binding of the H1-CRD and the H2-CRD to hybridoma antibodies. The murine
serum of an immunized mouse (s) and the supernatants of hybridomas from fusion A to C were tested in
duplicate by HRP-ELISA on the same plate.
Calcium sensitivity
The binding of hybridoma antibodies to the H1-CRD in the presence and absence of
calcium was tested in a HRP-ELISA. All antibodies interacted with the H1-CRD in high
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and low concentrated calcium buffers as well as in buffer with EDTA. The binding of
B01, C09, C14, C16, C18 and C21 antibodies was not calcium-dependent. In contrast,
the affinity of A47, C23, C26 and C48 to the H1-CRD was substantially and of C11 and
C22 slightly increased in the presence of 20mM calcium. A negative calcium-
dependence, showing a stronger binding in the presence of 2mM EDTA, was observed
for C19. Finally, for C17 antibodies, the lowest signal was obtained in the presence of
2mM calcium compared to 20mM calcium and 2mM EDTA, while for C35 antibodies, the
highest signal resulted in the presence of 2mM calcium (see Figure 60).
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Figure 60: Differences in the binding of the H1-CRD to hybridoma antibodies in the presence or absence of
calcium. The supernatants of hybridomas from fusion A to C were tested in duplicate in an HRP-ELISA on
the same plate.
3.4.1.3.4 Fluorescence flow cytometry
Extracellular flow cytometry with HL-60, Jurkat, K-562, THP-1 and HepG2 cells
HL-60, Jurkat, K-562 and THP-1 and HepG2 cells were extracellularly stained with
hybridoma supernatants and FITC-labeled goat anti-mouse Ig (polyvalent), without cell
fixation.
The antibodies of all 17 hybridomas A47, B01, C09, C11, C16, C17, C18, C19, C21,
C22, C23, C26, C27, C28, C33, C46 and C48, were not bound to the surface of HL-60,
Jurkat, K-562 and THP-1. Exceptions were C35, which recognized THP-1 cells and C14,
which in addition interacted with HL-60 cells.
All, but not the 7 hybridomas C19, C26, C27, C28, C33, C35 and C46, stained the
ASGPR-positive HepG2 cells. The fixation of the HepG2 cells with paraformaldehyde
however, prevented the binding of A47, C14, C16, C21 and C22 antibodies, whereas
stains were still observed with B01, C09, C11, C17, C18, C23 and C48 antibodies (see
Figure 61).
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Figure 61: Binding of the antibodies in the hybridoma supernatants to the surface of fixed or not fixed
HepG2 cells.
Intracellular flow cytometry of hybridomas
The hybridomas A04, A11, A12, A17, A24, A25, A41 and B01 were taken into culture
two days before they were screened by intracellular fluorescence flow cytometry to
examine their ability to produce antibodies.
Figure 62: Intracellular FACS of the hybridomas A04, A11, A17, A24 and A25 after a preincubation with
Brefeldin.
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The in intracellular staining of Brefeldin-treated hybridomas showed, that only the
hybridomas A11 and B01 preserved the antibodies production, with a clear shift of the
cell population in FL1-H. A minute shift was still detected for the hybridomas A17 and
A25, but no shift appeared in hybridomas A04 and A12. Interestingly, the hybridomas
A24 and A41 were composed of two cell populations, a positive and a negative one (see
Figure 62).
In contrary, in the AP-ELISA, all hybridoma supernatants were negative and contained
no anti-H1 antibodies, except the B01 supernatant of the positive control.
Dependent on the fingerprint characterization, hybridomas were selected for cloning and
further investigation of the monoclonal antibody characteristics. All hybridomas, which
failed in the staining of HepG2 cells, were excluded.
Selected 12 hybridomas, i.e. the A11, A24, A41, A47, B01, C09, C11, C14, C17, C18,
C23 and the C48, represented mainly IgG1, but each isotype class and subclass was
considered once, at least. The hybridomas C11, C18 and C23 were regarded as highly
promising candidates to be blocking antibodies. They preferentially bound to native H1-
CRD and in a calcium-dependent manner (see Table 15).
Table 15: Summary of the fingerprint characterization of the different hybridomas from fusions A to C The
FACS-negative hybridomas are written in italic, selected hybridomas are shaded in grey and most promising
hybridomas are written in bold.
Hybridoma Isotype IB HRP-ELISA Extracellular FACS
red non-red native H1 H1>>H2 Ca>>EDTA not fixed
HepG2
fixed
HepG2
A41 - + +
A47 IgM + - - + + + + -
B01 IgG1 ++ + + + - + +
C09 IgG1 ++ + + + - - + +
C11 IgG1 + + + + + + + +
C14 IgG2a ++ + + + - - + -
C16 IgM ++ - - + - - + -
C17 IgG2b ++ - + + - - + +
C18 IgG1 + + + + - - + +
C19 IgM ++ - - + - - - -
C21 IgM + - - + - - + -
C22 IgM + - - + - + + -
C23 IgG1 + + + + - ++ + +
C26 IgG1 - - - + + ++ - -
C27 IgM - - - + - + -
C28 IgM
(IgG1)
- - - + - - -
C33 IgG1 + - - + - - -
C35 IgG2a
(IgG1)
++ - + - - -
C46 - + - -
C48 IgG1 + - + + + ++ + +
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3.4.2 Production and propagation of clones
3.4.2.1 Terasaki single-cell cloning of hybridomas
The selected 12 hybridomas, i.e. the A11, A24, A41, A47, B01, C09, C11, C14, C17,
C18, C23 and the C48 were cloned in dilutions 10cells/well, 3cells/well, 1cell/well and
0.3cell/well on special 60-well Terasaki-plates in IL-6-supplemented medium.
The hybridomas A11, A24 and A41 were all cloned twice successfully, with cloning
efficiencies of 1.1-1.7cells/well. But all 298 clones of A11 stopped the antibody
production during expansion, all 87 clones of A24 never produced antibodies and all 169
clones of A41 stopped growing.
The hybridoma A47 of fusion A was cloned with a cloning efficiency of 21.0cells/well. All
48 clones of the cloning in dilutions 0.3 and 1cell/well were positive in the AP-ELISA.
Thereof, 12 clones (A47.1 to A47.12) were expanded. The antibodies of all clones were
of the IgM isotype, identical to the antibodies of the hybridoma A47 (see Figure 63).
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Cloning of hybridoma A47
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cloning 1
efficiency 21.0 cells/well
cells/well
Clone Dilution Isotype
A47 IgM
A47.1 - 2 1 IgM?
A47.3 0.3 IgM?
A47.4 - 5 0.3 IgM?
A47.6 - 12 0.3
Figure 63: Terasaki cloning of hybridoma A47. A: The cloning efficiency of A47 (21.0cells/well, top 96.7, K
0.046, r2 0.98). B: Positive clones with its cloning dilution and the isotype of the produced antibodies. The
selected clone for the characterization is shaded in grey.
The hybridoma B01 of fusion B was cloned with a cloning efficiency of 24.2cells/well. All
81 clones were ELISA-positive. Selected 6 clones (B01.1 to B01.6) of the cloning in
dilutions 0.3 to 3 were expanded. The clone B01.4 was isotyped, showing the same
subclass IgG1 as the originating hybridoma B01 (see Figure 64).
Clone Dilution Isotype
B01 IgG1
B01.1 - 3 0.3
RB.B01.4 1 IgG1?
RB.B01.5 1
RB.B01.6 3
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Figure 64: Terasaki cloning of hybridoma B01. A: The cloning efficiency of B01 (24.2cells/well, top 100.1, K
0.041, r2 1.00). B: Positive clones with its cloning dilution and the isotype of the produced antibodies. The
selected clone for the characterization is shaded in grey.
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All hybridomas of fusion C, i.e. the C09, C11, C14, C18, C23 and the C48, were cloned
and positive clones were expanded successfully, except hybridoma C17.
Hybridomas C09, C11, C14, C18 and C23 were cloned with cloning efficiencies of
8.9cells/well, 4.0cells/well, 26.3cells/well, 14.8cells/well and 5.2cells/well, respectively.
Dependent on this, all clones of the cloning in dilutions 0.3-1cell/well, 0.3cell/well, 0.3-
10cells/well, 0.3-3cells/well and 0.3-1cell/well were picked and screened by HRP-ELISA,
showing all clones to produce anti-H1 antibodies. The selected 4 of 15 clones from C09
(C09.1-C09.4), 4 of 33 clones from C11 (C11.1-C11.4), 6 of 74 clones from C14 (C14.1-
C14.6), 4 of 44 clones from C18 (C18.1-C18.4) and 8 of 48 clones from C23 (C23.1-
C23.8) were expanded for freezing. All clones produced antibodies of the same isotype
subclass as the originating hybridoma. All clones of C09, C11, C18 and C23 were of the
IgG1 class and all clones C14 were of the IgG2a class (see Figure 66).
The hybridoma C48 was cloned with an efficiency of 8.3cells/well and 48 clones of the
cloning in dilutions 0.3 and 1cell/well were transferred. The screening of the supernatant
indicated, that only 17 produced antibodies. During expansion of 9 selected positive
clones (C48.1 to C48.9), 44% of this clones (C48.1, C48.2, C48.5, C48.7) stopped the
antibody secretion (see Figure 65).
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Figure 65: Terasaki cloning of hybridoma C48. A: The cloning efficiency of C48 (8.3cells/well, top 100.3, K
0.120, r2 0.99). B: Positive clones with its cloning dilution and the isotype of the produced antibodies. The
selected clones for the antibody characterization are shaded in grey.
The hybridoma C17 was cloned twice with efficiencies of 37.3cells/well and
79.2cells/well, but no anti-H1 antibody-producing clone was received. Only 2 of 73
clones were positive in HRP-ELISA, but lost the ability to produce antibodies during
expansion for freezing.
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Figure 66: Terasaki cloning of hybridomas C09, C11, C14, C18 and C23. A: The cloning efficiency of
hybridoma C09 (8.9cells/well, top 9102.8, K 0.115, r2 0.98), C11 (4.0cells/well, top 103.6, K 0.259, r2 0.99),
C14 (26.3cells/well, top 101.0, K 0.038, r2 0.96), C18 (14.8cells/well, top 103.0, K 0.069, r2 0.99) and C23
(5.2cells/well, top 101.2, K 0.195, r2 1.00). B: Positive clones with their cloning dilution and the isotype of the
produced antibodies. Selected clones for the antibody characterization are shaded in grey.
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3.4.2.2 Propagation of clones
The clone A47.3 was propagated in RPMI enriched with 10% FCS, and 500ml
supernatant was harvested after 4 weeks. In contrast, the clone B01.4 was propagated
in RPMI supplemented with 3% FCS (low IgG), and 500ml supernatant were harvested
twice after 4 and 5 weeks, respectively. Similarly, the clones C09.1, C11.1, C14.6,
C18.1, C23.8 and C48.9 were propagated in RPMI with 3% FCS (low IgG), but only
250ml supernatant were harvested twice, 4-6 weeks after propagation start.
The clone C14.6 cells tended to clump during propagation, when the FCS concentration
was lowered. The clones C23.8 and C48.9 were very sensitive to low cell densities and
a low FCS concentration and therefore, they stopped cell division. Both hybridomas
tended to be instable in their antibody production, as tested in a HRP-ELISA.
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3.5 Antibody characterization
3.5.1 Monoclonal A47.3 IgM
3.5.1.1 Purification of A47.3 IgM
Murine IgM antibodies neither bind to Protein A nor to Protein G. Therefore, the
purification of A47.3 IgM by affinity chromatography using Protein L-Sepharose and H1-
Sepharose was tested.
Purification by Protein L spin chromatography
The IgM purification from culture supernatant of A47.3, containing 10% FCS, using a
Protein L-Sepharose spin column was not suitable. On the one hand, the purity was low,
showing a high content of BSA on the silver-stained reducing SDS-PAGE gel. On the
other hand, also the yield was minute. The HRP-ELISA let to conclude, that only a minor
fraction of A47.3 was extracted, because the column flow through showed still
approximately the same absorbance as the supernatant.
Purification by H1-CRD FPLC
The A47.3 IgM were also extracted from 10% FCS-containing culture supernatant, using
an H1-Sepharose column. Due to precipitation problems, the baseline was very instable
during loading. The supernatant was loaded onto the column twice. The IgM, which were
eluted at a pH of 3, were highly pure. Only the 25kDa and 80kDa bands of the light and
heavy chains were visible on a reducing SDS-PAGE gel (see Figure 67).
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Figure 67: IgM purification from culture supernatant of clone A47.3, containing 10% FCS. A: H1-CRD FPLC
chromatogram. B: Silver-stained reducing SDS-PAGE gel 10% of eluted A47.3 IgM, showing the 25kDa light
chain band and the about 80kDa heavy chain double band.
Benefit and Application of Antibodies Against the H1-CRD Results
151
The yield, determined by Bradford assay and absorbance A280 measurement, was
substantially better with 0.77mg A47.3 IgM in mean, equivalent to 7.7mg/L supernatant.
Thereof, the first extraction yielded 4.3mg/L and the second extraction 3.4mg/L
supernatant (see Figure 68). Also the H1-CRD affinity chromatography allowed only the
extraction of an A47.3 antibody fraction. Hence, the flow through was still positive in the
HRP-ELISA after twice clearing the supernatant.
Extraction H1-CRD
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Figure 68: Yield of A47.3 IgM, purified by affinity to Protein L and H1-CRD and quantified by Bradford micro-
assay and absorbance A280 measurement. Overall yield was 7.734mg/L (SEM 0.569mg/L) culture
supernatant of clone A47.3.
3.5.1.2 In vitro characterization
3.5.1.2.1 Immunoblotting
Identical amounts of the reduced, non-reduced and native H1-CRD as well as of the
reduced-alkylated and native-alkylated H1-CRD were blotted to nitrocellulose and were
stained, using A47.3 IgM in concentrations of 5?g/ml or 0.5?g/ml (see Figure 69).
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Figure 69: Immunoblot of the H1-CRD, stained using monoclonal A47.3 IgM. 1?g/band H1-CRD on PAGE
gels 15% under reducing, non-reducing denatured or native conditions were blotted to nitrocellulose and
were immunostained with A47.3 IgM, followed by detection with AP-labeled goat anti-mouse Ig (whole
molecule) in dilution 1:5000. A: Blot stained with 5?g/ml A47.3 IgM, showing the LMW marker (0), the
reduced (1), non-reduced (2) and native (3) H1-CRD. B: Blot stained with 0.5?g/ml A47.3 IgM, showing the
LMW marker (0), reduced (1), the reduced state of reduced-alkylated (2), the reduced state of native-
alkylated (3), non-reduced (4), the non-reduced state of native-alkylated (5), native (6) and the native state
of the native-alkylated (7) H1-CRD. C: Silver-stained reducing and non-reducing SDS-PAGE gel 15% of the
same probes used in B (0-5).
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On a Ponceau S-casted blot, the bands pattern was identical to the bands on the PAGE
gel (see Figure 69C). The intensities of the monomeric H1-CRD species were about the
same, independent of their alkylation state and much stronger than of dimeric H1-CRD.
The monoclonal A47.3 IgM specifically recognized monomeric and dimeric H1-CRD in
reduced, non-reduced and native state, but they also cross-reacted with the carbonic
anhydrase (bovine erythrocytes) of the LMW marker. The binding to native H1-CRD was
much weaker than to non-reduced and reduced H1-CRD.
With the lower A47.3 IgM concentration of 0.5?g/ml, the reduced H1-CRD appeared only
fairly in the stain, whereas neither non-reduced nor native H1-CRD was detected. The
alkylation of H1-CRD did not affect the binding on the reducing blot.
3.5.1.2.2 ELISA
The binding of the monoclonal A47.3 IgM to the H1-CRD (5?g/ml, 300?M) was titrated in
the concentration range of 0 - 10nM in a HRP-ELISA, using HRP-labeled goat anti-
mouse Ig (H+L) diluted 1:1000 for detection. For half maximal binding of the A47.3 IgM,
an EC50 of 12.20nM was calculated. However, this concentration lied out of the titrated
range (see Figure 70).
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Figure 70: Binding of the A47.3 IgM to H1-CRD in a HRP-ELISA. The A47.3 was titrated in the range of
0.017-10nM in duplicate (exponential dilution row) in the presence of 20mM calcium. The plate was coated
with 5?g/ml (300?M) H1-CRD and A47.3 detected with HRP-labeled goat anti-mouse Ig (H+L) diluted
1:1000. The EC50 was calculated, using a nonlinear regression fit (equation sigmoid dose-response, variable
slope, r2 0.99) of Prism4 software.
The calcium sensitivity of the A47.3 IgM binding to the H1-CRD in the HRP-ELISA was
tested. Therefore, A47.3 was caught in the presence of 20mM calcium or 1mM calcium
and in the absence of calcium, when calcium was chelated with 10mM EDTA. During all
other incubation steps, the same buffers were used, which included 1mM calcium prior
and 20mM calcium after the A47.3 capturing.
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Figure 71: Ca sensitivity of the A47.3 IgM binding to the H1-CRD in a HRP-ELISA in the presence of 20mM
calcium, 1mM calcium or in the absence of calcium, chelated with 10mM EDTA. The plate was coated with
3?g/ml H1-CRD (175?M) and the A47.3 IgM was titrated in the range of 0.001 – 1nM in triplicate. Bmax and
KD were calculated, using a nonlinear regression fit (equation one site binding, hyperbola, r
2 0.82 and 0.94)
of Prism4 software.
A47.3 IgM bound only very weak and independent of calcium in the titrated range. A
lower KD of 161mM and Bmax of 1.3·10
11% were calculated in the presence of 20mM
calcium compared to a KD of 2.1M and Bmax of 1.8·10
11% in the presence of 10mM
EDTA. But as the KD lied outside of the titrated range, this can only be regarded as a
finger hint (see Figure 71).
3.5.1.2.3 GalNAc-polymer assay
The competition of the A47.3 IgM with POD-labeled streptavidin-biotin ?-GalNAc-
polymer for binding to the H1-CRD was investigated in HAB buffer, containing 1mM
calcium.
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Figure 72: Competition of the A47.3 IgM and the GalNAc-polymer for binding to the H1-CRD in the polymer
assay. The plate was coated with 3?g/ml (175?M) H1-CRD. A47.3 IgM in the range of 0.04 – 10nM
(exponential dilution) in triplicate or tetricate, competed with 0.3?g/ml GalNAc-complex for binding. Nonlinear
regression fit (equation, one site competition).
Independent of the A47.3 concentration in the range of 0 – 10nM, the ?-GalNAc-complex
was not displaced. Therefore, A47.3 IgM and ?-GalNAc did not compete for binding to
H1-CRD (see Figure 72).
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3.5.1.3 On cell characterization
3.5.1.3.1 Immunofluorescence flow cytometry
ASGPR-positive hepatic HepG2 cells, ASGPR-negative hepatic SK-Hep1 cells,
macrophage-like THP-1 cells and primary human macrophages and dendritic cells were
indirectly extracellular stained with A47.3 IgM, without fixation of the cells.
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Figure 73: Flow cytometry of not fixed ASGPR-positive HepG2, ASGPR-negative SK-Hep1, THP-1,
macrophages and dendritic cells. Cells were indirectly extracellular stained with A47.3 IgM and FITC-labeled
goat anti-mouse Ig (H+L). The dead probidium-stained cells were excluded. The histogram shows an
overlay with the negative control (irrelevant IgG!).
The A47.3 IgM did not stain the HepG2, SK-Hep1, THP-1, macrophages and dendritic
cells. Hence, the A47.3 did not bind to the ASGPR on cells (see Figure 73).
Benefit and Application of Antibodies Against the H1-CRD Results
155
3.5.1.3.2 Immunofluorescence microscopy
The internalization of the Texas Red-labeled A47.3 IgM into HepG2 cells via the ASGPR
was investigated, using SK-Hep1 cells for negative control.
No fluorescent flats were visible in HepG2 and in SK-Hep1 cells, which confirmed, that
the A47.3 were not internalized (see Figure 74).
HepG2
SK-Hep1
Figure 74: Immunofluorescence microscopy of the HepG2 and SK-Hep1 cells, stained with TR-labeled
A47.3 IgM (40?g/ml, 45nM), followed by paraformaldehyde fixation.
Benefit and Application of Antibodies Against the H1-CRD Results
156
3.5.2 Monoclonal B01.4 IgG1
3.5.2.1 Purification of B01.4 IgG1
Murine IgG1 antibodies stronger bind to Protein G than to Protein A. For purification of
the monoclonal B01.4 IgG1 both, Protein A and G affinity chromatography, were tested.
Purification by Protein A FPLC
The salt concentration in the culture supernatant of clone B01.4, supplemented with 3%
FCS (low IgG), was increased to 3.3M NaCl and 1.5M glycine, before the antibodies
were extracted twice, using a Protein A-Sepharose column. The baseline was very
instable, when loading the supernatant. The B01.4 IgG1 eluted in a very broad peak.
The slow dissociation was probably due to a slightly too high elution pH of 4.
Purification by Protein G FPLC
The B01.4 IgG1 were three times extracted from culture supernatant of clone B01.4,
containing 3% FCS (low IgG), using a Protein G-Sepharose column. The loading
baseline was very stable, and the antibodies eluted at a pH of 3 in a narrow
concentrated peak (see Figure 75). The activity of the purified B01.4 IgG1 antibodies
after elution was verified by HRP-ELISA.
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Figure 75: IgG1 purification from culture supernatant of clone B01.4, containing 3% FCS (low IgG). A:
Protein G FPLC chromatogram with elution peaks of the first (1), the second (2) and the third (3) extraction
and B: Silver-stained reducing SDS-PAGE gel 12% of the eluted B01.4 IgG1, showing the 25kDa light and
the 55kDa heavy chain band.
The reducing SDS-PAGE gel confirmed the high purity of the B01.4 IgG1 for both
methods, showing only the 25kDa and 55kDa band of the light and heavy chain, without
BSA contamination (see Figure 75A and B).
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The yield, estimated by Bradford micro-assay, SDS-PAGE quantification and A280
measurement, was higher for Protein G chromatography with 26.0mg/L, than for Protein
A chromatography with 20.8mg/L supernatant. But this was the effect of the additional
third extraction step. The yield of each extraction was approximately the same with 11.2
– 11.8mg/L in the first extraction, 9.6 – 9.8mg/L in the second extraction and 4.4mg/L in
the third extraction (see Figure 76).
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Extraction Protein A Protein G
1 11.2mg/L 11.8mg/L
2 9.6mg/L 9.8mg/L
3 4.4mg/L
total 20.8mg/L 26.0mg/L
Figure 76: Yield of the B01.4 IgG1, purified by affinity to Protein A and Protein G and quantified by Bradford
micro-assay, SDS-PAGE quantification and absorbance A280 measurement. The overall yield was
24.280mg/L (SEM 1.539mg/L) culture supernatant of B01.4, in mean.
Overall, 24.3mg B01.4 IgG1 antibodies were purified from 1000ml culture supernatant of
clone B01.4. This is equivalent to a yield of 24.4mg/L supernatant. Multiple extractions
were crucial for high-yield IgG1 purification.
3.5.2.2 In vitro characterization
3.5.2.2.1 Immunoblotting
Identical amounts of the reduced, non-reduced and native H1-CRD as well as of the
reduced-alkylated and native-alkylated H1-CRD were blotted to nitrocellulose and were
stained with 5?g/ml and 0.5?g/ml B01.4 IgG1 (see Figure 77).
The Ponceau S-stained membrane and the silver-stained PAGE gel showed identical
bands pattern (see Figure 77C). The intensity of the monomeric H1-CRD species was
higher than of the dimeric species, but was independent of the H1-CRD to be alkylated
or not.
Monoclonal B01.4 IgG1 specifically recognized monomeric and dimeric H1-CRD in
reduced, non-reduced and native state. Even when using the high IgG1 concentration of
5?g/ml, no cross-reactions with LMW marker proteins were detected.
Already at the lower B01.4 IgG1 concentration, the reduced, non-reduced and native H1-
CRD were immunostained, but the intensities varied dependent on the alkylation state.
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Figure 77: Immunoblot of the H1-CRD, stained with the monoclonal B01.4 IgG1. 1?g/band H1-CRD on
PAGE gels 15% under reducing, non-reducing denatured or native conditions were blotted to nitrocellulose
and were immunostained with B01.4 IgG1, followed by the detection with AP-labeled goat anti-mouse IgG
(whole molecule) in dilution 1:5000. A: Blot stained with 5?g/ml B01.4 IgG1, showing non-reduced (1),
reduced (2) and native (3) H1-CRD. B: Blot stained with 0.5?g/ml B01.4 IgG1, showing reduced (1), the
reduced state of reduced-alkylated (2), the reduced state of native-alkylated (3), non-reduced (4), the non-
reduced state of native-alkylated (5), native (6) and the native state of native-alkylated (7) H1-CRD. C:
Silver-stained reducing and non-reducing SDS-PAGE gel 15%,  the same probes (B, 1-5). LMW marker (0).
The reduced-alkylated (alkylated after reduction) H1-CRD was only minute stained,
whereas strong bands were obtained for the not alkylated and native-alkylated (alkylated
without prior reduction) H1-CRD. Similarly, B01.4 recognized the native-alkylated and
the not alkylated H1-CRD in non-reduced or native state, respectively with identical
signal intensities.
Furthermore, a stronger staining was observed for dimeric H1-CRD species than for
monomeric, although band intensities were vice versa on silver-stained PAGE gels. This
effect was seen for non-reduced, but much stronger for native H1-CRD.
3.5.2.2.2 ELISA
The monoclonal B01.4 IgG1 was titrated in the concentration range of 0.1 - 300nM in an
HRP-ELISA. The binding to plates, which were coated with 5?g/ml (300?M) H1-CRD
was detected with HRP-labeled goat anti-mouse Ig (H+L) diluted 1:1000.
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Figure 78: Binding of the B01.4 IgG1 to the H1-CRD in a HRP-ELISA. B01.4 was titrated in the range of 0.1-
300nM in duplicate (exponential dilution row) in the presence of 20mM calcium. The plate was coated with
5?g/ml (300?M, 0.4?g/well) H1-CRD and B01.4 was detected with HRP-labeled goat anti-mouse Ig (H+L),
diluted 1:1000. The EC50 was calculated, using a nonlinear regression fit (equation sigmoid dose-response,
variable slope, r2 0.99) of Prism4 software.
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An EC50 of 0.340nM was calculated for half maximal binding (see Figure 78).
In an HRP-ELISA, the calcium sensitivity of the B01.4 IgG1 binding to the H1-CRD was
tested in the presence of 20mM calcium, 1mM calcium or 10mM EDTA to chelate all
calcium. Beside in this B01.4 antibody-capturing step, all buffers were composed
identically, containing the lower concentration of 1mM calcium before and the higher
concentration of 20mM calcium after this step.
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Figure 79: Ca sensitivity of the B01.4 IgG1 binding to H1-CRD in HRP-ELISA in the presence of 20mM
calcium, 1mM calcium or in the absence of calcium, chelated with 10mM EDTA. Plates were coated with
3?g/ml (175?M) (A) or 6?g/ml (350?M) (B) H1-CRD and B01.4 IgG1 was titrated in the range of 0.0625-
6.25nM (A) or 0.1875-187.5nM (B) in triplicate. Bmax and KD were calculated, using a nonlinear regression fit
(equation one site binding, hyperbola, r2 0.80 – 1.00).
When coating with 175?M H1-CRD, the B01.4 binding was slightly increased in the
presence of calcium, compared to no calcium, but was not influenced by the height of
the calcium concentration. The KD of 0.54nM and Bmax of 69.3% in 20mM calcium and KD
of 0.66nM and Bmax of 69.1% in 1mM calcium were about the same, compared to KD of
0.76nM and Bmax of 35.3% in 10mM EDTA. In contrary, when coating with 350?M H1-
CRD, about the same KD in the range of 0.17-0.28nM and Bmax in the range of 92.7-
96.7% were received, not dependent on the presence of calcium (see Figure 79).
3.5.2.2.3 GalNAc-polymer assay
The competition of the POD-labeled streptavidin-biotin ?-GalNAc-polymer and the B01.4
IgG1 for binding to the H1-CRD was tested in the presence of 1mM calcium. The B01.4
antibodies, which were titrated in the range of 0-625nM, competed against 0.3?g/ml ?-
GalNAc-complex for binding to the H1-CRD (see Figure 80).
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Figure 80: Competition of the GalNAc-polymer and the B01.4 (A) or the anti-Lewisa (B) IgG1 for binding to
the H1-CRD in the polymer assay. The plate was coated with 3?g/ml (175?M) H1-CRD. The B01.4 and the
anti-Lewisa antibodies, in the range of 0-625nM (exponential dilution) in triplicate or tetricate, competed with
0.3?g/ml GalNAc-complex for binding (nonlinear regression fit: equation, one site competition).
The B01.4 IgG1 showed an EC50 of 16-24nM, whereas the negative control antibody of
the same isotype, a murine anti-Lewisa IgG, had a calculated about five times higher
EC50 of 1.5. Hence, the blocking effect was not only the consequence of a high antibody
concentration but of steric or functional competition for binding to the H1-CRD.
3.5.2.2.4 Biacore
The binding constants and kinetics of the B01.4 IgG1 interaction with monomeric and
dimeric H1-CRD were examined and determined by Biacore assay (see Figure 81A).
Figure 81: Biacore assay of the B01.4 IgG1 binding to monomeric and dimeric H1-CRD. A: Sensoogram,
with a preliminary injection of 5mM galactose (g), B01.4 IgG1 injection (i), dissociation phase (d), followed by
a second 5mM galactose injection and an EDTA pulse (e), prior to regeneration with HCl (r). Data points
used for blotting (Int, Sta) are indicated by circles. B: Intensity after 5min injection (Int), blotted against the
quotient of the stability after 5min dissociation (Sta) and the intensity in buffer with 50mM calcium (1) or
3mM EDTA (2).
B01.4 at a constant concentration did not interfere with galactose binding and therefore
did not block the binding site. The difference between the first and the second galactose
signal was below 10%.140 The binding was slightly calcium-sensitive. Particularly, the
stability of the B01.4 binding to the H1-CRD decreased when EDTA was present. The
strength of the B01.4 interaction with dimeric H1-CRD however increased, indicated by
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the shift to the upper left. The intensity of the B01.4 binding to the H1-CRD in the
presence of calcium and to the monomeric H1-CRD in the presence of EDTA was
similar. Independent of calcium and EDTA, the interaction with dimeric H1-CRD was
stronger than with monomeric (see Figure 81B).
In the absence of calcium, due to 3mM EDTA, B01.4 IgG1 at different concentrations in
the range of 0.14-140nM bound fast, tight and in a concentration–dependent manner.
The dissociation was very slow. The dissociation constants KD of monomeric H1-CRD
with 308pM and dimeric H1-CRD with 334pM were similar, but when looking at kon and
koff separately, both rate constants were approximately twice as high for binding to
monomeric H1-CRD with kon of 5.32·10
5M-1s-1 and koff of 1.64·10
-4s-1 compared to the
binding to dimeric H1-CRD with kon of 2.69·10
5M-1s-1 and koff of 0.90·10
-4s-1 (see Figure
82).
Figure 82: Comparison of kinetic rates kon and koff of the B01.4 IgG1 binding to a monomeric and dimeric
H1-CRD species surface, after fitting to a Langmuir 1:1 binding model. A: Sensogram of the B01.4 IgG1
binding to H1-CRD in calcium-free buffer. B: calculated kon, koff and calculated KD.
3.5.2.2.5 Epitope excision and extraction
The epitope excision and extraction were performed with native and with alkylated H1-
CRD. In the extraction, using native trypsine-digested H1-CRD, fragments F2 (T6-R17)
and F3 (S18-R24) were found in the MS elution spectrum. In the corresponding excision
with trypsine, using alkylated H1-CRD, additional peaks of the double fragments F2+3
(T6-R24) and F4+5 (S25-R37) were visible (see Figure 83).
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Figure 83: MS elution spectra of the epitope extraction using native trypsine-digested H1-CRD (A) and of
the excision with trypsine, using alkylated H1-CRD (B). The wash spectra were clean (spectra not shown).
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The binding of the B01.4 to an epitope on this partial H1-CRD sequence was proved
twice. First in an HRP-ELISA, the B01.4 bound to biotin-labeled synthetic peptides F2
and F3, which were linked to streptavidin-coated plates. Second, in the epitope
extraction using the acetylated synthetic F2 and F3 peptides, these peptides were
recovered in the elution, but not in the wash spectra prior to elution (see Figure 84).
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Figure 84: MALDI-FT-ICR elution spectra from epitope extraction of the synthetic acetylated peptide F2
(TCacCacPVNWVEHER, [M+H]+ 1018.49) and F3 (SCacYWFSR, [M+H]+ 1613.72). No fragments were found
in the wash spectra (spectra not shown). A: MS elution spectrum of F2. B: MS elution spectrum of F3.
In the epitope excision of B01.4-bound H1-CRD with proteinase K, the epitope was
diminished. Partial sequences of F2 and F3 were large enough to be recognized by
B01.4. In the MS elution spectrum, fragments corresponding to amino acid sequences
V13-S18 and C19-S23 appeared uniquely in the elution, whereas fragments of all other
peaks were also present in the wash spectrum (see Figure 85).
1 13 19 23 145
Figure 85: Elution spectrum from epitope excision of alkylated H1-CRD, digesting with proteinase K. The
wash spectrum was clean (spectra not shown).
The B01.4 IgG1 epitope sequence VEHERSCYWFS exhibited homologies to sequences
of other C-type lectins in homo sapiens, i.e. the ASGPR-2a-c, the HBxAg-binding protein
(Hepatitis B antigen binding protein) and the macrophage lectin 2. Furthermore, similar
epitopes are also present in lectins of other mammals, i.e. in the ASGPR of canis
Fragment Amino acids
No. [M+H]+ No. Sequence
F2’ 13-19 VEHERS
F3’ 19-23 CaYWFS
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familiaris, marmota monax, mus musculus, rattus norvegius and in the macrophage
lectin of mus musculus and rattus norvegius (see Table 16).
Table 16: Blastp of the B01.4 epitope sequence VEHERSCYWFS against the database non-redundant
GenBank CDS (matrix PAM30). Identical amino acid residues are shaded and written in bold, and similar
residues are written in bold.
Sequence Identity Similarity Protein Species
VEHER SCYWFS B01.4 epitope Homo sapiens
VEHER SCYWFS 100% 100% ASGPR-1 Homo sapiens
VEHQG SCYWFS 81% 90% ASGPR-2a-c Homo sapiens
VEHQG SCYWFS 81% 90% HBxAg-binding protein Homo sapiens
VEHQD SCYWFS 81% 90% Macrophage lectin 2 (CLE14) Homo sapiens
VEHQD SCYWFS 81% 90% CLEC10A protein (pancreas, spleen) Homo sapiens
VEHEG SCYWFS 90% 90% ASGPR-1 Marmota monax
VEYEG SCYWFS 81% 90% ASGPR-1 Mus musculus
VEYEG SCYWFS 81% 90% ASGPR-1 Rattus norvegius
EYEG SCYWFS 80% 90% ASGPR-1 Canis familiaris
SCYWFS 100% 100% ASGPR-1 Bos Taurus
VEHEG SCYWFS 90% 90% ASGPR-2 Marmota monax
SCYWFS 100% 100% ASGPR-2 Mus musculus
SCYWFS 100% 100% ASGPR-2/3 Rattus norvegius
EHEG SCYWFS 90% 90% Macrophage lectin 1/2 Mus musculus
EHEG SCYWFS 90% 90% Macrophage lectin Rattus norvegius
EHVQ RCYWF 66% 77% Variant-specific antigen Plasmodium falciparum
R ICYWFS 85% 85% Hypothetical protein Trypanosoma brucei
3.5.2.3 On cell characterization
3.5.2.3.1 Immunofluorescence flow cytometry
The specific binding of the B01.4 IgG1 to the native entire ASGPR and the cross-
reactivity with similar receptors were tested by extracellular flow cytometry. HepG2, SK-
Hep1, THP-1, macrophages and dendritic cells were examined without fixation of the
cells (see Figure 86).
The B01.4 IgG1 stained the ASGPR-positive HepG2 cells, but not the ASGPR-negative
SK-Hep1 cells. Also the THP-1 cells, macrophages and dendritic cells that carry a
homologous receptor, failed in staining. Therefore, B01.4 IgG1 bound specifically to the
ASGPR.
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Figure 86: Flow cytometry of not fixed HepG2, SK-Hep1, THP-1, macrophages and dendritic cells, indirectly
extracellular stained with B01.4 IgG1 and FITC-labeled goat anti-mouse Ig (H+L). The dead probidium-
stained cells were excluded. The histogram shows an overlay with the negative control (irrelevant IgG).
3.5.2.3.2 Immunofluorescence microscopy
The internalization of the Texas Red-labeled B01.4 IgG1 into HepG2 cells was
investigated by immunofluorescence microscopy. To control the specificity of the
endocytosis via the ASGPR, the staining was also performed with SK-Hep1 cells.
HepG2
SK-Hep1
Figure 87: Immunofluorescence microscopy picture of the B01.4 IgG1 (40?g/ml, 250nM) endocytosis into
HepG2 and SKHep1 cells. Direct staining with TR-labeled B01.4 IgG1, followed by paraformaldehyde
fixation of the cells.
The HepG2 cells were intense stained and were strewn with very bright fluorescent
spots. In contrast, the SK-Hep1 showed only some or no single spots (see Figure 87).
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Hence, B01.4 was actively internalized by living HepG2 cells and the main fraction of the
B01.4 specifically via the ASGPR.
3.5.2.4 On tissue characterization
3.5.2.4.1 Immunohepatochemisty
Non-pathological human paraffin-embedded liver tissue sections were indirectly stained
with DAB, to test the binding ability of B01.4. The antigen was retrieved with various
steamer, microwave and enzymatic methods.
B01.4
Figure 88: Indirect staining of paraffin-embedded non-pathological liver tissue (antigen retrieval with
microwave at 98°C for 30min and staining with B01.4 at 4μg/ml, DAB).
No binding of the B01.4 to the hepatocyte surface was visible, independent of the tissue
pretreatement for antigen retrieval (see Figure 88).
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3.5.3 Monoclonal C09.1 IgG1
3.5.3.1 Purification of C09.1 IgG1
Murine C09.1 IgG1 were attempted to purification by Protein L and Protein G affinity
chromatography.
Purification by Protein L spin chromatography
The IgG1? were purified from culture supernatant of clone C09.1, containing 10% FCS.
But on the silver-stained reducing SDS-PAGE gel, only minute amounts of antibodies
were visible, and above all were of insufficient purity. The HRP-ELISA confirmed, that
the low yield was caused by low extraction efficiency. The supernatant and the column
flow through exhibited approximately the same absorbance. Therefore, this method was
not appropriate for the purification of C09.1 IgG1?.
Purification by Protein G FPLC
The IgG1 antibodies were purified from culture supernatant of C09.1, containing 3%
FCS (low IgG) by FPLC, using a Protein G-Sepharose column. The supernatant was
twice extracted, because the IgG1 binding to Protein G was not quantitative. The
antibodies eluted in a sharp peak and were of high purity (see Figure 89).
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Figure 89: Purification of the IgG1 from 200ml culture supernatant of clone C09.1, containing 3% FCS (low
IgG). A: Protein G FPLC chromatogram with elution peaks of the first (1) and the second (2) extraction. B:
Silver-stained reducing SDS-PAGE gel 12% of the eluted antibodies, showing the 25kDa light chain and the
55kDa heavy chain band.
The C09.1 IgG1 antibodies were quantified by A280 measurement, SDS-PAGE
quantification and by Bradford micro-assay. The yield of 11.9mg/L in the first and of
1.1mg/L in the second extraction indicated, that a double extraction is worthwhile (see
Figure 90).
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Figure 90: Yield of the C09.1 IgG1, purified by affinity to Protein G and Protein L and quantified by Bradford
micro-assay, SDS-PAGE quantification and absorbance A280 measurement. An overall yield of 12.968mg/L
(SEM 0.602mg/L) C09.1 culture supernatant was obtained.
Overall, 6.5mg IgG1 were purified from 500ml culture supernatant. This is equivalent to
a yield of 13mg/L supernatant.
3.5.3.2 In vitro characterization
3.5.3.2.1 Immunoblotting
Identical amounts of the reduced, non-reduced and native H1-CRD as well as of the
reduced-alkylated and native-alkylated H1-CRD were blotted to nitrocellulose and were
caught with 5?g/ml or 0.5?g/ml C09.1 IgG1 during immunostaining (see Figure 91).
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Figure 91: Immunoblot of the H1-CRD, captured with the monoclonal C09.1 IgG1. 1?g/band H1-CRD on
PAGE gels 15% under reducing, non-reducing denatured or native conditions were blotted to nitrocellulose
and were immunostained with C09.1 IgG1 followed by the detection with AP-labeled goat anti-mouse IgG
(whole molecule) in dilution 1:5000. A: Blot stained with 5?g/ml C09.1 IgG1, showing reduced (1), non-
reduced (2) and native (3) H1-CRD. B: Blot stained with 0.5?g/ml C09.1 IgG1, showing reduced (1), the
reduced state of reduced-alkylated (2), the reduced state of native-alkylated (3), non-reduced (4), the non-
reduced state of native-alkylated (5), native (6) and the native state of native-alkylated (7) H1-CRD. C:
Silver-stained reducing and non-reducing SDS-PAGE gel 15% of the same probes used in B (1-5) and the
LMW marker (0).
The bands pattern on a Ponceau S-stained membrane was identical to the silver-stained
PAGE gel (see Figure 91C). The monomeric H1-CRD species were stained more
intense than dimeric species, but the stain was independent of the H1-CRD alkylation.
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The monomeric and dimeric species of reduced, non-reduced and native H1-CRD were
specifically immunostained. No cross-reactions with other proteins of the LMW marker
were visible, even not after staining with the higher 5?g/ml antibody concentration.
When 0.5?g/ml C09.1 IgG1 were used, the band intensities varied, dependent on the
alkylation state. The C09.1 antibodies bound strongly to not alkylated or native-alkylated
H1-CRD in reduced state, but recognized only minor reduced-alkylated H1-CRD in
reduced state.
The dimeric species of non-reduced and much clearer of native H1-CRD were stronger
immunostained than monomeric species, although on the corresponding silver-stained
PAGE gel, the stain was vice versa.
3.5.3.2.2 ELISA
In an HRP-ELISA, the monoclonal C09.1 IgG1 in the concentration range of 0.1 - 300nM
were titrated to examine their binding to the H1-CRD (5?g/ml H1-CRD, 300?M). For half
maximal binding, an EC50 of 0.717nM was determined (see Figure 92).
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Figure 92: Binding of the C09.1 IgG1 to the H1-CRD in an HRP-ELISA. The C09.1 was titrated in the range
of 0.1-300nM in duplicate (exponential dilution row) in the presence of 20mM calcium. The plate was coated
with 5?g/ml (300?M) H1-CRD and C09.1 was detected with HRP-labeled goat anti-mouse Ig (H+L), diluted
1:1000. The EC50 was calculated, using a nonlinear regression fit (equation sigmoid dose-response, variable
slope, r2 1.00) of Prism4 software.
20mM calcium, 1mM calcium or 10mM EDTA were added during the capturing step of
the C09.1 IgG1 in an HRP-ELISA, to test the calcium sensitivity. All other assay steps
were identical and were performed in the presence of 1mM calcium prior to and in the
presence of 20mM calcium after the C09.1 binding.
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Figure 93: Ca sensitivity of the C09.1 IgG1 binding to the H1-CRD in an HRP-ELISA in the presence of
20mM calcium, 1mM calcium or of 10mM EDTA. The plates were coated with 3?g/ml (175?M) (A) or 6?g/ml
(350?M) (B) H1-CRD and the C09.1 IgG1 was titrated, in the range of 0.0625-62.5nM (A) or 0.1875-
187.5nM (B) in triplicate. Bmax and KD were calculated, using a nonlinear regression fit (equation one site
binding, hyperbola, r2 0.91 – 0.99).
At the low coating concentration of 175?M H1-CRD, the binding of C09.1 IgG1 in the
range of 0 - 62.5?M was slightly calcium-sensitive, showing an about twice as high KD of
4.6nM in the absence of calcium compared to a KD of 2.0-2.2nM in the presence of
calcium. Calculated maximal bindings Bmax were similar. At the higher coating
concentration of 350?M H1-CRD, the binding of C09.1 IgG1 in the range of 0 - 187.5?M
was independent of calcium (see Figure 93).
3.5.3.2.3 GalNAc-polymer assay
The competition of the C09.1 IgG1 antibodies and the POD-labeled streptavidin-biotin ?-
GalNAc-polymer for binding to the H1-CRD, in the presence of 1mM calcium, was
investigated (see Figure 94).
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Figure 94: Competition of the GalNAc-polymer and the C09.1 IgG1 antibodies for binding to the H1-CRD in
the polymer assay. The plate was coated with 3?g/ml (175?M) H1-CRD. The C09.1 in the range of 0-625nM
(exponential dilution) in triplicate or tetricate, competed with 0.3?g/ml GalNAc-complex for binding (nonlinear
regression fit: equation, one site competition).
The C09.1 IgG1 competed with the GalNAc-polymer for binding to the H1-CRD. A half
maximal effective concentration EC50 of 53.8nM was calculated.
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3.5.3.2.4 Biacore
In a Biacore assay, the binding of galactose to monomeric and dimeric H1-CRD was not
affected in the presence of a constant concentration of C09.1 IgG1. The first and the
second galacose signal differed less than 10% (see Figure 95A).
Figure 95: Biacore assay of the C09.1 IgG1 binding to monomeric and dimeric H1-CRD. A: Sensogram with
a preliminary injection of 5mM galactose (g), C09.1 IgG1 injection (i), dissociation phase (d), followed by a
second 5mM galactose injection and an EDTA pulse (e), prior to regeneration with HCl (r). Data points used
for blotting (Int, Sta) are indicated by circles. B: Intensity after 5min injection (Int), blotted against the
quotient of the stability after 5min dissociation (Sta) and the intensity, in buffer with 50mM calcium (1) or
3mM EDTA (2).
The binding of the C09.1 was slightly calcium-sensitive, showing a slightly increased
intensity in the presence of 3mM EDTA. The stability and the intensity of the binding to
monomeric and to dimeric H1-CRD were similar (see Figure 95B).
3.5.3.3 On cell characterization
3.5.3.3.1 Immunofluorescence flow cytometry
The specific binding of the C09.1 IgG1 to the full length ASGPR on not fixed cells was
examined by extracellular flow cytometry of the receptor-positive HepG2 cells and the
receptor-negative SK-Hep1 cells. Furthermore, THP-1, macrophages and dendritic cells
were immunostained, to control the cross-reactivity with ASGPR-homologous receptors.
The C09.1 antibodies stained HepG2 but not SK-Hep1 cells, which indicated, that C09.1
IgG1 specifically recognized the ASGPR. In addition, they cross-reacted with no similar
receptors on the surface of THP-1, macrophages and dendritic cells (see Figure 96).
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Figure 96: Flow cytometry of not fixed HepG2, SK-Hep1, THP-1, macrophages and dendritic cells, which
were indirectly extracellular stained with C09.1 IgG1 and FITC-labeled goat anti-mouse Ig (H+L). The dead
probidium-stained cells were excluded. The histogram shows an overlay with the negative control (irrelevant
IgG).
3.5.3.3.2 Immunofluorescence microscopy
The specific endocytosis of the Texas Red-labeled C09.1 IgG1 into HepG2 cells via the
ASGPR was analyzed. To exclude the unspecific internalization, SK-Hep1 cells were
stained in parallel (see Figure 97).
HepG2
SK-Hep1
Figure 97: Immunofluorescence microscopy picture of the directly stained HepG2 and SK-Hep1 cells, The
TR-labeled C09.1 IgG1 (40?g/ml, 45nM) were internalized into living cells, followed by parformaldehyde
fixation of cells.
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The HepG2 cells were strewn with very bright large spots, but the SK-Hep1 showed only
some single spots. This indicated, that the labeled C09.1 was internalized and
exclusively by the ASGPR-mediated endocytosis.
3.5.3.4 On tissue characterization
3.5.3.4.1 Immunohepatochemisty
Non-pathological human paraffin-embedded liver tissue sections were indirectly stained
with DAB, to test the binding ability of C09.1. The antigen was retrieved with various
steamer, microwave and enzymatic methods.
C09.1
Figure 98: Indirect stained non-pathological paraffin-embedded liver tissue (antigen retrieval with microwave
at 98°C for 30min and staining with C09.1 at 4μg/ml, DAB).
No binding of the C09.1 was visible, independent of the tissue pretreatment for antigen
retrieval (see Figure 98).
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3.5.4 Monoclonal C11.1 IgG1
3.5.4.1 Purification of C11.1 IgG1
The extraction of murine C11.1 IgG1 by Protein L and Protein G chromatography was
tested.
Purification by Protein L spin chromatography
The IgG1? antibodies were purified from culture supernatant of C11.1, supplemented
with 10% FCS, using Protein L-Sepharose spin columns. However, almost no antibodies
were eluted. On a silver-stained reducing SDS-PAGE gel, hardly any 25kDa and 55kDa
bands were detectable and in the HRP-ELISA, the supernatant and the flow through
showed about the same absorbance, whereas the elution was negative. Therefore this
method was unsuitable for the C11.1 IgG1? extraction.
Purification by Protein G FPLC
The IgG1 were also extracted from culture supernatant of C11.1, supplemented with 3%
FCS (low IgG) by FPLC, using a Protein G-Sepharose column. The extraction was not
quantitative and therefore, the supernatant was cleared twice. The antibodies eluted in a
sharp peak and were highly pure. On a reducing SDS-PAGE gel, only the 25kDa and the
55kDa band of the light and heavy chain were visible (see Figure 99).
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Figure 99: Extraction of the IgG1 from 250ml culture supernatant of C11.1, which contained 3% FCS (low
IgG). A: Protein G FPLC chromatogram with elution peaks of the first (1) and the second (2) extraction. B:
Silver-stained reducing SDS-PAGE gel 12% of the eluted antibodies, showing the 25kDa and the 55kDa
bands of the light and the heavy chain.
The yield was determined by A280 measurement, by SDS-PAGE quantification and by
Bradford micro-assay. 6.45mg C11.1 IgG1 antibodies were purified from 500ml culture
supernatant. That is equivalent to a yield of 12.9mg/L supernatant (see Figure 100).
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Figure 100: Yield of the C11.1 IgG1, purified by affinity to Protein G and Protein L and quantified by
Bradford micro-assay, SDS-PAGE quantification and absorbance A280 measurement. Overall, the obtained
yield was 12.867mg/L (SEM 0.521mg/L) culture supernatant of C11.1.
3.5.4.2 In vitro characterization
3.5.4.2.1 Immunoblotting
Identical amounts of the reduced, non-reduced and native H1-CRD as well as of the
reduced-alkylated and native-alkylated H1-CRD were blotted to nitrocellulose and were
immunostained with 5?g/ml and 0.5?g/ml C11.1 IgG1 (see Figure 101).
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Figure 101: Immunoblot of the H1-CRD, caught with the monoclonal C11.1 IgG1. 1?g/band H1-CRD on
PAGE gels 15% under reducing, non-reducing denatured or native conditions were blotted to nitrocellulose
and were immunostained with C11.1 IgG1, followed by the detection with AP-labeled goat anti-mouse IgG
(whole molecule), in dilution 1:5000. A: Blot, stained with 5?g/ml C11.1 IgG1, showing the reduced (1), non-
reduced (2) and native (3) H1-CRD. B: Blot, stained with 0.5?g/ml C11.1 IgG1, showing reduced (1), the
reduced state of reduced-alkylated (2), the reduced state of native-alkylated (3), non-reduced (4), the non-
reduced state of native-alkylated (5), native (6) and the native state of native-alkylated (7) H1-CRD. C:
Silver-stained reducing and non-reducing SDS-PAGE gel 15% of the same probes used in B (1-5) and the
LMW marker (0).
The bands pattern and the relative intensities of bands were identical on the Ponceau S-
stained membrane and on the silver-stained PAGE gel (see Figure 101C). The bands of
the dimeric H1-CRD species were less stained on the gel than the monomeric species,
independent of their alkylation state.
The C11.1 IgG1 antibodies specifically recognized monomeric and dimeric H1-CRD
species. No cross-reaction occurred with the LMW marker proteins, even not at the
higher C11.1 concentration of 5?g/ml. Also 0.5?g/ml C11.1 IgG1 still stained reduced,
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non-reduced and native H1-CRD, although the reduced form only fair. Looking at the
non-reduced and native blot, the bands of the dimeric species resulted in a stronger
signal than of the monomeric species, in contrast to the PAGE gel, which showed vice
versa staining intensities.
Overall, the C11.1 binding depended on the H1-CRD conformation and disulfide bridges.
The strongest bands were obtained for binding to the native, decreasing to the non-
reduced and the reduced H1-CRD. Furthermore, the recognition was influenced by the
alkylation. The reduced H1-CRD, which was previously not alkylated or native-alkylated
was stained, whereas with the reduced H1-CRD, which was reduced-alkylated before,
no staining was observed.
3.5.4.2.2 ELISA
In an HRP-ELISA, the monoclonal C11.1 IgG1, in the concentration range of 0.1 -
300nM, were titrated to 5?g/ml H1-CRD (300?M) and were detected with HRP-labeled
goat anti-mouse Ig (H+L) in dilution 1:1000. For the half maximal binding, an EC50 of
0.304nM was calculated (see Figure 102).
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Figure 102: Binding of the C11.1 IgG1 to the H1-CRD in an HRP-ELISA. C11.1 was titrated in the range of
0.1-300nM in duplicate (exponential dilution row), in the presence of 20mM calcium. The plate was coated
with 5?g/ml (300?M) H1-CRD and C11.1 was detected with HRP-labeled goat anti-mouse Ig (H+L), diluted
1:1000. The EC50 was calculated, using a nonlinear regression fit (equation sigmoid dose-response, variable
slope, r2 0.98) of Prism4 software.
The calcium sensitivity of the C11.1 IgG1 binding to the H1-CRD in an HRP-ELISA was
checked. C11.1 was caught in the presence of 20mM calcium, 1mM calcium or 10mM
EDTA. In the buffer of all prior steps 1mM calcium, and of all following steps 20mM
calcium was included.
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Figure 103: Ca sensitivity of the C11.1 IgG1 binding to the H1-CRD in an HRP-ELISA in the presence of
20mM calcium, 1mM calcium or of 10mM EDTA. The plates were coated with 3?g/ml (175?M) (A) or 6?g/ml
(350?M) (B) H1-CRD and the C11.1 IgG1 was titrated in the range of 0.0625-62.5nM (A) or 0.1875-187.5nM
(B) in triplicate. Bmax and KD were calculated, using a nonlinear regression fit (equation one site binding,
hyperbola, r2 0.67 – 0.99).
At the detection limit of the HRP-ELISA, when coating with 175?M H1-CRD to catch
C11.1 IgG1 in the concentration range of 0 - 62.5nM, the binding was not only
dependent on the presence, but also on the concentration of calcium. With 20mM
calcium, a maximal binding Bmax of 79.4% was obtained, nearly double the Bmax of 44.1%
with 1mM calcium or four times the Bmax of 19.9% with 10mM EDTA (see Figure 103A).
In contrast, at the higher coating concentration of 350?M H1-CRD and titrating C11.1 in
the range of 0 - 187.5nM, the same maximal bindings Bmax of 97-98% with 1mM and
20mM calcium, and only a slightly lower Bmax of 93% with 10mM EDTA were received. In
addition KD differed, showing the lowest KD of 0.14nM for binding with 20mM calcium
followed by a KD of 0.21nM with 1mM calcium and a KD of 0.29nM with 10mM EDTA
(see Figure 103B). All in all it can be supposed, that the binding of C11.1 to the H1-CRD
is calcium-sensitive, and that the binding decreases without calcium.
3.5.4.2.3 GalNAc-polymer assay
In the GalNAc-polymer assay, 0 - 625nM C11.1 IgG1 competed against 0.3?g/ml POD-
labeled ?-GalNAc-biotin-streptavidin-polymer, for binding to the H1-CRD, in the
presence of 1mM calcium (see Figure 104).
The high effective concentration EC50 of 790nM indicated, that the C11.1 IgG1 not or
fairly competed with the GalNAc-complex for binding to the binding site, but more
probable sterically hindered the binding at a higher antibody concentration.
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Figure 104: Competition of the GalNAc-polymer and the C11.1 IgG1 antibodies for binding to the H1-CRD in
the polymer assay. The plate was coated with 3?g/ml (175?M) H1-CRD. The C11.1 in the range of 0-625nM
(exponential dilution) in triplicates competed with 0.3?g/ml GalNAc-complex (nonlinear regression fit:
equation, one site competition, r2 0.81).
3.5.4.2.4 Biacore
The binding of galactose to the monomeric and the dimeric H1-CRD species was not
affected by the presence of a constant concentration of C11.1 IgG1, in a Biacore assay.
The first galactose signal prior to the C11.1 application and the second signal after
C11.1 binding differed less than 10% (see Figure 105A).
Figure 105: Biacore assay of the C11.1 IgG1 binding to monomeric and dimeric H1-CRD. A: Sensogram
with a preliminary injection of 5mM galactose (g), C11.1 IgG1 injection (i), dissociation phase (d), followed
by a second 5mM galactose injection and an EDTA pulse (e), prior to the regeneration with HCl (r). The data
points, used for blotting (Int, Sta) are circled. B: Intensity after 5min injection (Int), blotted against the
quotient of the stability after 5min dissociation (Sta) and the intensity in buffer with 50mM calcium (1) or
3mM EDTA (2).
The C11.1 binding to the H1-CRD was negative calcium-sensitive, showing an identical
stability, but only half the intensity in the presence of calcium. Dependent on calcium and
EDTA, the interaction of C11.1 with monomeric and dimeric H1-CRD differed. In the
presence of calcium, the binding intensity of dimeric H1-CRD was lower than of
monomeric H1-CRD, with identical stabilities. In contrast, in the presence of EDTA, the
binding stability was higher with identical intensities (see Figure 105B).
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In the absence of calcium, C11.1 IgG1 at different concentrations in the range of 0.14 -
140nM bound concentration-dependent, fast and tight. The association rate to the
monomeric H1-CRD surface with a kon of 3.29·10
5M-1s-1 was faster than to the dimeric
H1-CRD surface with a kon of 1.92·10
5M-1s-1. The dissociation was extremely slow,
especially from the dimeric surface. As a consequence, the dissociation rate and the KD
could only be calculated for binding of monomeric H1-CRD with a koff of 2.58·10
-5s-1 and
a KD of 78pM. Lower on and off rates of the C11.1 interaction with monomeric compared
to dimeric H1-CRD species indicated a slower but tighter binding, resulting in an
increased affinity (see Figure 106A and B).
Figure 106: Comparison of the kinetic on and off rates of the C11.1 IgG1 binding to the monomeric and
dimeric H1-CRD species surface, after fitting to a Langmuir 1:1 binding model. A: Sensogram of the C11.1
IgG1 binding to the H1-CRD in calcium-free buffer. B: calculated kon, koff and calculated KD.
3.5.4.2.5 Epitope excision and extraction
The C11.1 epitope extraction from reduced-alkylated and trypsine-digested H1-CRD
showed mainly the two fragments F2 (T6-R17) and F7 (F54-K76), but also F9 (N89-R117) in
the MS elution spectrum. All other peaks, which originated from H1-CRD, appeared in
the wash too (see Figure 107).
H1
mono
H1
di
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
kon
g
H1mono H1di
0.0
0.5
1.0
1.5
2.0
2.5
3.0
n.d.
koff
H1
mono
H1
di
0
10
20
30
40
50
60
70
80
90
100 H1mono
H1di
n.d.
KD
B
6
5
4
3
2
1
0
0 400 800 0 400 800
kR
U
s s
monomer dimerA
Benefit and Application of Antibodies Against the H1-CRD Results
180
1400 1900 2400 2900 3400 M/z
1
0
0
5
.4
3
3
1
2
4
1
.5
1
4
1
8
8
2
.9
8
1
2
0
1
5
.0
0
5
1
5
8
6
.6
9
8
1
5
0
8
.6
8
5
3
3
4
4
.5
2
6
–
 (
1
-4
)H
2
O
2
6
9
8
.3
3
6
2
6
5
0
.3
6
1
Fragment Amino acids
No. [M+H]+ No. Sequence
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Figure 107: MALDI-FT-ICR of the elution spectrum (A) and the wash spectrum (B) in the epitope extraction
of reduced-alkylated and trypsine-digested H1-CRD, using a C11.1-Sepharose column.
In an additional experiment, after binding of reduced-alkylated trypsine-digested H1-
CRD fragments to immobilized C11.1, the epitope was further excised with pronase K.
Among many peaks in the MS elution spectrum, some peaks were identified that
corresponded to partial sequences of fragment F9 and overlapped in the residues W90-
D96 (see Figure 108).
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Figure 108: MALDI-FT-ICR of the elution spectrum in the epitope extraction of trypsine-digested H1-CRD,
excised with pronase K on column. The wash spectrum was clean (spectrum not shown).
3.5.4.3 On cell characterization
3.5.4.3.1 Immunofluorescence flow cytometry
The ASGPR-positive HepG2 cells, the ASGPR-negative SK-Hep1 cells, THP-1 cells,
primary human macrophages and dendritic cells were indirectly extracellular stained with
C11.1 IgG1 and FITC-labeled goat anti-mouse Ig (see Figure 109).
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Figure 109: Flow cytometry of not fixed HepG2, SK-Hep1, THP-1, macrophages and dendritic cells, which
were indirectly extracellular stained with C11.1 IgG1 and FITC-labeled goat anti-mouse Ig(H+L). The dead
probidium-stained cells were excluded. The histogram shows the overlay with an irrelevant IgG (negative
control).
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The C11.1 IgG1 specifically bound to the entire ASGPR. Only the HepG2, but not the
SK-Hep1 cells, were stained. In addition, they did not cross-react with THP-1,
macrophages or dendritic cells, which are known to carry a homologous receptor.
3.5.4.3.2 Immunofluorescence microscopy
The endocytosis of the Texas Red-labeled C11.1 IgG1 into living HepG2 cells was
investigated by immunofluorescence microscopy, after paraformaldehyde fixation of the
cells. SK-Hep1 cells were stained in parallel to control the internalization, specifically to
be mediated via the ASGPR.
HepG2
SK-Hep1
Figure 110: Immunofluorescence microscopy picture of the directly stained HepG2 and SK-Hep1 cells. The
TR-labeled C11.1 IgG1 (40?g/ml, 45nM) was endocytosed into living cells, followed by paraformaldehyde
fixation of the cells.
The HepG2 cells were strewn with very bright spots, whereas the SK-Hep1 showed only
some or no single spots. Hence, the TR-C11.1 was internalized mainly via the ASGPR
(see Figure 110).
3.5.4.4 On tissue characterization
3.5.4.4.1 Immunohepatochemistry
Non-pathological human paraffin-embedded liver tissue sections were indirectly stained
with DAB, to test the binding ability of C11.1. The antigen was retrieved with various
steamer, microwave and enzymatic methods.
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C11.1
Figure 111: Indirect staining of non-pathological paraffin-embedded liver tissue (antigen retrieval with
microwave at 98°C for 30min and staining with C11.1 at 4μg/ml, DAB).
No binding of the C11.1 to the hepatocytes surface was visible, independent of the
tissue pretreatment for antigen retrieval (see Figure 111).
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3.5.5  Monoclonal C14.6 IgG2a
3.5.5.1 Purification of C14.6 IgG2a
The purification of C14.6 IgG2a by affinity chromatography on Protein L and Protein G-
Sepharose was investigated.
Purification by Protein L spin chromatography
The purification of IgG2a? from culture supernatant of C14.6, which contained 10% FCS,
using a Protein L-Sepharose spin column, was not suitable. A silver-stained reducing
SDS-PAGE gel showed, that the yield was minute and the purity low.
Purification by Protein G FPLC
The purification of IgG2a from culture supernatant of C14.6, which contained 3% FCS
(low IgG), by FPLC using a Protein G-Sepharose column, was very effective and nearly
quantitative in one extraction step. The eluted antibodies were high concentrated and of
excellent purity. On a reducing SDS-PAGE gel only the 25kDa light chain and the 55kDa
heavy chain bands were detected (see Figure 112).
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Figure 112: Purification of the IgG2a from 200ml culture supernatant of clone 14.6, containing 3% FCS (low
IgG). A: Protein G FPLC chromatogram and the elution peak of extraction 1 (1) and 2 (2). B: Silver-stained
reducing SDS-PAGE gel 12% of the eluted antibodies, showing the 25kDa and 55kDa bands of the light and
heavy chain.
The quantification by A280 measurement, by SDS-PAGE and by Bradford micro-assay,
resulted in a yield of 20.7mg/L for the first extraction and of only 0.3mg/L for the second
extraction from culture supernatant of clone C14.6 (see Figure 113).
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Figure 113: Yield of the C14.6 IgG2a, purified by affinity to Protein G and Protein L and quantified by
Bradford micro-assay, SDS-PAGE quantification and absorbance A280 measurement. Overall, obtained yield
was 21.098mg/L (SEM 1.086mg/L) culture supernatant of C14.6.
Overall, 10.6mg C14.6 IgG2a were purified from 500ml culture supernatant. This is
equivalent to a yield of 21.1mg/L culture supernatant.
3.5.5.2 In vitro characterization
3.5.5.2.1 Immunoblotting
Identical amounts of the reduced, non-reduced and native H1-CRD as well as of the
reduced-alkylated and native-alkylated H1-CRD were blotted to nitrocellulose and were
stained, using 5?g/ml and 0.5?g/ml C14.6 IgG2a.
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Figure 114: Immunoblot of the H1-CRD, caught with the monoclonal C14.6 IgG2a. 1?g/band H1-CRD on
PAGE gels 15% under reducing, non-reducing denatured or native conditions were blotted to nitrocellulose
and were immunostained with C14.6 IgG2a, followed by the detection with AP-labeled goat anti-mouse IgG
(whole molecule), in dilution 1:5000. A: Blot, stained with 5?g/ml C14.6 IgG2a, showing the reduced (1),
non-reduced (2) and native (3) H1-CRD. B: Blot stained with 0.5?g/ml C14.6 IgG2a, showing reduced (1),
the reduced state of reduced-alkylated (2), the reduced state of native-alkylated (3), non-reduced (4), the
non-reduced state of native-alkylated (5), native (6) and the native state of native-alkylated (7) H1-CRD. C:
Silver-stained reducing and non-reducing SDS-PAGE gel 15% of the same probes used in B (1-5) and of the
LMW marker (0).
The Ponceau S-stained membrane and the silver-stained PAGE gel of H1-CRD showed
the same bands pattern. On both, the band intensities of the dimeric species were higher
than of the monomeric species (see Figure 114C). The staining was independent of the
H1-CRD alkylation state.
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The monoclonal C14.6 IgG2a specifically recognized the monomeric and dimeric H1-
CRD in reduced, non-reduced and native state, but also cross-reacted with trypsinogen
of the LMW marker. When using C14.6 IgG2a at a concentration of 0.5?g/ml, the
strongest stain was obtained with the reduced H1-CRD, followed by the non-reduced
and native H1-CRD, which both showed approximately the same intensities.
Furthermore, the binding was not dependent on the alkylation. No differences in the
bands pattern and intensities were ascertained, when the alkylated forms were
compared to the not alkylated forms within the reduced, non-reduced or native H1-CRD,
respectively. The monomeric and dimeric species of the non-reduced and native H1-
CRD showed about the same signal intensities (see Figure 114A and B).
3.5.5.2.2 ELISA
The C14.6 IgG2a antibodies were titrated in the concentration range of 0.1 - 300nM in
an HRP-ELISA. When the plate was coated with 5?g/ml (300?M) H1-CRD and IgG2a
was detected with HRP-labeled goat anti-mouse Ig (H+L), diluted 1:1000, an EC50 of
9.7nM was calculated (see Figure 115).
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Figure 115: Binding of the C14.6 IgG2a to the H1-CRD in an HRP-ELISA. C14.6 was titrated in the range of
0.1-300nM, in duplicate (exponential dilution row), in the presence of 20mM calcium. The plate was coated
with 5?g/ml (300?M) H1-CRD and C14.6 was detected with HRP-labeled goat anti-mouse Ig (H+L), diluted
1:1000. The EC50 was calculated, using a nonlinear regression fit (equation sigmoid dose-response, variable
slope, r2 1.00) of Prism4 software.
To test the calcium sensitivity of the binding to the H1-CRD, the C14.6 IgG2a antibodies
were titrated in the presence of 20mM calcium, 1mM calcium and 10mM EDTA. All
incubation steps prior to the C14.6 capturing included 1mM calcium and all following
steps contained 20mM calcium.
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Figure 116: Ca sensitivity of the C14.6 IgG2a binding to the H1-CRD in an HRP-ELISA in the presence of
20mM calcium, 1mM calcium or of 10mM EDTA. The plates were coated with 3?g/ml (175?M) (A) or 6?g/ml
(350?M) (B) H1-CRD and the C14.6 IgG2a was titrated in the range of 0.0625-62.5nM (A) or 0.1875-
187.5nM (B) in triplicate. Bmax and KD were calculated, using a nonlinear regression fit (equation one site
binding, hyperbola, r2 0.91 – 0.99).
The binding of C14.6 IgG2a in concentrations of 0 – 187.5nM was not calcium-sensitive,
neither when coating with 175?M nor with 350?M H1-CRD. In the first case, the
estimated KD varied only slightly in the range of 5.3-9.4nM and Bmax of 90-96%. In the
second case, a KD in the range of 0.45-0.67nM and Bmax of 86-96% were assessed (see
Figure 116A and B).
3.5.5.2.3 GalNAc-polymer assay
The competition of 0 - 625nM C14.6 IgG2a and 0.3?g/ml POD-labeled streptavidin-biotin
?-GalNAc-polymer for the binding to the H1-CRD was investigated in the presence of
1mM calcium.
The C14.6 IgG2a prevented the binding of the GalNAc-complex to the H1-CRD. The
calculated concentration for the half maximal effect EC50 was low with 22.5nM (see
Figure 117).
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Figure 117: Competition of the GalNAc-polymer and the C14.6 IgG2a antibodies for binding to the H1-CRD
in a polymer assay. The plate was coated with 3?g/ml (175?M) H1-CRD. C14.6 in the range of 0-625nM
(exponential dilution) in triplicate or tetricate, competed with 0.3?g/ml GalNAc-complex for binding (nonlinear
regression fit: equation, one site competition, r2 0.86).
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3.5.5.3 On cell characterization
3.5.5.3.1 Immunofluorescence flow cytometry
The C14.6 IgG2a binding to the whole ASGPR was controlled by extracellular flow
cytometry of HepG2 and the cross-reactivity was checked by immunofluorescence
staining of SK-Hep1, THP-1, human macrophages and human dendritic cells.
100 101 102 103 104
FL1 H
10
20
30
40
50
0
FL1-H
c
o
u
n
ts
HepG2
100 101 102 103 104
20
40
60
80
100
0
FL1-H
c
o
u
n
ts
DC
100 101 102 103 104
FL1 H
20
40
60
80
100
0
FL1-H
c
o
u
n
ts
monocyte
10
0
10
1
10
2
10
3
10
4
20
40
60
80
100
0
FL1-H
c
o
u
n
ts
SK-Hep1
100 101 102 103 104
20
40
60
80
100
0
FL1-H
c
o
u
n
ts
THP-1
Figure 118: Flow cytometry of not fixed HepG2, SK-Hep1, THP-1, macrophages and dendritic cells, when
indirectly extracellular stained with C14.6 IgG2a and FITC-labeled goat anti-mouse Ig (H+L). The dead
probidium-stained cells were excluded. The histogram shows an overlay with the negative control (irrelevant
IgG).
C14.6 IgG2a specifically stained the ASGPR-positive HepG2 cells, but not the ASGPR-
negative SK-Hep1 cells. However, they also slightly cross-reacted with epitopes on the
surface of human dendritic cells, which carry a homologous receptor. Human
macrophages were not stained (see Figure 118).
3.5.5.3.2 Immunofluorescence microscopy
The specific endocytosis of Texas Red-labeled C14.6 IgG2a into living cells via the
ASGPR was investigated with HepG2 cells, using SK-Hep1 cells for the detection of
unspecific internalization. After internalization, cells were fixed with paraformaldehyde.
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Figure 119: Immunofluorescence microscopy picture of the directly stained HepG2 and SK-Hep1 cells. ,
The TR-labeled C14.6 IgG2a (40?g/ml, 45nM) were internalized into living cells, followed by
paraformaldehyde fixation of cells.
The HepG2 cells were highly strewn with very bright spots, whereas the SK-Hep1
showed only some spots. Therefore, the labeled C14.6 seemed to be internalized and
this mainly by the ASGPR (see Figure 119).
3.5.5.4 On tissue characterization
3.5.5.4.1 Immunohepatochemistry
Non-pathological human paraffin-embedded liver tissue sections were indirectly stained
with DAB to test the binding ability of C14.6. The antigen was retrieved with various
steamer, microwave and enzymatic methods.
C14.6
PBS
Figure 120: Indirect staining of paraffin-embedded non-pathological liver tissue (antigen retrieval with
microwave at 98°C for 30min and staining with C14.6 at 6μg/ml, DAB).
C14.6 specifically stained the sinusoidal surface of hepatocytes (see Figure 120).
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3.5.6 Monoclonal C18.1 IgG1
3.5.6.1 Purification of C18.1 IgG1
The murine C18.1 IgG1 purification by Protein L and Protein G affinity chromatography
was tested.
Purification by Protein L spin chromatography
The IgG1? purification from culture supernatant of clone 18.1, which contained 10%
FCS, using Protein L-Sepharose spin columns, was not effective. The silver-stained
reducing SDS-PAGE gel showed, that the yield was minute and the purity low. In an
HRP-ELISA, it was confirmed, that the extraction failed as the supernatant and the flow
through exhibited approximately the same absorbance.
Purification by Protein G FPLC
The IgG1 purification from culture supernatant of clone 18.1, which contained 3% FCS
(low IgG) by FPLC, using Protein G-Sepharose, was successful (see Figure 121A). The
supernatant was cleared twice, although in the first extraction already 95% of the
antibodies were bound. Eluted IgG1 were highly pure. On a reducing SDS-PAGE gel
only the 25kDa and the 55kDa band of light and heavy chains were visible (see Figure
121B).
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Figure 121: Extraction of the IgG1 from 250ml culture supernatant of clone C18.1, containing 3% FCS (low
IgG). A: Protein G FPLC chromatogram with elution peaks of the first (1) and the second (2) extraction. B:
Silver-stained reducing SDS-PAGE gel 12% of the eluted antibodies, showing the 25kDa light and the
55kDa heavy chain band.
A reliable quantification was achieved with a triple determination by A280 measurement,
by SDS-PAGE and by Bradford micro-assay. The yield was 20.8mg/L culture
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supernatant, with 19.8mg/L for the first extraction and 1.0mg/L for the second extraction
(see Figure 122).
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1 19.8mg/L
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Figure 122: Yield of C18.1 the IgG1, purified by affinity to Protein G and Protein L and quantified by
Bradford micro-assay, SDS-PAGE quantification and absorbance A280 measurement. Overall, a yield of
20.814mg/L (SEM 1.733mg/L) culture supernatant of C18.1 was obtained.
Overall, 10.4mg IgG1 were purified from 500ml culture supernatant of clone C18.1.
3.5.6.2 In vitro characterization
3.5.6.2.1 Immunoblotting
Identical amounts of the reduced, non-reduced and native H1-CRD as well as of the
reduced-alkylated and native-alkylated H1-CRD were blotted to nitrocellulose and were
caught with 5?g/ml and 0.5?g/ml C18.1 IgG1 during immunostaining.
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Figure 123: Immunoblot of the H1-CRD, caught with the monoclonal C18.1 IgG1. 1?g/band H1-CRD on
PAGE gels 15% under reducing, non-reducing denatured or native conditions were blotted to nitrocellulose
and were immunostained with C18.1 IgG1, followed by the detection with AP-labeled goat anti-mouse IgG
(whole molecule), in dilution 1:5000. A: Blot, stained with 5?g/ml C18.1 IgG1, showing the reduced (1), non-
reduced (2) and native (3) H1-CRD. B: Blot, stained with 0.5?g/ml C18.1 IgG1, showing reduced (1), The
reduced state of reduced-alkylated (2), the reduced state of native-alkylated (3), non-reduced (4), The non-
reduced state of native-alkylated (5), native (6) and the native state of native-alkylated (7) H1-CRD. C:
Silver-stained reducing and non-reducing SDS-PAGE gel 15% of the same probes used in B (1-5) and of the
LMW marker (0).
The bands pattern and the relative intensities of bands were identical on the Ponceau S-
stained membrane and on the silver-stained PAGE gel. The monomeric H1-CRD
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species were stronger stained than the dimeric species. The stain was independent of
the H1-CRD alkylation (see Figure 123C).
The monoclonal C18.1 IgG1 specifically interacted with the monomeric and dimeric H1-
CRD in reduced, non-reduced and native state. Event at the high IgG1 concentration of
5?g/ml, no cross-reactions with LMW marker proteins were visible.
On blots, which were stained with 0.5?g/ml C18.1 IgG1, the antibody recognized the
reduced, non-reduced and native H1-CRD. However, the stain intensities varied in
dependence of the H1-CRD alkylation. Interestingly, the reduced H1-CRD, which was
previously reduced-alkylated was minute stained, whereas the interaction of C18.1 with
reduced H1-CRD, which was not alkylated or native-alkylated before was strong. The
previously not alkylated or native-alkylated non-reduced and native H1-CRD,
respectively were bound to a similar extent.
In contrast to the band intensities on the silver-stained PAGE gel, the dimeric H1-CRD
species on the blots were more intensely stained than monomeric species (see Figure
123).
3.5.6.2.2 ELISA
The C18.1 IgG1 were titrated in a HRP-ELISA in the concentration range of 0 - 300nM,
after coating the plate with 5?g/ml (300?M) H1-CRD. An effective concentration EC50 of
0.495nM was calculated for the half maximal binding (see Figure 124).
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Figure 124: Binding of the C18.1 IgG1 to the H1-CRD in an HRP-ELISA. C18.1 was titrated in the range of
0.1-300nM, in duplicate (exponential dilution row) in the presence of 20mM calcium. The plate was coated
with 5?g/ml (300?M) H1-CRD and C18.1 was detected with HRP-labeled goat anti-mouse Ig (H+L) diluted
1:1000. The EC50 was calculated, using a nonlinear regression fit (equation sigmoid dose-response, variable
slope, r2 0.99) of Prism4 software.
The calcium sensitivity of the C18.1 IgG1 binding to the H1-CRD in an HRP-ELISA was
investigated. All incubation steps were identical, except the C18.1 capturing step, which
was performed in the presence of 20mM calcium, 1mM calcium or 10mM EDTA. In all
preceding steps 1mM calcium and in all following steps 20mM calcium were included.
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Figure 125: Ca sensitivity of the C18.1 IgG1 binding to the H1-CRD in an HRP-ELISA in the presence of
20mM calcium, 1mM calcium or 10mM EDTA. The plates were coated with 3?g/ml (175?M) (A) or 6?g/ml
(350?M) (B) H1-CRD and the C18.1 IgG1 was titrated in the range of 0.0625-62.5nM (A) or 0.1875-187.5nM
(B) in triplicate. Bmax and KD were calculated, using a nonlinear regression fit (equation one site binding,
hyperbola, r2 0.82 – 0.99).
When coating only with 175?M H1-CRD, the interaction with C18.1 IgG1 in
concentrations of 0 - 62.5nM was calcium-sensitive, but independent of calcium
concentration level. In the presence of calcium, Bmax of 70-72% and KD of 0.76-0.98nM
were higher compared to Bmax 27% and KD 0.42nM, in the absence of calcium (see
Figure 125A). In contrast, when a higher amount of 350mM H1-CRD was used for
coating, the binding to C18.1 in the range of 0 - 87.5nM differed neither in Bmax nor KD,
independent of calcium (see Figure 125B).
3.5.6.2.3 GalNAc-polymer assay
In the GalNAc-polymer assay, 0.3?g/ml POD-labeled streptavidin-biotin ?-GalNAc-
polymer and 0 - 625nM C18.1 IgG1 competed for binding to the H1-CRD in the presence
of 1mM calcium.
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Figure 126: Competition of the GalNAc-polymer and the C18.1 IgG1 antibodies for the binding to the H1-
CRD in a polymer assay. The plate was coated with 3?g/ml (175?M) H1-CRD. The C14.6 in the range of 0-
625nM (exponential dilution) in triplicate or tetricate competed with 0.3?g/ml GalNAc-complex for binding
(nonlinear regression fit: equation, one site competition, r2 0.88).
The C18.1 IgG1 antibodies hindered the binding of the GalNAc-complex to the H1-CRD
in a concentration-dependent manner. The calculated concentration for the half maximal
effect EC50 was 25.7nM (see Figure 126).
Benefit and Application of Antibodies Against the H1-CRD Results
194
3.5.6.2.4 Biacore
In a Biacore assay, the C18.1 IgG1 at a constant concentration did not affect the
galactose binding to monomeric and dimeric H1-CRD, and therefore, did not block the
binding site. The difference between the first galactose signal prior to the antibody
capturing, and the second galactose signal when antibodies were bound, was below
10% (see Figure 127A).140
Figure 127: Biacore assay of the C18.1 IgG1 binding to the monomeric and the dimeric H1-CRD. A:
Sensogram, with a preliminary injection of 5mM galactose (g), C18.1 IgG1 injection (i), dissociation phase
(d), followed by a second 5mM galactose injection and an EDTA pulse (e), prior to the regeneration with HCl
(r). Data points, used for blotting (Int, Sta), are indicated by circles. B: Intensity after 5min injection (Int),
blotted against the quotient of the stability after 5min dissociation (Sta) and the intensity in buffer with 50mM
calcium (1) or 3mM EDTA (2).
The binding was slightly calcium-sensitive. Especially the binding stability of C18.1 to the
H1-CRD decreased, when EDTA was present. The strengths of the C18.1 interactions
were similar and calcium-independent, except with dimeric H1-CRD, which showed an
increased intensity in the presence of EDTA (see Figure 127B).
Figure 128: Comparison of the kinetic on and off rates of the C18.1 IgG1 binding to the monomeric and the
dimeric H1-CRD species surface, after fitting to a Langmuir 1:1 binding model. A: Sensogram of the C18.1
IgG1 binding to H1-CRD in calcium-free buffer. B: Calculated kon, koff and calculated KD.
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In the presence of 3mM EDTA, the C18.1 IgG1 injected at concentrations 0.14 to 140nM
interacted fast, tight and in a concentration-dependent manner with dimeric and
monomeric H1-CRD (see Figure 128A).
The affinity of C18.1 IgG1 to the dimeric H1-CRD with a KD of 124pM was nearly double
than to the monomeric H1-CRD with a KD of 233pM (see Figure 128B). This was mainly
caused by the much lower off-rate of the dimer binding (kon 2.70·10
5M-1s-1 and koff
3.34·10-5s-1) compared to monomer binding (kon 3.73·10
5M-1s-1 and koff 8.69·10
-5s-1).
3.5.6.2.5 Epitope excision and extraction
The C18.1 epitope extraction and excision failed with native as well as with reduced-
alkylated H1-CRD. The change of the proteolytic enzyme, using ?-chrymotrypsine
instead of trypsine did not improve the results too. Hence, the results were not reliable.
3.5.6.3 On cell characterization
3.5.6.3.1 Immunofluorescence flow cytometry
The interaction of C18.1 IgG1 with the native entire ASGPR, and the cross-reactivity with
similar receptors was tested by extracellular flow cytometry. Not fixed HepG2, SK-Hep1,
THP-1, macrophages and dendritic cells were indirectly stained with FITC.
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Figure 129: Flow cytometry of not fixed HepG2, SK-Hep1, THP-1, macrophages and dendritic cells, which
were indirectly extracellular stained with C18.1 IgG1 and FITC-labeled goat anti-mouse Ig (H+L). The dead
probidium-stained cells were excluded. The histogram shows an overlay with the negative control (irrelevant
IgG).
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The C18.1 antibodies specifically stained the ASGPR-positive HepG2 cells, but not the
ASGPR-negative SK-Hep1 cells. No binding to the surface of THP-1 cells, macrophages
or dendritic cells, which are known to carry a homologous receptor, was detected (see
Figure 129).
3.5.6.3.2 Immunofluorescence microscopy
The specific endocytosis of Texas Red-labeled C18.1 IgG1 into living HepG2 cells via
the ASGPR was tested by immunofluorescence microscopy. SK-Hep1 cells were stained
in parallel, to distinguish the specific and the unspecific internalization.
HepG2
SK-Hep1
Figure 130: Immunofluorescence microscopy picture of the directly stained HepG2 and SK-Hep1 cells. The
TR-labeled C18.1 IgG1 (40?g/ml, 45nM) was internalized into living cells, followed by paraformaldehyde
fixation of cells.
The C18.1 was internalized and this primarily by the ASGPR. The HepG2 cells were
strewn with very bright spots, whereas in the SK-Hep1, only some single or no spots
were visible (see Figure 130).
3.5.6.4 On tissue characterization
3.5.6.4.1 Immunohepatochemistry
Non-pathological human paraffin-embedded liver tissue sections were indirectly stained
with DAB, to test the binding ability of C18.1. The antigen was retrieved with various
steamer, microwave and enzymatic methods.
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C18.1
Figure 131: Indirectly stained paraffin-embedded non-pathological liver tissue section (antigen retrieval with
microwave at 98°C for 30min and staining with C18.1 at 4μg/ml, DAB).
No binding of C18.1 to the hepatocyte surface was visible, independent of the tissue
pretreatment for the antigen retrieval (see Figure 131).
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3.5.7 Monoclonal C23.8 IgG1
3.5.7.1 Purification of C23.8 IgG1
The purification of C23.8 IgG1 by different affinity chromatographic methods, using
Protein L, Protein G and H1-Sepharose, were tested.
Purification by Protein L spin chromatography
The IgG1? extraction from culture supernatant of clone C23.8, containing 10% FCS,
using Protein L-Sepharose spin columns resulted in only partially pure antibodies. On
the silver-stained reducing SDS-PAGE gel, beside the 25kDa light and the 55kDa heavy
chain band, mainly a 66kDa band was visible, which was supposed to originate from
BSA of the FCS (see Figure 132B). The HRP-ELISA confirmed, that only a fraction of
C23.8 IgG1? was extracted. Approximately the same absorbances were obtained for the
supernatant and the flow through.
Purification by H1-CRD FPLC
The IgG1 were purified from culture supernatant of clone C23.8, which contained 10%
FCS, by FPLC, using an H1-Sepharose column. The antibodies were only partially pure.
In addition to the 25kDa and 55kDa bands of the light and heavy chains, a double band
of an approximately 66kDa protein was visible on the reducing SDS-PAGE gel (see
Figure 132). An HRP-ELISA confirmed, that the antibody extraction had been effective,
as the flow through was only slightly positive, compared to the supernatant.
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Figure 132: Extraction of the IgG1 from culture supernatant of clone C23.8, containing 10% FCS. A: H1-
CRD FPLC chromatogram. B: Silver-stained reducing SDS-PAGE gel 12% of the eluted antibodies from H1-
CRD FPLC (H1), from Protein G FPLC (G) and from Protein L spin columns (L), showing the 25kDa light
chain band, three bands of impurities in Protein G-purified antibodies, the 55kDa heavy chain band and one
or two other bands of about 66kDa in H1 and Protein L-purified antibodies, probably also glycosylated heavy
chains.
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Purification by Protein G FPLC
The purification of IgG1 from culture supernatant of C23.8, containing 3% FCS (low
IgG), by FPLC, using a Protein G-Sepharose column, was not successful. Only a minute
elution peak was detected, but an additional prepeak appeared at the end of the loading,
when the column flow was stopped for an instant to change from loading to the washing
buffer. The purity of the eluted antibodies was good (see Figure 132). The HRP-ELISA
indicated, that the bad yield was mainly due to an extremely low C23.8 IgG1
concentration in the culture supernatant and not due to a weak extraction efficiency.
The purified C23.8 IgG1 antibodies were quantified by SDS-PAGE and by Bradford
micro-assay. The highest yield was obtained, when C23.8 IgG1 were purified by H1-
CRD FPLC with 4.6mg/L supernatant, followed by extraction on Protein L with 3.1mg/L
supernatant. The Protein G chromatography of C23.8 yielded only 1.0mg/L supernatant
(see Figure 133).
H1-CRD Protein G Protein L overall
0.0
2.5
5.0
7.5 extraction 1
overall
extraction 2
method
Extraction H1-CRD Protein
G
Protein L
1 4.6mg/L 0.8mg/L 3.1mg/L
2 0.2mg/L
total 4.6mg/L 1.0mg/L 3.1mg/L
Figure 133: Yield of the C23.8 IgG1, purified by affinity to H1-CRD, Protein G and Protein L and quantified
by Bradford micro-assay and SDS-PAGE quantification. Overall yield received was 1.516mg/L (SEM
0.330mg/L) culture supernatant of C23.8.
Overall, 0.55mg C23.8 IgG1 were purified, which is equivalent to a yield of 1.5mg/L
supernatant.
3.5.7.2 In vitro characterization
3.5.7.2.1 Immunoblotting
Identical amounts of the reduced, non-reduced and native H1-CRD as well as of the
reduced-alkylated and native-alkylated H1-CRD were blotted to nitrocellulose and were
captured with 5?g/ml or 0.5?g/ml C23.8 IgG1 antibodies during immunostaining.
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Figure 134: Immunoblot of the H1-CRD, caught with the monoclonal C23.8 IgG1. 1?g/band H1-CRD on
PAGE gels 15% under reducing, non-reducing denatured or native conditions were blotted to nitrocellulose
and were immunostained with C23.8 IgG1, followed by the detection with AP-labeled goat anti-mouse IgG
(whole molecule), in dilution 1:5000. A: Blot, stained with 5?g/ml C23.8 IgG1, showing the reduced (1), non-
reduced (2) and native (3) H1-CRD. B: Blot, stained with 0.5?g/ml C23.8 IgG1, showing reduced (1), the
reduced state of reduced-alkylated (2), the reduced state of native-alkylated (3), non-reduced (4), the non-
reduced state of native alkylated (5), native (6) and the native state of native-alkylated (7) H1-CRD. C:
Silver-stained reducing and non-reducing SDS-PAGE gel 15% of the same probes used in B (1-5)and the
LMW marker (0).
The Ponceau S-stained membrane and the silver-stained PAGE showed the same
bands pattern and relative band intensities (see Figure 134C). The main fraction was
monomeric H1-CRD species and only a minor fraction was dimeric species. Within
reduced, non-reduced or native H1-CRD, respectively, the staining was independent of
the H1-CRD alkylation state.
The C23.8 IgG1 specifically bound reduced, non-reduced and native H1-CRD, with
increasing intensities in this order. Even at a high IgG1 concentration of 5?g/ml, no
cross-reactions with proteins of the LMW were detected.
When capturing the H1-CRD with only 0.5?g/ml IgG1, the antibodies still bound to the
H1-CRD, but with varying intensities in dependence of the alkylation state. The reduced
H1-CRD, which was reduced-alkylated before was only minute recognized. In contrast,
the binding of reduced, non-reduced and native H1-CRD was not affected by the
alkylation, as a similar and strong staining was obtained with not alkylated and native-
alkylated states of the H1-CRD.
Interestingly, although the main fraction of the H1-CRD was monomeric, the bands of
the dimeric species were stronger immunostained than of the monomeric species. This
effect was obvious for non-reduced H1-CRD, and much stronger for native H1-CRD (see
Figure 134).
3.5.7.2.2 ELISA
In an HRP-ELISA the C23.8 IgG1 antibodies in concentrations of 0 - 300nM were bound
to H1-CRD (5?g/ml, 300?M) and were detected with HRP-labeled goat anti-mouse Ig
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(H+L) diluted 1:1000. The calculated concentration for the half maximal effect EC50 was
0.457nM (see Figure 135).
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Figure 135: Binding of the C23.8 IgG1 to the H1-CRD in an HRP-ELISA. The C23.8 antibodies were titrated
in the range of 0.1-300nM, in duplicate (exponential dilution row) in the presence of 20mM calcium. The
plate was coated with 5?g/ml (300?M) H1-CRD and C23.8 was detected with HRP-labeled goat anti-mouse
Ig (H+L), diluted 1:1000. The EC50 was calculated, using a nonlinear regression fit (equation sigmoid dose-
response, variable slope, r2 1.00) of Prism4 software.
The calcium sensitivity of the C23.8 IgG1 binding to the H1-CRD was checked in an
HRP-ELISA. The C23.8-capturing step was performed in the presence of 20mM calcium,
1mM calcium or 10mM EDTA, whereas all other steps were identical. The preceding
incubations were run in the presence of 1mM calcium, whereas following steps included
20mM calcium.
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Figure 136: Ca sensitivity of the C23.8 IgG1 binding to the H1-CRD in an HRP-ELISA in the presence of
20mM calcium, 1mM calcium or 10mM EDTA. The plates were coated with 3?g/ml H1-CRD and the C23.8
IgG1 was titrated in the range of 0.0625-6.25nM in triplicate. Bmax and KD were calculated, using a nonlinear
regression fit (equation one site binding, hyperbola, r2 0.95-0.98).
On plates, coated only with 175?M H1-CRD, the binding of the C23.8 IgG1 in the range
of 0 - 6.25nM to the H1-CRD was calcium-sensitive. However, the interaction was not
dependent on the calcium concentration level, as the same binding behavior was
obtained in the presence of 20mM and of 1mM calcium, showing a KD of 0.3 and Bmax of
96- 101%. In contrast, in the absence of calcium, in 10mM EDTA, C18.1 bound
extremely weak with a KD of 1.6nM and Bmax of 7% (see Figure 136).
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3.5.7.2.3 GalNAc-polymer assay
0.3?g/ml POD-labeled streptavidin-biotin ?-GalNAc-polymer and C23.8 IgG1 antibodies
in concentrations of 0 - 18.75nM competed for binding to H1-CRD in the presence of
1mM calcium.
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Figure 137: Competition of the GalNAc-complex and the C23.8 IgG1 antibodies for binding to the H1-CRD
in a polymer assay. The plate was coated with 3?g/ml (175?M) H1-CRD. The C23.8 in the range of 0-
18.75nM (exponential dilution) in triplicate or tetricate competed with 0.3?g/ml GalNAc-complex for binding
(nonlinear regression fit: equation, one site competition, r2 0.72).
With a calculated concentration for the half maximal effect EC50 of 12nM, C23.8 IgG1
affected the binding of the GalNAc-conjugate in a concentration-dependent manner (see
Figure 137).
3.5.7.2.4 Biacore
The binding of the galactose to the monomeric and the dimeric H1-CRD surfaces in a
Biacore assay was not affected, when C23.8 IgG1 were captured. The first galactose
signal, prior to the antibody injection, and the second signal, after the IgG1 binding,
varied less than 10% (see Figure 138A).
Figure 138: Biacore assay of the C23.8 IgG1 binding to the monomeric and the dimeric H1-CRD. A:
Sensogram, with a preliminary injection of 5mM galactose (g), C23.8 IgG1 injection (i), dissociation phase
(d), followed by a second 5mM galactose injection and an EDTA pulse (e), prior to the regeneration with HCl
(r). Data points, used for blotting (Int, Sta), are indicated by circles. B: Intensity after 5min injection (Int)
blotted against the quotient of the stability after 5min dissociation (Sta) and the intensity in buffer with 50mM
calcium (1) or 3mM EDTA (2).
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A marginal calcium sensitivity was detected, showing an increased stability of the C23.8
binding to the H1-CRD in the presence of EDTA. In addition, the binding stability to
dimeric H1 CRD was higher than to monomeric H1-CRD. However, the intensity of the
C23.8 interaction with H1-CRD was identical and independent of calcium or EDTA (see
Figure 138B).
3.5.7.3 On cell characterization
3.5.7.3.1 Immunofluorescence flow cytometry
The binding of C23.8 IgG1 to the entire ASGPR on HepG2 cells and to the surface of
ASGPR-negative SK-Hep1 cells was investigated by extracellular flow cytometry.
Additionally, the cross-reactivity with homologous receptors on the surface of
macrophages, dendritic cells and THP-1 was tested. Not fixed cells were indirectly
stained with FITC.
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Figure 139: Flow cytometry of not fixed HepG2, SK-Hep1, THP-1, macrophages and dendritic cells, which
were indirectly extracellular stained with C23.8 IgG1 and FITC-labeled goat anti-mouse Ig (H+L). The dead
probidium-stained cells were excluded. The histogram shows an overlay with the negative control (irrelevant
IgG).
The C23.8 IgG1 specifically interacted with HepG2 cells and did not cross-react with SK-
Hep1, THP-1, macrophages and dendritic cells. Only the HepG2 cells were
fluorescence-stained (see Figure 139).
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3.5.7.3.2 Immunofluorescence microscopy
The endocytosis of the C23.8 IgG1 into HepG2 and SK-Hep1 was investigated by
immunofluorescence microscopy, to distinguish the specific and the unspecific
internalization. The cells were indirectly fluorostained with Cy3-labeled donkey anti-
mouse antibodies, after endocytosis, paraformaldehyde and permeabilization.
HepG2
SK-Hep1
HepG2
Figure 140: Immunofluorescence microscopy picture of the indirectly stained HepG2 and SK-Hep1 cells.
The IgG1 in the culture supernatant of clone C23.8 were internalized into living cells, followed by the
detection with Cy3-labeled donkey anti-mouse antibodies, after paraformaldehyde fixation and
permeabilization of the cells.
The C23.8 IgG1 were specifically endocytosed via the ASGPR. The HepG2 cells were
strewn with extremely bright spots, whereas the SK-Hep1 showed no spots. The HepG2
cells, which were only incubated with the Cy3-labeled detecting antibody, but not with
C23.8 IgG1, were not stained too (see Figure 140).
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3.5.8 Monoclonal C48.9 IgG1
3.5.8.1 Purification of C48.9 IgG1
The extraction of the C48.9 IgG1 by affinity chromatography was tried, testing Protein L,
Protein G and H1-Sepharose.
Purification by Protein L spin chromatography
The purification of IgG1? from culture supernatant of C48.9, containing 10% FCS, using
Protein L-Sepharose spin columns, was not successful. The silver-stained reducing
SDS-PAGE gel showed, that the antibodies were of low purity and, that the yield was
minute. In the HRP-ELISA, the supernatant as well as the flow through was positive.
Purification by H1-CRD FPLC
The C48.9 IgG1 antibodies were extracted from culture supernatant, containing 10%
FCS by FPLC, using an H1-Sepharose column. The baseline of the FPLC
chromatogram during loading was very unstable (see Figure 141A). The eluted
antibodies still contained impurities. On a reducing SDS-PAGE gel, two main other
proteins of about 66kDa were visible beside the 25kDa light chain band and the 55kDa
heavy chain band (see Figure 141B). The extraction was quantitative, as the
supernatant exhibited a strong and the flow through only a weak absorbance in the
HRP-ELISA.
Purification by Protein G FPLC
The purification of C48.9 IgG1 antibodies from culture supernatant containing 3% FCS
(low IgG), by FPLC, using a Protein G-Sepharose column, was not successful. During
elution only a minute peak was detected, but at the end of the loading when stopping the
flow to change the buffer, an unexpected prepeak appeared. On a reducing SDS-PAGE
gel, hardly any antibodies, but also no other proteins were detected. Therefore, the
purity seemed to be good (see Figure 141B). The HRP-ELISA indicated on the one
hand, that the concentration of C48.9 IgG1 in the culture supernatant was already low
and on the other hand, that the extraction was not complete. Both, the supernatant and
the flow through showed a similar and low absorbance.
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Figure 141: IgG1 extraction from culture supernatant of clone C48.9 containing 3% FCS (low IgG) A: FPLC
chromatogram using H1-Sepharose. B: Corresponding silver-stained reducing SDS-PAGE gel 12% of the
eluted antibodies of the H1-CRD (H1) and the Protein L (L) FPLC, showing mainly a double band for the
light chain and a triple band for the heavy chain.
A reliable quantification was achieved with a double estimation by SDS-PAGE
quantification and by Bradford micro-assay.
The highest C48.9 IgG1 yield was obtained by the H1-Sepharose chromatography, with
6.1mg/L supernatant, and the lowest by the extraction on Protein L-Sepharose, with
0.15mg/L supernatant. The Protein G-Sepharose affinity purification of C48.9 IgG1 from
culture supernatant yielded only 0.6mg/L supernatant, too (see Figure 142).
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Extraction H1-CRD Protein G Protein L
1 6.1mg/L 0.64mg/L 0.14mg/L
total 6.1mg/L 0.64mg/L 0.14mg/L
Figure 142: Yield of the C48.9 IgG1, purified by affinity to H1-CRD, Protein G and Protein L and quantified
by Bradford micro-assay and SDS-PAGE quantification. Overall yield received was 0.885mg/L (SEM
0.149mg/L) culture supernatant of C48.9.
Overall, 0.47mg C48.9 IgG1 were purified from about 500ml culture supernatant,
equivalent to a yield of 0.9mg/L.
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3.5.8.2 In vitro characterization
3.5.8.2.1 Immunoblotting
Identical amounts of the reduced, non-reduced and native H1-CRD as well as of the
reduced-alkylated and native-alkylated H1-CRD were blotted to nitrocellulose and were
immunostained with 5?g/ml or 0.5?g/ml C48.9 IgG1, followed by an AP-labeled goat
anti-mouse IgG (whole molecule).
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Figure 143: Immunoblot of the H1-CRD, caught with the monoclonal C48.9 IgG1. 1?g/band H1-CRD on
PAGE gels 15% under reducing, non-reducing denatured or native conditions were blotted to nitrocellulose
and were immunostained with C48.9 IgG1, followed by the detection with AP-labeled goat anti-mouse IgG
(whole molecule), in dilution 1:5000. A: Blot, stained with 5?g/ml C23.8 IgG1, showing the reduced (1), non-
reduced (2) and native (3) H1-CRD. B: Blot, stained with 0.5?g/ml C48.9 IgG1, showing reduced (1), the
reduced state of reduced-alkylated (2), the reduced state of native-alkylated (3), non-reduced (4), the non-
reduced state of native-alkylated (5), native (6) and the native state of native-alkylated (7) H1-CRD. C:
Silver-stained reducing and non-reducing SDS-PAGE gel 15% of the same probes used in B (1-5) and the
LMW marker (0).
The silver-stained PAGE gel and the Ponceau S-stained membrane showed the same
bands pattern and same relative band intensities. The dimeric H1-CRD species were
minor stained compared to the monomeric species. The different alkylation states of the
reduced, non-reduced or native H1-CRD looked identical in their band intensities (see
Figure 143C). The C48.9 specifically recognized the monomeric and the dimeric species
of the reduced, non-reduced and native H1-CRD. The strongest signal was received for
the binding to native H1-CRD, followed by the non-reduced and the lowest for the
interaction with reduced H1-CRD. No cross-reaction with proteins of the LMW marker
was detected.
Using the lower C48.9 IgG1 concentration of 0.5?g/ml for catching, the interaction with
reduced H1-CRD was alkylation-dependent. Whereas the previously reduced-alkylated
H1-CRD in reduced state was only minor recognized, the preliminary not alkylated and
native-alkylated H1-CRD in reduced state as well as in non-reduced and native state
were highly intense stained.
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Interestingly, the relative band intensities of the monomeric and dimeric H1-CRD species
on the C48.9-immunostained blot were vice versa compared to the Ponceau S-stained
blot or the silver-stained PAGE gel. The C48.9 IgG1 preferred the binding to the dimer
(see Figure 143).
3.5.8.2.2 ELISA
The binding of the monoclonal C48.9 IgG1 in concentrations of 0 - 300nM to the H1-
CRD (5?g/ml, 300?M) was detected with an HRP-labeled goat anti-mouse Ig (H+L)
diluted 1:1000, in an ELISA. An effective concentration EC50 of 1.9nM was calculated for
the half maximal binding (see Figure 144).
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Figure 144: Binding of the C48.9 IgG1 to the H1-CRD in an HRP-ELISA. The C48.9 was titrated in the
range of 0.1-300nM, in duplicate (exponential dilution row) in the presence of 20mM calcium. The plate was
coated with 5?g/ml (300?M) H1-CRD and C48.9 was detected with HRP-labeled goat anti-mouse Ig (H+L),
diluted 1:1000. The EC50 was calculated, using a nonlinear regression fit (equation sigmoid dose-response,
variable slope, r2 1.00) of Prism4 software.
The calcium sensitivity of the C48.9 IgG1 binding to the H1-CRD in the HRP-ELISA was
checked. The IgG1 were caught in the presence of 2mM calcium, 1mM calcium or 10mM
EDTA. All previous steps included 1mM calcium and all following steps 20mM calcium.
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Figure 145: Ca sensitivity of the C48.9 IgG1 binding to the H1-CRD in an HRP-ELISA in the presence of
20mM calcium, 1mM calcium or of 10mM EDTA. The plates were coated with 3?g/ml H1-CRD and C48.9
IgG1 was titrated in the range of 0.0625-6.25nM in triplicate. Bmax and KD were calculated using a nonlinear
regression fit (equation one site binding, hyperbola, r2 0.98-0.99).
The binding of C48.9 in concentrations of 0 - 6.25nM to 175?M H1-CRD-coated plates,
was substantially increased by the presence of calcium, but was independent of the
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calcium concentration level. The interactions were similar in 20mM calcium, with a KD of
0.09nM and Bmax of 96.1% and in 1mM calcium with a KD of 0.09nM and Bmax of 91.6%.
In contrast, in 10mM EDTA, hardly any binding was detected, showing an extremely low
Bmax of 3.8% and a KD of 0.01nM (see Figure 145).
3.5.8.2.3 GalNAc-polymer assay
The C48.9 IgG1 in the concentration range of 0 - 18.75nM competed with 0.3?g/ml
POD-labeled streptavidin-biotin ?-GalNAc-polymer for binding to the H1-CRD, in the
presence of 1mM calcium.
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Figure 146: Competition of the GalNAc-polymer and the C48.9 IgG1 antibodies for binding to the H1-CRD in
the polymer assay. The plate was coated with 3?g/ml (175?M) H1-CRD. C48.9 in the range of 0-18.75nM
(exponential dilution) in triplicate or tetricate competed with 0.3?g/ml GalNAc-complex for binding (nonlinear
regression fit: equation, one site competition, r2 0.77).
The C48.9 IgG1 inhibited the binding of the GalNAc-complex to the H1-CRD effectively
and concentration-dependent. The estimated concentration for the half maximal effect
EC50 was 5.9nM (see Figure 146).
3.5.8.2.4 Biacore
In a Biacore assay, the interaction of galactose with surfaces of the monomeric and the
dimeric H1-CRD species was not affected when the C48.9 IgG1 was bound. The
difference of the first galactose signal prior to the C48.9 injection and the second signal
after antibody capturing was below 10% (see Figure 147A).
The binding of the C48.9 IgG1 did not seem calcium-sensitive. The stability and the
intensity in the presence of 50mM calcium compared to 3mM EDTA was similar.
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Figure 147: Biacore assay of the C48.9 IgG1 binding to the monomeric and the dimeric H1-CRD. A:
Sensogram with a preliminary injection of 5mM galactose (g), C48.9 IgG1 injection (i), dissociation phase (d)
followed by a second 5mM galactose injection and an EDTA pulse (e) prior to the regeneration with HCl (r).
Data points used for blotting (Int, Sta) are indicated by circles. B: Intensity after 5min injection (Int) blotted
against the quotient of the stability after 5min dissociation (Sta) and the intensities in buffer with 50mM
calcium (1) or 3mM EDTA (2).
The binding intensity of the monomeric H1-CRD to the C48.9 was lower than of the
dimeric H1-CRD (see Figure 147B).
3.5.8.3 On cell characterization
3.5.8.3.1 Immunofluorescence flow cytometry
The interaction of the C48.9 IgG1 with the entire ASGPR on HepG2 cells and with the
surface of ASGPR-negative SK-Hep1 cells was checked by extracellular flow cytometry.
100 101 102 103 104
FL1 H
10
20
30
40
50
0
FL1-H
c
o
u
n
ts
HepG2
100 101 102 103 104
20
40
60
80
100
0
FL1-H
c
o
u
n
ts
monocyte
100 101 102 103 104
1
20
40
60
80
100
0
FL1-H
c
o
u
n
ts
DC
100 101 102 103 104
20
40
60
80
100
0
FL1-H
c
o
u
n
ts
THP-1
100 101 102 103 104
FL1 H
20
40
60
80
100
0
FL1-H
c
o
u
n
ts
SK-Hep1
Figure 148: Flow cytometry of not fixed HepG2, SK-Hep1, THP-1, macrophages and dendritic cells, which
were indirectly extracellular stained with C48.9 IgG1 and FITC-labeled goat anti-mouse Ig (H+L). The dead
probidium-stained cells were excluded. The histogram shows an overlay with the negative control (irrelevant
IgG).
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In addition, THP-1 cells, macrophages and dendritic cells, which are known to carry a
homologous receptor, were indirectly fluorescence-stained, to spot cross-reactivity.
The C48.9 IgG1 was specifically bound to the ASGPR-positive HepG2 cells, and no
cross-reaction with similar receptors on the surface of macrophages and dendritic cells
was detected. Only HepG2, but none of the other tested cell lines, were positive in flow
cytometry (see Figure 148).
3.5.8.3.2 Immunofluorescence microscopy
The endocytosis of C48.9 IgG1 into HepG2 and SK-Hep1 was investigated by
immunofluorescence microscopy to distinguish between the specific and the unspecific
internalization. The cells were indirectly stained with Cy3-labeled donkey anti-mouse
antibodies after endocytosis, fixation and permeabilization.
HepG2
SK-Hep1
Figure 149: Immunofluorescence microscopy picture of the indirectly stained HepG2 and SK-Hep1 cells.
The IgG1 in culture supernatant of clone C48.9 were internalized into living cells, followed by the detection
with Cy3-labeled donkey anti-mouse antibodies, after paraformaldehyde fixation and permeabilization of
cells.
The SK-Hep1 showed no spots, whereas in the HepG2 cells some bright spots were
visible. Also the tubuli were only very weakly stained with anti-tubuli IgG, followed by the
Cy3-labeled detecting antibody. The HepG2 cells only incubated with the detecting
antibody, but not with C48.9 IgG1, were not stained. Therefore, C48.9 was internalized
and mainly specifically by the ASGPR. The weak staining was supposed to be due to the
weak binding of the Cy3-labeled antibody (see Figure 149).
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4 Discussion
4.1 H1-CRD immunogenicity and antigenicity – a problem?
Antibodies are of primary importance in drug discovery and development, not only as
analytical and diagnostic tools, but also as carriers for drug targeting. Nowadays,
monoclonal and polyclonal antibodies against human target peptides and proteins are
still produced in animals. Therefore, the successful preparation of antibodies is highly
dependent on the antigen antigenicity and immunogenicity in the selected species. To
be immunogenic, antigen-intrinsic factors and antigen-extrinsic factors, especially the
phylogenetic distance to the host species are crucial.
Monoclonal antibodies are mostly produced by the hybridoma technique of Köhler and
Milstein.82 Since mainly murine and rarely rat cells are fused, especially conserved
proteins, which are highly homologous to mouse or rat proteins, may fail to induce an
immune response. In this case, artificial antibodies can be produced in vitro by the
Phage display technique of Smith155 or the newer Ribosome display technique of
Plückthun et al.156 or Taussig et al.157.
The H1-CRD and the MHL-1 exhibit 79% sequence identity. At the Gal binding site, the
homology is even higher with only 7% differing amino acids, i.e. residue D242 and D259.
Therefore, the chance of the H1-CRD to be immunogenic in mice seemed limited, and
the raise of antibodies against the binding site was found to be problematic. But at least
according to antigenicity, hydrophobicity and accessibility plots, the Gal binding site was
predicted to be a putative epitope region.
The H1-CRD was further compared to the CRD of homologous receptors on human and
mouse macrophages, dendritic cells and Kupffer cells, to assess the possibility that anti-
H1 antibodies may cross-react. On the one hand, such cross-reactions can be
advantageous, e.g. for the identification of homologous receptors in the same or other
species. On the other hand, they may be devastating for drug targeting or the induction
of an adequate immune response during immunization of mice. The moderate to high
sequence similarities of up to 66% for the entire receptors, 81% for the CRD or 87% for
the binding sites let assume, that cross-reactivity was probable.
In contrast to monoclonal antibodies, polyclonal antibodies for scientific application are
mainly produced in rabbits or goats, but seldom in chicken. Compared to the production
of rabbit IgG, the avian IgY preparation has the advantages that larger amounts of more
Benefit and Application of Antibodies Against the H1-CRD Discussion
213
diverse antibodies can be produced against conserved human antigens. As chicken is
phylogenetically more distant, it may respond to antigens, which are self-tolerated in
rabbit. Thus, also the ChHL-1 and its CRD are only 37% and the binding site 42%
identical with the ASGPR-1. Therefore, the production of polyclonal anti-H1 antibodies in
chicken was much more promising.
In conclusion, the high similarity of the murine and human hepatic lectin may hamper the
production of monoclonal antibodies against the H1-CRD, particularly against the Gal
binding site. The chances of success seemed highest, when the full length H1-CRD in
native and active state is used as antigen. On the one hand, this ensures best the
binding site to be in the native conformation. On the other hand, the immunogenicity of
the full length H1-CRD is expected to be higher than a part of the H1-CRD structure.
Additionally, with a molecular weight of 17kDa, the H1-CRD is much above the critical
antigenic size. Since avian are more distant to human than rabbit, and since IgY may
bind to distinct epitopes than IgG, polyclonal antibodies against the H1-CRD were best
risen in chicken.
4.2 H1-CRD production - from minute to gigantic yields
The mice and chickens immunization as well as the screening of hybridomas and the
characterization of antibodies depend on sufficient amounts of antigen. Therefore, at
least 50mg active H1-CRD should be recombinantly expressed in E.coli, before starting
the production of monoclonal and polyclonal antibodies. Unfortunately, the expression
and purification, according to Meier et al.26, supplied only a minute yield of about
130?g/L culture, which was only 18% of published 688?g/L culture.
In other words, to provide 50mg, the production of H1-CRD in approximately 400L would
have been required. As a consequence, the optimization of the H1-CRD production was
inevitable. First, the expression was increased by variation of E.coli intrinsic and extrinsic
factors, i.e. the expression vector, the E.coli strain and the expression conditions
(medium, inducer concentration, cell density, expression period). Second, the
purification method, mainly the solubilization and the refolding were improved (see
Figure 150).
Benefit and Application of Antibodies Against the H1-CRD Discussion
214
H1-CRD E.coli
Expression strains
Active
H1-CRD
H1-CRD E.coli
Production clone
Preparative scale
Expression
Preparative scale
IB solubilization
Preparative scale
Refolding
Preparative scale
Gal affinity purification
H1 insert
Restriction
H1-CRD production
Optimization
IB solubilization
Refolding
E.coli expression clone
Expression condition 
E.coli strainsexpression
Transformation
pEZZ18H1
Amplification
E.coli straincloning
Transformation
Vector / H1 insert
Ligation
H1 insert
PCR amplification
pET3H1 plasmid 
Amplification
pET3H1 plasmid
E.coli straincloning
pEZZ18 vectors
Dephosphorylation
pEZZ18 vector
Restriction
pEZZ18 vector
Amplification
pEZZ18 vector
E.coli strainclining
Size exclusion 
chromatography
Active “high pure”
H1-CRD
Figure 150: Overview of the H1-CRD production as antigen for the raise of monoclonal and polyclonal anti-
H1 antibodies and for their characterization.
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4.2.1 Optimization of E.coli intrinsic features – the vector-E.coli strain
relationship
The expression level is mainly influenced by the expression conditions (temperature, pH,
aeration, inducer concentration, cell density and expression period), but also by the
features of the protein and the encoding cDNA, by the expression vector and the E.coli
strain.
Therefore in a first step, E.coli intrinsic features were examined followed by the variation
of E.coli extrinsic features for expression in the selected E.coli expression clone.
Selection of the optimal vector / E.coli partners
Beside the original pET3b expression vector, the pEZZ18 was selected for recombinant
gene expression of H1-CRD (see Appendix 4, page 281). The pET3b vector encodes no
tag and allows inducible cytoplasmic expression of H1-CRD in inclusion bodies.26 In
contrast, the pEZZ18 vector encodes the protein A signal sequence and the ZZ domain
tag that allows to express the H1-CRD fused to the synthetic IgG binding domain and
that directs the fusion protein to the periplasm or the medium. The periplasmic
expression and the fused ZZ domain probably facilitate the native folding by enforced
pairing of disulfide bridges and simplify the purification.
The pET3H1, encoding the H1-CRD, was provided by Spiess M.158 To get the H1-CRD
encoding pEZZ18H1, the high-fidelity Pfu DNA polymerase amplified H1-CRD cDNA
was blunt-blunt-ended and blunt-sticky-ended introduced into pEZZ18. But no E.coli
transformants were obtained that contained the recombinant pEZZ18H1 plasmid. The
restriction probably failed, because the restriction sites of Sma I and BamH I are only
separated by 3bp.
The pEZZ18 vector strategy was no longer progressed, due to experiences with this
vector system by Dragic.159
There are several (DE3) E.coli expression strains available that are compatible with the
pET3H1 plasmid. Due to the fact, that the H1-CRD sequence contains 7 Cys, which are
paired in 3 S-S bonds, and that 4% of the H1-CRD cDNA encoded amino acids are rare
in E.coli, the two strains AD494(DE3) and Rosetta-gami(DE3) promised to enhance
expression levels of the H1-CRD decisively (see Appendix 3, page 280). Compared to
the original expression strain JM109(DE3), AD494(DE3) facilitate disulfide pairing in the
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reducing cytoplasm. Rosetta-gami(DE3) additionally encodes the rare E.coli amino acid
residues.
The comparison of the H1-CRD expression levels in clones of JMpET3H1, ADpET3H1
and RGpET3H1 clearly indicated, that the highest yields were obtained with ADpET3H1
clones. Interestingly, the expression level did not only differ strongly between the
different E.coli strains, but also between different clones of the same E.coli strain; i.e.
clone ADpET3H1.4 provided an about 6-fold higher H1-CRD yield than clone
ADpET3H1.1.
In conclusion, the highest expression level was assessed in E.coli clone ADpET3H1.4,
which produced 11-fold more H1-CRD than the original expression clone of JMpET3H1.
Therefore, the excellent clone ADpET3H1.4 was selected for the H1-CRD production.
Verification of H1-CRD cDNA and amino acid sequence
Prior to the preparative expression of the H1-CRD, ADpET3H1.4 was verified to express
the correct peptide. On the one hand, the H1-CRD cDNA sequence contained no point
mutations or frame shifts and was correct. On the other hand, the determined molecular
mass in ESI-FT-ICR was 61Da higher than the calculated mass of the full length native
H1-CRD.
However, the penultimate amino acid Gly at the N-terminus let to suppose, that the
starting Met is posttranslationally removed160. Considering this deletion (-131Da) and
assuming, that 6 of 7 Cys are involved in disulfide bridges (-6Da), the mass deficit
switched to a mass surplus of 76Da. Due to the circumstance, that ?-mercaptoethanol
was used during solubilization of the H1-CRD, it was suggested that a forth S-S bond
with the remaining free Cys was formed. The ?-mercaptoethanol adduct was lately
proved by Ricklin.140 Therefore, assuming that the H1-CRD contains three intramolecular
S-S bonds, no starting Met and a ?-mercaptoethanol adduct at the free Cys, the
calculated and the measured masses were identical. In addition, the correct mass of the
H1-CRD without starting Met was proved under reducing conditions.
Since only the positions of the two H1-CRD disulfide bridges Cys36-Cys131 (Cys181-Cys276
in the H1 subunit) and Cys109-Cys123 (Cys254-Cys268) were determined in X-ray26, but the
position of the third still has to be defined, the native trypsine-digested H1-CRD was
analyzed using MALDI-FT-ICR. A third S-S bond linked the vicinal Cys7-Cys8 (Cys152-
Cys153) and therefore most probable, the Cys19 (Cys164) is linked to ?-mercaptoethanol or
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involved in the dimerization of the H1-CRD (see Figure 151).140 However, all Cys were
also found in the reduced state. This was probably due to the opening of disulfide
bridges, which mostly occurs under basic conditions.137 Since the native H1-CRD was
digested at neutral pH, an exchange of disulfide bridges during proteolysis cannot be
excluded.
152  153 164 181 254 268 276
ME
A
ME
152  153 164 181 254 268 276
B
Figure 151: Disulfide bridges of the H1-CRD with a ?-mercaptoethanol adduct. A: Proposed disulfide
linkage according to MS (see Section 3.2.2.4). B: Suggested disulfide pairing by Meier et al.26
In summary, the selected clone ADpET3H1.4 expressed surprisingly high amounts of
correct full length H1-CRD.
4.2.2 Optimization of E.coli extrinsic features – the expression conditions
The maximal expression level is only achieved under optimal growth and expression
condition of the defined E.coli expression system. The main E.coli extrinsic parameters,
which affect the expression, are medium composition and pH, culture density, aeration,
temperature, inducer concentration and the period of expression.52
1 2 3 4 5 6
OD600
1 6
Expression
period
1h
9h
IPTG
0.02mM
0.08mM
Figure 152: Setup of the experiments for the optimization of the IPTG concentration, the cell density for
induction and the expression period. The expression cultures were induced at an OD600 of 1-6 with
0.2–0.4mM IPTG, and the expressions were run for 5h, while taking samples every 1h.
In parallel-incubated ADpET3H1 expression cultures, the four determinants, i.e. medium,
cell density, IPTG concentration and expression period, were systematically varied (see
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Figure 152). The other important variables temperature, aeration and pH were
controlled, but kept constant.
Medium  – TB versus LB with or without a pinch of glucose
ADpET3H1.4 in the higher-nutrient TB medium grew slightly faster during log phase and
reached a higher maximal cell density during stationary phase than in the originally used
LB medium. This was not surprising, because in the richer TB medium, nutrients get
later limiting. When induced at the same cell densities, similar yields were obtained in
both media. The prolonged log phase in TB medium however, may enable the
expression in more dense cultures, which increases the yield. Furthermore, no basal
expression occurred prior to induction, even not in the absence of glucose. Although
glucose was not necessary to prevent basal expression, it exhibited a variable, but
positive effect onto the yield.
Cell density – expression until toxic?
Since optimal unlimited conditions are essential during expression, cells must still be in
the log phase. Consequently, the protein expression is generally induced at a low cell
density, at an OD600 of 0.8 – 1. But as ADpET3H1 grew exponentially until an OD600 of 4
- 5, the induction at a much higher density seemed possible and promising to increase
the expression level. Therefore, the expression was started at various cell densities in
the log phase, up to the stationary phase. Interestingly, when the cell density exceeded
an OD600 of 3, the pH decreased during expression. This indicated suboptimal culture
conditions by metabolic product accumulation and that may hamper the expression.
Therefore, it was assumed, that the cell densities in ADpET3H1.4 expression cultures
should not exceed an OD600 of 3.
IPTG concentration – give E.coli the right “kick”
The maximal expression may exhaust the production capacity of E.col i . As a
consequence, lowering the expression rate, but increasing the expression period may
permit to achieve higher yields.119 Meier et al.26 initiated the expression with 1mM IPTG,
whereas for maximal induction of pET3 vector an IPTG concentration of 0.4mM is
recommended.119 Hence, the protein expression was started in ADpET3H1.4 by addition
of half the concentration, the recommended concentration and double the concentration
of IPTG, needed for maximal induction. The highest H1-CRD yields were obtained with
recommended inducer concentration of 0.4mM. Since an excessive induction may cause
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cell damage with release of the expressed protein, the medium was inspected, but no
H1-CRD was found.
Expression period  - endurance of E.coli
In general, the expression period is 3h but may be up to 20h. The highest expression
level was assessed 3-5h after induction, independent of the IPTG concentration used to
initiate the production. However, when the expression period was further prolonged, the
observed amount of H1-CRD decreased, probably due to degradation. Interestingly, in
parallel to the loss of H1-CRD, the cell density and consequently, the total cell protein
mass increased. This second growth phase may be caused by IPTG depletion and as a
consequence by stopped expression, or may be due to carbenicilline degradation,
allowing the growth of cells that lost the plasmid. Therefore, the expression was
reinduced after 5h, but no further increase of the expression level was achieved.
In conclusion, the highest expression level in ADpET3H1.4 was maintained, when the
H1-CRD expression was initiated with 0.4mM IPTG at a cell density below an OD600 of 3
and was run for 5h. Additionally, the glucose supplementation contributed to improve the
H1-CRD expression.
4.2.3 Optimization of the purification procedure
The cytoplasmic expressed protein is either soluble or aggregates in insoluble inclusion
bodies. The location and form of the expressed protein defines the purification
procedure, needed to recover high yields of active protein.
Since H1-CRD was uniquely expressed in the insoluble and inactive form of inclusion
bodies, three main purification steps were necessary to obtain active H1-CRD: the
solubilization of inclusion bodies, the refolding and the isolation of active H1-CRD by
affinity to galactose. To optimize the recovery of active H1-CRD, three different
solubilization methods (FD, NFD, IB) in combination with four distinct refolding systems
(A, B, C, D) were compared (see Figure 153).
The different purification procedures were performed in parallel, isolating H1-CRD from
the same expression pellet, to exclude external factors best.
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Expression
H1-CRD was expressed in ADpET3H1.4, harvested cultures
pooled and divided into thee equal portions to get the same starting
material for all purification renaturation procedures.
Denaturation and reduction
Proteins were denatured and reduced comparing three procedures
in parallel: the “Fast dilution” (FD), the “Non fast dilution” (NFD) and
the “Inclusion body” (IB) method. Solubilized proteins were divided
into two equal portions.
Refolding
Solubilized FD and NFD-derived proteins were refolded in refolding
systems A and C and IB derived proteins in refolding systems B
and D.
Affinity chromatography
Refolded H1-CRD of each portion was extracted separately by
affinity to Gal-Sepharose.
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Figure 153: Optimization of the H1-CRD purification, composed of three main steps: the denaturation, the
refolding and the affinity chromatography using Gal-Sepharose.
Reductive solubilization
The FD method was identical to the original solubilization method of Meier et al. The
NFD method was adapted from the FD method. Both reduced and denatured the
inclusion bodies without separation from soluble bacterial proteins and differed mainly in
the protein concentration upon solubilization. Whereas in the FD solubilization, the total
cell proteins were solubilized in a small volume and were fast diluted prior to the
refolding, in the NFD solubilization, the proteins were solubilized in a large volume and
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were no more diluted prior to the refolding. Consequently, the protein concentration
during solubilization and the protein, the denaturant and the reductant concentration at
the refolding start differed.
In contrast to both other methods, the IB method isolated the insoluble inclusion bodies
from soluble bacterial proteins prior to the solubilization. Therefore, the total protein
concentration, but not the H1-CRD concentration at the refolding start, was much lower
compared to the other methods. Another main difference was, that proteins were
reduced with ?-mercaptoethanol in the FD and NFD, but with DTT in the IB procedure,
which may strongly influence the following refolding.
Oxidative refolding
The refolding system A was identical to the original refolding method of Meier M. et al.
and refolded proteins in a single calcium-containing salt buffer (see Figure 154). The
presence of calcium may be essential for the proper refolding of active H1-CRD, as the
native H1-CRD contains 3 integral calcium ions. Since during refolding, the 7 Cys have
to pair in 3 correct S-S bonds, the effect of thiol-active compounds onto the refolding of
the H1-CRD were investigated. DTT was only included in the first two refolding steps of
refolding systems B and D to slow the refolding rate and therefore, to minimize the
formation of false disulfide bridges.137 Reduced and oxidized glutathione were added in
the last two refolding steps of refolding systems A, B and C to reshuffle misspaired
disulfide bonds of refolding intermediates. Finally, glycerol that assists hydration and
structure stabilization of globular proteins56 was included in the first four steps of
refolding systems B and D.
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Figure 154: Refolding buffer systems A to D, were composed of the basic refolding buffer, with or without
additives, during 6 refolding steps. A only used 1, the basic buffer in all 6 steps. C used 2 buffers, containing
additive glycerol in the first 4 and glutathione in the last 2 steps. B consisted of 3 buffers, additionally
contained DTT in the first 2, no additives in the following 2 and glutathione in the last 2 steps. Finally, D was
composed of 3 buffers, identical to B, but in addition contained glycerol in the first 4 steps.
  : Basic buffer
  : Glycerol
  : GSH / GSSG
 : DTT
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Whereas glycerol had no effect, the addition of thiol-active compounds significantly
influenced the refolding of the H1-CRD. However, also the rate of buffer exchanges was
delicate. A slow removal of denaturant and reductant during the first and second
refolding step was crucial to prevent aggregation. Since the refolding of the NFD-
solubilized proteins was successful, when reducing with ?-mercaptoethanol, but failed,
when reduction was performed with DTT, there can be speculated, that a critical
reductive-capacity concentration exists for the correct refolding (see Figure 155). The
presence of a low concentration of thiol-active compounds may facilitate the proper S-S
bond formation. When the reductant concentration falls too fast below the critical
concentration, correct disulfide bridges may not yet be formed and the H1-CRD
aggregate. But when the critical concentration is reached after finishing the proper S-S
bond pairing, the H1-CRD may not precipitate and is refolded quantitatively. Therefore, it
was suggested, that the precipitation was mainly due to the formation of false disulfide
bridges. The ?-mercaptoethanol seemed to facilitate the correct disulfide formation
compared to DTT.
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Figure 155: Effect of the reductants ?-mercaptoethanol and DTT onto the refolding.
Whereas the loss of H1-CRD during NFDDTT procedure was caused by the formation of
an insoluble H1-CRD aggregate, the low yield of FDA and FDC procedures was mainly
due to the refolding to a soluble, but inactive H1-CRD intermediate, which could not bind
to Gal-Sepharose.
Affinity chromatography
The extraction of the refolded active H1-CRD by affinity to galactose was efficient.
Surprisingly, dependent on the refolding method, one or two species of monomeric and
dimeric H1-CRD were extracted with Gal-Sepharose, seen on a non-reducing SDS-
PAGE gel and a native PAGE gel. This could be explained by the formation of the
native H1-CRD and a folding intermediate, which is also active, but differs in the disulfide
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bridge pattern. Considering the refolding buffer composition, it can be suggested, that
glutathione caused the variation. Since glutathione can reshuffle disulfide bonds, the H1-
CRD intermediate may be converted into proper folded active H1-CRD with a uniform
disulfide pattern.
The highest yields of active H1-CRD were purified by the IB and slightly less by the NFD
procedures. Compared to the yield received, following the original purification method
FDA, the yields of IB and NFD methods were more than double (see Figure 156).
Yieldmethod
Absolut
(mg/L)
FDA
norm.
Spiess et al.
norm.
FDA 10.2 100% 1486%
FDC 11.8 115% 1709%
NFDA 20.1 196% 2918%
NFDC 20.5 200% 2976%
IBB 21.9 214% 3188%
IBD 22.4 219% 3259%
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Figure 156: Comparison of the 6 different purification procedures. FDA yielded 10.2mg/L (SEM 1.2mg/L),
FDC 11.8mg/L (SEM 2.2mg/L), NFDA 20.1mg/L (SEM 2.0mg/L), NFDC 20.5mg/L (SEM 2.2mg/L), IBB
21.9mg/L (SEM 0.8mg/L) and IBD 22.4mg/L (SEM 3.6mg/L) culture.
Since the NFD method is less time consuming, exhibited better reproducibility and
supplied uniform active H1-CRD when refolded in buffer system C, the NFDC purification
procedure, using reductant ?-mercaptoethanol is the method of choice for the H1-CRD
extraction.
In summary, the uniformity of active H1-CRD seemed independent of the solubilization
method, but was significantly influenced by the refolding buffer system. Highly uniform
H1-CRD was only obtained after refolding in buffer systems B to D, which all contained
the reshuffling agent glutathione. In contrast, the yield of active H1-CRD was strong
dependent on the solubilization method, mainly on the used reductant and on the protein
concentration, but was only minor affected by the refolding system.
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4.2.4 Conclusion – the optimized H1-CRD “protein-factory”
The original expression system, identical to the published by Meier et al. yielded only
incredibly low amounts of H1-CRD with 128?g/L culture. This was also 82% lower than
published with 688?g/L (see Figure 157). To produce the planned amount of 50mg, the
H1-CRD would have had to be purified from 400L expression.
It was inevitable to optimize the procedure for the preparative production of the H1-CRD.
Three different steps were improved, i.e. the E.coli strain used for expression, the
expression conditions and the purification procedure for extraction of active H1-CRD.
An outstanding contribution was achieved by expression of the H1-CRD in another E.coli
expression strain and clone. The switch from JMpET3H1 to ADpET3H1.4 expression
cultures increased the yield 820% to 1.2mg/L. The adaptation of the expression
conditions to the needs of clone ADpeT3H1.4 resulted in an additional 82% higher yield
of 2.1mg/L. Finally, the renaturation optimization raised the yield of active H1-CRD
another 186% to 6.1mg/L.
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Figure 157: Optimization of the H1-CRD production. The yield obtained with the original expression system
(B1, 100%) was 82% lower than published by Meier et al. The optimization of the E.coli expression strain
increased the yield 820% (A2) to 920% (B2), the optimization of expression conditions 82% (A3) to 1670%
(B3) and the optimization of the purification procedure another 186% (A4) to 4770% (B4).
The optimized production resulted in an impressive 48-fold higher yield compared to the
amount received with the original strategy or a 9-fold higher yield compared to the
published yield by Spiess et al. (see Figure 157B). This method enabled to produce
50mg H1-CRD in only 8L ADpET3H1 culture.
Since the H1-CRD eluted highly concentrated, the ultrafiltration was no longer
necessary. Consequently, the substantial loss of 10-60% H1-CRD in the ultrafiltration
step was omitted and the H1-CRD yield further increased to 20mg/L culture.
In future, this will permit to achieve quantities of 50mg in only 2.5L ADpET3H1.4 culture.
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4.3 From active H1-CRD to highly pure monomeric and dimeric
H1-CRD species – a one step strategy
For the production of polyclonal antibodies, an outstanding purity of the H1-CRD antigen
was crucial. Therefore, it was necessary to remove traces of impurities still present after
the affinity purification. In addition, the separation of monomeric and dimeric H1-CRD for
the characterization of produced anti-H1 antibodies was suggested to be of advantage.
To fulfill both needs in one step, SEC was the method of choice.
In buffer containing 20mM calcium, the H1-CRD did not elute, until the buffer was
changed to water and the ionic strength decreased approximately to zero. This buffer did
not allow the separation of monomeric and dimeric H1-CRD, but foreign proteins were
successfully removed. The H1-CRD seemed to bind to the matrix. Ionic interactions with
the matrix can appear, if the ionic strength of the buffer is below 0.5M, which was not the
case. However, considering that Sephadex is a polymer, consisting of D-galactose and
3,6-anhydro-L-galactose, it may be hypothesized, that the H1-CRD specifically bound to
the galactose residues of the Sephadex in the presence of calcium, although 3’-OH of
galactose, which interacts with the H1-CRD, was not free but linked to 3,6-anhydro-L-
galactose.14 Another explanation may be, that galactose and anhydrogalactose were not
quantitatively linked, exposing enough free 3’-OH groups for H1-CRD binding. To verify
the calcium-dependent specific binding, SEC was also run with calcium-free buffers.
In buffer containing only the integral calcium of H1-CRD, several small peaks overlapped
and the H1-CRD eluted over a long period of time. The H1-CRD eluted in a mixture of
monomeric and dimeric H1-CRD. As active intermediates were obtained in the previous
step (see Section 4.2.3), it was supposed, that the fractionation was not driven by the
molecular weight but by affinity differences of the various H1-CRD folding intermediates
to the matrix. In contrast, in buffer with 1mM EDTA, the monomeric and dimeric H1-
CRD eluted according to the molecular weight in an overlapping peak, and therefore
were only partially separated. The lower flow rate did not enhance the resolution.
In conclusion, the H1-CRD SEC was only partially successful in buffer, containing EDTA
to chelate calcium. In the presence of calcium, a specific interaction between the H1-
CRD and the Sephadex matrix was observed. Therefore, FPLC SEC only enabled to
remove traces of foreign proteins but was not suitable to separate monomeric and
dimeric H1-CRD species.
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4.4 Monoclonal and polyclonal anti-H1 antibodies – overview of
the production, purification and characterization
Monoclonal and polyclonal antibodies have other features. Depending on the
application, the one or the other can be of advantage.
Strategies for the production of polyclonal and monoclonal anti-H1 antibodies differed,
but there existed also some similarities. For both, animals were first immunized with the
active H1-CRD and finally, purified antibodies were characterized by identical in vitro, on
cell and on tissue assays. But in contrast to the supply of polyclonal antibodies, for the
raise of monoclonal antibodies, lymphocytes had to be fused with immortal cells to
generate incessant antibody-producing hybridomas in culture (see Figure 158).
In the preparation of monoclonal antibodies, hybridomas are screened to identify specific
anti-H1 antibody-producing cells, whereas in the production of polyclonal antibodies no
selection takes place. As a consequence, the purity of the antigen used for immunization
is of different importance. Pure antigen is crucial for high quality polyclonal but not
decisive for monoclonal antibodies. Hence, for mice immunization active H1-CRD was
taken, whereas for chicken immunization active H1-CRD was supplementary cleared by
SEC.
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Figure 158: Overview of the monoclonal and polyclonal anti-H1 antibody production and the antibody
characterization in vitro, on cell, and on tissue level.
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4.5 Polyclonal antibodies – the way from hen to pure anti-H1 IgY
Chicken IgY are closely related to mammalian IgG, and both have many characteristics
in common. As a consequence, polyclonal yolk IgY can be applied instead of polyclonal
serum IgG in immunochemical methods.
Hens were immunized with highly pure H1-CRD, as a higher purity of the antigen
increases the portion of specific antibodies in the polyclonal antibodies.65 Specific IgY
appear in the egg 20 days and reach the plateau 30 days post immunization,85 and
hence, eggs were collected starting after day 30. To keep the specific IgY concentration
high, hens were boosted once prior and three times during the egg collection (see Figure
159).
Hen 1-3
Egg collection and pooling
i b1 b2 b3 b4
Figure 159: Immunization scheme of hens to produce polyclonal anti-H1 IgY in eggs: immunization (i) and 4
boost injections (b1 to b4) every 20-40 days. Eggs were collected after b2 for a period of about 120 days.
The IgY separation from IgM and IgB is easier than the IgG extraction from total serum
Ig due to the compartmentalization in eggs. In the yolk, large amounts of IgY but no IgM
and IgB are present, whereas in the egg white only traces or no IgY are found.
Unfortunately however, IgY bind neither to Protein A nor to Protein G, a feature that is
exploited for simple isolation of IgG from serum. Nevertheless, there exist a big array of
other chromatographic or precipitation procedures for IgY extraction.
Since none of these is a standard method and since the various isolation methods are
discussed controversially in literature, it was worthwhile to compare the effectiveness of
several extraction strategies prior to the purification of IgY in preparative scale.
Most procedures have four purification steps in common, i.e. the separation of yolk and
egg white, the precipitation of lipids, the extraction of the total IgY and finally, the
isolation of the antigen-specific IgY. The first step is identical for all and the last step
depends on the antigen and is given. Only the second and third step can vary. For each
of both steps, three methods were chosen and combined, which resulted in a panel of
nine distinct methods (see Figure 160). All were ranked according to the obtained yield,
purity and activity.
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Figure 160: Extraction of specific IgY from egg yolk in four purification steps: separation of egg white and
yolk ?, removal of lipids to get the total proteins ?, extraction of the total IgY from total proteins ? and
isolation of the specific IgY from total IgY ?.
Lipid precipitation – separation of water soluble and insoluble yolk portions
The WD and F/T methods were significantly less efficient in the precipitation of lipids
than the PEG method, since they only yielded about 40% and 25% of the total yolk
proteins/egg. In contrast, the ranking according to the activity/egg clearly favored the
WD method over PEG and F/T methods. In respect to the activity but not to the yield, the
observation was in agreement with Nakai S et al.161. They reported the WD method to be
superior to the PEG, regarding yield and activity.
Total IgY precipitation – extraction of IgY from crude yolk proteins
The AS method removed the irrelevant proteins insufficiently. The most prominent
contaminant was supposed to be the 41kDa lipovitellin. In addition, some 45kDa
ovalbumin and traces of phosphovitin that dissociated into a variety of different proteins,
remained. In contrast the IgY, which were isolated by the PEG and the PEG/EtOH
method exhibited a high purity. Consequently, the IgY yields/egg were only about 20%
and 10% compared to the AS method. But decisive was the IgY activity/egg that was
even slightly higher for PEG methods than for the AS method. As expected, the yield
and activity of PEG/EtOH-derived IgY was lowest, since the procedure included an
additional precipitation step.
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In reference to the yield but not to the activity, Svendsen L. et al.143 and Schwarzkopf C.
et al.162 observed the same. They reported the highest recovery and activity of the total
and the specific IgY by the AS, followed by the PEG/EtOH and the PEG method.
Anti-H1 IgY isolation – separate unspecific from specific IgY
The specific anti-H1 IgY were extracted from total IgY by affinity to H1-Sepharose. One
drawback of this chromatographic method was, that the matrix-coupled H1-CRD and the
H1-CRD used for the hens immunization were identical. As a consequence, also traces
of irrelevant proteins may be linked to the support, which allow irrelevant IgY to bind
specifically, too.
The portion of specific IgY was four times higher in the PEG-derived total IgY than in the
AS-derived total IgY. This was expected, since the purity of the AS-derived total IgY was
lower. In mean, the resulting amounts of AS-derived and PEG-derived specific IgY were
similar (see Figure 161). However, AS-originated specific IgY still contained
contaminants.
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Figure 161: IgY yield/egg arranged by the method used for the total IgY extraction.
The extraction of the specific IgY by H1-Sepharose chromatography was efficient as the
activity recovery was high.
Nine procedures - lipid and IgY extraction in combination
The optimal extraction procedure should not only provide a good yield but more
importantly should supply pure IgY with the highest activity. For the isolation of the
specific anti-H1 IgY, the total yolk proteins may directly be applied to the H1-Sepharose
column without prior extraction of the total IgY.
All in all, procedure M8 is optimal for the extraction of the total IgY. Furthermore, a
procedure composed of the WD method, showing the highest recovered activity, and the
H1-CRD affinity chromatography may be superior to isolate the specific anti-H1 IgY. But
since the total IgY are often as suitable as pure specific IgY in immunological assays
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and since unspecific IgY can stabilize and protect the specific IgY from degradation,162
procedure M8 was selected for the preparative scale extraction to obtain the total IgY.
Preparative scale extraction of polyclonal anti-H1 IgY – from hundreds of eggs to grams
of pure total IgY
The scale-up of procedure M8 was accompanied by an increased yield of total IgY/egg.
Schwarzkopf et al.162 reported this positive scaling-up effect too and recommended the
processing of more than 10 eggs in once. Though the obtained yield of 45mg/egg total
IgY was still quite low, but the portion of specific IgY was rather good with 7%. Published
are yields of 50-100mg/egg total IgY, which contain 2-10% specific IgY.163
12g total IgY antibodies were achieved from 3 hens in about 120 days. In other words,
each hen provided about 1g/month IgY. This is only half the amount reported by Schade
R. et al.164 but still 5-fold the amount of serum IgG/month, obtained from one rabbit.
Polyclonal anti-H1 IgY features – application in vitro and on cell
The purified IgY antibodies were successfully applied in some but not in all
immunochemical methods.
In vitro the specific as well as the total IgY were suitable in immunoblotting of non-
reduced and reduced, denatured H1-CRD and native H1-CRD. Since they bound to
traces of H1-CRD oligomers, which were not visible on a silver-stained PAGE gel, it can
be supposed, that their avidity is high. Extra bands on the blot may originate from the
specific interaction between an irrelevant IgY and its antigen, which contaminated the
H1-CRD, or from binding of specific anti-H1 IgY to another protein that carried a related
epitope.65 Since on the blot only monomeric H1-CRD in reduced state and no other
proteins were detected, it was assumed, that higher molecular weight proteins are H1-
CRD oligomers or aggregates.
The total and the specific IgY also worked in AP-ELISA, but they have further to be
titrated to determine their EC50 and to proof their concentration-dependent binding.
On cell level, the TR-labeled specific IgY were internalized into HepG2 cells, but also
unspecifically into SK-Hep1 cells. Hence, the immunostaining of cells has further to be
refined to minimize the cross-reactivity.
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4.6 Monoclonal antibodies – the way from mice to anti-H1 Ig
4.6.1 Mice, fusion and hybridomas – from mortal to immortal anti-H1
“antibody factories”
The standard method for the production of monoclonal antibodies is still the hybridoma
technique, which was introduced by Köhler and Milstein82 30 years ago.
Only the specific antibody-producing cells are selected and thus, the antigen purity is not
of prime importance. The native and active antigen structure however is crucial to
maximize the portion of hybridomas, which provide antibodies that recognize a
conformational epitope at the protein surface. Unfortunately, it was not known, if the H1-
CRD changed the conformation, when emulsified with the adjuvant for immunizations.
Two strategies were followed to get the monoclonal anti-H1 antibody-producing
hybridomas. They differed in the immunization (mouse strain, antigen dose,
immunization schedule) and in the PEG fusion procedure.
Immunization – H1-CRD goes in vivo
In the first strategy, outbred NMRI mice were immunized and boosted with 20?g H1-
CRD in emulsion sc in the neck. Each mouse was three times finally boosted 3, 2 and 1
day prior to fusion with 20?g H1-CRD in solution, also sc in the neck. In contrast, in the
second strategy, inbred Balb/c mice were immunized and boosted with a 10-fold higher
amount of 200?g H1-CRD in emulsion ip. Each mouse was only once finally boosted 3
days prior to fusion with 200?g H1-CRD in solution but iv (see Figure 162).
Both strategies had in common, that CFA and IFA were used to improve the immune
response, and that mice were boosted every about 20 days.
Inbred mice and especially mice of the Balb/c strain are generally taken, whereas
outbred mice, e.g. mice of the NMRI strain are rarely used. Outbred strains however are
often advantageous when the immune response is low, due to the lack of a suitable
MHCII receptor or due to self-tolerance. But for some highly conserved antigens, the
immunization may fail in one mouse strain due to tolerance but can induce an immune
response in another strain.102 Therefore, testing both types of strains seemed promising.
The dose of H1-CRD, used for immunization, was in the middle range or very high, with
20?g or 200?g, respectively. Amounts of 5-50?g/injection are normally used.102 Both
routes, ip and sc, are recommended for immunization and boost injections.102 Only for
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the final boosting, iv or ip are favored, because after sc injection, the response is too
slow and low. But the H1-CRD antigen led already sc and ip to a good immune
stimulation, as the spleens were huge. The immune response to a final iv boost was
excessive and killed mice. Taking the high sequence similarity of the ASGPR-1 and the
MHL-1 into consideration, the death of mice was probably caused by an autoimmune
reaction or an anaphylactic shock.102
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bfm1
†m1
bfm2
†m2ts
i: 200?g H1-CRD/CFA ip.
b1-2: 200?g H1-CRD/IFA ip.
bf: 200?g H1-CRD iv. (ip.)
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i b1 b2 bf1-3
Fusion
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i: 20?g H1-CRD/CFA sc.
b1-2: 20?g H1-CRD/IFA sc.
bf: 20?g H1-CRD sc.
Figure 162: Immunization scheme of mice to produce monoclonal anti-H1 antibodies by the hybridoma
technology, showing the immunization (i) with H1-CRD / CFA emulsion, at least two boosts (b1 to b2) with
H1-CRD / IFA emulsion followed by the serum titer (ts) determination and three final boosts 1, 2 and 3 days
prior to fusion (bf1-3) or one final boost of mice 1-3 (bfm1 to bfm3) 1 day prior to fusion, with H1-CRD solution.
Two mice died after final boosting (†m1 and †m2) iv.
For further immunizations, a lower dose and the use of the NZB mouse strain could be
advantageous.  NZB mice tolerate the autoantibody production easier than others.102
PEG fusion – it is fusion time
In the first strategy, cells were fused using PEG1500, and the hybridomas were plated
on macrophages feeder-layer in IMDM-5. In the second strategy, the fusion was initiated
with PEG4000 and the hybridomas were cultured in RPMI-15, supplemented with ?-
mercaptoethanol and human IL-6.
Both strategies had in common, that splenocytes and Balb/c P3X63-Ag8.563 myeloma
cells were fused, and that hybridomas were selected with HAT. The growth-factor-
secreting macrophages or IL-6 were essential for hybridomas growth at this stage. The
use of IL-6 was preferred since no additional mice were needed to prepare
macrophages. Both strategies provided a high number of hybridomas.
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4.6.2 Hybridomas screening, expansion and fingerprint characterization –
sift the chaff from the wheat
During expansion, 88% (fusion A) and 0% (fusion B) of NMRI-derived hybridomas and
60% (fusion C) of Balb/c-derived hybridomas were lost (see Figure 163). They either
stopped the antibody production or the cell division. During propagation or mainly during
single-cell cloning 8% (fusion A) and 17% (fusion C) of the hybridomas were instable.
The screening ELISA was selective for hybridomas, which recognized an accessible
epitope at the surface of the active H1-CRD.
A B C
0
10
20
30
40
50
60 stop growth
stop Ab
positive (instable)
positive (stable)
fusion
Figure 163: Total number of hybridomas from fusions A, B and C, subdivided into stable and instable
positive, specific anti-H1 antibody-secreting hybridomas. Latter were subdivided according to the reason for
loss: hybridomas, which stopped to grow, which gave up the secretion of anti-H1 antibodies or which were
instable during propagation or single-cell cloning.
The anti-H1 antibodies of the different hybridomas were compared in various in vitro and
on cell assays to identify the most promising ones for further characterization. The
selected hybridomas should include one IgM and at least one IgG of each subclass. To
have the entire set of (sub)classes is advantageous for simultaneous indirect multi-
detection. The IgG are preferred due to their lower molecular weight and valency.
The hybridomas were favored those antibodies preferentially bound to native and not
denatured H1-CRD in immunoblotting. They may recognize a predominantly
conformational epitope also present at the ASGPR surface on cells, and probably even
may bind the binding site epitope. Also in respect of the desired blocking antibody,
calcium-sensitive binding in ELISA was guessed to be superior. Furthermore, a higher
affinity to the H1-CRD compared to the H2-CRD was preferred.
However, decisive was, that the antibodies recognized the ASGPR on HepG2 cells. Only
the corresponding hybridomas were selected, because the epitope accessibility in the
entire ASGPR is a prerequisite for potential therapeutic or diagnostic application.
Ten candidates passed the selection, i.e. the hybridomas A41, A47, B01, C09, C11,
C14, C17, C18, C23 and C48. A41 was excluded, because it was very instable.
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The antibodies of all selected hybridomas worked fine in immunoblotting. C11, B01, C18
and C23 were the most promising as they favored the binding to native compared to
reduced H1-CRD. Interestingly, all antibodies of the IgG1 isotype recognized the native
similar or better than the reduced H1-CRD, whereas all non-IgG1 showed a comparable
or stronger interaction with reduce than with native H1-CRD. All antibodies were
applicable in ELISA. Most interesting features were maintained for C11 and C48, in the
H1/H2 selectivity as well as in the calcium sensitivity ELISA. Their affinity to the H1-CRD
was higher than to the H2-CRD and was further increased in the presence of calcium.
A47, B01, C17 and C23 bound calcium-dependent stronger, too.
Seow et al.11 reported, that beside HepG2 also Jurkat cells express the ASGPR, but HL-
60 cells do not, and that human macrophages are known to express the ASGPR-
homologous macrophage lectin. Hence, the antibodies of selected hybridomas were
tested for the binding to HepG2, HL-60 and THP-1 cells and B01 additionally for the
interaction with Jurkat cells. Only C14 cross-reacted with HL-60 and THP-1 cells. In
contrast to Seow et al, B01 was not able to recognize Jurkat cells. This was probably
caused by receptor loss on Jurkat cells during cell passages, since carcinogenic cell are
instable in their characteristics.
A47 IgM C14 IgG2a C17 IgG2b
IB
ELISACa
ELISAH1/H2
FACSHepG2
C11 IgG1 B01 IgG1 C09 IgG1
IB
ELISACa
ELISAH1/H2
FACSHepG2
C18 IgG1 C23 IgG1 C48 IgG1
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ELISACa
ELISAH1/H2
FACSHepG2
Figure 164: Selected hybridomas and their features (bad , balanced  and good ) in the fingerprint
characterization. IB was regarded to be superior, when binding to the native H1-CRD was favored compared
to the reduced H1-CRD; ELISA was best, when the binding to H1-CRD was preferred to H2-CRD and when
the affinity to H1-CRD was stronger in the presence of calcium; FACS was valued to be good, when HepG2
were specifically stained and balanced when in addition other cells were recognized.
In the fingerprint ranking, most promising hybridomas were C11 and C48, decreasing to
B01, C23 and C18, then to C17, C09 and C14 and lastly to A47 (see Figure 164).
Prior to further investigations of the selected hybridomas, they were single-cell cloned, to
ensure their antibodies to be monoclonal.
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4.7 Monoclonal anti-H1 Ig – features in vitro, on cell and on
tissue
In the result part, each monoclonal antibody is described individually, whereas a cross-
comparison will follow in this chapter. This may permit to assess, which one is most
suitable for the application in different assays. Only one monoclonal antibody, the B01.4
will be discussed in detail in the following section. But, this will explain most features of
the other seven monoclonal antibodies too.
The H1-CRD used for the characterization was a mixture of mainly monomeric species
with a low fraction of two different dimeric species, if not clearer defined.
4.7.1 Antibody B01.4 – take a look at the monoclonal anti-H1 IgG1
Clone B01.4 was derived from hybridoma B01. The following section will give a closer
look to the features of the monoclonal B01.4 antibody.
The B01.4 antibody is a member of the IgG? class and IgG1? subclass, which is the
main antibody class of the second immune response in blood.
4.7.1.1 Purification
The yield of murine B01.4 IgG1, extracted by affinity to Protein G and Protein A was
identical. Due to the low affinity of IgG1, only a small fraction was extracted in once and
thus, multiple extractions of the supernatant were necessary. The low elution pH did not
harm the B01.4 IgG1. The antibody was still active in the HRP-ELISA. Because Protein
G chromatography is simpler (no increase of the ionic strength is necessary) and
supplies the same yield and activity, this method was favored.
4.7.1.2 Epitope mapping by immunoaffinity / MS
The characterization of the B01.4 epitope has had some pitfalls. These were not
surprising in reference to the SEC and immunoblotting (see Sections 3.7.1.3 and 4.3).
To test the binding specificity of the H1-CRD to B01.4, immobilized on Sepharose, native
and alkylated H1-CRD was also applied to blank Sepharose. The H1-CRD tended to
adhere to Sepharose, similar to the observation in SEC. Furthermore, the binding of
reduced-alkylated H1-CRD in the excision and slightly in the extraction turned out to be
tricky. In agreement with the immunoblotting results, the affinity of reduced-alkylated H1-
CRD was low. The observation, that the extraction of alkylated H1-CRD was less
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affected than the excision, is probably due to the separation of the sterically interfering
alkylation and the epitope residues onto different fragments (probably F2 and F3).
Fragments T151-R162 and S163-R169 were found in the extraction of the trypsine-digested
H1-CRD. Additionally, the corresponding double fragment T151-R169 was present in the
excision. This demonstrated nicely the shielding effect, which protected the paratope-
bound epitope against proteolysis. The independent binding of both fragments T151-R162
and S163-R169 also indicated, that the minimal epitope was either discontinuous, including
continuous sequences on each fragment, or continuous, overlapping both fragments.
To diminish the antigenic site, the B01.4-bound H1-CRD was also excised with
proteinase K. Many not identifiable fragments appeared in the wash and the elution.
They were supposed to origin from B01.4. Probably, the antibody was less resistant to
the proteinase K than to the trypsine digest. However, the two fragments V158-S163 and
C164-S168 were identified, which represented a partial sequence of the epitope fragments
obtained in the trypsine digest. To sum up, it can be suggested, that some residues of
the continuous minimal epitope V158EHERSCYWFS168 form the functional epitope and
mainly contribute to the binding affinity.
The minimal epitope is located on strands ?1 and ?2 of the H1-CRD and close to the N
and C-terminus. Therefore the epitope is situated opposite to the Gal binding site in the
molecule (see Figure 165). The calcium 3 is in close proximity to the epitope, but none of
the epitope residues is involved in the calcium coordination (V190, E196, E277).26
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Figure 165: Minimal epitope of the monoclonal B01.4 IgG1.
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Welling et al.80 suggested, that His, Lys, Ala, Leu, Asp and Arg are the most frequent
amino acids in epitopes. In the B01.4 epitope, only H and R are represented once.
The comparison with the antigenicity plots showed, that the partial B01.4 epitope
VEHER indeed lies in a high antigenic, accessible and hydrophilic region of the H1-CRD,
but that the partial epitope CYWFS is low antigenic and accessible due to the reduced
polarity and the high content of aromatic amino acids.
In human, epitopes that differ only in two amino acid residues from the B01.4 epitope are
present in the ASGPR-2, the macrophage lectin 2 and the CLEC10A protein of the
pancreas and spleen. Unwanted cross-reactivity with these receptors seems probable.
In addition, the ASGPR and the macrophage lectins of other mammals exhibit high
homologous epitopes and consequently, B01.4 might also be applicable for
investigations of the ASGPR in these species. Surprisingly, a variant-specific antigen of
Plasmodium falciparum, as well as a protein of Trypanosoma brucei is quite similar.
4.7.1.3 Immunoblotting
The B01.4 antibody was applicable in immunoblotting, and it stained specifically. B01.4
recognized a denaturation-resistant epitope since the blot of the native as well as of the
denatured H1-CRD showed a clear signal.
The dimeric H1-CRD was stronger detected than the monomeric H1-CRD. This let
assume, that both Fv of the B01.4 antibody can bind simultaneously to the two identical
epitopes of the dimeric H1-CRD species.
In the context of the epitope mapping results (see previous section), which indicated,
that the epitope fragment F2+3 included the Cys152, Cys153 and Cys164, the native and
the reduced H1-CRD were alkylated (see Figure 166).
The alkylation of the free or ?-mercaptoethanol-paired Cys residue of the monomeric
H1-CRD (see Section 4.2.1) did not alter the binding of B01.4. This was not surprising,
since the dimerization of the H1-CRD via this Cys did not hinder the binding too. Also
dimeric H1-CRD was recognized by B01.4, and the H1-CRD is really a much bulkier
“group” than the acetamide group. However, the alkylation of at least one Cys, which is
natively paired in a disulfide bridge, prevented the binding of B01.4. The four Cys, which
are involved in the disulfide bridges C181-C276 and C236-C268, lie outside of the epitope
region and are supposed not to contribute to this effect. The remaining two Cys form part
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of the epitope. Two hypotheses seemed possible, depending on the position of the third
S-S bond (see Figure 166, A and B) that is not yet defined in X-ray.
152 153 164 181 254 268 276
ME
A
ME
152 153 164 181 254 268 276
B
B01.4 epitope
B01.4 epitope
No signal
152 153 164 181 254 268 276
152 153 164 181 254 268 276
AAAAAA  AA AA AA AA
152 153 164 181 254 268 276
AA
1
2
3
ME
152 153 164 181 254 268 276
152 153
164
181 254 268 276
AA
152 153 164 181 254 268 276
152 153
164
181 254 268 276
4
5
ME
152 153 164 181 254 268 276
152 153
164
181 254 268 276
152 153 164 181 254 268 276
152 153
164
181 254 268 276
AA
6
7
H1-CRD monomer H1-CRD dimer 
N
a
ti
v
e
R
e
d
u
c
e
d
d
e
n
a
tu
re
d
N
o
n
-r
e
d
u
c
e
d
d
e
n
a
tu
re
d
Figure 166: Immunoblotting with B01.4. A: Proposed disulfide linkage according to MS (see Section
3.2.2.4). B: Suggested disulfide linkage by Meier et al.
26
Blotting of reduced denatured H1-CRD without
alkylation (1), reduced-alkylated (2) or native-alkylated (3) with acetamide (AA); Blotting of non-reduced
denatured H1-CRD without alkylation (4) or native-alkylated (5); Blotting of native H1-CRD without alkylation
(6) or native-alkylated (7). Numbers designate the Cys position in the H1-CRD amino acid sequence; ?-
mercaptoethanol (ME).
The hypothesis A bases on the MS result (see Section 4.2.1) that determined a disulfide
bridge between the vicinal Cys152 and Cys153 (although reshuffling of disulfide bridges
under experimental conditions was not excluded). In this case, the alkylation of Cys152/153
adjacent to the minimal epitope might sterically hinder the binding of B01.4. However,
this would also mean, that the C164 in the determined minimal epitope is the free Cys,
which did not alter the binding, when alkylated. This seems astonishing, as at least steric
hindrance of the antibody-antigen interaction would be expected.
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The hypothesis B is based on the assumption of Meier et al.26 that one of the vicinal
Cys152/153 is paired with Cys164. In that case, the C164 alkylation may cause the failure of
the binding, whereas the alkylation of the two adjacent Cys has no effect or hinders
sterically. Hence, it could be speculated, that the Cys164 is part of the functional epitope.
In summary, B01.4 recognized a denaturation-resistant, probably discontinuous epitope.
The binding of B01.4 to the structural epitope is independent of the Cys, which is
involved in the H1-CRD dimerization but might be dependent on the accessibility of the
two other Cys, in or adjacent to the minimal epitope.
4.7.1.4 Immunoassay
The monoclonal B01.4 was first titrated in an antibody-capturing ELISA to estimate the
EC50. As the H1-CRD contains integral calcium ions, which are important for the ligand
recognition and the structural maintenance, the calcium sensitivity of the B01.4 binding
was investigated. Finally in a competitive assay, the influence of B01.4 onto the binding
of a polymer, exposing GalNAc residues, was tested to identify blocking ability.
Estimation of B01.4 avidity, EC50
The monoclonal B01.4 IgG was titrated in an antibody-capturing HRP-ELISA in the
presence of 20mM calcium to enforce the calcium-dependent native conformation of the
H1-CRD. With an EC50 of about 3·10
-10M, the avidity was subnanomolar and in the
middle range of the expected affinities for IgG antibodies of 10-7 to 10-12M.65
The titration allowed a rough estimation of the avidity. The exact affinity is most accurate
determined by Biacore assay (see Section 4.7.1.5).
Calcium sensitivity of B01.4 binding
The binding of B01.4 in the presence of a high and a low calcium concentration was
compared to the binding in the absence of calcium. To minimize avidity effects due to a
high local concentration of the H1-CRD, the plate was coated at a lower concentration.
Hence the assay reached the detection limit and therefore, small absorbance variations
resulted in high proportional binding differences.
The interaction between B01.4 and the H1-CRD was slightly calcium-sensitive. Calcium
enforced the binding but independent of its level. Probably, a calcium-induced
conformational change of the H1-CRD might cause a distinct exposure of the B01.4
epitope and lead to a decreased maximal binding. However, the calcium might directly
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be involved into the binding of the antibody too, or differences in the ionic strength during
capturing might influence the affinity.
In contrast, when the local concentration of the H1-CRD increased, it seemed, that
independent of calcium, the same maximal binding occur, but that the affinity might be
slightly lower without calcium. It may be speculated, that in the absence of calcium, the
affinity of B01.4 to its epitope is lower, but that due to avidity effects, i.e. concerted
reaction, the B01.4 avidity increase. This effect may overlap with and conceal the
calcium dependence.
Competition of GalNAc and B01.4 IgG1 for binding to H1-CRD
The B01.4 IgG1 clearly interfered concentration-dependent with the GalNAc binding to
the H1-CRD. An irrelevant IgG1 exhibited an approximately five times higher IC50.
Unfortunately, the blocking effect cannot only be caused by real competition for binding
to the Gal binding site. B01.4 may induce and stabilize an H1-CRD conformation, which
abolishes the binding of GalNAc. This seemed probable, since the putative epitope lies
opposite to the Gal binding site. Nevertheless, steric hindrance of the GalNAc interaction
may occur too, since the molecular weight of the H1-CRD is approximately a tenth of the
weight of B01.4 and much below the weight of the GalNAc-polymer.
In summary, B01.4 worked excellent in immunoassays, with an EC50 in the
subnanomolar range. At a low H1-CRD or antibody concentration, the binding of B01.4
seemed to be slightly calcium-dependent. It hindered the binding of the GalNAc-polymer,
most probably not by competition but by steric or conformational interference.
4.7.1.5 Affinity and kinetics of the B01.4 IgG1 by Biacore
The first screen to investigate the calcium sensitivity, intensity and stability of the binding
and the differences in the binding to monomeric and dimeric H1-CRD was performed at
a constant B01.4 concentration. The following fine-resolution screen for the
determination of binding kinetics used various B01.4 concentrations.140
The B01.4 binding to the monomeric, but especially to the dimeric H1-CRD surface was
slightly calcium-sensitive. In the presence of calcium particularly the stability was
increased. Calcium and EDTA however did not affect the binding strength. Only the
B01.4 interaction with dimeric H1-CRD was increased in the presence of EDTA. The
loss of structure-maintaining calcium ions probably facilitated conformational changes,
necessary for the concerted binding of one B01.4 molecule to both epitopes on the H1-
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CRD dimer. In respect to the epitope mapping (see Section 4.7.1.2) it can be
speculated, that B01.4 is sensitive for the calcium in site 3.
The B01.4 affinity to the monomeric and dimeric H1-CRD was similar and in the
subnanomolar range. A closer look however revealed huge differences in their kinetics.
The on and off-rates of the dimer are approximately half the values of the monomer and
hence, the dimer binding is much slower but tighter. The reduced epitope accessibility
may cause a lower association rate, while a higher local epitope concentration may
enhance rebinding and concerted binding, and therefore reduce the dissociation rate.
In contrast to the GalNAc-polymer assay, B01.4 IgG1 did not hinder the galactose
binding to the Gal binding site of the monomeric and dimeric H1-CRD (see Sections
4.7.1.4, 4.7.2.4. and 4.7.2.5 too). The discrepancy is supposed to originate from the
different approaches of both assays. The Biacore assay determines real competition of
galactose and B01.4 for the interaction with the Gal binding site. In contrast, the GalNAc-
polymer assay mainly detects steric hindrance of the GalNAc-polymer binding.
In summary, B01.4 binds slightly calcium-sensitive to the H1-CRD with an affinity KD of
approximately 0.3nM. The rate constants of the interaction between B01.4 and the H1-
CRD monomer are about double compared to the binding to the H1-CRD dimer, but this
compensate in the calculated KD. Finally, B01.4 did not interfere with the galactose
binding.
4.7.1.6 Immunostaining of cells and tissue
The monoclonal B01.4 was tested in the immunostaining of various hepatic and
extrahepatic cells and of non-pathological liver tissue.
Interaction of B01.4 with the ASGPR on cells
The B01.4 antibody bound to HepG2 hepatoma cells, which express the ASGPR. In
contrast, SK-Hep1 hepatoma cells, which do not carry the ASGPR were not recognized.
Hence, the B01.4 IgG1 epitope is also accessible in the entire ASGPR. Since human
macrophages and immature dendritic cells expose the homologous macrophage and
dendritic cell ASGPR respectively, these primary cells and the continuous THP-1 cell
were investigated by flow cytometry. B01.4 however did not cross-react with any
epitopes on these cells, and thus specifically recognizes the hepatic ASGPR.
The examination by immunofluorescence microscopy showed bright fluorescent cellular
vesicles. This demonstrates, that B01.4 not only bound to the receptor but also initiated
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internalization into living HepG2. Because SK-Hep1 did not invaginate B01.4, the
endocytosis is regarded to be ASGPR-specific.
Interaction of B01.4 with the ASGPR in tissue
B01.4 was further applied in the immunostaining of paraffin-embedded non-pathological
liver tissue sections. Although they successfully stained paraformaldehyde-fixed cells,
they failed in tissue staining. Hence, the B01.4 epitope is either altered or not yet
accessible after antigen retrieval, although various methods were tested.
Nevertheless, B01.4 might probably work in the staining of cryopreserved liver tissue
sections or of pathological liver tissue. Autoimmune hepatitis tissue might differ in the
expression of the ASGPR, because in some types of autoimmune hepatitis anti-ASGPR
antibodies are detected in blood.
In conclusion, B01.4 bound not only to the purified H1-CRD but also and specifically to
the entire hepatic ASGPR on fixed and not fixed HepG2 cells. The binding to living
HepG2 cells initiated endocytosis. The antibody worked excellent in the fluorophor-
staining of HepG2 cells but failed in the chromophor-staining of non-pathological liver
tissue.
4.7.2 Comparison of the monoclonal anti-H1 Ig – which one is “the best”
4.7.2.1 Extraction of different isotypes of antibodies from culture supernatant
Analogous to polyclonal antibodies, monoclonal antibodies are purified by precipitation
or extraction methods, mainly by Protein A or Protein G affinity chromatography. In
general, chromatography yields higher amounts of purer antibodies in a shorter time.
Since Protein A and G binds strong to murine IgG2a, but only fair to IgG1 and not to
IgM, also the chromatographic extraction using Protein L and H1-CRD were tested. The
interaction with Protein L is independent of the heavy chain isotype and though, IgM can
be purified; but the light chain must be ?. The advantage of the extraction by affinity to
Protein L and H1-CRD versus Protein A and G is, that they exhibit lower affinity to
bovine Ig. Hence, the hybridoma clone propagation in medium, containing a suboptimal
low concentration of expensive FCS (low IgG) can be circumvented. This was crucial for
clones C23.8 and C48.9, which grew and secreted antibodies only in dense cell cultures
and in the presence of growth-stimulating IL-6 or of a high FCS concentration.
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The murine IgG1 better bind to Protein G than to Protein A, especially at a low ionic
strength. But as a consequence, IgG1 bound to Protein G often elute at a lower pH than
IgG bound to Protein A. The acidic condition may cause antibody aggregation or
inactivation.102 The comparison of both methods showed however, that the extraction by
Protein G was less troublesome and restored the activity of all anti-H1 IgG1 antibodies.
The antibody yields varied significantly in the range of 1 - 24mg/L culture (see Figure
167). This can be explained by variation of the cell numbers and periods until harvesting.
Both depends on the sensitivity of the clones towards suboptimal grow conditions (low
FCS concentration, low pH of the medium).
A47.3 B01.4 C09.1 C11.1 C14.6 C18.1 C23.8 C48.9
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Figure 167: Monoclonal antibody yields of the eight clones from 1L cultures.
The obtained yields of anti-H1 Ig were rather low, since batch cultures generally provide
20-50mg/L antibodies.102
4.7.2.2 Epitope mapping by immunoaffinity / MS
Epitope mapping by excision and extraction in combination with MS is a promising
technique. In contrast to most other methods, excision enables not only the identification
of continuous but also of discontinuous epitopes.
The immunoaffinity / MS technique however, turned out troublesome for the
characterization of the antibodies C11.1 and C18.1. One possible reason is, that in the
epitope excision the shielding effect was weak and therefore, the epitopes were cut to
several fragments, which separately exhibited a too low affinity. A second reason may
be, that the Cys alkylation prevented the binding (see also immunoblotting, following
section). Additionally, it cannot be excluded, that the paratopes were degraded in the
excision, although antibodies are generally resistant to proteolysis. The epitope
extractions probably failed, because their epitope are conformational or were
proteolytically cleaved in the trypsine digest.
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Nevertheless, in the extraction of trypsine-digested alkylated H1-CRD with C11.1, three
fragments could be identified. The fragment T151CCPVNWVEHER162 is located on strand
?1 and ?2, fragment F199VQHHIGPVNTWMGLHDQNGPWK221 on helix ?2, strand ?3
and on loop1. The fragment N234WRPEQPDDWYGHGLGGGEDCAHFTDDGR262
includes the binding site. The extraction of the trypsine-digested alkylated H1-CRD,
followed by excision of the bound fragments with pronase K allowed to diminish the
epitope fragment N234-R262 to a minimal epitope of W235RPEQPD241. Since R236PEQPD241
is part of the binding site, Q239 and D241 coordinate the essential calcium in site 2 and
interact also with GalNAc, the C11.1 is a highly promising candidate an antibody,
blocking the Gal binding site (see Figure 168).
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Figure 168: Distinct immunogenic epitopes on the surface of the H1-CRD, recognized by B01.4 and by
C11.1 antibodies.
To sum up, it can be suggested, that W235-D241 mainly forms the C11.1 epitope, but that
residues T151-R162 and F199-W221 contribute to the binding too. This indicates, that the
epitope is predominantly discontinuous and conformational, which is in agreement with
the result of the immunoblotting (see Section 4.7.2.3). The putative epitope of C11.1 and
the blocking ability however have to be demonstrated in further experiments.
First characterizations of the C18.1 epitope indicated the epitope to be located C-
terminal in the area of R273-L290. In addition, first data of the C14.6 mapping showed, that
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its epitope is probably located in the areas of T151-R162 and F199-K221 (results not shown).
However, both have further to be investigated.
In conclusion, only the B01.4 epitope has been proven yet. The epitopes of C11.1,
C14.6 and C18.1 were also investigated, but for these the epitope can only be assumed.
It seems likely, that more than one epitope at the surface of the H1-CRD is
immunogenic, and that these antibodies might be directed against distinct epitopes.
Particularly C11.1 is promising, since its epitope may overlap with the Gal binding site.
4.7.2.3 Immunoblotting
On the one hand, immunoblotting permits to characterize a monoclonal antibody, but on
the other hand also to explore the features of the antigen.
Applicability and sensitivity of anti-H1 Ig
The parallel investigation of the distinct monoclonal anti-H1 Ig makes it not only possible
to see if they are applicable in immunoblotting and if they bind to a denaturation-resistant
or denaturation-sensitive epitope but also to compare their sensitivities.
All monoclonal antibodies were very sensitive except A47.3, which needed a 10-fold
higher antibody concentration (m/w). This may be the consequence of the distinct
isotype, i.e. class IgM versus IgG, the isotype of all others. The sensitivity and therefore
the avidity on the immunoblot was highest for C09.1, C18.1 and C14.6 followed by
B01.4, C23.8 and C48.9 and lowest for C11.1 antibodies.
Characterization of anti-H1 Ig epitopes
Most of them, C09.1, C18.1, C23.8 and C48.9 recognized the denatured as well as the
native H1-CRD, while C11.1 preferentially bound to the native H1-CRD. C14.6 and
A47.3 almost uniquely interacted with the denatured H1-CRD. This let suggest, that the
epitope of C11.1 is predominantly discontinuous and the epitope of C14.6 mainly
continuous, but partially buried in the undenatured conformation. All other investigated
antibodies may recognize more continuous epitopes, which are situated at the surface of
the H1-CRD too.
Based on the findings for B01.4, all monoclonal antibodies were tested simultaneously
for binding to H1-CRD modifications, which differed in the Cys alkylation pattern (see
Figure 169). This could indicate if the monoclonal antibodies recognize B01.4-related
epitopes. The antibodies C09.1, C18.1, C23.8 and C48.9 exhibited the same
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immunostaining pattern as B01.4. Hence, they probably interact with an identical or
overlapping structural epitope (see Section 4.7.1.3). The C11.1 binding pattern seemed
similar to B01.4 too, but bands of reduced H1-CRD were hardly detected. In contrast to
all other monoclonal anti-H1 IgG, the binding of C14.6 to alkylated and not alkylated H1-
CRD was completely indifferent. Hence, it can be assumed, that its epitope contains no
Cys.
In conclusion, antibodies B01.4, C09.1, C18.1, C23.8 and C48.9 worked excellent in
immunoblotting, and they may recognize the same or overlapping structural epitopes.
This epitope either includes one Cys or is adjacent to a Cys, which sterically hinder the
binding, when alkylated. The C14.6 antibody however, tends to cross-reaction with
irrelevant proteins, and it recognizes a distinct structural epitope, containing no Cys that
must be accessible. The immunoblotting with A47.3 antibodies is less sensitive and
therefore, is not recommendable.
4.7.2.4 Immunoassay
Two distinct antibody-capturing HRP-immunoassays were performed, a non-competitive
and a competitive assay. In the non-competitive ELISA, the anti-H1 antibodies were
titrated to estimate their EC50. Since the H1-CRD includes three integral calcium ions,
which are essential for structure and more importantly for Gal binding, the calcium
sensitivity of the antibody binding was investigated. In the competitive GalNAc-polymer
assay, the interference of the GalNAc and the antibodies for binding to the H1-CRD was
tested.
Applicability of monoclonal anti-H1 antibodies in ELISA
The titration of the monoclonal anti-H1 antibodies in the antibody-capturing HRP-ELISA
was performed in the presence of 20mM calcium to stabilize the H1-CRD in its native
calcium-dependent conformation. Nevertheless, it cannot be excluded, that due to the
immobilization on the plastic surface, the H1-CRD changed conformation.165
The titration permitted to rank the distinct anti-H1 Ig according to their affinities, but was
not accurate to determine KD values. Antibody affinities with lower koff rates would be
overestimated, as the outcome of an immunoassays mainly depends on the stability of
the antibody-antigen complex, to survive long incubation times and stringent washing.
So, KD and binding kinetics were best determined by Biacore assays (see Section
4.7.2.5).
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All IgG1 antibodies, C11.1, B01.4, C23.8, C18.1 and C09.1 have similar and C48.9 only
a slightly higher, still subnanomolar EC50. In contrast, the EC50 of C14.6 IgG2a and
A47.3 IgM are approximately ten times higher (see Figure 170). The lower avidity of
C14.6 and A47.3 compared to the others agreed with the findings in immunoblotting.
These two preferred the binding to the denatured H1-CRD compared to the native H1-
CRD (see Section 4.7.2.5). In addition, IgM are often of lower affinity, as they are the
main antibodies of the first immune response, which lack the affinity maturation.
Calcium sensitivity of anti-H1 Ig binding
As already mentioned, calcium-dependent binding of the anti-H1 Ig may be initiated by
mimicking the binding mode of Gal and GalNAc, but more probably by calcium-induced
changes of the epitope conformation or by direct coordination with calcium.
On the basis of their calcium-dependence, the anti-H1 Ig could be grouped in three
sensitivity types (see Figure 169). The first type included only C14.6 that bound calcium-
independent. The second type is formed by B01.4, C09.1, C23.8 and C48.9. Their
binding was dependent on the presence of calcium, but was not sensitive to the calcium
level. Particularly the C23.8 and C48.9 interaction was nearly abolished in the absence
of calcium. Finally, C11.1 referred to the third type. Its binding was sensitive to the
calcium level. These observations let assume once more, that the C14.6 epitope is
linear, whereas the others more probably recognize a mainly conformational epitope.
type 1 type 3type 2a
Figure 169: Types of calcium sensitivity
For all antibodies, the calcium effect was only detected at a low local H1-CRD
concentration, as discussed for B01.4 (see Section 4.7.1. 4).
In conclusion, all anti-H1 IgG1 worked excellent in ELISA and had a subnanomolar EC50.
Only the binding of C14.6 IgG2a and A47.3 IgM antibodies was fair.
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Epitope characterization by GalNAc-polymer and anti-H1 Ig competition
As discussed for B01.4 (see Section 4.7.1.4), anti-H1 Ig may not only interfere with the
GalNAc binding by real blocking, due to the recognition of the binding site epitope, but
also by other mechanisms. First, anti-H1 Ig can interact with a binding site-overlapping
or an adjacent epitope and sterically hinder the GalNAc binding. This is very likely, since
the molecular weight of the GalNAc-complex and the antibody is more than ten times the
weight of the H1-CRD monomer. Second, the anti-H1 Ig binding may induce another H1-
CRD conformation, which prevents the GalNAc interaction. Hence, the GalNAc-polymer
assay allows only the antibody ranking either according to the inhibition concentrations
(IC50) or to the inhibition factors (IC50/EC50). Whereas the IC50 also depends on the
antibody affinity, the inhibition factor only reflects the interference and therefore, may tell
about the epitope localization relative to the Gal binding site.
All anti-H1 IgG but not A47.3 IgM hindered the GalNAc-polymer binding in a
concentration-dependent manner. The anti-H1 IgG, except C11.1 have similar IC50 and
inhibition factors (see Figure 170). Since the IC50 and particularly the inhibition factor of
C11.1 are higher, the interference mechanism and probably the location of the C11.1
epitope may be distinct from the other antibodies.
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Figure 170: Ranking of the anti-H1 Ig according to the EC50 in the non-competitive assay, the IC50 in the
competitive GalNAc-polymer assay with the corresponding inhibition factor and the relative inhibition I% in
Biacore assay. The inhibition factor compares EC50 and IC50, determined on plates with the same H1-CRD
coating concentration and in TBS or HAB buffer with 1mM calcium. The relative inhibition I% describes
difference of the second Gal injection signal in % of the first Gal injection signal.
Taking the immunoblot findings and the putative epitope of C11.1 and B01.4 into
account, a hypothesis can be suggested.
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The anti-H1 antibodies B01.4, C09.1, C18.1, C23.8, C48.9 showed a similar binding
pattern in immunoblotting and a similar interference with the GalNAc binding. Hence,
they may bind to epitopes in the area of the B01.4 epitope, opposite to the Gal binding
site. Nevertheless, the GalNAc interaction may sterically be hindered or simultaneously,
the antibody binding may stabilize an inactive H1-CRD conformation.
C11.1 may recognize another epitope, hopefully the proposed epitope, which overlaps
with the Gal binding site and the calcium site 2. The steric hindrance was probably
diminished by stabilization of the active binding site conformation, which enforced the
GalNAc binding. However, since the epitope is not proven yet, C11.1 may also bind to
another epitope, which simply did not interfere with the GalNAc binding.
The hypothesis is supported by Irimura et al.166 They reported, that the homologous
mouse macrophage C-type lectin changes calcium-dependently the conformation, and
that a monoclonal antibody directed against this lectin, binds calcium-dependently to its
epitope. The epitope was separated from the carbohydrate binding site, but the antibody
binding stabilized the carbohydrate binding activity by a conformational lock of the CRD.
Unlike to the GalNAc-polymer assay, the anti-H1 Ig binding did not interfere with the
galactose binding in the Biacore assay. This discrepancy may be caused by the use of
distinct interfering sugars in type (Gal versus GalNAc) and in size (monosaccharide
versus polymer). Hence, kinetics and steric hindrance of the sugar binding can vary.
Though, since the putative physiological ASGPR ligands are glycoproteins and
glycolipids of larger molecular weight, the antibodies may prevent the binding on cell too.
In summary, all anti-H1 IgG block the binding of GalNAc in a concentration-dependent
manner. All except C11.1 exhibit similar IC50. The interference is probable not due to real
competition for binding to the Gal binding site. To enhance the assay reliability, the anti-
H1 Ig and an irrelevant antibody of the same isotype should be examined in parallel on
the same plate. This comparison would allow to distinguish accurately between specific
and unspecific interference and to rank the distinct anti-H1 Ig properly.
4.7.2.5 Affinity and kinetics of anti-H1 IgG1 by Biacore
Biacore permits to determine the affinities KD and also the binding kinetics, i.e. the
association constants kon and the dissociation constants koff. All monoclonal anti-H1 IgG1
antibodies were screened for binding to the monomeric and dimeric H1-CRD, comparing
both, and were ranked according to their binding intensity, binding stability, blocking
properties and calcium sensitivity of the binding.
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Ranking screen of monoclonal anti-H1 IgG1
In contrast to the competitive GalNAc-polymer assay (see Section 4.7.2.4), all antibodies
evinced a non-blocking behavior, slightly varied in their binding to the monomeric and
dimeric H1-CRD species and bound very stable. The high binding stability was expected
as the screening to select anti-H1 Ig-producing hybridomas is based on ELISA that
favors antibodies, which bind stable.
The binding kinetics of the monomeric H1-CRD fluctuated stronger than the kinetics of
the dimeric H1-CRD in the presence of EDTA. This might be explained by the lack of the
two calcium ions in site 1 and 3, which are involved in the structural maintenance. Thus,
conformational changes are more likely. These influence the accessibility of the epitopes
in the monomeric and dimeric H1-CRD and the antibody binding behavior.
Compared to the monomeric H1-CRD, the dimeric H1-CRD exhibited identical or higher
binding stabilities and intensities to the anti-H1 Ig, independent of calcium and EDTA.
The sole exception was C11.1 that bound with decreased intensity to dimeric H1-CRD in
the presence of calcium. The higher stability is supposed to be the consequence of
avidity effects. The bivalent IgG may bind to both identical epitopes of dimeric H1-CRD.
The variation of the binding intensities may result from differences in the epitope
accessibilities. In the presence of EDTA, the H1-CRD conformation is probably less
stringent controlled and that may facilitate the binding of one IgG antibody to both
epitopes of the dimer by induced fit. The restricted interaction of C11.1 with the dimeric
H1-CRD is possibly due to the partial epitope concealment in the dimer (see Figure
171).
Figure 171: Plot of the monoclonal anti-H1 IgG1 ranking in Biacore assay, in the presence of 50mM calcium
or 3mM EDTA. The binding of antibodies to the monomeric (red) and dimeric (blue) H1-CRD was compared.
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Calcium and EDTA particularly influenced the binding intensity. Nevertheless, the
ranking of the anti-H1 IgG1 remained the same. The strongest binding was observed
with B01.4, followed by C11.1 and C18.1 and finally by C09.1, C48.9 and C23.8. The
highest stability however was detected for C11.1 and C09.1, lowered to C18.1 and down
to B01.4. In contrast to these three antibodies, the stability of the H1-CRD interaction
with C23.8 and C48.9 varied calcium-dependently, in agreement with the findings in
ELISA (see Section 4.7.2.4).
High-resolution screen of selected anti-H1 IgG1
Since for most applications IgG antibodies with a fast and tight binding profile are
preferred, the three antibodies B01.4, C11.1 and 18.1 were selected for further
screening of their binding kinetics to the monomeric and dimeric H1-CRD surfaces.
All bound in a concentration-dependent manner and exhibited a very slow dissociation.
While the KD differences of the monomeric and dimeric H1-CRD were rather low in the
case of B01.4, the affinity of C18.1 to the dimer was almost double. All showed the
tendency of a slower but tighter binding to the dimeric (lower kon and koff) than to the
monomeric H1-CRD (see Figure 172).
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Figure 172: Binding kinetics of the anti-H1 IgG1 B01.4, C11.1 and C18.1.
In conclusion, none of the anti-H1 IgG1 clearly hindered the interaction between
galactose and the Gal binding site. Most exhibited a slight calcium-dependent binding.
The binding to dimeric H1-CRD was tighter and more stable in the presence of EDTA.
The high resolution screening of the tightest binders B01.4, C11.1 and C18.1 showed,
that mainly an extreme slow dissociation caused high affinities. This high stability is an
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important advantage for the application in most immunomethods, since after antibody
capturing bleeding effects may be minimal. The highest affinity was obtained for C11.1.
4.7.2.6 Immunofluorescence staining of cells and tissue
The monoclonal anti-H1 Ig antibodies were further investigated on cell level by indirect
and direct immunofluorescence flow cytometry and microscopy of fixed and not fixed
cells. In addition, the anti-H1 IgG binding to non-pathological paraffin-embedded liver
tissue sections was examined.
Anti-H1 Ig binding to the entire ASGPR and cross-reaction with homologous receptors
Several human hepatoma cell lines like the HepG2, HUH-7 and PRF/5 cells are known
to express the ASGPR whereas the receptor is not present on SK-Hep1 and Chang
hepatoma cells. HepG2 and SK-Hep1 (see Appendix 5, page 282) cells were
extracellularly stained with anti-H1 Ig to confirm, that their epitope is also accessible in
the entire ASGPR, and that the recognition is ASGPR-specific. Since macrophages and
immature dendritic cells express the ASGPR-homologous macrophage lectin and the
dendritic cell ASGPR respectively, continuous THP-1 cells, primary macrophages and
dendritic cells were examined to assess specific cross-reactions. Monocytes were
isolated from human blood and their differentiation to dendritic cells was induced with IL-
2.
All anti-H1 IgG bound to the ASGPR on not fixed HepG2 except A47.3 IgM. The
brightest staining was obtained with C09.1, C18.1 and B01.4, followed by C11.1, C48.9
and C14.6 and finally by C23.8, ranked on the basis of the median. Since C23.8 showed
to initiate endocytosis very efficiently (see below), internalization may cause the weak
staining. In contrast to the anti-H1 Ig the commercial monoclonal anti-ASGPR antibody
(Calbiochem) failed in the staining of HepG2 cells.
The other cells, SK-Hep1, THP-1, monocytes and dendritic cells did not cross-react with
the anti-H1 Ig, except C14.6. The C14.6 antibodies recognized also an epitope on
dendritic cells. In contrast to the originating hybridoma C14 however, they did not
interact with THP-1 cells.
Binding and internalization of anti-H1 Ig via the ASGPR
The ability of the different anti-H1 Ig to initiate internalization into living HepG2 cells upon
ASGPR binding was examined by fluorescence microscopy. SK-Hep1 cells were stained
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in parallel to distinguish unspecific invagination and specific endocytosis of antibody-
ASGPR complexes into endosomes.
The anti-H1 C23.8 and C11.1 were extensively and B01.4 and C18.1 highly internalized
into HepG2 cells. All showed the same pattern of big bright spots. Compared to these,
C09.1 and C14.6 were only poorly endocytosed and exhibited another staining pattern
with more but smaller dots. It might be speculated, that they differed in the patch
formation at the cell surface, the internalization rate or even in the endocytosis pathway.
Hence, the antibodies C09.1 and C14.6 probably only bound to the ASGPR but did not
induce endocytosis and therefore may only be constitutively internalized with the
ASGPR. A47.3 IgM and the commercial anti-ASGPR antibody bound but were not
internalized into HepG2. Since none of the anti-H1 antibodies interacted with or were
taken up into SK-Hep1, the endocytosis into HepG2 seemed to occur via the ASGPR.
However, only the immunostaining of ASGPR-transfected (e.g. SK-Hep1) cells would
proof the specificity.
In summary, the different anti-H1 IgG worked fine in the immunostaining of cells. Only
A47.3 IgM failed. All anti-H1 IgG are able to recognize their epitope in the entire ASGPR
and specifically on HepG2. They do not cross-react with SK-Hep1, THP-1, monocytes or
dendritic cells, except C14.6. Finally, all are internalized into HepG2 but to different
extent.
Staining of non-pathological liver tissue
Non-pathological paraffin-embedded liver tissue was stained with the anti-H1 antibodies
to test their applicability in immunohistochemistry.
All anti-H1 Ig failed except C14.6. The fixation and embedding procedure seemed to
mask or alter their epitopes. This is not surprising, since C14.6 was found to recognize a
denaturation-resistant more continuous epitope, whereas all other anti-H1 Ig are
supposed to bind a more conformational epitope. However, they would probably work on
cryo-conserved, not paraffin-embedded tissue. Furthermore they might stain
pathological tissue. As in autoimmune hepatitis patients, anti-ASGPR antibodies can be
found in blood, the ASGPR expression on hepatocytes may differ in pathological tissue.
C14.6 specifically stained the sinusoidal, basolateral surface of hepatocytes, which
express the ASGPR.
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4.8 Conclusion
Although the similarity of the ASGPR-1 and MHL-1 CRD is high, hybridoma clones were
obtained and monoclonal anti-H1 antibodies were produced successfully in mice.
The characterization enables to rank the antibodies, on the one hand according to their
applicability in different immunochemical methods (see Figure 173) and on the other
hand according to their potential value in diagnostic or therapeutic applications.
A47.3 IgM? B01.4 IgG1? C09.1 IgG1? C11.1 IgG1?
IBred
IBnonred
IBnative
ELISAEC50 6 1 3 1
ELISAcalcium 3 4 1
GalNAc PAIC50 2 3 4
IFCHepG2 1 1 2
IFMHepG2 1 2 1
IHCliver *
Fair Good Excellent
C14.6 IgG2a? C18.1 IgG1? C23.8 IgG1? C48.9 IgG1?
IBred †
IBnonred †
IBnative
ELISAEC50 5 2 2 4
ELISAcalcium 4 3 2 2
GalNAc PAIC50 2 2 1 1
IFCHepG2 †2 1 2 2
IFMHepG2 3 2 1 2
IHCliver 1 * *
*: not tested †: cross reaction with other cells
Figure 173: Applicability and ranking of the monoclonal anti-H1 antibodies. Binding to the H1-CRD in the
reducing, non-reducing and native immunoblotting (IBred, IBnonred and IBnative), in the ELISA according to the
calcium-dependence (ELISAcalcium) and the EC50 in the presence of calcium (ELISAEC50) and in the GalNAc-
polymer assay (GalNAC PAIC50). Binding to the ASGPR on HepG2 cells in the immunofluorescence flow
cytometry (IFCHepG2) and in the immunofluorescence microscopy (IFMHepG2) and on non-pathological liver
tissue in the immunohistochemistry (IHCliver). Numbers indicate the ranking of the monoclonal antibodies.
All selected monoclonal IgG antibodies B01.4, C09.1, C11.1, C14.6, C18.1, C23.8 and
C48.9 worked fine in the tested immunochemical methods, but not the A47.3 IgM. This
IgM may be inactivated during purification, when eluted at a low pH.
B01.4
B01.4 is a stable and robust clone that also grows fine at a low FCS concentration and
provides the highest yield/L culture. The B01.4 IgG1 antibodies work excellent in all
immunochemical applications, except in the staining of paraffin-preserved non-
pathological liver tissue. Although the B01.4 epitope is opposite to the Gal binding site,
B01.4 interfere with the binding of high molecular weight ligands and may block the
binding of natural ligands to the ASGPR, maybe also in vivo. The epitope lies in the H1-
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CRD dimerization area and the putative binding area for induction of conformational
changes or fit, needed for ligand binding. Consequently, B01.4 may be a precious tool
for the ASGPR structure examination and for the investigation of the ligand-induced up
regulation of the endocytosis or the signal transduction mechanism. The B01.4 IgG1
may be rewarding for commercial use due to its unproblematic handling, stability and
broad applicability.
C09.1 and C18.1
C09.1 and C18.1 clones are stable and neither delicate in growth nor in the antibody
production. C09.1 and C18.1 IgG1 are similar to B01.4 IgG1, stain slightly less intensive
in immunofluorescence microscopy but are more sensitive in immunoblotting. Hence,
they are suitable for the use in all immunochemical methods too, except in the
immunostaining of paraffin-embedded liver tissue. Assuming that these three antibodies
do not bind to the same epitope region, their combination to pooled anti-H1 IgG1 could
be advantageous for some applications.
C23.8 and C48.9
C23.8 and C48.9 clones are troublesome. Especially C48.9 is instable, but both need
high FCS or IL-6 supplemented medium for proper growth and the antibody production.
Hence, to obtain acceptable yields, they must be cultured in enriched medium, and their
antibodies then be purified by H1-Sepharose affinity chromatography to get rid of the
bovine Ig.
C23.8 and C48.9 IgG1 are good or excellent applicable in all tested immunochemical
methods in the presence of calcium. They only failed in immunohistochemistry. C23.8
are particularly valuable for studies of the endocytosis by immunofluorescence
microscopy. C48.9 IgG1 may be interesting when a maximal specificity is essential,
since in affinity they seem to distinguish even between H1 and H2-CRD.
The two antibodies C23.8 and C48.9 cannot be recommended for routine applications
due to their difficult supply, but they may be the first choice for special investigations. If
recurrent antibody supply is needed they are best subcloned to get more stable clones.
C14.6
C14.6 is a stable clone, which endures the suboptimal growth conditions during antibody
production without any problems.
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The C14.6 IgG2a are sensitive in all immunochemical methods even in
immunohistochemistry. The specificity however is low. They cross-react with irrelevant
proteins in immunoblotting and with dendritic cells in immunofluorescence flow
cytometry. This may be of advantage for the discovery of ASGPR-homologous
receptors. The main advantage is, that its epitope is denaturation-resistant, but as a
consequence, the affinity in ELISA is poor. C14.6 seem to bind to but not to increase the
internalization rate via the ASGPR. It might be interesting to test, if they block the
binding and the signal transduction of high molecular weight ligands and to investigate
the ligand-induced endocytosis rate of unlabeled synthetic low molecular weight ligands
by co-internalization of labeled C14.6.
C14.6 IgG2a may be interesting for commercial use, particularly because they bind to a
denaturation-resistant epitope and work excellent in immunohistochemistry. It may also
be advantageous for simple double staining e.g. in combination with B01.4, detecting
with a subclass specific secondary antibody.
C11.1
The C11.1 clone is stable and can be propagated for the antibody production without
significant problems.
The C11.1 IgG1 seem to be “the best” ones. The putative conformational and
denaturation-sensitive epitope overlaps with the Gal binding site and the calcium site 2,
which coordinates the calcium essential for binding. The C11.1 affinity is calcium-
sensitive and high, particularly due to the extraordinary stable binding. Furthermore,
C11.1 antibodies induce extensive internalization via the ASGPR on HepG2 cells and do
not cross-react with the ASGPR-homologous receptors on monocytes and dendritic
cells. However, C11.1 IgG1 are not only ASGPR-specific, but even seem to prefer
significantly the binding to the H1-CRD compared to the H2-CRD, considering the
fingerprint characterization of C11. All together, C11.1 IgG1 may be the desired
antibodies, which interfere with the binding site. It would be tremendous to further
characterize the epitope, blocking ability, action in tissue and in vivo i.e. in a mouse
model.
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The collection of distinct monoclonal anti-H1 antibodies and of polyclonal anti-H1
antibodies enables to find a suitable one for all immunochemical applications and
probably also for diagnostic and therapeutic applications. Especially C14.6 and C11.1
are promising candidates. C14.6 may be of diagnostic value, particularly in vitro. C11.1
may be precious for diagnostic but also for therapeutic purpose to target genes or drugs
into hepatocytes.
These antibodies may allow further structure and function studies of the H1-CRD and of
the ASGPR in vivo, under physiological and pathological conditions. It would be
interesting to see if they may be valuable for diagnosis and detection of liver diseases,
which are accompanied by a change in the ASGPR expression level, e.g. a decreased
expression as found in cirrhotic or cancer liver tissue. Additionally, autoantibodies
against the ASGPR, mainly against the H1 subunit are found in 80% of all patients with
chronic active autoimmune hepatitis, in more than 70% with hepatitis B and in about
20% of the patients with primary biliary cirrhosis.167 The antibody-based detection of
distinct ASGPR expression pattern may permit to localize damaged tissue, similarly to
the Tc99-galactosyl-human serum albumine-diethylenetriamine-pentaacetic acid
scintigraphy, introduced by Kokudo et al.168 that is a routine test for liver function in
Japan. Furthermore, it would be exciting to see if these antibodies or fragments of them
could be applied as carrier for therapy of liver diseases and gene defects. Until
nowadays, only natural ligand-based (ASF, ASOR, asialotransferrin), galactosylated
polymer-based (Gal-polylysine, Gal-histones, Gal-lipopolyamine) and Senday virus F
protein-based delivery systems were tested.1 In contrast to these delivery systems,
which are founded on carbohydrate-protein interactions, targeting with antibodies rely on
protein-protein recognitions that exhibit in general higher affinity and stability. In addition,
fewer cross-reactions with other cell types may occur. E.g. the antibody-based targeting
systems may enhance the specificity of the liver tumor treatment by the targeted rescue
method, reported by Fukuma et al.1 or of the targeted therapy with antiviral or anti-
malaria drugs.
The monoclonal anti-H1 antibodies may open a new window in research, diagnosis and
therapy and further investigations of their applicability are promising and crucial.
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Appendix 1: Substances
Substance Designation Source
?-GalNAc BP ?-N-acetyl-D-galactosamine BP Synthesome
?-GalNAc FP ?-N-acetyl-D-galactosamine FP Synthesome
ABTS (HRP substrate) ABTS Peroxidase substrate kit
(2,2’-azino-di-[3-ethylbenzthiazoline-6-sulfonic acid])
Biorad
Acetic acid Acetic acid glacial 99% Hänseler
Acetone Acetone Fluka
Acetonitrile Acetonitrile Fluka
Acrylamide 30% Acrylamide 30%
(acrylamide:bisacrylamide, 37.5:1)
AppliChem
AD494(DE3) Escherichia coli AD494(DE3) expression host
Resistance: kan
Novagen
Agar BactoTM Agar, for microbiological culture Becton Dickinson BD
Agarose Agarose, molecular biology grade Eurogent
Aminocapronic acid 6-Aminocapronic acid, ?99% Fluka
Ammoniumsulfate Ammoniumsulfate, grade I, ?99.0% Sigma
Amphotericine B Amphotericine B (250?g/ml, 100x) Sigma
Ampicilline Na Ampicilline sodium Sigma
Anti-?-tubulin antibody Monoclonal mouse anti-?-tubulin antibody Boeringer Mannheim
Anti-ASGPR antibody Anti-human(mouse) asialoglycoprotein receptor antibody
(1:100)
Calbiochem
APS Ammonium persulfate, >98%, for electrophoresis Sigma
Asialofetuin Asialofetuin (type I) from fetal calf serum Sigma
BamH I
5’-g?gatcc-3’
3’-cctag?g-5’
BamH I restriction enzyme
from Bacillus amyloliquefaciens H (10’000U/ml)
BamH I buffer (10x), 37°C, 50-fold overdigest
New England BioLabs
Biotin-polymer-GalNAc Biotin-polyacrylamide ?-GalNAc glycoconjugate
(5mol% biotin, 20mol% GalNAc)
Lectinity holding
BL-21(DE3) Escherichia coli BL-21(DE3) expression host
Resistance: kan
Novagen
Brefeldin A Brefeldin A, from penicillium brefeldianum (ZLF)
Bromphenol blue Bromphenol blue, for electrophoresis Biorad
BSA Bovine Serum Albumine, Fraktion V, >98% Sigma
BSA Bovine Serum Albumin (400μg/ml) Protein Standard Sigma
CaCl2?2H2O Calciumchloride dihydrate, pa ?99.0% Fluka
Carbenicilline Na2 Carbenicilline disodium Sigma
Chloroform-phenol
Chymotrypsine ?-Chymotrypsine, TLCK treated, from bovine pankreas Sigma
CIAP Calf intestine alkaline phosphatase (1U/?l)
CIAP buffer (10x)
MBI Fermentas
Ciprofloxacine Ciproxine infusion 2mg/ml (100x) Bayer (ZLF)
Collagen S Collagen S (type I, 3mg/ml, pH3.0) Roche
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Substance Designation Source
Coomassie Blue G250 Coomassie Brilliant Blue G250 Biorad
DAM-IgG(H+L)-Cy3 Donkey anti-mouse IgG(H+L), Cy3 labeled Jackson Immuno Research
Dendritic cell Dendritic cells differentiated from monocytes
(human blood)
De Libero G.
Diethanolamine Diethanolamine, ?98% Sigma
Divinylsulfone Divinylsulfone, purum Fluka
DMEM high glucose Dulbecco’s Modified Eagle’s Medium high glucose GibcoTM
DMEM high glucose
(HEPES)
Dulbecco’s Modified Eagle’s Medium high glucose
(without phenolred, with 25mM HEPES)
GibcoTM
DMSO Hybrimax? dimethyl sulfoxide, sterile Sigma
DMSO Dimethyl sulfoxide, >99.9% Sigma
DNA molecular ladder DNA molecular weigh marker X
(12216-75bp)
Roche
dNTP 2’-Desoxynucleoside-5’-triphosphate MBI Fermentas
DPBS Dulbecco’s Phosphate Buffered Saline
(without Ca, without Mg)
BioWhittakerTM (ZLF)
DPBS Dulbecco’s Phosphate Buffered Saline
(without Ca, without Mg)
GibcoTM
DTT Dithiothreitol, >99%, molecular biology Sigma
EDTA?2H2O Na2 Disodium ethylendiamintetraacetate dihydrate Sigma
Ethanolamine Ethanolamine, ps. Sigma
Ethanol 99% Ethanol 99% Fluka
Ethidium bromide Ethidium bromide solution (10mg/ml) Boeringer Mannheim GmbH
EZNA gel extraction kit ENZA® Gel Extraction Kit PEQLAB
FACSrinse FACSrinse solution (hypoton) Becton Dickinson (ZLF)
FACSsafe FACSsafe solution (isoton) Becton Dickinson (ZLF)
FCS Fetal Calf Serum (US) BioWhittakerTM (ZLF)
FCS Fetal Calf Serum (Australia) GibcoTM
Freund’s complete (CFA) Complete Freund’s Adjuvans Sigma
Freund’s incomplete (IFA) Incomplete Freund’s Adjuvans Sigma
Galactosamine D-galactosamine Pfanstiehl Laboratories
Galactose D-galactose Senn chemicals
Galactose D-galactose Merck
GAB-IgG-HRP Goat anti-biotin IgG, horseradish peroxidase labeled Sigma
GAM-Ig(H+L)-FITC Goat anti-mouse IgG(H+L), fluorescein isothiocyanate labeled Southern Biotechnology SBA
GAM-Ig(H+L)-HRP Goat anti-mouse IgG(H+L), R phycoerythrine labeled Southern Biotechnology SBA
GAM-Ig(polyvalent)-AP Goat anti-mouse Ig (polyvalent) alkaline phosphatase conjugate
(1:3’000)
Sigma
GAM-IgG(Fc)-AP Goat anti-mouse IgG (Fc specific) alkaline phosphatase
conjugate (1:40’000)
Sigma
GAM-IgG(H+L)-AF488 Goat anti-mouse IgG (H+L) Alexa Fluor 488 conjugate Molecular Probes
GAM-IgG(whole)-AP Goat anti-mouse IgG (whole molecule) alkaline phosphatase
conjugate (1:30’000)
Sigma
GAM-IgM/G/A(H+L)-FITC Goat anti-mouse IgM+IgG+IgA (H+L) fluorescein isothiocyanate
conjugate (1?g/106cells)
Southern Biotechnology SBA
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Substance Designation Source
GAM-IgM/G/A(H+L)-HRP Goat anti-mouse IgM+IgG+IgA (H+L) horseradish peroxidase
conjugate (1:8’000)
Southern Biotechnology SBA
(ZLF)
GAM-IgM/G/A(H+L)-RPE Goat anti-mouse IgM+IgG+IgA (H+L) R phycoerythrine
conjugate (0.1?g/106cells)
Southern Biotechnology SBA
Gel filtration standard Gel filtration standard (5 proteins) Biorad
Gel loading solution Gel loading solution (6x), for molecular biology Sigma
Gentamicine Gentamicine sulfate solution 50mg/ml (1000x) Sigma
GKN (ZLF)
Glucose D-glucose Merck
GlutaMAX GlutaMAX® I 200mM (100x) GibcoTM (ZLF)
Glutathione oxidized Glutathione oxidized, free acid Calbiochem
Glutathione reduced Glutathione reduced, free acid Calbiochem
Glycerol Glycerol 98% Fluka
Glycerol anhydrous Glycerol anhydrous, for molecular biology Fluka
Glycine Glycine, ?99.0% Fluka
GMCSF Human granulocyte-macrophage colony-stimulating factor De Libero G.
H2SO4 Sulphuric acid Fluka
H3PO4 85% Ortho-phosphoric acid 85% Fluka
HAT media supplement Hybrimax® HAT media supplement (50x)
(500mM hypoxanthine, 2mM aminopterine, 80mM thymidine)
Sigma
HAT media supplement HAT media supplement (50x)
(500mM hypoxanthine, 2mM aminopterine, 80mM thymidine)
GibcoTM (ZLF)
HCl Hydrochloric acid 37% Fluka
HEPES 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid Fluka
HEPES HEPES Buffer (1M, 0.85% NaCl) BioWhittakerTM
HEPES HEPES Buffer (1M, pH7.2-7.5, pKa 7.3 at 37°C) Gibco
TM
HepG2 Human cell line HepG2 (ATCC: HB-8065)
Hepatocellular carcinoma (liver)
Morphology: epithelial (adherent)
DSMZ  GmbH
HL-60 Human cell line HL-60 (ATCC: CCL-240)
Acute promyelocytic leukaemia (peripheral blood)
Morphology: myeloblastic (suspension)
De Libero G.
HSA Human Serum Albumine 3% University hospital Basel
HT media supplement Hybrimax® HT media supplement (50x)
(500mM hypoxanthine, 80mM thymidine)
Sigma
HT media supplement HT media supplement (50x)
(500mM hypoxanthine, 80mM thymidine)
GibcoTM (ZLF)
Human IL-2 Human interleukin-2 containing supernatant De Libero G.
Human IL-6 Human interleukin-6 containing supernatant De Libero G.
Human serum Human serum De Libero G.
IMDM Iscove’s Modified Dulbecco’s Medium
(with GlutaMAX I, 25mM Hepes)
GibcoTM
Iodoacetamide (IAA) Iodoacetamide, Sigmapure Sigma
IPTG Isopropyl-?-D-thiogalactopyranoside Promega
IPTG Isopropyl-?-D-thiogalactopyranoside Roche
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Isopropanol Isopropanol, puriss. Fluka
Isotyping ELISA ClonotypingTM System/HRP
ELISA (GAM-Ig-HRP(1:500), ABTS)
Southern Biotechnology SBA
Isotyping strip IsoStrip mouse monoclonal antibody isotyping kit Roche
JM109 Escherichia coli JM109 transformation host
Resistance: none
Promega
JM109(DE3) Escherichia coli JM109(DE3) expression host
Resistance: none
Promega
Jurkat Human cell line Jurkat (ATCC: TIB-152)
Acute T-cell leukaemia (T-lymphocyte)
Morphology: lymphoblast (suspension)
De Libero G.
K-562 Human cell line K-562 (ATCC: CCL-243)
Chronic myeloid leukaemia (bone marrow)
Morphology: lymphoblast (suspension)
De Libero G.
Kanamycine Kanamycine sulfate solution (10mg/ml, 100x) GibcoTM (ZLF)
Kanamycine SO4 Kanamycine monosulfate (component A, B, C) Fluka
KCl Potassium chloride, pa. Fluka
KH2PO4 Potassium dihydrogenphosphate, pheur Fluka
KOAc Potassium acetate Fluka
Lactose D-lactose Merck
Lambda ? DNA Standard ? DNA (250?g/ml) MBI Fermentas
L-glutamine L-glutamine (200mM, 100x) GibcoTM
LPS Lipopolysaccharid from E.coli serotype 055:B5 (5mg/ml) Fluka
Lysozyme Lysozyme (111’000U/mg), from hen egg white Boeringer Mannheim
MEM Minimal Essential Medium
(without L-glutamine, with Earl’s salt)
BioWhittakerTM (ZLF)
Mercaptoethanol ?-mercaptoethanol Fluka
Methanol Methanol Fluka
Metofane Methoxyflurane Schering-Plough animal health
MgCl2·6H2O Magnesium chloride hexahydrate, molecular biology Fluka
MgSO4·7H2O Magnesium sulfate heptahydrate Fluka
Milk powder not fat dried Not fat dried milk powder Coop
Monocyte Monocytes isolated from human blood De Libero G.
Mouse Balb/c Balb/c mouse
Inbred, albino
Mouse NMRI National Medical Research Institute mouse
Outbred, albino
B i o l o g i c a l R e s e a r c h
Laboratories
Mowiol Mowiol Hoechst 4-88 Calbiochem
MW marker protein
(high range)
SigmaMarkerTM, protein high range
(MW 36’000-205’000)
Sigma
MW marker protein
(low range)
SigmaMarkerTM, protein low range
(MW 6’500-66’000)
Sigma
Myeloma cell Balb/c mouse myeloma cells P3X63-Ag8.563
(ATCC CRL-1580)
Morphology: lymphoblast (suspension)
De Libero G., Fischer R.
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Na2HPO4 Disodium hydrogenphosphate, anhydrous Fluka
NaBH4 Sodium borohydride Fluka
NaBorate·10H2O Sodium borate decahydrate, SigmaUltra Sigma
N-Acetylgalactosamine N-Acetyl-D-galactosamine Acros Organics
N-Acetylgalactosamine N-Acetyl-D-galactosamine Pfanstiehl laboratories
NaCl Sodium chloride, puriss pa ?99.5% Fluka
NaHCO3 Sodium hydrogencarbonate, pa. Fluka
NaN3 Sodium azide Fluka
NaOAc·3H2O Sodium acetate trihydrate Fluka
NaOH Sodium hydroxide Merck
NaPyruvate 100x Sodium pyruvate 100mM (100x) BioWhittakerTM (ZLF)
NBT-BCIP solution NBT-BCIP solution (1.1g/ml)
(nitro-blue tetrazoliumchloride, 5-bromo-4-chloro-3-
indolylphosphate toluidine, 67% DMSO)
Fluka
Nde I
5’-ca?tatg-3’
3’-gtat?ac-5’
Nde I restriction enzyme
from Neisseria denitrificans (20’000U/ml)
NEBuffer (10x) 4, 37°C, 20-fold overdigest
New England BioLabs
NEAA 100x MEM Non Essential Amino Acids (100x) BioWhittakerTM (ZLF)
NP-40 Nonidet P40 (Tergitol) Fluka
NPP (AP substrate) Sigma 104? NPP tablet
(p-nitrophenylphosphate, 5mg)
Sigma
OPD (HRP substrate) Sigma fastTM  OPD tablet
(o-phenylenediamine dihydrochloride, 400?g/ml)
Sigma
Oxalic acid Oxalic acid, pa. Fluka
Paraformaldehyde Paraformaldehyde Fluka
PEG 1500 Polyethylene glycol, MW 1’500 Boehringer Mannheim (ZH)
PEG 4000 Polyethylene glycol, MW 4’000 (9727) Merck
PEG 8000 Polyethylene glycol, MW 8’000 Sigma
PenStrep Penicilline (104U/ml), streptomycine (10mg/ml, 100x) GibcoTM
Pfu DNA polymerase Pfu DNA polymerase
from Pyrococcus furiosus (2.5U/?l)
Pfu DNA polymerase buffer (10x)
Promega
Pfu DNA polymerase Pfu DNA polymerase
from Pyrococcus furiosus (2.5U/?l)
Pfu DNA polymerase buffer (10x)
Stratagene
Plasmid extraction kit Plasmid DNA Extraction Kit Quiagen
Plasmid extraction kit GFXTM Micro Plasmid Prep Kit Amersham Pharmacia
Plasmid pET21c Bacterial plasmid vector
Resistance: amp, T7 promotor, T7-tag(N), His-tag(C)
Novagen
Plasmid pET3b Bacterial plasmid vector
Resistance: amp, T7 promotor, T7-tag(N)
Novagen
Plasmid pET3H1 Plasmid pET3b with H1-CRD insert Martin Spiess (BZ)
Plasmid pEZZ18 Bacterial plasmid vector
Resistance: amp, protein A-tag (ZZpeptide)
Amersham Pharmacia
PMSF Phenylmethane sulfonylfluoride, >99% Fluka
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Substance Designation Source
Ponceau S Ponceau S solution 0.1% (5% acetic acid) Sigma
Primer H1-bw H1-backward primer, 21bp (ggatccttattaaaggagagg) Microsynth
Primer H1-fw H1-foreward primer, 21bp (catatgggctcagaaaggacc) Microsynth
Primer M13 standard M13 standard primer Microsynth
Primer T7 T7 primer for forward sequencing Microsynth
Primer T7term T7term primer for backward sequencing Microsynth
Probidiumiodide Probidiumiodide (ZLF)
Protease Protease from Streptomyces griseus Sigma
Protein G agarose Protein G agarose, lyophilized Sigma
Proteinase K Proteinase K from Tritirachium album Sigma
RACh-IgG(whole)-AP Rabbit anti-chicken IgG (whole molecule) alkaline phosphatase
conjugate (1:35’000)
Sigma
RACh-IgG(whole)-FITC Rabbit anti-chicken IgG (whole molecule) fluoresceine
isothiocyanate conjugate (1:640)
Sigma
RNAse A RNAse A (10mg/ml) from bovine pancreas Roche
Rosetta-gamiTM(DE3) E.coli Rosetta-gamiTM(DE3) expression host
Resistance: kan, tet, cam
Novagen
RPMI1640 RPMI1640 (without L-glutamine) BioWhittakerTM (ZLF)
Saponine Saponine from quillaja bark (ZLF)
SDS Sodiumdodecylsulfate, for electrophoresis Biorad
Sepharose 4B Sepharose® 4B, CH-activated, lyophilized
(bead diameter 40-165?m)
Sigma
Sepharose 6B Sepharose® 6B, for chromatography
(bead diameter 45-165?m)
Fluka
Silver staining kit Plus oneTM  silver staining kit protein Amersham biosciences
SK-Hep1 Human cell line SK-Hep1
Adencarcinoma (liver)
Morphology: epithelial (adherent)
DSMZ  GmbH
Sma I Sma I restriction enzyme
From Serratia marcescens S (10U/?l)
Y+/TangoTM buffer, 30°C, 50-fold overdigest
MBI Fermentas
Streptavidin-peroxidase Streptavidin-peroxidase (POD) conjugate Roche
Sucrose Sucrose (Saccharose) Sigma
T4 DNA ligase T4 DNA ligase (400U/?l)
From T4 infected E.coli
T4 DNA ligase buffer (10x)
New England BioLabs
Taq DNA polymerase Taq DNA polymerase (5U/?l)
From Thermus aquaticus recombinant in E.coli
Taq PCR buffer with MgCl2 (10x)
Sigma
TCA Trichloracetic acid Fluka
TEMED N,N,N,N`-Tetra-methylene-diamine Serva
Texas Red labeling kit FluoReporter® Texas Red® X protein labeling kit
Active Texas Red-X dye (A), DMSO anhydrous (B)
Molecular Probes
TFA Trifluoracetic acid Fluka
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THP-1 Human cell line THP-1 (ATCC TIB-202)
Acute monocytic leukaemia (peripheral blood)
Morphology: monocyte (suspension)
De Libero G.
Top10 Escherichia coli Top 10 cloning host
Resistance: none
Invitrogen
Tris Tris(hydroxymethyl)aminomethane, ?99.0% Fluka
Triton-X100 Triton-X100 (PEG ter-octylphenylether) Fluka
Trypsine Trypsine modified, sequencing grade 20?g/vial Promega
Trypsine-EDTA Trypsine-EDTA in HBSS (1x)
(0.25% trypsine, 1mM Na4EDTA)
GibcoTM
Trypan blue Trypan blue 0.4% GibcoTM
Tryptone BactoTM Trypto Peptone
(for microbiological culture)
Becton Dickinson BD
Tween20 Tween20 (polyoxyethylenesorbitan monolaurate) Sigma
Urea Urea, purum pa Fluka
Water MilliQ Double distilled filtrated water (ZLF)
Water Nanopure Double distilled filtrated water
Yeast extract BactoTM Yeast Extract
(for microbiological culture)
Becton Dickinson BD
Benefit and Application of Antibodies Against the H1-CRD Appendices
276
Appendix 2: Equipments
Equipment Designation Source
Blotting cell, semi-dry Trans-Blot?SD, demi-dry electrophoretic transfer cell Biorad
Cell sieve Cell sieve (ZLF)
Cell counting chamber Improved Neubauer counting chamber Brand
Centrifuge Heraeus Megafuge 1.0 Heraeus Instruments (ZH)
Centrifuge Heraeus 400R (Functionline) Heraeus Instruments (ZLF)
Centrifuge, bench Centrifuge 5415D Vaudaux-Eppendorf
Centrifuge, labor Centrifuge 5804R Vaudaux-Eppendorf
Chromatography apparature BioLocig HR work station
Auto injection valve AV7-3, low pressure
Biorad
Column AminoLink plus AminoLink Plus Immobilization Trial Kit Pierce
Column FPLC 10ml Bio-Scale MT10 column Biorad
Column FPLC 20ml Bio-Scale MT20 column Biorad
Column HPLC 2ml Bio-Scale MT2 column Biorad
Column Mobicol 1ml Mobicol 1ml MoBiTec
Column Protein A 1ml Affi-gel protein A agarose cartridge Biorad
Column Protein G 1ml HiTrap protein G HP Amersham Biosciences
Column Protein L spin NabTM Protein L spin purification kit Pierce
Column SEC 15ml Bio-Prep SE-10/17 column Biorad
Coverslip Coverslip round (18mm) Menzel-Gläser
Cryotube, 1.2ml Cryotubes, 1.2ml, free standing Techno Plastic Products TPP
Cryotube, 1.8ml CryotubeTM 1.8ml (PP), conical, free standing Nunc Brand (ZLF)
Cuvette quartz semi-micro Cuvette quartz semi-micro
Cuvette semi-micro Cuvette semi-micro (10·10·45mm) Greiner
Dialysis mini unit Slide-A-Lyzer® mini dialysis unit (MWCO 10’000) Pierce
Dialysis tube ZelluTrans/Roth 6.0, 25mm (MWCO 10’000) Roth GmbH
Electrophoresis chamber Agarose gelelectrophoresis, flat
Electrophoresis, cell Mini-PROTEAN 2 system, vertical Biorad
FACS reader FACScan Becton Dickinson BD (ZLF)
Filter syringe MILLEX GP (0.22μm) Millipore
Filter centrifugal unit 0.5ml Biomax ultrafree®-0.5 centrifugal filter unit
(MWCO 10’000)
Millipore
Filter centrifugal unit 0.5ml Microcon® YM-10 centrifugal filter unit
(MWCO 10’000)
Millipore
Filter centrifugal unit 2.0ml Centricon® YM-10 centrifugal filter unit
(MWCO 10’000)
Millipore
Filter disc membrane Supor® (0.45?m), low protein binding Pall Gelman Laboratory
Filter Mobicol column Mobicol large filter (35?m pore size)
Mobicol small filter (35?m pore size)
MoBiTec
Filter paper (blot) Chromatography paper 3MM Whatman
Filter round paper Filter MN615 Macherey-Nagel
Filter syringe (0.2?m) IC-Millex-LG (0.2μm), low protein binding Millipore (ZLF)
Benefit and Application of Antibodies Against the H1-CRD Appendices
277
Equipment Designation Source
Filter syringe (0.22?m) Millex-GV (0.22?m), low protein binding Millipore (ZLF)
Filter vacuum StericupTM StericupTM (0.22μm) vacuum-driven filter unit, sterile Millipore
Flask T150 Tissue culture flask (690ml/150cm2), vent Techno Plastic Products TPP
Flask T175 Tissue culture flask (175cm2), filter FalconTM Becton Dickinson (ZLF)
Flask T25 Tissue culture flask (60ml/25cm2), vent Techno Plastic Products TPP
Flask T75 Tissue culture flask (270ml/75cm2), vent Techno Plastic Products TPP
Gel documentation GelDocTM 2000 Biorad
Glass fritte glass fritte (borosilicate 3.3, pore 4)
Incubator CO2 Hera cell Heraeus Instruments
Incubator CO2 Revca ultima, model 05000T-7-VBB Kendro Laboratory product (ZLF)
Incubator shaker Innova 4000 New Brunswick Scientific
Laminar flow Heraeus HSP18 class II Heraeus Instruments (ZLF)
Laminar flow (vertical) Skanair MSF 120 (model 1.2) Skan AG
Laminar flow (vertical) Skanair MSF 90 (model 0.9) Skan AG
Mass spectrometer
Microscope Inverse microscope Nikon TMS Nikon (ZLF)
Microscope Inverse microscope Zeiss IM
binocular KpI-W10x/18
objective F2.5/0.08
objective Ph1F10/0.25
objective F-LD20/0.025
Zeiss
Microscope Apofluorescence microscope
binocular 10x/20
objective 100x/1.3oil Ph3plan-neofluor
filter red BP546/FT580/LP590
filter green 450-490/FT510/515-565
Zeiss
Microscope slide Microscope slide (extra white) Huber
Needle (middle) MicrolanceTM 3 (18G·40mm) Becton Dickinson BD
Needle (thick) MicrolanceTM 3 (25G·25mm) Becton Dickinson BD
Needle (thin) MicrolanceTM 3 (27G·13mm) Becton Dickinson BD
Nitrocellulose membrane Trans-Blot® Transfer Medium (0.45?m) Biorad
Paper towel Kimwipe Kimwipe, precision paper towel Kimberly Clark
Petri dish ? 60mm Petri dish with vent (60·15mm) Greiner
Petri dish ? 94mm Petri dish with vent (94·16mm) Greiner
Pipet 10?l Eppendorf research 10 Vaudaux-Eppendorf
Pipet 1000?l Gilson® Pipetman 200-1000?l Gilson
Pipet 10ml Serologic pipet 10ml (1/10ml), sterile FalconTM Becton Dickinson (ZLF)
Pipet 10ml Serologic pipet 10ml (1/10ml), sterile Techno Plastic Products TPP
Pipet 1ml Serologic pipet 1ml (1/100ml), sterile Techno Plastic Products TPP
Pipet 20?l Gilson® Pipetman 5-20?l Gilson
Pipet 200?l Gilson® Pipetman 20-200?l Gilson
Pipet 25ml Serologic pipet 25ml (2/10ml), sterile FalconTM Becton Dickinson (ZLF)
Pipet 25ml Serologic pipet 25ml (2/10ml), sterile Techno Plastic Products TPP
Pipet 2ml Serologic pipet 2ml (1/100ml), sterile FalconTM Becton Dickinson (ZLF)
Pipet 2ml Serologic pipet 2ml (1/100ml), sterile Techno Plastic Products TPP
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Pipet 5’000?l Eppendorf research 5000 Vaudaux-Eppendorf
Pipet 5ml Serologic pipet 5ml (1/10ml), sterile FalconTM Becton Dickinson (ZLF)
Pipet 5ml Serologic pipet 5ml (1/10ml), sterile Techno Plastic Products TPP
Pipet multichannel 1200?l
(multidispense)
Eppendorf research multichannel pro 1200 Vaudaux-Eppendorf
Pipet multichannel 300?l Eppendorf research multichannel 300 Vaudaux-Eppendorf
Pipet pipetboy Easypet Vaudaux-Eppendorf
Pipet Terasaki Terasaki-plate multipipet (Hamilton syringes)
Plate ELISA (96 wells) Nunc-ImmunoTM 96 well plate MaxiSorpTM
(400?l/2.7cm2)
Nunc Brand
Plate FACS (96 wells) MicrotestTM 96 well TC plate, U bottom
(0.32ml/0.36cm2)
FalconTM Becton Dickinson (ZLF)
Plate TC (12 wells) Test culture plate 12 wells plate, flat (6.30ml/3.66cm2) Techno Plastic Products TPP
Plate TC (24 wells) MicrotestTM 24 well TC plate, flat bottom
(3.5ml/2.0cm2)
FalconTM Becton Dickinson (ZLF)
Plate TC (24 wells) Test culture plate 24 wells plate, flat bottom
(3.29ml/1.91cm2)
Techno Plastic Products TPP
Plate TC (6 wells) MicrotestTM 6 well TC plate, flat bottom
(15.5ml/9.6cm2)
FalconTM Becton Dickinson (ZLF)
Plate TC (6 wells) Test culture plate 6 wells plate, flat (15.53ml/9.03cm2) Techno Plastic Products TPP
Plate TC (96 wells) MicrotestTM 96 well TC plate, flat bottom
(0.37ml/0.32cm2)
FalconTM Becton Dickinson (ZLF)
Plate TC (96 wells) Test culture plate 96 wells plate, flat bottom
(0.34ml/0.31cm2)
Techno Plastic Products TPP
Plate Terasaki (60 wells) NunclonTM ? surface (mini tray, 6x10) Nunc (ZLF)
Plate washer (96 wells) EL X50 auto strip washer Bio-Tek Instruments (ZLF)
Power supply POWER Pac 300 Biorad
Software (FACScan) CellQuest Pro Becton Dickinson BD
Software (FPLC analysis) EZLogic Biorad
Software (GelDocTM 2000) Quantity one? version 4.1 Biorad
Software (graphs) Prism4 sofware
Software (platereader) SOFTmax PRO version 4.0 Molecular devices
Sonication apparatus VibraCell Sonics & Materials
Spectrophotometer
(UV/Vis, cuvette)
SmartSpecTM 3000 cuvette reader
(200-800nm)
Biorad
Spectrophotometer
(UV/Vis, plate reader)
Spectramax 190 plate reader
(190-850nm)
Molecular devices
Syringe 10ml Syringe DiscarditTM II 10ml (0.5) Luer, sterile Becton Dickinson BD
Syringe 10ml Syringe 10ml (0.5) Luer, sterile Once (ZLF)
Syringe 1ml Syringe PlastipakTM 1ml (0.01) Luer, sterile Becton Dickinson BD
Syringe 20ml Syringe 20ml (1.0) Luer, sterile Once (ZLF)
Syringe 2ml Syringe DiscarditTM II 2ml (0.1) Luer, sterile Becton Dickinson BD
Syringe 50ml Syringe PlastipakTM 50ml (0.2) Luer, sterile Becton Dickinson BD
Syringe 5ml Syringe DiscarditTM II 5ml(0.2) Luer, sterile Becton Dickinson BD
Syringe 5ml Syringe 5ml (0.2) Luer, sterile Once (ZLF)
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Thermal cycler Icycler thermal cycler, gradient Biorad
Tip 1000?l Micropipet ect blue 1/1000?l Treff
Tip 20?l Micropipet tip micro cristall 0.5/20?l Treff
Tip 200μl Sarstedt tip yellow stock pack 1/200μl Sarstedt (ZLF)
Tip 200?l Micropipet tip yellow 1/200?l Treff
Tip multichannel 1250?l EpTIPS standard 50-1250μl Vaudaux-Eppendorf
Tip multichannel 200?l EpTIPS standard 2-200μl Vaudaux-Eppendorf
Tip multichannel 300?l EpTIPS standard 20-300μl Vaudaux-Eppendorf
Tip pipet EpTIPS standard 100-5’000μl Vaudaux-Eppendorf
Tissue potter Glass potter, conical Fisher scientific (ZH)
Tube 0.5ml Microtube 0.5ml, click cap, conical Treff
Tube 1.5ml Microtube 1.5ml, click cap, conical Treff
Tube centrifugal 15ml Centrifuge tube 15ml (PS), screw cap, conical FalconTM Becton Dickinson
Tube centrifugal 15ml Blue maxTM tube 15ml (PS), conical FalconTM Becton Dickinson (ZLF)
Tube centrifugal 15ml Centrifuge tube 15ml (PP), screw cap, conical Techno Plastic Products TPP
Tube centrifugal 50ml Centrifuge tube 50ml (PP), screw cap, conical FalconTM Becton Dickinson
Tube centrifugal 50ml Blue maxTM tube 50ml (PP), conical FalconTM Becton Dickinson (ZLF)
Tube centrifugal 50ml Centrifuge tube 50ml (PP), screw cap, conical Techno Plastic Products TPP
Tube culture 14ml Culture tube 14ml (PP), dual snap cap, round FalconTM Becton Dickinson
Tube FACS FACS tubes, TPS-05 Milan Geneve (ZLF)
Tube test 5ml Test tube 5ml (PS), dual snap cap, round FalconTM Becton Dickinson
Ultracentrifuge Beckman L7 ultracentrifuge
Rotor type 50.2Ti (50’000rpm)
Beckman coulter
ZipTip ZipTip C-18, 0.6?l Millipore
Benefit and Application of Antibodies Against the H1-CRD Appendices
280
 Appendix 3:Expression vectors
pET3b IPTG induction Characteristics
EcoR I
pET3b Bgl II
Amp
T7
T7
B
g
l
II
B
a
m
H
I
N
d
e
I
E
c
o
R
I
E
c
o
R
V
catatggctagcatgactggtggacagcaaatgggtcgcggatcc
Nde I BamH I
Promotor T7, coding for AmpR, no tag (or a N terminal T7?tag).
Length 4639bp (pBR322 plasmid derivative).
Multiple cloning site N-terminal Nde I (549) to C-terminal BamH I
(510) with the T7?tag between. Restriction sites Hin III (29), BamH
I (510), Nde I (549), Sal I (927), Pst I (3889) and EcoR I (4637).
T7 promotor 614-630
T7 transcription start 613
T7?tag 518-550
T7 terminator 404-450
pBR322 origin 2813
bla coding region (AmpR) 3574-4431
pEZZ18 Heat induction Characteristics
cccggggatcc
Sma I BamH I
Not I
Cla I
pEZZ18
Amp
F1ori
Ori
pAS
ZZ
lacZ’
S
m
a
I
B
a
m
H
I
N
o
t
I
C
la
I
pAS ZZ lacZ’
S
m
a
I
N
o
t
I
C
la
I
pAS ZZ lacZ’
Promotors lacUV5 and Protein A (staphylococcus aureus), coding
for AmpR, N-terminal fusion protein, ZZ peptid of 14kD (secretion
sequence / IgG binding domain, cleavable by factorXa)
?-complementation (blue/white screening).
Length 4591bp (pEMBL8+ plasmid derivative).
Multiple cloning site N-terminal to C-terminal Eco RI (2914), Sac I
(2920), Kpn I (2926), Sma I (2930), BamH I (2935), Xba I (2941),
Sal I (2947), Pst I (2953), Sph I (2959) and Hind III (2965).
Protein A promotor (pspa) 2390-2400 and 2366-2377
lacUV5 promotor (plac) 2144-2149 and 2180-2200
Protein A signal sequence 2432-2539
Partial E domain 2540-2557
Synthetic ZZ domain 2558-2731 and 2732-2905
Multiple cloning site 2914-2970
lacZ’ coding region 2973-3130
f1 origin region 3136-4352
bla coding region (AmpR) 154-1059
Origin 1820
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Appendix 4: E.coli cloning and expression strains
E.coli strain Genotype Characteristics
JM109 endA1 recA1 gyrA96 thi hsdr17 (rk
-
,
mk
+
) relA1 supE44 ?(lac-proAB) F’
[traD36 proAB lacI
q
Z?M15]
JM109 is a cloning host for general cloning, which allows
blue/white screening.
JM109(DE3) endA1 recA1 gyrA96 thi hsdr17 (rk
-
,
mk
+
) relA1 supE44 ?(lac-proAB) F’
[traD36 proAB lacI
q
Z?M15] (DE3)
JM109(DE3) is the same as JM109 but is an expression
host and allows induction of protein expression by adding
IPTG. The only difference is, that the ? prophage gene,
coding for the T7 RNA polymerase, is inserted, which
allows the induction of protein expression by adding IPTG,
if it contains a plasmid with a T7 or T7lac promotor.
AD494(DE3)
(K-12 derivative)
?ara-leu 7697 ?lacX74 ?phoAPvuII
phoR ?malF3 F’[ l a c1(lacq)pro]
trxB::kan(DE3)
AD494(DE3) is a trxB mutant expression host, which
therefore allows a better disulfide bond formation in the
cytoplasm and is used to maximize the amount of soluble
properly folded protein. The strain is kanamycine
resistant.
Rosetta-gami(DE3)
(K-12 derivative)
?ara-leu 7697 ?lacX74 ?phoAPvull
phoR araD139 galE galK rpsL F’
[lac
+
(lacI
q
)pro]
gor522::Tn10(TcR)trxB::kan (DE3)
pRARE (argU, argW, ileX, glyT,
leuW, proL) (CmR)
Rosetta-gami(DE3) is a trxB/gor mutant expression host,
which therefore allows a better disulfide bond formation in
the cytoplasm. Furthermore it contains a pRARE plasmid,
which codes for all amino acids tRNAs , known to be rare
in E. coli strains as arg / gly / pro / leu / ile. The strain is
kanamycine, tetracycline and chloramphenicol resistant.
Compatible vectors must carry a ColE1-based origin of
replication (as pBR, pUC). Rosetta-gami is compatible
with E. coli promotor based vectors as tac, trc, T5, ?.
Rosetta-gami(DE3) as ?DE3 lysogen strainis compatible
with T7 and T7lac based pET vectors.
Top10 F-, mcrA ?(mrr- hsdRMS- mcrBC)
?80lacZ?M15 ?lacX74 hsdR(rK- mK+)
rpsL(str
R
) thi-1 mcrB P3 [kan
R
amp
R
(amber) tet
R
(amber)]
Top10 is used for cloning, expression and for library
construction.
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Appendix 5: Cell lines
Cell line Characteristics
P3X63Ag8.653 Organism:
Strain:
Cell type:
Life span:
Properties:
Mus musculus
Balb/c
B-lymphoblast, myeloma
Infinite
Suspension, 8-azaguanine resistant, HAT sensitive, no immunoglobuline
secretion
HepG2 Organism:
Strain:
Cell type:
Morphology:
Life span:
Properties:
Homo sapiens
Caucasian
Liver, carcinoma, hepatocellular
Epithelial-like
Infinite
Adherent
SK-Hep1 Organism:
Strain:
Cell type:
Morphology:
Life span:
Properties:
Homo sapiens
Caucasian
Liver, adenocarcinoma
Epithelial-like
Infinite
Adherent
K-562 Organism:
Strain:
Cell type:
Morphology:
Life span:
Properties:
Homo sapiens
Caucasian
Pleural effusion, leucaemic, chronic myeloid
Lymphoblast-like
Infinite
Suspension , undifferentiated
HL-60 Organism:
Strain:
Cell type:
Morphology:
Life span:
Properties:
Homo sapiens
Caucasian
Peripheral blood, leucaemia, promyelocytic
Lymphoblast-like
Infinite
Suspension, differentiated , phagocytosis
THP-1 Organism:
Strain:
Cell type:
Morphology:
Life span:
Properties:
Homo sapiens
Caucasian
Peripheral blood, monocytic leukaemia
Monocyte
Infinite
Suspension
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Cell line Characteristics
Jurkat Organism:
Strain:
Cell type:
Morphology:
Life span:
Properties:
Homo sapiens
Caucasian
T-lymphocyte, acute T-cell leukaemia
Lymphoblast-like
Infinite
Suspension
Monocytes Organism:
Properties:
Homo sapiens
Suspension, primary cells
Dendritic cells Organism:
Properties:
Homo sapiens
Suspension , primary cells, differentiated from monocytes with IL-2
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